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Kidney transplantation has revolutionised the treatment of end stage renal
disease (ESRD), offering a significant increase in life expectancy, quality of life
and cost-effectiveness when compared with dialysis. However, the provision
of transplantation is under immense pressure due to the vastly insufficient
number of donor organs, the growing incidence of ESRD and the increasing
age and burden of comorbidity of the ESRD population. There is evidence for
considerable disparities in access to transplantation across transplant centres
in the UK and in the outcomes and prognosis of individual patients. This
raises complex issues regarding the assessment of patient suitability for
transplantation, maximisation of transplant outcomes and equitable access
to transplantation at an individual as well as a societal level.
The aims of this thesis were to address the following key questions:
1) What factors may be contributing to inequity in access to transplantation
in the UK?
2) How do patient factors including comorbidity affect graft and patient
survival after renal transplantation, and do survival rates differ between
centres in the UK?
3) Do patient reported outcome measures differ after living and deceased
donor kidney transplantation?
8
4) What factors affect the survival of patients on dialysis, and can these risk
factors be quantified in a survival prediction score aimed at reducing inequity
and standardising access to the waiting list?
The research was conducted as part of the national prospective cohort study
Access to Transplantation and Transplant Outcome Measures (ATTOM),
which is the first study to include ESRD patients from all 72 renal units in the
UK. The study included a total of 6844 patients recruited into three different
cohorts; incident dialysis, incident transplant and prevalent matched control
waiting list cohorts.
The findings showed significant variation between UK centres with regard to
the level of comorbidity among patients accepted to the waiting list and to
transplantation. Thus, centre differences in selection criteria, patient
assessment and risk tolerance are likely to be contributing to inequity in
access to transplantation across the UK.
The data highlighted significant socio-demographic differences between
dialysis, waiting list and transplant patients. Older, more socially deprived
patients and patients with a lower level of educational attainment were
significantly less likely to be listed for transplantation. These same groups of
patients in addition to patients from ethnic minorities were additionally
disadvantaged with regard to undergoing living donor transplantation and
pre-emptive transplantation. Geographic factors also contributed to
disparities in living donor transplantation.
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The key comorbid conditions that predict poorer two year graft and patient
survival after kidney transplantation were identified. Peripheral vascular
disease and obesity were associated with a higher risk of graft failure, while
cerebrovascular disease, heart failure and chronic liver disease were
associated with inferior patient survival after transplantation. The risks
associated with these conditions have been quantified and can be used to
fully inform patients of their individual risks, thereby facilitating shared
decision-making and informed consent. Contrary to previous reports, there
was no evidence of any inter-centre variation in survival outcomes of
transplant patients in the UK.
Living donor kidney transplantation was associated with better patient
reported health status, wellbeing, quality of life and treatment satisfaction
compared with deceased donor kidney transplantation. Patients who
underwent pre-emptive transplantation reported significantly worse
treatment satisfaction compared with patients who received a period of
dialysis prior to transplantation.
Analysis of patients on dialysis showed that older age, female gender, lower
serum albumin, being underweight or having diabetes, heart failure, atrial
fibrillation, chronic respiratory disease, chronic liver disease or malignancy
were important predictors of mortality within two years of starting dialysis.
These results were developed into a survival prediction score that was
internally validated. This score could be easily implemented in the clinical
setting to provide patients with individual survival prediction and could also
be used as a tool to aid listing decisions.
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The findings of this thesis have the ability to positively impact the care of
patients with ESRD by driving initiatives to reduce inequity in access to
transplantation, targeting disadvantaged patient groups, providing individual
survival prediction for patients, informing national guidelines for fairer
transplant listing and allocation and guiding future research into improving
outcomes for all patients.
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LAY SUMMARY
Patients with end stage renal disease (ESRD) require renal replacement
therapy in the form of dialysis or kidney transplantation in order to survive.
Transplantation is associated with better life expectancy, quality of life and
cost-effectiveness when compared with dialysis. However, for some patients,
transplantation may not be the best option due to their overall health,
meaning that the operation is high risk and may not be beneficial. This is an
important issue because the number of people who potentially fall into this
category is increasing, and also because there is a shortage of donors.
Currently, there is no clear consensus on which patients should be considered
suitable for transplantation and there is evidence that practice varies across
the transplant centres in the UK.
The aims of this thesis were to address the following key questions:
1) What factors may be contributing to inequity in access to transplantation
in the UK?
2) How do patient factors including comorbidity affect graft and patient
survival after renal transplantation, and do survival rates differ between
centres in the UK?
3) Do patient reported outcome measures differ after living and deceased
donor kidney transplantation?
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4) What factors affect the survival of patients on dialysis, and can these risk
factors be quantified in a survival prediction score aimed at reducing inequity
and standardising access to the waiting list?
The research was conducted as part of the national prospective cohort study
Access to Transplantation and Transplant Outcome Measures (ATTOM),
which is the first study to include ESRD patients from all 72 renal units in the
UK. The study included a total of 6844 patients recruited into three different
groups; incident dialysis (new patients starting dialysis), incident transplant
(new patients receiving a transplant) and prevalent matched control waiting
list (existing patients already on the waiting list, matched to the transplant
group so that they have similar patient characteristics).
The findings showed that some centres in the UK were accepting higher risk
patients for transplantation compared with other centres. Thus, there is no
clear consensus across the UK as to which patients should be considered
suitable for transplantation and this may result in a post-code lottery i.e.
patients seen in one hospital may be less likely to be accepted for
transplantation than if they were seen in another hospital elsewhere.
Patients who were older, from poorer backgrounds and with a lower level of
education were less likely to be on the waiting list for transplantation. These
groups of patients in addition to patients from ethnic minorities were also
less likely to undergo living donor transplantation and pre-emptive
transplantation (transplantation without prior dialysis). Geographic factors
also contributed to disparities in living donor transplantation.
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The health conditions that predict poorer two year graft and patient survival
after kidney transplantation were identified. Peripheral vascular disease and
obesity were associated with a higher risk of the kidney transplant failing,
while cerebrovascular disease, heart failure and chronic liver disease were
associated with a higher risk of death after transplantation. The risks
associated with these conditions have been quantified and can be used to
ensure that patients are fully aware of their individual risks before agreeing
to go ahead with a transplant. Contrary to previous reports, there was no
evidence of any difference in survival outcomes of transplant patients treated
in different transplant centres across the UK.
Living donor kidney transplantation was associated with better patient
reported health status, wellbeing, quality of life and treatment satisfaction
compared with deceased donor kidney transplantation. Patients who
underwent pre-emptive transplantation reported significantly worse
treatment satisfaction compared with patients who received a period of
dialysis prior to transplantation.
Analysis of patients on dialysis showed that older age, female gender, lower
serum albumin, being underweight or having diabetes, heart failure, atrial
fibrillation, chronic respiratory disease, chronic liver disease or malignancy
had a higher risk of death within two years of starting dialysis. These results
were developed into a score that could be used to help predict the likelihood
of survival of patients on dialysis, and it could also be used as a tool to aid
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decisions about which patients should be accepted onto the transplant
waiting list.
The findings of this thesis have the ability to positively impact the care of
patients with ESRD by driving initiatives to reduce inequity in access to
transplantation, targeting disadvantaged patient groups, providing individual
survival prediction for patients, informing national guidelines for fairer
transplant listing and allocation and guiding future research into improving
outcomes for all patients.
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ABBREVIATIONS
APD Automated peritoneal dialysis
ABPI Ankle brachial pressure index
ATTOM Access to Transplantation and Transplant Outcome Measures
BMI Body mass index
CABG Coronary artery bypass graft
CAPD Continuous ambulatory peritoneal dialysis
CCI Charlson comorbidity index
CI Confidence interval
CIT Cold ischaemic time
CKD Chronic kidney disease
cRF Calculated reaction frequency
CVA Cerebrovascular accident
DBD Donor after brain death
DCD Donor after circulatory death
DDKT Deceased donor kidney transplantation
DGF Delayed graft function
EQ-5D EuroQoL five dimensions
ESRD End stage renal disease
HD Haemodialysis
HDF Haemodiafiltration
HLA Human leukocyte antigen
IQR Interquartile range
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IRODaT International Registry on Organ Donation and Transplantation
KHA-CARI Kidney Health Australia - Caring for Australasians with Renal
Impairment
KO Kidney only
LDKT Living donor kidney transplantation
MM Mismatches
NHS National Health Service
NHSBT NHS Blood and Transplant
NIHR National Institute for Health Research
NSTEMI Non-ST segment elevation myocardial infarction
OR Odds ratio
PCI Percutaneous coronary intervention
PD Peritoneal dialysis
pmp Per million population
PROMs Patient reported outcome measures
PVD Peripheral vascular disease
RDQoL Renal-Dependent Quality of Life
RRT Renal replacement therapy
RTSQc Renal Treatment Satisfaction Questionnaire change version
RTSQs Renal Treatment Satisfaction Questionnaire status version
SE Standard error
SPK Simultaneous pancreas-kidney
SRR Scottish Renal Registry
STEMI ST segment elevation myocardial infarction
TIA Transient ischaemic attack
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UK United Kingdom
UKRR UK Renal Registry
US United States
W-BQ12 12-item Well-being Questionnaire





1.1. Treatment options for end stage renal disease
End stage renal disease (ESRD) is an irreversible loss of renal function defined
as a glomerular filtration rate of <15 ml/min/1.73 m2.1 It represents the final
stage of chronic kidney disease (CKD) and patients require renal replacement
therapy (RRT) in the form of dialysis or renal transplantation in order to
survive. Although CKD is asymptomatic, the decline in renal function that
leads to ESRD eventually results in manifestations such as fluid overload,
anaemia, hypertension, hyperkalaemia and symptoms related to uraemia
which may include nausea, anorexia, fatigue, malnutrition, bone disease and
neuropathy. In the UK the leading cause of ESRD is diabetic nephropathy, and
other common causes include glomerulonephritis, polycystic kidney disease,
renal vascular disease, hypertension and pyelonephritis.2 This embodies a
diverse spectrum of patients across all ages, with varying levels of
comorbidity. Deciding on the optimal RRT modality for individual patients is
challenging and may be subject to uncertainty and subjectivity from patients
and professionals alike, and evidence shows there are significant variations
in practice throughout the UK.3-6
1.1.1. Transplantation
In just 50 years, kidney transplantation has undergone a dramatic
transformation, from an experimental procedure to a highly successful and
established treatment that has revolutionised the management and prognosis
of ESRD. Innovations in surgical technique, immunosuppression, organ
preservation and stem cell technology have propelled transplantation to the
forefront of pioneering medicine. In selected patients, kidney transplantation
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offers up to a three-fold increase in life expectancy, improved quality of life
and better cost-effectiveness, compared with dialysis.7-10 The potentially
negative aspects of transplantation include the risks of the major operation
and lifelong immunosuppression which comes with increased risk of
malignancy, infections, cardiovascular disease and psychiatric disease.
Kidneys may be donated from living donors, donors after brain death (DBD)
or donors after circulatory death (DCD). The critical shortage of donor organs
is arguably the greatest limitation and challenge currently facing the field of
transplantation worldwide. The shortage of organ donors has led to the
emergence of unethical practices in transplantation. In less economically
developed countries, organ trafficking, transplant commercialism and
transplant tourism have become a major issue, resulting in the exploitation
of vulnerable and deprived populations through the removal and sale of
organs. These practices are prohibited by The World Health Organisation
(WHO) Guiding Principles on Human Cell, Tissue and Organ Transplantation11
and The Declaration of Istanbul,12 which provide international ethical
standards for organ transplantation.
In the UK, significant progress has been made in the past decade to reduce
the discrepancy between the number of patients on the waiting list and the
number of available donors. Training, clinical and organisational
improvements have led to a progressive increase in the number of deceased
kidney donors and transplants and a decrease in the size of the waiting list
over for the last 9 consecutive years (Figure 1.1).13
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Figure 1.1. UK deceased donor kidney programme. Number of donors, transplants
and patients on the active kidney transplant list at 31 March 2018. (Source: NHS
Blood and Transplant Organ Donation and Transplantation Activity Report
2017/2018)13
Although this is a remarkable achievement, there is still more progress to be
made. The decrease in the number of active patients on the waiting list has
corresponded with a steady increase in the number of patients suspended
from the waiting list (Figure 1.2). The primary reason for suspending patients
from the waiting list is a deterioration in the patient’s health which means
they are no longer fit enough to undergo transplantation. Suspension can be
temporary or permanent. In 2017-2018, 3203 patients were suspended from
the list, a further 439 patients were permanently removed from the list and
245 patients died whilst on the list. This is concerning and may represent the
increasing age and comorbidity of the ESRD population. The current median
waiting time for deceased donor kidney transplantation (DDKT) is 2.1 years.
An increasing proportion of patients on the waiting list do not have sufficient
health to survive this wait. Identifying these patients through accurate






survival prediction at the start of dialysis would improve prognostication and
management of the waiting list.
Figure 1.2. Number of patients on the kidney transplant waiting list 2009-2018.
(Source: NHS Blood and Transplant Annual Report on Kidney Transplantation
2017/2018) 14
In the UK, living donor kidney transplantation (LDKT) accounts for around
30% of all kidney transplants14 and this is fairly representative of most
western countries.15 In contrast, in many Asian and Middle Eastern countries
such as Japan, South Korea and Turkey the vast majority of transplants are
from living donors, due to the lack of cultural acceptance of deceased organ
donation.16, 17 LDKT is associated with significantly better graft and recipient
survival compared with DDKT.18 The UK Transplant Registry at NHS Blood and
Transplant (NHSBT), holds information relating to donors, recipients and
outcomes for all kidney transplants performed in the UK. The latest figures
from NHSBT show a survival difference of up to 19% at 10 years for LDKT
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versus DDKT (10 year patient survival: LDKT 91%, DBD 76%, DCD 72%; 10 year
graft survival: LDKT 82%, DBD 76%, DCD 76%).13 Living donor organs have not
been exposed to the detrimental effects of the dying process or prolonged
periods of ischaemia, thus leading to optimal post-transplant organ function.
LDKT also provides other advantages over DDKT: the transplant procedure
can be scheduled electively at a time when both donor and recipient health
are optimal, patients avoid long waiting times and the exposure to pre-
transplant dialysis and its morbidity is minimised or avoided. For these
reasons, LDKT provides the greatest chance of undergoing pre-emptive
transplantation, which is associated with significantly better outcomes than
transplantation after the initiation of dialysis.19, 20 Pre-emptive rates are 40%
and 16% in LDKT and DDKT respectively.13 Living donors are usually relatives,
spouses or friends of the patient. However, altruistic donation, where the
donor does not have a genetic or pre-existing emotional relationship with the
recipient, accounts for an increasing number of transplants (Figure 1.3).14
Sharing schemes have also been developed to enable blood or human
leukocyte antigen (HLA) incompatible donor-recipient pairs to be matched
with other incompatible pairs, in order to achieve compatible transplants. The
clear benefits of LDKT have led to a drive to increase living donation rates,
and this has been identified as a major priority for transplantation in the UK.21
Despite this, the advantages of LDKT must be carefully weighed against the
small but not insignificant risks to the donor,22-25 and their safety and welfare
should always take precedence over the need for transplantation.26
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Figure 1.3. Adult living donor kidney transplants in the UK 1 April 2003 – 31 March
2018 (Source: NHS Blood and Transplant Annual report on Living Donor Kidney
Transplantation 2017/2018)27
Worldwide, the majority of kidneys transplanted from deceased donors are
recovered from DBD donors. The concept of brain death was first proposed
by Harvard Medical School in 1967.28 Advances in intensive care techniques
meant that comatose patients could be maintained on mechanical ventilation,
despite loss of brainstem function and associated loss of the capacity for
spontaneous respiration and consciousness. Therefore, it was proposed that
such cases of irreversible coma due to permanent damage to the brain could
be defined as death.28 Subsequently, the concept of brain death was gradually
accepted elsewhere. The diagnosis of brain death is confirmed by strict
neurological criteria which differ considerably between countries. Conversely,
in DCD, donation occurs after the irreversible cessation of cardiorespiratory
function. The clinical scenario in which cardiorespiratory arrest occurs can be
classified into four different categories known as the Maastricht
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Classification, which were first described in 199529 and subsequently updated
in 2013.30 DCD donations are most commonly Maastricht category III or so
called “controlled” DCD. This is usually in the context of a critically ill patient
with catastrophic brain injury who does not fulfil the criteria for brainstem
death, but where life-sustaining cardiorespiratory support is no longer
considered to be in the patient’s best interests and is withdrawn under
controlled circumstances. Transplantation of DCD donors is still an emerging
concept and not universally accepted.31 However, in some countries including
the UK and the Netherlands, DCD donation now accounts for around half of
all deceased donations.14, 31 This is due to the need to expand the donor pool
and the growing evidence that the long-term outcomes of DCD and DBD
kidney grafts are comparable.32, 33 In order to receive a kidney graft from a
deceased donor, patients must be allocated a kidney according the national
kidney allocation scheme (see section 1.2.2).
1.1.2. Dialysis
Although transplantation has superior outcomes compared with dialysis, for
some patients, transplantation may not be suitable. Due to comorbidity or
frailty, the risk of the transplant procedure may outweigh the potential
benefits. Other patients may lack an available donor or may decide against
transplantation through their own choice. Dialysis may be administered in the
form of haemodialysis or peritoneal dialysis. There are no randomised
controlled trials comparing the two dialysis modalities but observational
research suggests equivalent survival outcomes.34-36 Dialysis is an intensive
therapy. Haemodialysis usually requires at least three sessions of around four
hours every week while peritoneal dialysis usually involves around four
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exchanges every day (although this can be done at night using an automated
machine).37 Both modalities can be administered either at a dialysis facility or
at the patients home. Home based therapy is associated with significantly
better quality of life and promotes independence and self-efficacy in patients
in managing their disease.38, 39 During dialysis, solutes are removed from the
body by diffusion across a semipermeable membrane (or in peritoneal
dialysis, across the peritoneal membrane) and ultrafiltration is used to
remove fluid. However, dialysis can only provide around 10% of the solute
clearance of normal renal function.37 Therefore patients on dialysis often
continue to suffer from uraemic symptoms and are at significant risk of
progressive cardiovascular disease.  In some elderly patients with extensive
comorbidities, dialysis may not improve their length or quality of life, and the
patient may opt for conservative treatment of their symptoms rather than
undergoing dialysis.
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1.2. Access to renal transplantation
In order to receive a kidney transplant, patients must undergo a two-step
process. First, they must be accepted on the waiting list, and second, they
must either be allocated a deceased donor kidney via the national allocation
algorithm or else they must find a suitable living donor.
1.2.1. Access to the transplant waiting list
For most patients with ESRD, kidney transplantation offers the greatest
potential for achieving a healthy life. However, not all patients are suitable
candidates for transplantation. There are relatively few contraindications to
transplantation in the UK (Table 1.1.), and access to the waiting list is often
determined by an assessment of the perceived risks and benefit for individual
patients. Estimation of risk is a key part of the evaluation process for
transplantation. This is particularly pertinent when considering the fact that
the ESRD population often have a complex medical history and high
prevalence of comorbidity.




Any condition with a life expectancy < 2 years
Relative contraindications
Predicted patient survival < 5 years
Predicted risk of graft loss > 50% at 1 year
Patients unable or unlikely to adhere with immunosuppressant therapy
Immunosuppression predicted to cause life threatening complications
Source: Adapted from NHSBT Patient Selection for Deceased Donor Kidney Only
Transplantation Policy40
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Various patient and centre factors have been shown to influence access to the
transplant waiting list. A study by Oniscu et al. in 2003 demonstrated major
disparities for patients in Scotland in the likelihood of being placed on the
renal transplant waiting list and of receiving a kidney transplant.4 Two
subsequent UK studies confirmed these findings, and found that inequities
also existed for patients in England and Wales.3, 5 The findings of these studies
are summarised in Table 1.2.
It is well-recognised that various patient factors including age, gender, social
deprivation and ethnicity act as barriers to wait-listing, and this has also been
shown to be the case in countries outside of the UK.41-45 The reasons for these
disparities are not fully understood, and are likely to represent a complex
interaction between comorbidity, clinical, socioeconomic, lifestyle and
cultural factors.46 Due to the poor understanding of these disparities, there
have been a lack of effective solutions, leading to the persistence of inequity
in access to transplantation. Furthermore, although it is known that these
factors affect access to DDKT, at the time of conception of the ATTOM study,
Table 1.2. Patient- and centre-specific factors influencing access to the deceased
donor kidney transplant waiting list
Reference Study
Design






Older age, female, diabetes, high deprivation






Older age, diabetes, high deprivation category,






Older age, diabetes, non-white ethnicity,
treated in non-transplanting renal unit, centre
effect
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little work had been done to investigate whether similar barriers existed in
access to LDKT. More recently, research to address this gap in knowledge is
now emerging, including qualitative studies exploring disparities in LDKT in
the UK.47, 48
A finding of additional concern is that the renal centre in which a patient is
treated significantly affects the likelihood of listing for transplantation. For
example, in the study by Oniscu et al., patients starting dialysis in a
transplanting unit had a 28% better chance of listing compared with those
treated in non-transplanting units.4 This evidence for an apparent “post-code
lottery” may imply differences in centre protocols, organisational aspects or
disparities in clinicians’ estimation of patient risk in the context of kidney
transplantation. Akolekar et al. showed that the assessment processes for
determining patient suitability for renal transplantation and the acceptance
criteria used, varied widely across the UK.6 Some centres lacked a formal
assessment clinic and/or multidisciplinary team meeting suggesting that
patient cases may not be discussed with other members of the transplant
team prior to making a decision about listing, and that patients may not be
seen by a surgeon until being admitted for the actual transplant procedure.6
A similar UK study also demonstrated inconsistencies in the attitudes
towards patient selection for renal transplantation, amongst nephrologists
and transplant surgeons across the country.49
All of these issues are not surprising given the lack of clear and consistent
guidance on access to transplantation.50 Given the increasing prevalence of
higher risk patients with significant comorbidity in the ESRD population,
30
more and more decisions will need to be made regarding the optimal
treatment for these patients, in whom the survival advantage of
transplantation may be less certain. Currently, there is a lack of an agreed and
clear definition for “high risk” patients and the available evidence on the
outcome for such patients is limited and conflicting.51-55 As the NHS strives
towards reducing variations in the quality of administered medical care
irrespective of where a patient is treated, the inequity of care that is evident
across the UK for ESRD patients is clearly an issue that needs to be prioritised
and addressed. There is a need to establish clear, national, evidence-based
guidelines, in order to reduce inequities in care and maximise outcomes for
all patients with ESRD. The development of a survival probability score could
guide clinicians in the estimation of risk in the context of kidney
transplantation, leading to more objective and standardised access to the
waiting list.
1.2.2. Allocation of donor kidneys
The ongoing shortage of donor kidneys means that allocation of this scarce
resource is increasingly challenging and complex. In the US, the number of
patients on the waiting list has doubled over the past decade reaching around
100 000 patients, median waiting time has increased by 50% to over 4.5 years
and nearly 5000 patients die whilst waiting for a deceased donor kidney
transplant every year.56 In the UK, significant progress has been made in
recent years in promoting organ donation and transplantation,57 resulting in
a fall in the number of patients on the waiting list. However, in 2018 there
were still 5033 patients waiting for a transplant with a median waiting time
of 2 years.13 Moreover, between 2017-2018 in the UK, 245 patients died whilst
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waiting for a kidney transplant and 439 patients were removed from the list
(typically due to clinical deterioration resulting in becoming unsuitable for
transplantation).13
The allocation of deceased donor kidneys raises an ethical dilemma centred
on the competing values of utility (maximum outcomes) and equity (fairness).
Consideration must be given to the efficient use of organs to optimise
outcomes and the overall benefit to society, but also to the welfare of
individual patients and fair access to transplantation.58 Utility-based
allocation prioritises patients with the best chance of a favourable outcome,
aiming to achieve the maximum benefit from every transplanted organ.
Inevitably, this gives rise to debate over how benefit should be measured – i.e.
graft survival, patient survival, life years gained from transplant or quality of
life? Furthermore, it disadvantages patients less likely to experience a good
outcome, such as patients who are older, diabetic, have more comorbidity or
have been on dialysis for a longer period of time.19, 59-62 An increasing
proportion of patients on the waiting list fall into these categories, yet still
derive a significant survival benefit from transplantation.7, 63-65 The principle
of equity necessitates fairness in organ allocation, however this may be
interpreted in various ways. Equity is commonly conceived as “equal
opportunity” i.e. every person who may benefit from a transplant should have
equal opportunity of receiving one.66 It is important not to misinterpret this
as equality; although equality involves treating all patients exactly the same
(i.e. allocation by lottery), it neglects the fact that patients do not start from
equal circumstances.67 The discovery of HLA-matching as a major determinant
of graft survival led to its principal role in the first formal allocation
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schemes.68-70 However, it became apparent that such schemes resulted in
inequitable access to transplantation for difficult to match patients.71-73
Consequently, most schemes now award extra priority to highly-sensitised
patients and patients with rare HLA-types (most commonly from ethnic
minorities) who are biologically disadvantaged in finding a compatible donor,
in order to equalise their opportunity for transplantation. “Queuing” (first-
come, first-served) is another concept of equity that has been widely
considered in kidney allocation. However, with the increasing age and
morbidity of patients on the waiting list, this approach has been challenged
for favouring those who are able to survive the ever-increasing wait.
Furthermore, with growing evidence for disparities in access to the waiting
list, many schemes now measure waiting time from the start date of dialysis
as opposed to the listing date, although some countries are yet to adopt this
approach. Priority for paediatric patients is universally acknowledged in view
of the detrimental impact of renal failure and prolonged dialysis on growth
and development (although the age cut-off and level of priority varies
substantially between different schemes). In contrast, the prioritisation of
younger adults over older adults is widely disputed. While advocates of the
“fair innings” concept believe equity should be measured by the opportunity
to reach a normal life expectancy, critics argue that preferential allocation to
younger patients is age discrimination.74 The “prudential lifespan” provides
an alternative concept of equity through the allocation of kidneys by age-
matching. This justifies the allocation of younger (and therefore “higher
quality” kidneys) to younger recipients and the allocation of older kidneys to
older recipients since all patients are treated similarly in a particular stage of
life.75 However, this approach becomes problematic if there is a discrepancy
33
in the age distribution of donor and recipient pools. Moreover, age is just one
of many factors which influence the outcome of transplanted kidneys.
The current UK national kidney allocation scheme was last modified in 2006.
Under this scheme, DBD kidneys are matched to potential recipients
according to HLA-type and blood group, and priority is then awarded to
recipients based on a patients HLA sensitisation level, HLA homozygosity,
paediatric status and the level of the HLA match, in addition to a points score
derived from various factors (waiting time, recipient age and HLA match
combined, proximity of the donor to the recipient centre, donor-recipient age
difference, HLA-DR and HLA-B homozygosity, blood group match), with
waiting time being the most influential.76 The algorithm was developed in
response to evidence that the previous utility based scheme of 1998 (which
assigned priority to better matched grafts), disadvantaged certain groups of
patients (i.e. those with rare HLA types or those highly sensitised).77, 78 By
placing more emphasis on waiting time, the aim was to shift the balance back
towards equity. As of September 2014, DCD kidneys were also allocated using
the principles of the national allocation scheme, but on a regional basis only
and one kidney is always offered preferentially to the local transplant centre
(both kidneys are retained locally if the donor is <5 or >64 years).79
The current scheme does not give any consideration to the “quality” of the
donor kidney, and apart from avoiding extreme age mismatches, there is no
attempt to match estimated graft life with estimated patient survival. As a
result, donor kidneys with longer estimated survival may be transplanted into
recipients with much shorter estimated survival, thus leading to death with a
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functioning graft. This translates into the loss of potential benefit from the
graft. Higher rates of death with a functioning graft occur with increasing age
and comorbidity of recipients,80-85 and with these patients accounting for a
growing proportion of transplant candidates, it is likely that a greater number
of functioning grafts will be lost this way. Moreover, in the reverse
circumstance, younger patients may be allocated grafts with much shorter
estimated survival, which may result in higher rates of re-transplantation and
higher levels of sensitisation as well as further increasing the demand for
donor organs.
With the ongoing organ shortage crisis that exists worldwide, there is now
great interest within the international transplant community in developing
organ allocation systems based on net transplant benefit. In the US, a new
kidney allocation system based on “longevity matching” has recently been
described, whereby a range of survival predictors are utilised to allocate
kidneys based on matching of estimated graft and recipient survival.86, 87
Sophisticated donor-recipient survival matching may well be the optimal
compromise between utility and equity that the transplant community strives
for.
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1.3. Outcomes of patients with end stage renal
disease
1.3.1. Survival
The survival benefits of transplantation over dialysis are well recognised. A
pivotal study by Wolfe et al. compared a large cohort of transplant recipients
and age-matched controls on the waiting list in the US between 1991 and
1997. Despite an initial higher short term risk of mortality, transplantation
resulted in an average increase in life expectancy of 10 years.7 Using similarly
constructed studies, comparable results have been reported in Canada,
Germany, Sweden and Scotland, despite the lower dialysis mortality in these
countries compared with the US.8, 65, 88, 89 Oniscu et al. investigated the survival
benefit of transplantation for patients in Scotland, and demonstrated an
overall 12 year increase in projected life expectancy for wait-listed patients
who were transplanted, compared with those who remained on dialysis
(Figure 1.4.).8
Figure 1.4. Relative risk of mortality over time after transplantation versus diaysis
patients on the waiting list in the first 24 months post-transplant. Non-proportional
Cox models adjusted for age, gender, primary renal disease, social deprivation, time
since wait-listing (model 1), and comorbidity (model 2). (Source: Oniscu et al.8)
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However, the demographics of the ESRD population have changed
considerably in recent years. The prevalence of comorbidity and complex
multimorbidity is increasing and the survival advantage for such patients may
not be as clear. A small number of studies have demonstrated that comorbid
conditions are important predictors of mortality on dialysis90-93 and after
transplantation.62, 94 These studies have largely been retrospective registry or
single centre analyses. Further work is required to fully investigate the impact
of comorbidity on the survival of ESRD patients in a national prospective
cohort study. Shared decision making and accurate communication of risks
to patients is increasingly important in the informed consent process. There
is a need for up to date evidence to guide treatment decisions in the UK. This
work is particularly meaningful in the present context of the shortage of
donor organs and has implications for listing and allocation policy.
1.3.2. Patient reported outcome measures
Patient reported outcome measures (PROMS) are increasingly recognised as
important goals and indicators of quality of care. In addition to health related
quality of life measures, many other outcome measures have been developed
to encompass the multidimensional aspects of a patient’s life such as
psychological well-being and treatment satisfaction. Furthermore, condition-
specific PROMS are increasingly used to gain insights into the impact of a
patient’s specific health condition on their quality of life. Better PROMS have
been linked to improvements in key laboratory values, mortality,
hospitalisation rates and adherence to therapy.95-97
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Systematic reviews have not found any statistical difference in PROMS
between patients undergoing haemodialysis and peritoneal dialysis, although
there is a tendency towards better outcomes with peritoneal dialysis.98-100
The obvious benefits of receiving a transplant over remaining on dialysis
include the freedom from the intensive treatment schedule of dialysis,
increased independence, return to work, freedom from dietary and fluid
restrictions, psychological well-being and physical capability. Most studies to
date confirm that transplantation improves quality of life over dialysis.63, 101-103
There is a lack of research into whether the type of kidney transplant received
affects PROMS. The choice of LDKT or DDKT can be a difficult decision for
patients and their families, and one that may cause considerable
consequences on patients’ quality of life and emotional well-being. Some
studies have reported that recipients of LDKT experience increased feelings
of anxiety and guilt towards the donor after transplantation.104, 105 Further
work is needed to assess whether the drive to increase and promote LDKT
rates in the UK based on the clinical benefits, is also validated by PROMS.
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1.4. Summary
Kidney transplantation has revolutionised the treatment of ESRD, offering a
significant increase in life expectancy, quality of life and cost-effectiveness
when compared with dialysis. However, the provision of transplantation is
under immense pressure due to the vastly insufficient number of donor
organs, the growing incidence of ESRD and the increasing age and burden of
comorbidity of the ESRD population. There is evidence for considerable
disparities in access to transplantation across transplant centres in the UK
and in the outcomes and prognosis of individual patients. This raises complex
issues regarding the assessment of patient suitability for transplantation,
maximisation of transplant outcomes and equitable access to transplantation
at an individual as well as a societal level. There is a lack of high quality
studies on how patient and centre factors influence access to and outcomes
from renal transplantation in the UK.
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1.5. Aims
The aims of this thesis were to address the following key questions in the
context of a national prospective cohort study involving all renal units in the
UK:
1) What factors may be contributing to inequity in access to transplantation
in the UK?
2) How do patient factors including comorbidity affect graft and patient
survival after renal transplantation, and do survival rates differ between
centres in the UK?
3) Do patient reported outcome measures differ after living and deceased
donor kidney transplantation?
4) What factors affect the survival of patients on dialysis, and can these risk
factors be quantified in a survival prediction score aimed at reducing inequity






The work within this thesis was conducted as part of the Access to
Transplantation and Transplant Outcome Measures (ATTOM) research
programme, funded by the National Institute for Health Research. This
national research programme was designed to identify the reasons for
variations in access to renal transplantation across the United Kingdom (UK),
and to develop methods to improve outcomes for patients with end stage
renal disease (ESRD). The research programme was designed as a UK-wide
prospective cohort study and encompassed the following workstreams:
1) Access to the transplant waiting list and access to transplantation
2) Factors affecting survival on dialysis and after transplantation
3) Patient reported outcome measures on dialysis and after transplantation
4) Health economic analyses for alternative approaches to organ allocation
Each workstream was investigated by individual researchers with supervision
from a workstream lead. Each team devised the methodology and conducted
the research for their own workstream. The primary focus of this thesis was
workstream 2, but inevitably there was some crossover, and where relevant it
was necessary to conduct some analyses pertaining to themes from other
workstreams. The overall research programme was overseen by a steering
group which included transplant surgeons, nephrologists, health
psychologists, health economists, epidemiologists, statisticians, bioethicists
and patient representatives. Members of the steering group are listed in
Appendix A.1. The steering group met biannually to evaluate progress within
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each workstream and provide feedback. Ultimately the aim was to combine
the research from all workstreams and provide a comprehensive scientific
basis for the development of new listing and allocation policy in the UK, that
achieves the best balance between equity of access, prolongation of life,
quality of life, acceptability to patients and society and cost effectiveness.
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2.2. Study population
Patients aged 18-75 years were recruited to ATTOM from all 72 UK renal units
(of which 23 are renal transplant centres). In each unit, recruitment took place
over a 12-month continuous period, at any point between 1st November 2011
and 31st March 2013, aiming to capture all patients starting renal replacement
therapy (RRT). There was a total of 6844 registrations to ATTOM, and patients
were recruited into three different cohorts: incident dialysis cohort (n=2623),
incident transplant cohort (n=2262) and prevalent waiting list cohort
(n=1959) (Figure 2.1).
Figure 2.1. ATTOM study population and cohort distribution
Patients were recruited at the time of starting dialysis, at the time of renal
transplantation or from the waiting list as matched controls to the transplant
patients. All types of renal transplant were eligible for recruitment including
living donor, deceased donor, kidney only and simultaneous pancreas-kidney
(SPK) transplants. Matched controls were identified from the waiting list on a
fortnightly basis and were matched to transplant patients for six criteria
(Table 2.1).
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Table 2.1. Matching criteria
1. Transplant centre Same centre
2. Age Within -/+ 5 years
3. Time on the waiting list Within -/+ 100 days if time is ≤1000 days
Within -/+ 10% if time is >1000 days
<365 days if unlisted living donor transplant
4. Type of transplant Kidney only / SPK
5. Diabetic
(based on primary renal disease) Yes / No
6. Pre-emptive Yes / No
Since the matching process was used to identify waiting list controls,
matching occurred prior to their recruitment and therefore prior to the
collection of comprehensive data for the study. Thus, matching criteria were
based on variables that were available from the UK transplant registry
database. Diabetes as a matching criterion was based on primary renal disease
rather than any diagnosis of diabetes because the latter is not collected as
part of the UK transplant registry database. Although this may have resulted
in some loss of accuracy with regards to matching, it is unlikely to have major
implications on the analyses. This is because all analyses will be fully adjusted
for a comprehensive set of confounding factors including comorbidity, and
the extent to which diabetes affects outcomes will be explored using the detail
captured in the diabetes variable i.e. any diagnosis of diabetes, diabetes as a
primary renal disease, type I diabetes and type 2 diabetes.
The aim of including a matched control cohort was to enable a comparison of
outcomes on dialysis to outcomes after transplantation, with minimisation of
confounding factors. It would not have been possible to directly compare the
incident dialysis cohort to the incident transplant cohort due to the bias
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introduced by the selection process for transplantation, which inherently
selects a fitter group of patients. Therefore, we aimed to recruit a comparable
cohort of ESRD patients who had already been through the selection process
for transplantation i.e. patients on the waiting list.
In all, 471 patients changed cohorts within the recruitment period (13
patients changed twice) (Figure 2.2). This occurred when for example, waiting
list patients went on to receive a transplant. In this situation, patients were
recruited again to the new cohort as a separate registration and therefore
contributed data to more than one cohort. There were 6844 registrations to
ATTOM and this represented a total of 6360 individual patients.
Figure 2.2. Number of patients who changed cohorts
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2.3. Data variables
Extensive baseline data were collected prospectively for every patient at the
time of recruitment to each cohort. The baseline dataset was designed to
capture information on variables that are known or suspected to have an
influence on outcomes, including potential confounding factors.
Demographic, socioeconomic, clinical and comorbidity variables exceeding
that available from national registries were collected for all patients at the
time of recruitment. Dialysis, transplant and waiting list specific variables
were collected for the respective cohorts (Appendix A.2). Variable definitions
are given in Appendix A.3. Data on 16 comorbidity variables were collected
for every patient and this data were fundamental to the novelty of the survival
analyses within this thesis. From previous retrospective and single centre
studies, it is known that comorbidity likely plays a major role in influencing
the survival outcomes of patients on dialysis and patients undergoing kidney
transplantation. However, comorbidity variables are not routinely collected
by national registries, and to date no studies have collected prospective
comorbidity data on a national basis, thus ATTOM is the first study to do so.
In chapters where the aim was to investigate survival outcomes, the individual
comorbidity variables were used in the statistical models. However, in other
chapters where the focus was more on how socioeconomic factors influence
access to transplantation, the comorbidity variables were combined to create
a comorbidity score for each patient using the index described by
Hemmelgarn et al.106 This enabled each patients level of comorbidity to be
summarised into a single score, thereby reducing the number of factors (and
degrees of freedom) in the predictive models and improving the accuracy of
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the effects of the studied socioeconomic variables, while still allowing
adjustment for comorbidity. The comorbidity index by Hemmelgarn et al. is
based on the widely used Charlson Comorbidity Index (CCI)107 but is modified
to specifically predict the survival of patients with ESRD. The index consists
of weighted scores assigned to 14 comorbid conditions (myocardial
infarction, congestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic pulmonary disease,
rheumatological disease, peptic ulcer disease, diabetes without
complications, diabetes with complications, leukaemia, lymphoma, moderate-
severe liver disease and metastatic disease). Our dataset did not include 2 of
the conditions (rheumatological disease and peptic ulcer disease) therefore
scores were calculated from the remaining 12 variables (Table 2.2).
Definitions for the variables used in the index are given in Appendix A.4.
Table 2.2. Modified Charlson Comorbidity Index
Comorbidity variable Score
Myocardial infarction 2
Congestive heart failure 2
Peripheral vascular disease 1
Cerebrovascular disease 2
Dementia 1
Chronic pulmonary disease 1
Rheumatological disease Excluded*
Peptic ulcer disease Excluded*
Diabetes without complications 2
Diabetes with complications 1
Leukaemia 2
Lymphoma 5
Moderate-severe liver disease 2
Metastatic disease 10
*Not collected in the ATTOM dataset and therefore excluded from the score
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The limitations of using the modified CCI were that we were unable to
calculate the full score as the ATTOM dataset did not include two of the
required variables, and also that the index was originally developed to predict
the survival of ESRD patients in Canada, thus its validity in UK ESRD patients
is uncertain. However, the aim of using the score was not to predict survival
in our cohort, but purely to provide a summary of each patient’s level of
comorbidity in a single score. Compared to other available comorbidity
indices, the modified CCI contained the most similar variables as the ATTOM
dataset and has been validated among ESRD patients in multiple countries
with good performance.91, 94, 106, 108-111
Data on patient reported outcome measures (PROMS) were collected at
various time points for patients from all cohorts in the ATTOM research
programme. The PROMS data of specific interest to and used for analyses
within this thesis included questionnaires measuring patients self-reported
health status (EuroQoL five dimensions [EQ-5D-5L] and the EuroQoL visual
analogue scale [VAS]), well-being (12-item Well-being Questionnaire [W-
BQ12]), general and renal-dependent quality of life (Renal-Dependent Quality
of Life Questionnaire [RDQoL]) and treatment satisfaction (Renal Treatment
Satisfaction Questionnaire status version [RTSQs] and Renal Treatment
Satisfaction Questionnaire change version [RTSQc]). These questionnaires
were administered to a subset of patients from the incident transplant cohort
at 1 year post-transplantation. Descriptions of the PROMs questionnaires are
given in Appendix A.5.
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2.4. Data collection
A team of 23 trained research nurses collected the data. Each nurse was based
in one of the 23 UK renal transplant centres and also covered that centre’s
referring renal units (Appendix A.6). The defined baseline dataset was
collected from patient interview, case notes, local electronic patient
information systems and confirmed with the patients named consultant if
required. All data were uploaded in real time onto a secure website using
mobile encrypted broadband enabled laptops. PROMs questionnaires were
either posted to patients or were completed online and were provided in other
languages if required. Research nurses uploaded questionnaire responses to
the online database. This was stored on a secure server maintained by the UK
Renal Registry (UKRR) which conformed to NHS data protection requirements.
An independent validation of 5% of data entries in all research sites confirmed
>98% concordance for all data fields. Outcome data including activation on
the transplant waiting list and 2 year graft and patient survival are already
collected to a high standard by the national registries and as such were




The statistical methods used in each analysis will be provided in detail in each
chapter. In general, survival was examined using the Kaplan-Meier method.
Appropriate multi-level models (e.g. Cox proportional hazards regression,
logistic regression etc.) were developed to analyse the association of patient-
level and centre-level factors with the outcomes of interest. All models were
built using both statistically significant variables as well as clinically
important variables. Potential interactions between variables were tested.
Appropriate sensitivity analyses were included. All analyses were conducted
using SAS® 9.4 (SAS Institute Inc, Cary, USA).
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2.6. Patient and public involvement
Patient representatives were involved in the study from the outset and
attended all steering group meetings throughout the duration of the study.
Representatives included patients on dialysis, renal transplant recipients and
members of the National Kidney Federation (a national kidney charity run by
kidney patients). They provided valuable advice on the design of the study,
data collection and outcome measures. They ensured that patient views were
represented in the conduct and reporting of the study. Lay summaries of the
completed research will be jointly produced with the National Kidney
Federation who will play a key part in dissemination of the findings to kidney
patients across the UK.
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2.7. Funding and ethical approval
The ATTOM research programme was funded by the National Institute for
Health Research under the grant number RP-PG-0109-10116. The funding
body had no role in the study design, data collection, data analysis, data
interpretation or writing of this thesis. Ethical approval was granted by the
East of England Research Ethics Committee (reference number 11/EE/0120).
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CHAPTER 3
Variations in the Comorbidity Burden of Patients
Accepted for Kidney Transplantation Across the UK
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3.1. Introduction
Kidney transplantation is now widely accepted as the best treatment for end
stage renal disease (ESRD). Despite an initial higher risk of mortality in the
immediate post-operative period, in the long-term, transplantation offers up
to a three-fold increase in life expectancy, improved quality of life and better
cost-effectiveness, compared with dialysis.7-10 With the success and advances
of kidney transplantation, many patients who would previously have been
deemed unsuitable, are now considered for this treatment option.
Nevertheless, such treatment decisions must involve careful consideration of
the potential risks that comorbidity may confer on individual patient
outcomes. Comorbidity is an important predictor of mortality, but there is a
paucity of data on how it affects the risk-benefit ratio of kidney
transplantation. This is largely due to difficulties in collecting accurate pre-
transplant comorbidity data at a population level. Comorbidities represent a
large and heterogeneous group of conditions with differing levels of severity,
making precise measurement problematic and time-consuming. The UK Renal
Registry (UKRR) attempts to collect national comorbidity data for ESRD
patients in the UK but data completeness is poor at around 56% and the
Scottish Renal Registry (SRR) does not collect comorbidity data for ESRD
patients in Scotland.112, 113 Other national registries of patients with ESRD in
Europe, Japan and the US also lack comprehensive comorbidity information.114
With a lack of evidence as to how comorbidity affects post-transplantation
outcomes, it is conceivable that variation exists in the interpretation of
comorbidity in the context of transplant suitability. Several studies have
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demonstrated significant variation in access to kidney transplantation
between centres in the UK.3-5 However, the reasons for these disparities are
not well understood and have not been fully explored. Lack of adjustment for
comorbidity in these analyses, means that the perceived variation could be
explained by some centres having sicker patient populations than others,
thereby justifying a lower listing and transplantation rate. On the other hand,
centre differences in acceptance criteria for kidney transplantation and in risk
tolerance, could be contributing to inequitable access to transplantation.
The aim of this study was to characterise the comorbidity burden of patients
starting dialysis, patients on the waiting list and patients receiving a kidney
transplant, and determine whether this differs between kidney transplant




This analysis included all 6844 patients recruited to the ATTOM research
programme (2623 dialysis patients, 2262 transplant patients and 1959
waiting list controls). Patients were recruited from all 72 UK renal units (of
which 23 are transplant centres) between 1 November 2011 and 31 March
2013. Full recruitment methods are described in Chapter 2.
3.2.2. Data variables
Extensive baseline demographic, socioeconomic, clinical and comorbidity
data were collected for each patient, either at the time of starting dialysis,
receiving a transplant or identification as a matched control on the waiting
list (Appendix A.2). The primary variables of interest in this analysis included
comorbidities reported at the time of recruitment to the study, including
diabetes, ischaemic heart disease, heart failure, atrial fibrillation, cardiac
valve replacement, pacemaker, cerebrovascular disease, peripheral vascular
disease, abdominal aortic aneurysm, chronic respiratory disease, chronic liver
disease, blood borne viruses, malignancy, mental illness, dementia and
obesity (Definitions provided in Appendix A.3). As well as assessing
comorbidity by the presence or absence of these conditions, we also
calculated a comorbidity score for each patient using the modified Charlson
Comorbidity Index (CCI)106 as described in Chapter 2.
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3.2.3. Statistical analysis
Descriptive analyses were used to characterise differences in demographic,
socioeconomic, clinical and comorbidity variables between the 3 cohorts and
between centres. Baseline characteristics were presented as numbers with
percentages (%) compared by chi-squared tests for categorical data and
medians with interquartile ranges (IQR) compared with Wilcoxon tests or
Kruskal-Wallis tests for non-parametric continuous data. Renal units were
grouped to their referral transplant centre for centre analyses (grouping
detailed in Appendix A.6). The number of recruited patients in each
transplant centre (after grouping of renal units) is shown in Table 3.1. Patients
with missing data were excluded from analyses (Table 3.2.). All analyses were
carried out using SAS® 9.4 (SAS Institute Inc, Cary, USA).
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Belfast 95 76 78 249
Birmingham 376 129 121 626
Bristol 135 81 103 319
Cambridge 170 175 196 541
Cardiff 75 69 103 247
Coventry 3 13 25 41
Edinburgh 89 73 99 261
Glasgow 123 97 101 321
Leeds 58 94 107 259
Leicester 72 43 43 158
Liverpool 236 111 111 458
London – Bart’s 119 58 69 246
London – Guy’s 134 160 202 496
London - Royal Free 67 78 80 225
London - St George’s 191 102 93 386
London - West 153 78 92 323
Manchester 84 113 163 360
Newcastle-upon-Tyne 62 78 94 234
Nottingham 63 62 64 189
Oxford 27 109 146 282
Plymouth 31 28 40 99
Portsmouth 106 78 77 261
Sheffield 154 54 55 263
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Age 0 [0%] 0 [0%] 0 [0%]
Gender 0 [0%] 0 [0%] 0 [0%]
Ethnicity 10 [0.4%] 6 [0.3%] 9 [0.4%]
Socioeconomic variables
Civil status 167 [6.4%] 104 [5.3%] 162 [7.2%]
Qualifications 163 [6.2%] 106 [5.4%] 165 [7.3%]
Employment 162 [6.2%] 103 [5.3%] 161 [7.2%]
Car ownership 159 [6.1%] 99 [5.1%] 159 [7.0%]
Home ownership 163 [6.2%] 100 [5.1%] 162 [7.2%]
Clinical variables
Primary renal disease 30 [1.1%] 22 [1.1%] 12 [0.5%]
Dialysis modality 13 [0.5%] 14 [0.7%] 16 [0.7%]
Previous transplant 12 [0.5%] 16 [0.8%] 14 [0.6%]
Comorbidity variables
Obesity 418 [15.9%] 180 [9.2%] 124 [5.5%]
Diabetes 25 [1.0%] 22 [1.1%] 7 [0.3%]
Ischaemic heart disease 31 [1.2%] 23 [1.2%] 11 [0.5%]
Heart failure 33 [1.3%] 25 [1.3%] 10 [0.4%]
Atrial fibrillation 34 [1.3%] 23 [1.2%] 10 [0.4%]
Cardiac valve replacement 34 [1.3%] 23 [1.2%] 13 [0.6%]
Pacemaker 33 [1.3%] 24 [1.3%] 11 [0.5%]
Cerebrovascular disease 34 [1.3%] 25 [1.3%] 11 [0.5%]
Peripheral vascular disease 34 [1.3%] 23 [1.2%] 11 [0.5%]
Abdominal aortic aneurysm 35 [1.3%] 24 [1.3%] 11 [0.5%]
Chronic respiratory disease 33 [1.3%] 24 [1.3%] 10 [0.4%]
Liver disease 32 [1.2%] 27 [1.4%] 10 [0.4%]
Blood Borne Viruses 32 [1.2%] 24 [1.3%] 11 [0.5%]
Malignancy 29 [1.1%] 23 [1.2%] 10 [0.4%]
Mental Illness 31 [1.2%] 27 [1.4%] 10 [0.4%]
Dementia 33 [1.3%} 23 [1.2%] 12 [0.5%]




The baseline demographic, socioeconomic and clinical characteristics of the
study population (n=6844) are presented in Table 3.3. The study population
consisted of 2623 dialysis, 1959 waiting list and 2262 transplant patients.
Compared with the waiting list and transplant populations, the dialysis
population were significantly older, more predominantly male and a higher
proportion had a primary renal diagnosis of diabetes or renal vascular
disease. Dialysis patients were significantly less likely to have obtained
qualifications at secondary or higher education level, and had lower rates of
employment, car ownership and home ownership, suggesting they were a
more socioeconomically deprived population compared with the waiting list
and transplant populations. Compared with the transplant population, a
significantly higher proportion of the waiting list population were female,
from Black, Asian or Minority Ethnic (BAME) backgrounds and were divorced,
separated or widowed. Significantly fewer patients on the waiting list had
achieved qualifications at secondary or higher education level, were employed
and owned a car or a house compared with the transplant population.
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Table 3.3. Patient characteristics by cohort
Dialysis Waiting List Transplant p-value
Demographic variables
Median age (years) 58.4 [47.5 – 67.2] 51.1 [41.7 – 60.3] 50.3 [40.1 – 59.9] <0.0001
Gender <0.0001
Male 1703 [64.9%] 1135 [57.9%] 1421 [62.8%]
Female 920 [35.1%] 824 [42.1%] 841 [37.2%]
Ethnicity <0.0001
White 2099 [80.3%] 1463 [74.9%] 1866 [82.8%]
Asian 294 [11.3%] 242 [12.4%] 212 [9.4%]
Black 185 [7.1%] 213 [10.9%] 140 [6.2%]
Other 35 [1.3%] 35 [1.8%] 35 [1.6%]
Socioeconomic variables
Civil status <0.0001
Married / Living with partner 1504 [61.2%] 1083 [58.4%] 1288 [61.3%]
Divorced / Separated /
Widowed
474 [19.3%] 329 [17.4%] 298 [14.2%]
Single 478 [19.5%] 443 [23.9%] 514 [24.5%]
Qualifications <0.0001
Higher education level 396 [16.1%] 366 [19.8%] 469 [22.4%]
Secondary education level 1016 [41.3%] 902 [48.7%] 1046 [49.9%]
No qualifications 1048 [42.6%] 585 [31.6%] 582 [27.8%]
Employment status <0.0001
Employed 489 [19.9%] 644 [34.7%] 756 [36.0%]
Unemployed 180 [7.3%] 163 [8.8%] 173 [8.2%]
Long term sick / disability 775 [31.5%] 535 [28.8%] 595 [28.3%]
Retired 908 [36.9%] 406 [21.9%] 420 [20.0%]
Other 109 [4.4%] 108 [5.8%] 157 [7.5%]
Car ownership 1754 [71.2%] 1444 [77.6%] 1765 [83.9%] <0.0001
Home ownership 1327 [53.9%] 1043 [56.1%] 1321 [62.9%] <0.0001
Clinical variables
Primary renal diagnosis <0.0001
Diabetic nephropathy 711 [27.4%] 238 [12.3%] 322 [14.3%]
Glomerulonephritis 434 [16.7%] 432 [22.3%] 554 [24.6%]
Polycystic kidney disease 212 [8.2%] 321 [16.6%] 333 [14.8%]
Pyelonephritis 188 [7.3%] 230 [11.9%] 267 [11.9%]
Hypertensive nephropathy 170 [6.6%] 119 [6.1%] 127 [5.6%]
Renal vascular disease 91 [3.5%] 18 [0.9%] 39 [1.7%]
Other 386 [14.9%] 310 [16.0%] 357 [15.9%]
Uncertain 401 [15.5%] 269 [13.9%] 251 [11.2%]
Dialysis modality -
Haemodialysis 1843 [70.6%] 1166 [60.0%] 1163 [51.8%]
Haemodiafiltration 221 [8.5%] 149 [7.7%] 54 [2.4%]
CAPD 331 [12.7%] 160 [8.2%] 313 [13.9%]
APD 215 [8.2%] 146 [7.5%] 214 [9.5%]
Pre-dialysis - 324 [16.7%] 478 [21.3%]
Failing transplant - - 24 [1.1%]
Previous transplant 300 [11.5%] 514 [26.5%] 294 [13.1%] <0.0001
Data are median [IQR] or number [%]. Some data were missing and excluded from percentage calculations,
numbers of missing data are shown in Table 3.2. Kruskal-Wallis test for age. All others chi-squared test.
CAPD; Continuous ambulatory peritoneal dialysis, APD; Automated peritoneal dialysis
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3.3.2. Comorbidity prevalence
The prevalence of comorbidity amongst the 3 cohorts is shown in Table 3.4.
Overall the most common comorbidity was diabetes, followed by obesity and
ischaemic heart disease. The dialysis population had a significantly higher
prevalence of most of the studied comorbidities compared with the waiting
list and transplant populations, with the exception of cardiac valve
replacements, blood borne viruses and dementia. There were no significant
differences in the prevalence of comorbidities between the waiting list and
transplant cohorts. In the dialysis population, 40.3% patients had a CCI score
of 0, compared with 65.9% of the waiting list population and 67.3% of the
transplant population.
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Table 3.4. Prevalence of comorbidity by cohort
Dialysis Waiting List Transplant p-value
Diabetes 1074 [41.3] 344 [17.7] 437 [19.4] <0.0001
Ischaemic heart disease 534 [20.6] 179 [9.3] 193 [8.6] <0.0001
Heart failure 193 [7.5] 60 [3.1] 57 [2.6] <0.0001
Atrial fibrillation 113 [4.4] 48 [2.5] 37 [1.6] <0.0001
Cardiac valve replacement 31 [1.2] 27 [1.4] 19 [0.8] 0.2
Pacemaker 40 [1.5] 16 [0.7] 14 [0.7] 0.005
Cerebrovascular disease 238 [9.2] 104 [5.4] 111 [4.9] <0.0001
Peripheral vascular disease 234 [9.0] 69 [3.6] 74 [3.3] <0.0001
Abdominal aortic aneurysm 44 [1.7] 6 [0.3] 6 [0.3] <0.0001
Chronic respiratory disease 315 [12.2] 138 [7.1] 175 [7.8] <0.0001
Chronic liver disease 67 [2.6] 25 [1.3] 44 [2.0] 0.009
Blood borne viruses 70 [2.7] 62 [3.2] 51 [2.3] 0.2
Malignancy 346 [13.3] 135 [7.0] 145 [6.4] <0.0001
Mental illness 225 [8.7] 141 [7.3] 133 [5.9] 0.001
Dementia 8 [0.3] 5 [0.3] 3 [0.1] 0.4
Obesity 716 [32.5] 372 [20.9] 439 [20.5] <0.0001
CCI Score <0.0001
0 1042 [40.3%] 1271 [65.9%] 1513 [67.3%]
1 500 [19.3%] 288 [14.9%] 365 [16.2%]
2 488 [18.9%] 258 [13.4%] 229 [10.2%]
≥3 555 [21.5%] 112 [5.8%] 141 [6.3%]
Data are number [%]
Some data were missing and excluded from percentage calculations, numbers of missing
data are shown in Table 3.2.
3.3.3. Comorbidity by centre
To compare the overall burden of comorbidity of patients between centres,
the proportion of dialysis, waiting list and transplant patients with a CCI score
of 2 or more in each centre were compared (Table 3.5. and Figure 3.1). There
was significant inter-centre variation in the proportion of patients with a CCI
score of 2 or more for patients on dialysis (range 21.2% – 50.0%, p=0.002),
patients on the waiting list (range 11.5% – 36.2%, p=0.025) and transplanted
patients (range 7.6% – 27.6%, p=0.008). One centre (Coventry) was excluded
from this calculation due to the low number of patients recruited. As
expected, the proportion of patients with a CCI score of 2 or more was higher
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in the dialysis population than in the waiting list and transplant populations
in all centres. The proportion of patients with a CCI score of 2 or more tended
to be similar between centres’ transplant and waiting list populations, except
in 2 centres where the waiting list population had a significantly higher
burden of comorbidity than the transplant population (Plymouth and Cardiff).
Table 3.5. Proportion of patients with CCI score ≥ 2
Dialysis Waiting list Transplant
CENTRE n % n % n %
Belfast 45 48.4 14 18.4 14 18.0
Birmingham 142 37.9 28 21.7 23 19.0
Bristol 43 32.1 13 16.1 15 14.6
Cambridge 84 49.4 29 16.6 36 18.8
Cardiff 35 46.7 25 36.2 22 21.4
Edinburgh 44 50.0 14 19.4 20 20.2
Glasgow 45 38.8 27 29.7 27 27.6
Leeds 20 36.4 19 20.9 15 14.0
Leicester 36 50.0 9 20.9 9 20.9
Liverpool 108 46.0 24 21.6 14 12.6
London – Bart’s 38 32.8 8 13.8 9 13.0
London – Guy’s 58 43.3 24 15.0 30 14.9
London - Royal Free 14 21.2 12 15.8 14 17.7
London - St George’s 67 35.3 18 17.7 10 10.8
London - West 55 38.2 15 20.0 20 22.0
Manchester 32 39.5 14 13.0 12 7.6
Newcastle-upon-Tyne 30 48.4 16 20.8 12 12.8
Nottingham 25 39.7 10 16.7 14 21.9
Oxford 5 21.7 22 21.4 33 22.6
Plymouth 14 45.2 9 33.3 5 12.5
Portsmouth 40 37.7 9 11.5 8 10.4
Sheffield 63 40.9 9 16.7 6 10.9
p-value 0.002 0.025 0.008
Coventry not included due to insufficient numbers
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Figure 3.1. Proportion of patients with CCI score ≥ 2 by centre and by cohort.
Graph is ordered from left to right by increasing proportion of transplant patients
with CCI score ≥ 2.
The proportion of patients with the three most prevalent comorbidities
(diabetes, obesity and ischaemic heart disease) in each cohort and at each
centre were also compared. In each analysis one centre (Coventry) was
excluded due to the low number of patients recruited from this centre.
Figure 3.2. and Table 3.6. compare the proportion of patients with diabetes in
each cohort at each centre. There was no significant difference between
centres in the proportion of dialysis patients with diabetes (range 32.1% -
50.0%, p=0.691), however there was significant inter-centre variation in the
proportion of listed patients (range 7.8% - 34.0%, p=0.0001) and transplanted
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patients (range 9.4% - 44.5%, p<0.0001) who had diabetes. The proportion of
patients with diabetes was highest in the dialysis population across all
centres. In general, the waiting list and transplant populations in each centre
had similar rates of diabetes. There were two notable exceptions to this rule
(Plymouth and Leicester) where the waiting list population comprised of
around 14% more diabetics than the transplant population. Another anomaly
is the centre of Oxford, where the rate of diabetes in transplanted patients
(44.5%) and listed patients (34%) was significantly higher than in all other
centres.
Figure 3.2. Proportion of patients with diabetes by centre and by cohort.
Graph is ordered from left to right by increasing proportion of transplant patients
with diabetes.
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Table 3.6. Proportion of patients with diabetes
Dialysis Waiting list Transplant
CENTRE n % n % n %
Belfast 36 37.9 11 14.5 14 18.0
Birmingham 155 41.2 26 20.2 17 14.1
Bristol 57 42.5 15 18.5 17 16.5
Cambridge 68 40.0 27 15.4 45 23.0
Cardiff 28 37.3 12 17.4 25 24.3
Edinburgh 41 46.1 14 19.4 22 22.2
Glasgow 51 43.2 19 20.4 17 17.0
Leeds 21 38.2 13 14.3 10 9.4
Leicester 35 48.6 12 27.9 6 14.0
Liverpool 102 43.4 11 9.9 11 9.9
London – Bart’s 48 41.4 13 22.4 10 14.5
London – Guy’s 57 42.5 28 17.5 43 21.3
London - Royal Free 31 46.3 19 24.7 15 19.0
London - St George’s 61 32.1 12 11.8 9 9.7
London - West 71 48.0 22 29.0 26 28.3
Manchester 33 40.2 11 10.2 28 17.7
Newcastle-upon-Tyne 27 43.6 6 7.8 12 12.8
Nottingham 28 44.4 9 14.8 11 17.2
Oxford 12 50.0 36 34.0 65 44.5
Plymouth 10 32.3 7 25.9 5 12.5
Portsmouth 40 37.7 11 14.1 16 20.8
Sheffield 62 40.3 10 18.5 13 23.6
p-value 0.691 0.0001 <0.0001
Coventry not included due to insufficient numbers
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The proportion of patients with obesity in each cohort in each centre is shown
in Table 3.7. and Figure 3.3. There was no significant inter-centre variation in
the proportion of patients with obesity for the dialysis cohort (range 20.3% -
41.7%, p=0.354), the waiting list cohort (range 12.1% - 33.3%, p=0.146) and the
transplant cohort (range 12.7% - 31.0%, p=0.230).
Table 3.7. Proportion of patients with obesity
Dialysis Waiting list Transplant
CENTRE n % n % n %
Belfast 30 38.0 18 24.0 14 18.0
Birmingham 86 32.3 25 21.6 26 21.7
Bristol 33 35.1 11 15.5 15 16.9
Cambridge 47 28.5 28 16.4 30 15.6
Cardiff 17 39.5 18 33.3 28 29.8
Edinburgh 27 32.1 7 12.1 15 16.7
Glasgow 38 41.3 20 24.4 20 20.8
Leeds 18 34.0 24 26.1 19 18.6
Leicester 20 28.2 12 28.6 7 16.3
Liverpool 81 35.1 25 22.7 27 24.6
London – Bart’s 25 30.1 8 15.4 8 12.7
London – Guy’s 43 34.1 34 21.7 32 16.4
London - Royal Free 13 20.3 15 20.0 17 21.3
London - St George’s 49 29.2 15 15.2 17 18.5
London - West 31 24.4 10 14.7 13 17.3
Manchester 26 40.6 19 22.4 35 24.7
Newcastle-upon-Tyne 16 25.8 12 15.6 22 23.4
Nottingham 18 30.5 10 16.7 15 23.4
Oxford 5 35.7 21 24.7 34 24.6
Plymouth 5 41.7 2 14.3 9 31.0
Portsmouth 37 37.8 19 26.0 18 23.7
Sheffield 51 34.5 16 31.4 16 29.6
p-value 0.354 0.146 0.230
Coventry not included due to insufficient numbers
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Figure 3.3. Proportion of patients with obesity by centre and by cohort.
Graph is ordered from left to right by increasing proportion of transplant patients
with obesity.
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The proportion of patients with ischaemic heart disease in each cohort and
in each centre is shown in Table 3.8. and Figure 3.4. There was no significant
inter-centre variation in the proportion of patients with ischaemic heart
disease for the waiting list cohort (range 3.8% - 16.1%, p=0.185), but the
proportion of patients with ischaemic heart disease was significantly
different between centres for the dialysis (range 10.6% - 35.2%, p=0.0003) and
the transplant cohorts (range 0% - 23.9%, p<0.0001).
Table 3.8. Proportion of patients with ischaemic heart disease
Dialysis Waiting list Transplant
CENTRE n % n % n %
Belfast 24 25.5 9 11.8 12 15.4
Birmingham 76 20.3 9 7.0 6 5.0
Bristol 15 11.2 9 11.1 4 3.9
Cambridge 43 25.3 16 9.1 14 7.3
Cardiff 12 16.0 9 13.0 11 10.7
Edinburgh 17 19.1 6 8.2 8 8.1
Glasgow 33 27.7 15 16.1 17 17.2
Leeds 10 18.2 7 7.7 7 6.5
Leicester 16 22.2 5 11.6 3 7.0
Liverpool 58 24.7 10 9.0 6 5.4
London – Bart’s 17 14.7 3 5.2 2 2.9
London – Guy’s 27 20.2 6 3.8 21 10.4
London - Royal Free 7 10.6 4 5.2 8 10.0
London - St George’s 29 15.3 11 10.8 7 7.5
London - West 51 35.2 12 16.0 22 23.9
Manchester 14 17.1 6 5.6 3 1.9
Newcastle-upon-Tyne 12 19.4 8 10.4 10 10.6
Nottingham 9 14.3 5 8.3 6 9.4
Oxford 5 21.7 14 13.2 16 11.0
Plymouth 9 29.0 3 11.1 2 5.0
Portsmouth 20 18.9 8 10.3 8 10.4
Sheffield 30 19.5 3 5.6 0 0.0
p-value 0.0003 0.185 <0.0001
Coventry not included due to insufficient numbers
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Figure 3.4. Proportion of patients with ischaemic heart disease by centre and by
cohort.
Graph is ordered from left to right by increasing proportion of transplant patients
with ischaemic heart disease.
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3.4. Discussion
This analysis has showed for the first time that the comorbidity burden of
dialysis, waiting list and transplant patients differs significantly between
kidney transplant centres in the UK. These results provide two potential
explanations for previously reported centre differences in the proportion of
patients listed for and receiving a kidney transplant.3-5 First, the fact that each
centre serves a dialysis population with significantly different levels of
comorbidity, means that centres with sicker patient populations may have
justifiably lower listing and transplantation rates. Secondly, our findings
suggest that the comorbidity burden of listed and transplanted patients also
differs significantly between centres, implying variable acceptance criteria
and risk tolerance which may be contributing to inequity in access to kidney
transplantation.
The findings of this study highlight the importance of adjusting for
comorbidity in any future analyses comparing patient outcomes between
centres, as comorbidity is likely to be a significant confounding factor.
Furthermore, the demonstrated differences in case-mix between centres may
enable improved allocation of resources and planning of services to better
match patient population needs.
The strengths of this study are that for the first time we have presented
prospectively collected accurate comorbidity data for large national cohorts
of dialysis, waiting list and transplant patients in the UK. The UKRR
previously reported comorbidity data for UK adult incident RRT patients in
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2014,115 however data was complete for only 55.7% of patients. In the present
study a maximum of 10% of data were missing for any comorbidity variable,
with the majority of variables only missing around 1% data. Furthermore,
UKRR only collected comorbidity data for patients starting dialysis or
receiving a pre-emptive transplant and did not examine the prevalence of
comorbidity amongst waiting-list or transplant populations. The main
limitation of this study is the potential for selection bias, as we were unable
to recruit the entire UK ESRD population. However, we recruited around two-
thirds of all dialysis, waiting list and transplant patients from the study era
and included patients from all UK renal units in order to minimise bias.
Unfortunately, patient numbers were too small for 1 centre which had to be
excluded from the analysis.
Our data highlighted striking differences between dialysis, waiting list and
transplant patients. Dialysis patients had significantly lower levels of
educational attainment, employment, car ownership and house ownership
compared with waiting list and transplant patients. Interestingly, the same
socioeconomic factors were also less common in waiting list patients when
compared with transplant patients. This is in keeping with previous studies
showing that socioeconomic deprivation acts as an important factor in access
to transplantation in the UK.4, 5, 116-118 The dialysis population in our study were
significantly older and had a higher comorbidity burden than the waiting list
and transplant populations. Age and comorbidity are recognised barriers to
selection for transplantation,42, 119, 120 but our results suggest that comorbidity
may be interpreted differently during the assessment of transplant
suitability, between centres in the UK.
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The finding that dialysis populations in different centres had significantly
different levels of comorbidity is not surprising. However, the assessment
process for determining a patient’s suitability for transplantation should be
uniform between centres and lead to selection of a group of patients with
comparable comorbidity burden. Our results suggest that some centres are
listing and transplanting patients with significantly higher comorbidity than
others. The rate of diabetes, obesity, ischaemic heart disease and a modified
CCI of 2 or more among listed and transplanted patients, differed between
centres by up to 35%. In most centres, the comorbidity burden of the waiting
list cohort was largely similar to that of the transplant cohort. However, in a
few specific centres there appeared to be a pattern where the waiting list
population had a significantly higher level of comorbidity than the transplant
population, perhaps signifying a further selection process between listing and
transplantation. Interestingly, a few centres consistently had the highest rates
of comorbidity among their transplant populations. Oxford and Cardiff were
in the top five centres with the highest rates of comorbidity for all of the
conditions analysed (diabetes, obesity, ischaemic heart disease and a CCI of
two or more). Similarly, London West was in the top five centres for three of
the analyses (diabetes, ischaemic heart disease and a CCI of two or more), and
Glasgow for two of the analyses (ischaemic heart disease and a CCI of two or
more). This does suggest that specific centres may have a higher risk
tolerance with regards to transplantation and comorbidity. Within the scope
of this study we were unable to explore the reasons for the demonstrated
centre differences. It is plausible that centres with sicker dialysis populations
would be more likely to accept higher risk patients for kidney transplantation.
However, the results of this study showed that this was not the case; the
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comorbidity burden of centres’ dialysis populations did not correlate with
that of their waiting list and transplant populations. A previous study
reported considerable variation in the assessment processes and exclusion
criteria for transplantation between UK renal transplant centres based on the
responses of nephrologists, surgeons and transplant coordinators to a
questionnaire.6 Differences in centre practices in determining patient
suitability for transplantation may depend on the experience of clinical staff
and local availability of resources.
It is known that survival rates following kidney transplantation are
comparable between centres in the UK.121 Therefore, centres transplanting
patients with higher comorbidity have not been shown to have inferior
outcomes. It could be argued that more selective and risk-averse centres may
be disadvantaging some patients who could benefit from good outcomes
from transplantation and could expand their selection criteria to include such
patients. However, further work is needed to analyse the effect of comorbidity
on the outcomes of dialysis and transplanted patients in the UK. Patient
selection for transplantation should be fair, transparent and based on
validated criteria, and should not be affected by the centre that a patient is
seen in. The development of an individualised survival prediction tool for
ESRD patients would provide a more objective and evidence-based guide to
treatment decisions and could be used to implement national selection
criteria in order to standardise access to kidney transplantation in the UK.
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CHAPTER 4
Access to Living Donor Kidney Transplantation
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4.1. Introduction
It is now widely acknowledged that living donor kidney transplantation
(LDKT) provides better clinical outcomes than deceased donor kidney
transplantation (DDKT).18, 19, 122 Kidneys from living donors are generally
healthier and have not been exposed to the detrimental effects of brain death,
circulatory death or prolonged periods of ischaemia. UK transplant registry
data show that patient and graft survival rates are consistently higher for
LDKT than DDKT (Table 4.1). This is despite significantly poorer levels of
human leukocyte antigen (HLA) matching (26% level 4 matches [1DR + 2B
mismatches or 2DR mismatches] in LDKT compared to 6% in DDKT).13
Table 4.1. Patient and graft survival rates for kidney transplantation in the UK
Patient survival (%) Graft survival (%)
1 year 5 year 10 year 1 year 5 year 10 year
Living donor 99 94 91 97 92 82
Donor after brain death 96 88 76 93 87 76
Donor after circulatory
death
95 85 72 93 86 76
Includes adult transplants performed between 1 April 2004 – 31 March 2006. Data from NHS
Blood and Transplant.13
LDKT also provides more timely access to transplantation. The elective LDKT
procedure can be scheduled without delay and can be performed at a time
when both donor and recipient health is optimal. Currently, the median
waiting time for DDKT in the UK is 2 years.14 LDKT enables patients to avoid
the long waiting list for DDKT, and thereby minimises the exposure to pre-
transplant dialysis and its associated morbidity. LDKT provides the more
likely prospect of avoiding dialysis entirely, through pre-emptive
transplantation. Evidence shows that time on dialysis prior to transplantation
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confers a considerable dose-dependent negative impact on post-transplant
outcomes and is considered by many to be the most important modifiable
risk factor in transplant outcomes.19, 20, 123 Avoidance of dialysis also makes
pre-emptive transplantation the most cost-effective treatment option for
patients with end-stage renal disease (ESRD).124 In 2018, the rate of pre-
emptive transplantation in the UK was 16.5% for DDKT and 40.2% for LDKT.13
UK Renal Association guidelines recommend that LDKT be considered the
treatment of choice for all patients suitable for kidney transplantation,
whenever an appropriate living donor is available.125 The guidelines also
highlight the fact that pre-emptive LDKT should be the optimal treatment
strategy.
Figure 4.1. Number of adult kidney transplants by donor type (Source: NHS Blood
and Transplant annual report on kidney transplantation 2008-2018)14
Despite the numerous advantages of LDKT, currently only around one third
of kidney transplants undertaken in the UK are from living donors (Figure
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4.1). Concerningly, LDKT numbers have fallen by 9.5% since 2014, but this has
corresponded with an increase in the number of DDKTs. Of 74 countries
submitting data on LDKT to the International Registry on Organ Donation and
Transplantation (IRODaT) in 2017,15 the UK ranked 14th for number of LDKTs
per million population (pmp) (Figure 4.2). The UK rate of 15 transplants pmp
is only around half that of the best performing countries. It is important to
bear in mind that a country’s LDKT rate is influenced by the DDKT rate and
that many of these top performing countries do not have an established
deceased donor programme. However, several countries with successful
LDKT and DDKT programmes still have a higher LDKT rate than the UK, such
as the Netherlands, Israel, South Korea, USA, Denmark, New Zealand and
Switzerland, suggesting substantial scope for further expansion of the UK
living donor pool.
Figure 4.2. Top 20 countries for number of living donor kidney transplants per
million population (pmp) 2017 (Source: International Registry on Organ Donation
and Transplantation (IRODaT)15)
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Improving LDKT activity has been recognised as a major priority for
transplantation in the UK. A strategy set out by NHS Blood and Transplant
(NHSBT) in 2014 aims to increase the LDKT rate to 26 transplants pmp by
2020.21 The key objectives of the strategy are to increase LDKT activity whilst
maintaining donor safety and welfare, ensure all suitable recipients have
equity of access to LDKT, embed the principle of “transplant first” as best
clinical practice across the UK and expand the National Living Donor Kidney
Sharing Schemes. However, with the current UK LDKT rate static at 15 pmp
there is significant progress to be made. There are limited data on the factors
that may inhibit or facilitate patients to receive a LDKT or a pre-emptive LDKT
in the UK. A better understanding of these factors is vital to enable
identification of target patient groups and aid the development of
appropriate interventions to improve LDKT rates. The aim of this analysis was
to investigate the factors influencing access to LDKT in the UK. The principle
objectives were to examine a national sample of UK kidney transplant
recipients to identify the recipient characteristics associated with achieving
LDKT compared with DDKT, and also to investigate whether any recipient
variables were associated with receiving pre-emptive LDKT versus LDKT after




This analysis included kidney transplant recipients from the incident
transplant cohort of ATTOM (n=2262). Patients were recruited at the time of
transplantation from all 23 UK transplant centres. In each centre, recruitment
took place over a 12-month period between 1 November 2011 and 31 March
2013. Patients aged 18 – 75 years were eligible for recruitment. For full details
about patient recruitment methods please see Chapter 2. For the purposes of
this analysis, patients undergoing simultaneous pancreas-kidney transplants
(n=150) and other multi-organ transplants (n=12) were excluded. Thus, the
final study population included 2100 kidney-only transplant recipients. The
study population represented 73.2% of patients in the national kidney-only
transplant population who were eligible for recruitment to the study (Figure
4.3).
Figure 4.3. Study population
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4.2.2. Data variables
Baseline demographic, socioeconomic, clinical, comorbidity and transplant
data were collected for each patient at the time of transplantation (Appendix
A.2.). The predictor variables of interest in this analysis included:
(a) demographic variables: age, gender, ethnicity, country
(b) socioeconomic variables: civil status, highest qualification, employment
status, car ownership, home ownership, health literacy, first language,
country of birth
(c) clinical variables: primary renal disease, modified Charlson Comorbidity
Index (CCI), body mass index (BMI), smoking status, previous transplantation,
sensitisation level
Variable definitions are given in Appendix A.3. For the purposes of this
analysis, recipient age was divided into the following groups: 18-34, 35-49,
50-64 and 65-75 years. Patients were classified by the country in which they
underwent transplantation. Civil status was divided into 3 groups; married or
living with partner, divorced or separated or widowed and single. Health
literacy was assessed by a single item screening question: “How often do you
need help to read instructions, leaflets or other written material from your
doctor or pharmacy?”. Answers of “Never” or “Rarely” were recorded as
normal health literacy, and answers of “Sometimes”, “Often” or “Always” were
recorded as limited health literacy. A modified Charlson Comorbidity Index
(CCI) designed specifically for patients with ESRD was calculated for each
patient using the methods described in Chapter 2. In order to reduce the
number of degrees of freedom, the modified CCI was used during modelling
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rather than considering each comorbidity variable separately. This allowed
more factors to be considered in the model. The modified CCI was divided
into 4 groups; 0, 1, 2 and ≥3. BMI was grouped in accordance with the World
Health Organisation (WHO) BMI classifications of Underweight (<18.5 kg/m2),
Normal (18.5 - 24.9 kg/m2), Overweight (25.0 - 29.9 kg/m2) and Obese (≥30.0
kg/m2).126 Highly sensitised patients were defined as those with a calculated
reaction frequency (cRF) of more than 85%, as per the NHSBT definition.79
4.2.3. Statistical methods
Baseline characteristics of LDKT and DDKT recipients and donors were
presented as numbers with percentages (%) compared by chi-squared tests for
categorical data and medians with interquartile ranges (IQR) compared with
Wilcoxon tests for non-parametric continuous data.
The primary outcome measure was the type of transplant received. Recipient
variables associated with receiving LDKT versus DDKT were analysed using
logistic regression. A manual backward elimination method was used to build
the multivariable model. Variables leading to a change in log likelihood at
p<0.15 on univariable analysis were entered into the multivariable model. The
importance of each variable in the model was then tested by examining the
difference in log-likelihood between the model with and without the variable.
If the difference was not significant (p>0.05) on likelihood ratio test, the
variable was removed. Each time a variable was removed, the effect of
removing each of the remaining variables was retested until the most
parsimonious model was achieved. Continuous variables were explored as
linear, fractional polynomials and categorical variables. Potential interactions
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between variables were tested; none were significant. Correlation between
categorical variables was tested using Cramer’s V correlation coefficient, with
values >0.15 considered to show strong correlation.127
The proportion of missing values did not exceed 10% for any variable (Table
4.2). For modelling purposes, missing values were imputed using the fully
conditional specification logistic regression method. Ten imputed datasets
were modelled separately, then combined to produce final parameter
estimates. Sensitivity analysis using case-wise deletion of missing values did
not change conclusions.
Complex links between socioeconomic deprivation and ethnicity with respect
to access to and outcomes from renal replacement therapy (RRT) have
previously been reported.128, 129 To avoid any confounding and/or interaction
from ethnicity, a subgroup analysis was undertaken in White patients only,
using the same multivariable modelling methods as described above.
A second subgroup analysis examined the recipient variables associated with
receiving a transplant pre-emptively versus after the initiation of dialysis in
the LDKT cohort. Multivariable modelling methods were the same as
described above.
All data were analysed using SAS®9.4 (SAS Institute Inc, Cary, USA).
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Table 4.2. Missing data
Variable n [%]
Recipient age 0 [0]
Recipient gender 0 [0]
Recipient ethnicity 4 [0.2]
Recipient country of residence 0 [0]
Recipient civil status 148 [7.1]
Recipient qualifications 149 [7.1]
Recipient employment status 145 [6.9]
Recipient car ownership 143 [6.8]
Recipient home ownership 146 [7.0]
Recipient health literacy 146 [7.0]
Recipient first language 141 [6.7]
Recipient country of birth 141 [6.7]
Recipient primary renal disease 6 [0.3]
Recipient modified CCI 8 [0.4]
Recipient BMI 106 [5.1]
Recipient smoking status 201 [9.6]
Recipient previous transplant 11 [0.5]




Donor age 0 [0]
Donor gender 1 [0.1]
Donor ethnicity 19 [0.9]
Donor relationship 8 [0.4]
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4.3. Results
4.3.1. Study population characteristics
As shown in Figure 4.3, the study population represented 73.2% of all patients
undergoing kidney-only transplantation in the UK during the study
recruitment period who were eligible for recruitment to the study. The chi-
square goodness of fit test was used to compare the patient demographics of
the national adult kidney-only transplant population (n=2868) and those who
were recruited to the study (n=2100) (Table 4.3). There were no significant
demographic differences, indicating that the study population was a
nationally representative sample for the recruitment time period.
Table 4.3. Patient demographics of kidney-only transplant









18 – 34 16.6 17.2
35 – 49 29.7 30.1
50 – 64 37.9 37.9










Type of transplant 0.164
Living donor 37.2 38.7
Deceased donor 62.8 61.3
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Of the 2100 kidney-only transplant recipients in the study, 1288 (61.3%)
underwent DDKT and 812 (38.7%) underwent LDKT. There were considerable
differences in the characteristics of LDKT and DDKT recipients (Table 4.4 and
4.5). LDKT recipients were significantly younger (median age 46 vs 54 years)
and a higher proportion were of White ethnicity (87.1% vs 79.7%) and married
or living with a partner (65.1% vs 60.2%). Compared with DDKT recipients, a
higher proportion of LDKT recipients had achieved secondary education level
qualifications (52.9% vs 47.1%), higher education level qualifications (27.2% vs
19.0), employment (43.4% vs 31.5%), car-ownership (91.0% vs 80.4%) and
home-ownership (66.1% vs 62.5%), indicating they were a less
socioeconomically deprived population. LDKT recipients were more likely to
have normal health literacy (92.4% vs 86.6%), English as a first language (91.1%
vs 86.3%) and to have the UK as their country of birth (87.2% vs 79.1%). There
was a significantly lower prevalence of overall comorbidity and of diabetes,
polycystic kidney disease, hypertension and renal vascular disease as the
primary cause of renal failure in the LDKT group. A significantly higher
proportion of LDKT recipients received pre-emptive transplants compared
with DDKT recipients (35.7% vs 12.2%, p<0.0001). For patients who did
undergo dialysis, the median time spent on dialysis before transplantation
was 1.57 years for LDKT and 3.4 years for DDKT (p<0.0001).
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Median age (years) 46 [34 – 56] 54 [44 – 63] <0.0001
Age group <0.0001
18 – 34 229 [28.2] 132 [10.3]
35 – 49 263 [32.4] 369 [28.7]
50 – 64 252 [31.0] 543 [42.2]
65 – 75 68 [8.4] 244 [18.9]
Gender 0.267
Male 500 [61.6] 824 [64.0]
Female 312 [38.4] 464 [36.0]
Ethnicity 0.0002
White 707 [87.1] 1023 [79.7]
Asian 62 [7.6] 140 [10.9]
Black 35 [4.3] 96 [7.5]
Other 8 [1.0] 25 [2.0]
Civil status <0.0001
Married / Living with partner 497 [65.1] 715 [60.2]
Divorced / Separated / Widowed 68 [8.9] 210 [17.7]
Single 199 [26.1] 263 [22.1]
Qualifications <0.0001
Higher education level 208 [27.2] 225 [19.0]
Secondary education level 446 [58.4] 657 [55.4]
No qualifications 110 [14.4] 305 [25.7]
Employment status <0.0001
Employed 332 [43.4] 375 [31.5]
Unemployed 59 [7.7] 94 [7.9]
Long term sick / disability 184 [24.1] 352 [29.6]
Retired 115 [15.0] 297 [25.0]
Other 75 [9.8] 72 [6.1]
Car ownership 695 [91.0] 959 [80.4] <0.0001
Home ownership 504 [66.1] 744 [62.5] 0.107
Health literacy <0.0001
Normal 706 [92.4] 1030 [86.6]
Limited 58 [7.6] 160 [13.5]
English is first language 698 [91.1] 1029 [86.3] 0.001
Born in UK 668 [87.2] 944 [79.1] <0.0001
Data are median [IQR] or number [%]. Data are missing for some participants and excluded
from percentage calculations. Numbers of missing data are shown in Table 4.2.
p-value derived from Wilcoxon test for median age. All others chi-squared test.
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Primary renal disease <0.0001
Diabetic nephropathy 48 [5.9] 134 [10.4]
Glomerulonephritis 232 [28.7] 320 [24.9]
Polycystic kidney disease 112 [13.9] 219 [17.0]
Pyelonephritis 128 [15.8] 138 [10.7]
Hypertensive nephropathy 37 [4.6] 89 [6.9]
Renal vascular disease 9 [1.1] 29 [2.3]
Other 157 [19.4] 194 [15.1]
Uncertain 85 [10.5] 163 [12.7]
Modified CCI <0.0001
0 627 [77.6] 880 [68.5]
1 91 [11.3] 170 [13.2]
2 61 [7.6] 142 [11.1]
≥3 29 [3.6] 92 [7.2]
BMI 0.121
Underweight 23 [3.0] 26 [2.1]
Normal 312 [40.8] 461 [37.5]
Overweight 282 [36.9] 462 [37.6]
Obese 147 [19.2] 281 [22.9]
Smoking status 0.702
Non-smoker 437 [60.1] 710 [60.6]
Smoker 78 [10.7] 137 [11.7]
Ex-smoker 212 [29.2] 325 [27.7]
Previous transplant 117 [14.5] 165 [12.9] 0.297




Haemodialysis 352 [43.6] 737 [57.5]
Haemodiafiltration 14 [1.7] 40 [3.1]
Continuous ambulatory
peritoneal dialysis
73 [9.1] 209 [16.3]
Automated peritoneal dialysis 66 [8.2] 132 [10.3]
Failing transplant 14 [1.7] 8 [0.6]
Pre-emptive 288 [35.7] 156 [12.2]
Data are median [IQR] or number [%]. Data are missing for some participants and excluded
from percentage calculations. Numbers of missing data are shown in Table 4.2.
p-value for chi-squared test.
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There were also substantial geographic differences in the type of kidney
transplants that were performed. The proportion of kidney transplants that
were LDKTs was significantly higher in Northern Ireland at 68.9%, compared
with 38.4% in England, 35.4% in Wales and 30.2% in Scotland (p<0.0001) for
patients included in this study (Figure 4.4.).
Figure 4.4. Distribution of type of transplants undertaken in each of the four UK
countries
Donor characteristics are shown in Table 4.6. Compared to deceased donors,
living donors were significantly younger and more likely to be female than
deceased donors. A higher proportion of deceased donors were of White
ethnicity compared with living donors. In all, 353 (43.9%) living donors were
not genetically related to the recipient.
91






Median age (years) 48 [39 – 57] 54 [42 – 64] <0.0001
Age group <0.0001
0 - 17 0 [0] 31 [2.4]
18 – 34 143 [17.6] 160 [12.4]
35 – 49 298 [36.7] 303 [23.5]
50 – 64 308 [37.9] 512 [39.8]
65 – 75 61 [7.5] 234 [18.2]
>75 2 [0.3] 48 [3.7]
Gender 0.001
Male 379 [46.7] 696 [54.0]
Female 432 [53.3] 592 [46.0]
Ethnicity <0.0001
White 720 [88.7] 1208 [95.2]
Asian 52 [6.4] 21 [1.7]
Black 28 [3.5] 23 [1.8]
Other 12 [1.5] 17 [1.3]
Donor-recipient relationship -
Parent 147 [18.3]
Son / Daughter 75 [9.3]
Sibling 195 [24.3]
Other blood relative 34 [4.2]
Spouse / partner 188 [23.4]
Pooled / altruistic 93 [11.6]
Other non-related 72 [9.0] 1288 [100]
Data are median [IQR] or number [%]. Data are missing for some participants and excluded
from percentage calculations. Numbers of missing data are shown in Table 4.2.
Wilcoxon test for median age. All others chi-squared test.
4.3.2. Factors associated with living donor kidney transplantation
Associations between recipient variables and the likelihood of undergoing
LDKT versus DDKT were characterised using univariable and multivariable
logistic regression (Tables 4.7, 4.8, 4.9).
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Table 4.7. Univariable logistic regression analysis of recipient sociodemographic





18 – 34 1 [ref]
35 – 49 0.41 [0.32, 0.54] <0.0001
50 – 64 0.27 [0.21, 0.35] <0.0001
65 – 75 0.16 [0.11 ,0.23] <0.0001
Recipient gender
Male 1 [ref]
Female 1.11 [0.92, 1.33] 0.268
Recipient ethnicity
White 1 [ref]
Asian 0.64 [0.47, 0.88] 0.006
Black 0.53 [0.35, 0.79] 0.002
Other 0.46 [0.21, 1.03] 0.060
Recipient civil status
Married / Living with partner 1 [ref]
Divorced / Separated / Widowed 0.47 [0.35, 0.63] <0.0001
Single 1.09 [0.88, 1.35] 0.443
Recipient qualifications
Higher education level 1 [ref]
Secondary education level 0.73 [0.59, 0.92] 0.007
No qualifications 0.39 [0.29, 0.52] <0.0001
Recipient employment status
Employed 1 [ref]
Unemployed 0.71 [0.50, 1.01] 0.059
Long term sick / disability 0.59 [0.47, 0.74] <0.0001
Retired 0.44 [0.34, 0.57] <0.0001
Other 1.18 [0.83, 1.68] 0.370
Recipient car ownership
Yes 1 [ref]
No 0.41 [0.31, 0.54] <0.0001
Recipient home ownership
Yes 1 [ref]
No 0.86 [0.71, 1.04] 0.108
Recipient health literacy
Normal 1 [ref]
Limited 0.53 [0.39, 0.73] <0.0001
Recipient english is first language
Yes 1 [ref]
No 0.61 [0.45, 0.82] 0.001
Recipient born in UK
Yes 1 [ref]
No 0.56 [0.43, 0.72] <0.0001
CI; confidence interval, ref; reference
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Table 4.8. Univariable logistic regression analysis of clinical and






Diabetic nephropathy 1 [ref]
Glomerulonephritis 2.02 [1.40, 2.93] 0.0002
Polycystic kidney disease 1.43 [0.96, 2.13] 0.082
Pyelonephritis 2.59 [1.72, 3.89] <0.0001
Hypertensive nephropathy 1.16 [0.70, 1.92] 0.564
Renal vascular disease 0.87 [0.38, 1.96] 0.731
Other 2.26 [1.53, 3.34] <0.0001
Uncertain 1.46 [0.86, 2.22] 0.081
Recipient modified CCI
0 1 [ref]
1 0.75 [0.57, 0.99] 0.041
2 0.60 [0.44, 0.83] 0.002
≥3 0.44 [0.29, 0.68] 0.0002
Recipient BMI (kg/m2)
Normal 1 [ref]
Underweight 1.31 [0.73, 2.33] 0.365
Overweight 0.90 [0.73, 1.11] 0.327
Obese 0.77 [0.60, 0.99] 0.040
Recipient smoking status
Non-smoker 1 [ref]
Smoker 0.93 [0.68, 1.25] 0.614
Ex-smoker 1.06 [0.86, 1.31] 0.588
Recipient previous transplant
No 1 [ref]








Wales 0.88 [0.57, 1.35] 0.554
Northern Ireland 3.55 [2.15, 5.87] <0.0001
Scotland 0.69 [0.50, 0.97] 0.030
CI; confidence interval, ref; reference
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The multivariable model (Table 4.9) demonstrated that with each sequential
increase in age group, there was a marked reduction in the probability of
LDKT versus DDKT, such that patients aged 65-75 years had 89% lower odds
of undergoing LDKT compared with patients aged 18-34 years (odds ratio
[OR] 0.11, 95% confidence interval [CI] 0.07, 0.17, p<0.0001). Compared with
White patients, Asian patients (OR 0.52, 95% CI 0.36, 0.74, p=0.0004) and
Black patients (OR 0.60, 95% CI 0.38, 0.95, p=0.030) were less likely to undergo
LDKT than DDKT. Having English as a first language and being born in the UK
were significantly associated with LDKT on univariable analysis, however
were not found to be significant in the multivariable model. This was due to
very strong correlation between these variables and ethnicity (Ethnicity +
English first language; Cramer’s V=0.618, Ethnicity + Born in UK; Cramer’s
V=0.651, English first language + Born in UK; Cramer’s V=0.740). Of the 3
variables, ethnicity showed the strongest association to LDKT and was
retained in the final multivariable model. Patients who were divorced,
separated or widowed (OR 0.62, 95% CI 0.45-0.86, p=0.004) and single (OR
0.75, 95% CI 0.56, 1.00, p=0.048) had a lower probability of LDKT compared
with patients who were married or living with a partner. Having no formal
qualifications (OR 0.55, 95% CI 0.40, 0.76, p=0.0002) and having only
secondary education qualifications (OR 0.78, 95% CI 0.61, 1.00, p=0.049)
reduced the odds of LDKT compared with patients with higher education
qualifications. Health literacy was univariably associated with LDKT but was
not significant in the multivariable model, due to its strong correlation with
the qualification variable (Cramer’s V=0.269). Not owning a car (OR 0.51, 95%
CI 0.37, 0.71, p<0.0001) and not owning a home (OR 0.69, 95% CI 0.54, 0.89,
p=0.0004) also decreased the odds of LDKT versus DDKT.  With adjustment
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for recipient variables, the odds of LDKT versus DDKT were over 3-fold higher
for patients in Northern Ireland (OR 3.29, 95% CI 1.92, 1.42, p<0.0001)
compared with patients in England. Further analysis by changing the
reference value in the model showed the odds of LDKT in Northern Ireland
were also higher than in Wales (OR 3.62, 95% CI 1.80, 7.30, p=0.0003) and
Scotland (OR 4.43, 95% CI 2.36, 8.31, p<0.0001). There were no significant
differences in the likelihood of undergoing LDKT in England, Wales and
Scotland.
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Table 4.9. Multivariable logistic regression analysis of factors associated





18 – 34 1 [ref]
35 – 49 0.34 [0.25, 0.47] <0.0001
50 – 64 0.19 [0.14, 0.27] <0.0001
65 – 75 0.11 [0.07, 0.17] <0.0001
Recipient ethnicity
White 1 [ref]
Asian 0.52 [0.36, 0.74] 0.0004
Black 0.60 [0.38, 0.95] 0.030
Other 0.46 [0.19, 1.09] 0.079
Recipient civil status
Married / Living with partner 1 [ref]
Divorced / Separated / Widowed 0.62 [0.45, 0.86] 0.004
Single 0.75 [0.56, 1.00] 0.048
Recipient qualifications
Higher education level 1 [ref]
Secondary education level 0.78 [0.61, 1.00] 0.049
No qualifications 0.55 [0.40, 0.76] 0.0002
Recipient car ownership
Yes 1 [ref]
No 0.51 [0.37, 0.71] <0.0001
Recipient home ownership
Yes 1 [ref]
No 0.69 [0.54, 0.89] 0.004
Country
England 1 [ref]
Wales 0.88 [0.55, 1.42] 0.603
Northern Ireland 3.29 [1.92, 5.63] <0.0001
Scotland 0.72 [0.50, 1.04] 0.082
CI; confidence interval, ref; reference
4.3.3. Factors associated with living donor kidney transplantation amongst
kidney transplant recipients of White ethnicity
A sensitivity analysis was conducted in a subgroup of White patients only
using the same modelling methods as above. This confirmed that the effects
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of socioeconomic factors on the likelihood of LDKT versus DDKT were
independent of ethnicity (Table 4.10).
Table 4.10. Multivariable logistic regression analysis of factors





18 – 34 1 [ref]
35 – 49 0.31 [0.22, 0.44] <0.0001
50 – 64 0.17 [0.11, 0.24] <0.0001
65 – 75 0.10 [0.06, 0.16] <0.0001
Recipient civil status
Married / Living with partner 1 [ref]
Divorced / Separated / Widowed 0.59 [0.42, 0.83] 0.003
Single 0.68 [0.49, 0.94] 0.018
Recipient qualifications
Higher education level 1 [ref]
Secondary education level 0.75 [0.57, 0.98] 0.035
No qualifications 0.53 [0.37, 0.75] 0.0004
Recipient car ownership
Yes 1 [ref]
No 0.51 [0.36, 0.75] 0.0004
Recipient home ownership
Yes 1 [ref]
No 0.71 [0.54, 0.95] 0.019
Country
England 1 [ref]
Wales 0.93 [0.57, 1.52] 0.774
Northern Ireland 3.47 [2.00, 6.01] <0.0001
Scotland 0.73 [0.50, 1.06] 0.101
CI; confidence interval, ref; reference
4.3.4. Factors associated with pre-emptive living donor kidney transplantation
A further subgroup analysis in the LDKT group examined factors associated
with achieving pre-emptive transplantation versus transplantation after the
initiation of dialysis (Table 4.11). Patients with a previous transplant were
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excluded, because pre-emptive transplantation refers to the receipt of a
kidney transplant before the point at which maintenance dialysis is required
due to a progressive deterioration in renal function, and is therefore only
relevant to patients undergoing their first transplant. Multivariable modelling
demonstrated a significantly decreased likelihood of pre-emptive LDKT for
Asian patients (OR 0.45, 95% CI 0.24, 0.87, p=0.017), unemployed patients (OR
0.46, 95% CI 0.22, 0.97, p=0.042), patients unable to work due to long term
sickness/disability (OR 0.46, 95% CI 0.30, 0.72, p=0.0006), retired patients (OR
0.47, 95% CI 0.29, 0.75, p=0.002), not owning a car (OR 0.35, 95% CI 0.16, 0.74,
p=0.006) and not owning a home (OR 0.64, 95% CI 0.43, 0.95, p=0.027).
Table 4.11. Multivariable logistic regression analysis of factors






Asian 0.45 [0.24, 0.87] 0.017
Black 1.24 [0.56, 2.75] 0.604
Other 1.14 [0.17, 7.54] 0.895
Recipient employment status
Employed 1 [ref]
Unemployed 0.46 [0.22, 0.97] 0.042
Long term sick / disability 0.46 [0.30, 0.72] 0.0006
Retired 0.47 [0.29, 0.75] 0.002
Other 1.38 [0.78, 2.45] 0.271
Recipient car ownership
Yes 1 [ref]
No 0.35 [0.16, 0.74] 0.006
Recipient home ownership
Yes 1 [ref]
No 0.64 [0.43, 0.95] 0.027
CI; confidence interval, ref; reference
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4.4. Discussion
Amongst patients undergoing kidney transplantation in the UK, there are
significant age, ethnic, socioeconomic and geographic disparities in the
utilisation of living donor versus deceased donor kidney transplantation.
Older age, Black and Asian ethnicity, being divorced, separated, widowed or
single, lower educational attainment and measures of greater socioeconomic
deprivation (non car and home ownership) were significantly and
independently associated with a reduced likelihood of LDKT versus DDKT.
For the period of the study, geographic differences were also noted, with
patients in Northern Ireland having a greater probability of LDKT versus
DDKT compared with patients in the rest of the UK. Furthermore, the study
demonstrated that amongst those who do undergo LDKT, ethnic and
socioeconomic disparities persist in determining whether LDKT is received
pre-emptively.
In recent years, a great deal of attention has been directed towards addressing
disparities in access to DDKT in the UK. Individuals who are older, more
socially deprived, from ethnic minority backgrounds or treated in certain
transplant centres are less likely to be put on the waiting list for and
subsequently receive DDKT.3-5, 117, 130 Despite LDKT providing optimal clinical
outcomes for patients with ESRD, there have been limited data on whether
patients experience disparities in utilising this treatment. Udayaraj et al.
reported a lower probability of LDKT for patients with greater socioeconomic
deprivation and patients from Black and South Asian backgrounds in the
UK.118 However, Udayaraj examined the rates of LDKT amongst patients
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starting RRT, without adjustment for comorbidity. Therefore, a major
confounding factor in their study is the higher rate of comorbidity amongst
more socioeconomically deprived and ethnic minority populations, which
provides an alternative explanation for their reduced likelihood of LDKT due
to medical unsuitability for transplantation. In our study we avoided the
confounding effect from comorbidity by collecting extensive comorbidity
data and also by choosing to examine a cohort of patients who were all
deemed suitable to undergo transplantation. This is a select population of
patients who have already successfully navigated the process of transplant
referral, evaluation and listing. Therefore, it is concerning that the striking
disparities observed appear to occur over and above the well-recognised
inequities that patients face before even reaching this stage. These findings
are not confined to the UK. Our results are consistent with those of a US study
by Gore et al. which reported lower odds of LDKT relative to DDKT for
patients who were older, from ethnic minority groups, with lower
socioeconomic status and lower levels of education.131 Roodnat et al. showed
the same factors reduced the likelihood of LDKT versus DDKT in the
Netherlands.132 It is interesting that similar results have been demonstrated
both within publicly funded as well as private healthcare systems, suggesting
factors other than financial disadvantage play an important role.
The well-recognised markers of socioeconomic deprivation (car ownership
and home ownership) were strongly associated with a reduced likelihood of
LDKT versus DDKT in this study. A subgroup analysis of White patients only
confirmed that the effects of socioeconomic deprivation were independent of
ethnicity. Lower rates of LDKT in socioeconomically deprived patients have
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also been reported in Australia133 and the US134, 135. The reasons behind this
finding are unclear. It is known that living donor-recipient pairs usually come
from the same socioeconomic group.136 Greater socioeconomic deprivation is
linked to poorer health,137 potentially limiting the pool of living donors
available to more deprived patients. In the UK, kidney transplantation
including medication and after-care are provided free of charge under the
National Health Service (NHS). However, it is possible that other costs such as
transportation, childcare and lost income from time off work could play a
role in deterring potential living donors or deterring those in need of a kidney
from approaching potential donors.138 A financial reimbursement policy for
expenses incurred by living donors does exist in the UK, but it may not be
implemented consistently by transplant centres. A recent qualitative study of
DDKT recipients found that many were unaware of the living donor
reimbursement policy.48 Despite this, socioeconomically deprived patients
have been reported as not perceiving financial concerns to be a major barrier
to LDKT in the UK, whereas passivity and disempowerment in treatment
decisions, short-term focus and lack of social support were seen as more
significant obstacles to LDKT.48
It is well recognised that ethnic minority patients wait longer for DDKT in the
UK, due to the mismatch between the HLA types of minority patients and
those of the predominantly White donor pool.78 One might therefore expect a
higher uptake of LDKT in ethnic minority patients. Our study found the
opposite, with patients from Black and Asian backgrounds having lower odds
of LDKT than DDKT, compared with White patients. The effect of ethnicity on
the likelihood of LDKT was independent to the effects of social deprivation
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and education. Similar disparities have been reported in the US129, 139 and
Canada.140 These disparities have worsened over time, and are likely
contributing to differences in outcomes between White and non-White
patients.141, 142 One US study showed that while the rates of LDKT have
increased amongst White patients between 1995 and 2014, they have
decreased for Blacks and Hispanics over the same time period.142 Possible
explanations cited for these disparities include cultural and religious
beliefs,143, 144 reluctance to engage with the medical system,145, 146 institutional
prejudice147, 148 and language barriers.149 In our analysis, having English as a
first language was univariably associated with LDKT, and was highly
correlated to ethnicity. However, English as a first language was not
significant in the multivariable model, and it did not attenuate the effect of
the Ethnicity variable. Thus the language barrier does not appear to explain
the lower access to LDKT by ethnic minorities. Being born outside of the UK
was also associated with a lower likelihood of LDKT on univariable analysis
and was highly correlated to ethnicity but not significant on multivariable
analysis. However, adding this variable to the multivariable model did reduce
the association of the ethnicity variable with LDKT, specifically for Black
patients. Thus, being born outside of the UK partially accounts for some of
the association of Black ethnicity with reduced access to LDKT. One potential
explanation for this is that a high proportion of the potential donors available
to Black patients who are born outside of the UK (e.g. family members) may
reside in other countries.  There is currently a policy in place in the UK that
allows non-UK residents to be considered as potential donors.150 The process
is logistically complex and involves arranging blood tests to be sent to the UK
for matching, organising investigations and medical review in the donors
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country and application to the home office for a visa to allow the donor to
enter the UK, supported by a letter from the recipient’s transplant centre. The
recipient must provide evidence that they will be able to provide
accommodation for the donor during their stay in the UK, and there is a
process for claiming reimbursement of travel expenses. There is no data
available on whether patients are aware of this policy, how often the policy is
utilised and how often visa applications are rejected. However, increasing
public awareness of the policy and identifying parts of the process which
could be improved, may help to increase access to LDKT for some ethnic
minority recipients. Another potential reason for the lower rates of LDKT in
ethnic minority patients is concern over a higher risk for living donors from
minority ethnic backgrounds.22, 151, 152 It is known that ethnic minorities have a
higher prevalence of hypertension and diabetes with associated ESRD, and
thus patients from these backgrounds are more likely to be excluded from
kidney donation.153, 154 As such, ethnic minority patients may have to consider
a much wider range of potential donors before being able to identify a
medically suitable and willing donor, and efforts should be made to aid
patients in this process.
We have demonstrated that a patient’s level of educational attainment is
independently associated with their likelihood of LDKT versus DDKT. Higher
educational attainment may be linked to a better ability to understand the
benefits of LDKT and participate in informed and shared decision making.
Education is an important modifiable determinant of LDKT disparities. We
found that educational attainment was highly correlated with health literacy.
Health literacy is an individuals' capacity to obtain, process and understand
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health information and services needed to make appropriate health
decisions.155 Health literacy has been shown to be an important factor for both
potential kidney transplant recipients as well as potential living donors in
successfully navigating the living donation and transplantation process.156
Although both educational attainment and health literacy were significantly
associated with LDKT on univariable analysis in our study, educational
attainment was the stronger risk factor and thus was retained in the final
multivariable model. This suggests that more advanced academic
achievement confers an additional advantage above and beyond having
“normal” health literacy. This could relate to other aspects of the LDKT
journey and may reflect further targets for interventions. For example, the
ability to communicate with and convey information to potential donors may
be equally important as the ability to understand information about LDKT. As
the health literacy variable was self-reported, another potential explanation
is that there is a discrepancy between patients’ own perception of their level
of health literacy and their actual level of health literacy. This would be
supported by the fact that 25.7% of DDKT recipients were recorded as having
no qualifications, whereas only 13.5% reported limited health literacy.
The finding that patients who were married or living with a partner had better
access to LDKT is likely to be related to the opportunity for spousal donation.
Spouses represented a considerable proportion (23.4%) of living donors in this
study. Being married or living with a partner may also confer other benefits
such as having a better social support network or access to more unrelated
or son/daughter donors.
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Older age was associated with dramatically reduced odds of LDKT versus
DDKT. Previous research has demonstrated that older age is associated with
a lower probability of attempted donor recruitment.157 Older patients have
reported an unwillingness to put younger donors at risk, particularly their
children.158 In our study 18.3% of the living donors were parents whereas only
9.3% were sons/daughters.
Despite adjustment for demographic and socioeconomic factors, we found
striking geographic differences in LDKT activity, with patients in Northern
Ireland experiencing significantly higher odds of LDKT versus DDKT
compared with patients in England, Wales and Scotland. Our results reflect
the actual number of LDKTs pmp which were around twice as high in
Northern Ireland (31.1 pmp) compared with the rest of the UK (England 15.9
pmp, Wales 16.6 pmp, Scotland 10.9 pmp) at the time of the study.159 Around
this time, an initiative was instigated in Northern Ireland to promote LDKT
and pre-emptive transplantation as the treatment of choice. The key measures
included education to promote a change of mind-set amongst nephrologists
(particularly non-transplant nephrologists) as well as the entire transplant
team, together with improved infrastructure and more streamlined services
to enable timely work-up and transplantation (e.g. one-stop living donor
assessment clinic). Effective leadership, persistence and gaining the support
of commissioners and management were critical in achieving these changes
(personal communication, A. Courtney, 17/01/2017). Our results and the
national figures indicate that such a strategy can be very successful in
increasing LDKT utilisation. The higher LDKT rate in Northern Ireland has
resulted in a substantial reduction in the DDKT waiting list. In 2018, the
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number of patients on the active kidney transplant waiting list in Northern
Ireland was 50 pmp, compared with 77.8 pmp in England, 60.8 in Wales and
79.6 in Scotland.14 Moreover, the number of LDKTs in Northern Ireland has
continued to increase (35.5 pmp in 2018, one of the highest in the world),
demonstrating that the changes have led to a sustained improvement rather
than a temporary peak in activity. This is encouraging when exploring
potential avenues to improve LDKT across the UK as a whole.
Our study showed for the first time in the UK that socioeconomic deprivation,
unemployment and Asian ethnicity were independently associated with a
lower likelihood of pre-emptive LDKT. These findings are consistent with
studies from the US and Australia.20, 131, 133 The disparity experienced by
socioeconomically deprived individuals is likely to be related to an increased
likelihood of late referral to specialist renal services,160 however this does not
explain the disparity for patients of Asian ethnicity.
A major strength of the present study is that we recruited all patients
prospectively and collected accurate, reliable and comprehensive data. A large
proportion (73%) of the national adult kidney transplant population were
included in the study. Nevertheless, as it was not possible to recruit the entire
kidney transplant population, it must be recognised that the study is limited
by a risk of selection bias. Reassuringly, the age, gender and ethnicity
distribution of study participants were not significantly different to the
national adult kidney transplant population. Furthermore, the study cohort
included patients from all 23 UK renal transplant centres as well as nationally
comparable proportions of LDKT, DDKT and pre-emptive recipients, thereby
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reducing the potential for bias. However, differences in other unmeasured
characteristics between study participants and non-participants cannot be
ruled out. Furthermore, due to the observational nature of the study, the
results can only describe associations, and as such causality of the observed
relationships cannot be inferred.
LDKT, and in particular pre-emptive LDKT provides optimal clinical outcomes
for patients with ESRD, yet its uptake is variable within the UK. This study
has identified specific patient groups with a lower likelihood of undergoing
LDKT relative to DDKT. We have demonstrated that demographic,
socioeconomic and geographic factors are more strongly associated with the
type of transplant received, than clinical factors including comorbidity,
primary renal disease, BMI, HLA sensitisation or previous transplantation. It
is concerning that even amongst patients who do attain LDKT, additional
disparities affect the chance of receiving pre-emptive transplantation. This
demonstrates the strength of social factors in influencing access to healthcare
and may reflect similar inequities across a wide range of healthcare services.
The demonstrated disparities may reflect both barriers in certain patient
groups as well as important positive factors in others. Furthermore, these
influencing factors are likely to apply to both potential recipients and donors.
Equity is a core value of the NHS, therefore if particular patient groups
experience avoidable barriers to receiving a LDKT or donating a kidney, there
is a responsibility to provide tailored resources to remove these barriers.
Improving access to LDKT will not only benefit individual patients, but will
also have favourable effects for the wider ESRD population by effectively
increasing the overall pool of available organs and thus reducing the size of
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the transplant waiting list. However, both donor and recipient welfare and
autonomy undoubtedly remain the primary focus. Some patients may prefer
not to pursue LDKT due to concerns about risks to their potential donors,
just as some potential donors may decide against donation.158, 161 The aim is
not to persuade all patients to undergo LDKT but to provide all patients with
equitable opportunity to explore the option of LDKT. Identifying
disadvantaged patient groups is an essential first step towards improving
equity in access to LDKT. The findings of this study can guide further research
into the development of targeted interventions. Several studies in the US have
explored strategies including culturally sensitive education programs,162, 163
home-based education164, 165 and patient advocates166 with promising results
for reducing disparities in LDKT. Recently, some initiatives in the UK have
also been launched. The “Acceptance, Choice and Empowerment in Living
Donor Kidney Transplantation” (ACE LDKT) is a pilot study funded by NHSBT,
and uses volunteers as peer educators in a home-education programme for
Black and Asian patients with ESRD.167 Two pilot sites are enrolled; West
Midlands (Queen Elizabeth Hospital, Birmingham Asian patients) and South
London (Guy’s & St. Thomas’ Foundation Trust, London, African and
Caribbean patients). Home education is also currently being explored in
Edinburgh where tailored education about LDKT and other treatment options
is delivered by a dedicated home educator (Renal Education and choices at
home - REACH project). The results of these studies are eagerly awaited, and
other similar programs should be pursued in order to improve equity of
access to LDKT across the whole of the UK.
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CHAPTER 5
Impact of Recipient Comorbidity on Graft and
Patient Survival after Kidney Transplantation
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5.1. Introduction
The demographics of the kidney transplant population have changed
considerably in recent years. For example, over the past decade, the
proportion of deceased donor kidney transplant recipients older than 60
years of age has increased from 15% to 32% in the UK (Figure 5.1).13
Accordingly, the burden of comorbidity among patients undergoing kidney
transplantation has grown substantially.62, 168, 169 Comorbidities such as
diabetes, hypertension and obesity which contribute to the development of
end stage renal disease (ESRD) are on the rise,170 while ESRD itself is an
important risk factor for conditions such as cardiovascular disease.171, 172
Figure 5.1. Deceased donor kidney transplant recipients by age group (Source: NHS
Blood and Transplant annual activity reports 2008-2018)13
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18% 18% 12% 13% 13% 11% 13% 14% 12% 13% 13%
41% 39%
35% 32% 32% 30%








































0-17 18-34 35-49 50-59 >60
111
With continued advances in transplant care, the influence of more
traditionally reported immunological and transplant related factors on post-
transplant outcomes is diminishing, and patient factors such as comorbidity
likely play an increasingly important role in both graft and patient survival.173-
177
Despite this, there is a lack of evidence for how recipient comorbidity may
affect transplant outcomes. A small number of studies have demonstrated
the overall detrimental effect of comorbidity on transplant outcomes using
various comorbidity indices.62, 94, 178, 179 However, this does not allow
characterisation of the risks associated with specific comorbid conditions and
as such is of limited value when assessing individual patient risks.
Retrospective registry analyses have identified some comorbidities as risk
factors for transplant outcomes, but the results show considerable
heterogeneity and are limited by the reliability of registry data.180-182
Furthermore, many studies investigating factors that affect transplant
outcomes use a composite outcome that combines graft failure and patient
death.169, 183 This is often seen as a useful outcome as it demonstrates the
“overall” success of the transplant. However, the risk factors that increase the
risk of graft loss are likely to be different to those for patient death, and more
in depth analysis is required to distinguish and characterise specific risks.
Understanding how different comorbid conditions affect both graft and
patient survival is essential for assessing the suitability of patients for
transplantation, for fully informed discussion with patients regarding their
individual risks and outcomes and for facilitation of shared decision making
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and informed consent. The aim of this analysis was to investigate the impact
of recipient baseline comorbidity on two year survival outcomes following




The study population for this analysis was the incident transplant cohort of
ATTOM. This consists of 2262 kidney transplant recipients recruited at the
time of transplantation, from all 23 UK transplant centres. Full details of the
recruitment methods are included in Chapter 2. For the purposes of this
analysis, patients undergoing multi-organ transplants other than
simultaneous pancreas-kidney (SPK) transplants were excluded (n=12). The
cohort included kidney only (KO) (n=2100) and SPK (n=150) transplant
recipients. Both deceased donor (n=1438) and living donor (n=812)
transplants were included.
Figure 5.2. Study population
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Thus, the final study population included 2250 kidney transplant recipients.
The cohort represented 73.2% of the national kidney transplant population
who were eligible for recruitment to the study (Figure 5.2).
5.2.2. Study design and data variables
This was a prospective cohort study. Baseline recipient comorbidity data as
well as a number of other recipient, donor and transplant variables were
collected at the time of transplantation (Appendix A.2.). Patients were then
followed up for two years from the date of transplant. The relationship
between baseline comorbidity and two year survival outcomes were analysed,
adjusting for relevant confounders.
The exposure variables of interest included diabetes, obesity (body mass
index [BMI] ≥30), ischaemic heart disease, heart failure, atrial fibrillation,
cardiac valve replacement, pacemaker, cerebrovascular disease (CVD),
peripheral vascular disease (PVD), abdominal aortic aneurysm, chronic
respiratory disease, chronic liver disease (CLD), blood borne viruses,
malignancy, mental illness and dementia (definitions given in Appendix A.3.).
The primary outcome measures were graft survival, patient survival and
transplant survival. Graft survival was defined as the time from
transplantation to graft failure (graft failure defined as the earliest of return
to dialysis or re-transplantation), with censoring for death with a functioning
graft, at last follow-up or at 2 years. Patient survival was defined as the time
from transplantation to patient death, with censoring at last follow-up or at
2 years. Transplant survival was defined as the time from transplantation to
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the earliest of graft failure or patient death, with censoring at last follow-up
or at 2 years.
Potential confounders considered in multivariable analyses included:
(a) recipient variables: age, gender, ethnicity, primary renal disease, time on
dialysis, smoking status, previous transplantation, sensitisation level, blood
group
(b) donor variables: age, gender, ethnicity, blood group, BMI
(c) transplant variables: human leukocyte antigen (HLA) mismatches (MM),
type of transplant (living donor KO, deceased donor KO or SPK), cold
ischaemic time (CIT)
Variable definitions are given in Appendix A.3. Recipient calculated reaction
frequency (cRF) ≥85% was used to define highly sensitised recipients, in line
with the NHS Blood and Transplant (NHSBT) definition.79 BMI was grouped in
accordance with the World Health Organisation (WHO) BMI classifications of
Underweight (<18.5 kg/m2), Normal (18.5 - 24.9 kg/m2), Overweight (25.0 -
29.9 kg/m2) and Obese (≥30.0 kg/m2).126 HLA mismatches were classified into
4 levels as defined by the current UK deceased donor kidney allocation
scheme: level 1 (000 HLA-A, B, DR MM), level 2 (0DR + 0/1B MM), level 3 (0DR
+ 2B MM) or (1DR + 0/1B MM) and level 4 (1DR + 2B MM) or (2DR MM).61 A
donor risk index for UK deceased donor kidneys has previously been
described by Watson et al,184 however, the risk index was developed
specifically for deceased donor kidneys. In the current analysis, both living
and deceased donor kidney transplants were included because the focus was
on the impact of recipient comorbidity rather than donor factors on
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outcomes. Therefore, the UK kidney donor risk index was not suitable for use
in this analysis, and models were adjusted for individual donor factors
including donor type instead.
5.2.3. Statistical methods
Baseline characteristics were presented as numbers with percentages (%) and
medians with interquartile ranges (IQR). Categorical data were compared by
chi-squared test or Fisher’s exact test. The impact of recipient comorbidity on
2 year graft, patient and transplant survival was examined using Kaplan-Meier
survival curves and the log-rank test, as well as univariable and multivariable
Cox proportional hazards regression. Multivariable models were constructed
using a manual backward elimination method. All comorbidities were
considered for inclusion in the multivariable models. Potential confounding
variables with a p-value of <0.15 on univariable analysis were included in the
initial model. The importance of each variable in the multivariable model was
then tested by examining the difference in log-likelihood between the model
with and without the variable. If the difference was not significant (p>0.05)
on testing with a likelihood ratio test, the variable was removed. The effect of
removing each of the remaining variables was retested until the most
parsimonious model was achieved. A decision was made a priori to retain the
type of transplant and recipient age variables in all models due to clinical
relevance. Continuous variables were explored as linear, fractional
polynomials and categorical variables. Potential interactions between
variables were tested, none were significant. Correlation between categorical
variables was tested using Cramer’s V correlation coefficient, with values
>0.15 considered to show strong correlation.127 The proportional hazards
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assumption was tested using log cumulative hazards plots and Schoenfeld
residuals and found to be satisfied for all variables. A frailty model with
transplant centre as a random effect was used to check for between-centre
variation in survival. The extent of missing data did not exceed 10% for any
one variable (Table 5.1). For modelling purposes, missing values of covariates
were imputed using the fully conditional specification logistic regression
method to produce ten imputed datasets (using the SAS procedure PROC MI).
Outcome data were not imputed. Each imputed dataset was modelled
separately and then estimates were combined (using the SAS procedure PROC
MIANALYZE). Models using a dataset with deletion of missing values rather
than imputed values were checked and did not change conclusions. All
analyses were conducted using SAS® 9.4 (SAS Institute Inc, Cary, USA).
5.2.4. Sensitivity analyses
To test the robustness of the results, the analyses described above were also
performed on three sub-cohorts:
(a) kidney only transplant recipients i.e. excluding the SPK recipients
(b) first transplant recipients i.e. excluding patients with a previous
transplant
(c) deceased donor transplant recipients i.e. excluding living donor
transplant recipients
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Table 5.1. Missing data
Variable n [%]
Diabetes 6 [0.3]
Ischaemic heart disease 10 [0.4]
Heart failure 9 [0.4]
Atrial fibrillation 9 [0.4]
Cardiac valve replacement 12 [0.5]
Pacemaker 10 [0.4]
Cerebrovascular disease 10 [0.4]
Peripheral vascular disease 10 [0.4]
Abdominal aortic aneurysm 10 [0.4]
Chronic respiratory disease 9 [0.4]
Chronic liver disease 9 [0.4]
Blood borne viruses 10 [0.4]
Malignancy 9 [0.4]
Mental illness 9 [0.4]
Dementia 11 [0.5]
Recipient BMI 123 [5.5]
Recipient age 0 [0]
Recipient gender 0 [0]
Recipient ethnicity 9 [0.4]
Primary renal disease 11 [0.5]
Time on dialysis 0 [0]
Smoking status 215 [9.6]
Previous transplantation 12 [0.5]
Sensitisation level 0 [0]
Recipient blood group 0 [0]
Donor age 0 [0]
Donor gender 1 [0.04]
Donor ethnicity 23 [1.0]
Donor blood group 0 [0]
Donor BMI 93 [4.1]
HLA MM level 0 [0]
Transplant type 0 [0]
CIT 87 [3.9]
Graft survival 5 [0.2]
Patient survival 4 [0.2]
Transplant survival 5 [0.2]
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5.3. Results
5.3.1. Study population characteristics
The study population represented 73.2% of all patients undergoing kidney
transplantation during the study recruitment period who were eligible for
recruitment to the study (Figure 5.2.). Patient demographics of the national
adult kidney transplant population (n=3072) were compared to the study
population (n=2250) using the one sample chi-square goodness of fit test
(Table 5.2). Compared with the national kidney transplant population, the
recruited study population had a similar distribution of age, gender and type
of transplant, but comprised of a significantly higher proportion of White
patients and fewer patients from Black, Asian and other ethnic backgrounds.
Table 5.2. Demographics of kidney transplant recipients –









18 – 34 17.3 17.5
35 – 49 31.8 31.6
50 – 64 36.8 37.0














Baseline recipient, donor and transplant characteristics for the entire study
cohort (n=2250) are shown in Tables 5.3 and 5.4. Both recipients and donors
had a median age of 50 years, were predominantly male and of White
ethnicity. The primary renal disease was diabetes in 322 (14.8%) patients.
Most patients underwent dialysis prior to transplantation, however 483
(21.5%) patients received a pre-emptive transplant. Overall, 2100 patients
received a kidney-only transplant (812 living donor, 1288 deceased donor)
and 150 patients received an SPK transplant.
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Table 5.3. Baseline recipient characteristics of the study cohort










Polycystic kidney disease 332 [14.8]
Diabetic nephropathy 322 [14.4]
Glomerulonephritis 554 [24.7]
Pyelonephritis 266 [11.9]
Hypertensive nephropathy 126 [5.6]





0 - 1 year 380 [16.9]
1 - 3 years 590 [26.2]
3 - 5 years 361 [16.0]





Previous transplant 292 [13.1]






Data are median [IQR] or number [%].
Data are missing for some participants and excluded from percentage
calculations. Number of missing data are shown in Table 5.1.
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Table 5.4. Baseline donor and transplant variables
Donor variables










Underweight [<18.5] 0 [0.0]
Normal [18.5 - 24.9] 809 [37.5]
Overweight [25.0 - 29.9] 929 [43.1]













Living donor KO 812 [36.1]
Deceased donor KO 1288 [57.2]
SPK 150 [6.7]
CIT (hours) 11.3 [4.0 – 15.7]
Data are median [IQR] or number [%].
Data are missing for some participants and excluded from percentage
calculations. Number of missing data are shown in Table 5.1.
The prevalence of comorbidity at the time of transplantation among all
recipients in the study is shown in Table 5.5. The most common comorbidity
among kidney transplant recipients was obesity (20.6%), followed by diabetes
(19.5%), ischaemic heart disease (8.6%) and chronic respiratory disease (7.8%).
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At the time of transplantation, 44.2% patients had no comorbidity, 34.5% had
1 comorbidity, 14.4% had 2 comorbidities and 6.9% had 3 or more
comorbidities.
5.3.2. Impact of recipient comorbidity on 2 year graft survival
Of the 2250 kidney transplant recipients in the study, 5 patients had missing
data for graft survival. Among the 2245 patients with complete graft survival
data, 113 (5.0%) experienced graft failure within the 2 year follow up period,
69 (3.1%) were censored due to death with a functioning graft, 183 (8.2%) were
censored at last follow-up and 1880 (83.7%) were censored at 2 years. Of the
Table 5.5. Prevalence of recipient comorbidity in the study cohort
n [%]
Diabetes 437 [19.5]
Ischaemic heart disease 193 [8.6]
Heart failure 55 [2.5]
Atrial fibrillation 37 [1.7]
Cardiac valve replacement 19 [0.9]
Pacemaker 15 [0.7]
Cerebrovascular disease 111 [5.0]
Peripheral vascular disease 74 [3.3]
Abdominal aortic aneurysm 6 [0.3]
Chronic respiratory disease 174 [7.8]
Chronic liver disease 40 [1.8]
Blood borne viruses 51 [2.3]
Malignancy 144 [6.4]
Mental illness 133 [5.9]
Dementia 2 [0.1]
BMI, kg/m2
Underweight (<18.5) 52 [2.4]
Normal (18.5 - 24.9) 851 [40.0]
Overweight (25.0 - 29.9) 786 [37.0]
Obese (≥30.0) 438 [20.6]
Data are missing for some participants and excluded from percentage
calculations. Number of missing data are shown in Table 5.1.
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183 patients censored at last follow up, median censoring time was 670 days
(IQR 365 - 707 days). Of the 113 graft failures, 40 (35.4%) occurred within the
first 30 days, 20 (17.7%) between 30 days and 6 months, 16 (14.2%) between
6 months and 1 year and 37 (32.7%) between 1 and 2 years post-
transplantation. Using the Kaplan-Meier method, estimated graft survival was
98.2% (95% confidence interval [CI] 97.6, 98.7) at 30 days, 97.3% (95% CI 96.5,
97.9) at 6 months, 96.6% (95% CI 95.7, 97.3) at 1 year and 94.8% (95% CI 93.8,
95.7) at 2 years.
Unadjusted survival analysis using Kaplan-Meier estimates identified
recipients with PVD and obesity as having worse graft survival at 2 years post-
transplantation (Figure 5.3. and 5.4.). Graft survival for patients with PVD was
89.0% compared with 95.0% for patients who did not have PVD at the time of
transplantation (p=0.016). The risk of graft failure among PVD patients
appeared to be highest within the first 30 days following transplantation,
which is when 75% of graft failures occurred. This is demonstrated in the
Kaplan-Meier plot by the initial sharp reduction in graft survival, followed by
a flatter curve. Graft survival at 2 years among obese patients was 92.9%
compared with 95.3% in non-obese patients (p=0.045). Examination of the
Kaplan-Meier curve for obesity demonstrates a more gradual decline in graft
survival over the 2 year period. Among obese patients, 53% of graft failures
occurred within the first year and 47% within the second year post-
transplantation.
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Figure 5.3. Kaplan-Meier survival plot for effect of PVD on 2 year graft survival
Figure 5.4. Kaplan-Meier survival plot for effect of obesity on 2 year graft survival
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The association of each recipient comorbidity (Table 5.6), as well as recipient
(Table 5.7), donor and transplant variables (Table 5.8) with graft survival was
examined using univariable Cox regression. Recipient comorbidities that were
significantly associated with 2 year graft survival on univariable analysis
included heart failure, PVD and obesity. However, all comorbidities were
considered for inclusion in the multivariable model. Other covariates that
were considered in the multivariable modelling process based on the
univariable results and a priori decisions included recipient age, recipient
ethnicity, time on dialysis, previous transplantation, highly sensitised, donor
age, HLA MM level, transplant type and CIT.
Table 5.6. Univariable Cox regression analysis of recipient comorbidities
affecting 2 year graft survival
Variables HR [95% CI] p-value
Comorbidities
Diabetes 1.32 [0.86, 2.03] 0.211
Ischaemic heart disease 0.81 [0.39, 1.66] 0.562
Heart failure 2.34 [1.03, 5.32] 0.043
Atrial fibrillation 1.62 [0.51, 5.09] 0.413
Cardiac valve replacement . . .
Pacemaker 1.38 [0.19, 9.85] 0.750
Cerebrovascular disease 1.75 [0.88, 3.45] 0.109
Peripheral vascular disease 2.38 [1.16, 4.88] 0.018
Abdominal aortic aneurysm . . .
Chronic respiratory disease 1.57 [0.88, 2.80] 0.126
Chronic liver disease 1.56 [0.50, 4.92] 0.445
Blood borne viruses 1.60 [0.59, 4.34] 0.356
Malignancy 0.82 [0.36, 1.86] 0.628
Mental illness 1.55 [0.81, 2.96] 0.189
Dementia . . .
BMI (kg/m2)
Underweight (<18.5) 1.60 [0.49, 5.22] 0.440
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 1.38 [0.86, 2.20] 0.185
Obese (≥30.0) 1.89 [1.14, 3.11] 0.013
CI; confidence interval, HR; hazard ratio, ref; reference. (.) number is 0 or too small to calculate
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Table 5.7. Univariable Cox regression analysis of recipient factors
affecting 2 year graft survival
Variables HR [95% CI] p-value
Age (per 10 year increase) 1.00 [0.87, 1.15] 0.996
Gender
Male 1 [ref]
Female 0.82 [0.55, 1.21] 0.315
Ethnicity
White 1 [ref]
Asian 1.01 [0.53, 1.95] 0.969
Black 2.38 [1.38, 4.11] 0.002
Other 0.60 [0.08, 4.29] 0.609
Primary renal disease
Polycystic kidney disease 1 [ref]
Diabetic nephropathy 1.49 [0.71, 3.13] 0.287
Glomerulonephritis 1.41 [0.72, 2.77] 0.320
Pyelonephritis 1.24 [0.56, 2.76] 0.596
Hypertensive nephropathy 1.56 [0.62, 3.97] 0.349
Renal vascular disease 1.45 [0.33, 6.49] 0.625
Other 1.77 [0.88, 3.58] 0.111
Uncertain 1.47 [0.67, 3.23] 0.332
Time on dialysis
Pre-emptive 1 [ref]
0 - 3 years 1.25 [0.67, 2.32] 0.483
> 3 years 2.88 [1.62, 5.14] 0.0003
Smoking status
Non-smoker 1 [ref]
Smoker 1.02 [0.56, 1.84] 0.960
Ex-smoker 0.92 [0.60, 1.43] 0.722
Previous transplant 1.71 [1.07, 2.73] 0.024
Highly sensitised (cRF≥85%) 2.04 [1.27, 3.27] 0.003
Recipient blood group
A 1 [ref]
B 0.70 [0.34, 1.43] 0.329
AB 0.83 [0.30, 2.31] 0.720
O 1.23 [0.83, 1.83] 0.307
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
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Table 5.8. Univariable Cox regression analysis of donor and transplant
factors affecting 2 year graft survival
Variables HR [95% CI] p-value
Donor variables
Donor Age (per 10 year increase) 1.21 [1.06, 1.39] 0.004
Donor Gender
Male 1 [ref]
Female 1.07 [0.74, 1.54] 0.728
Donor Ethnicity
White 1 [ref]
Asian 0.51 [0.13, 2.06] 0.344
Black 1.15 [0.37, 3.64] 0.807
Other 1.25 [0.31, 5.07] 0.754
Donor BMI (kg/m2)
Underweight (<18.5) . . .
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 1.04 [0.68, 1.58] 0.873
Obese (≥30.0) 1.03 [0.61, 1.75] 0.908
Donor blood group
A 1 [ref)
B 0.52 [0.22, 1.23] 0.138
AB 1.27 [0.46, 3.56] 0.647




2 2.32 [1.02, 5.28] 0.044
3 1.95 [0.89, 4.26] 0.096
4 1.20 [0.49, 2.93] 0.696
Transplant type
Living donor KO 1 [ref]
Deceased donor KO 2.05 [1.32, 3.19] 0.001
SPK 0.84 [0.29, 2.41] 0.748
CIT (per hour) 1.05 [1.02, 1.08] 0.001
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
After adjustment for relevant confounding factors in the multivariable model
(Table 5.9.), recipient PVD (hazard ratio; HR 2.77, 95% CI 1.33, 5.79, p=0.007)
and obesity (BMI≥30 kg/m2) (HR 1.96, 95% CI 1.18, 3.27, p=0.009, compared
with BMI 18.5-24.9 kg/m2) were confirmed to be independent risk factors for
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graft loss within 2 years. In the modelling process, the obesity variable was
explored both as a continuous BMI variable (linear, quadratic and log
transformations) and also as a categorical variable. Categories considered
included BMI ≥30 kg/m2, ≥35 kg/m2 and ≥40 kg/m2, both as dichotomous
yes/no variable and also as a variable containing the categories <18.5 kg/m2,
18.5 - 24.9 kg/m2, 25.0 - 29.9 kg/m2. The variable categorised as 4 BMI groups
as shown in Table 5.9 produced the best fit in the multivariable model and
allowed comparison of obese patients to patients with a “normal” BMI. There
was a trend for increasing risk of graft failure with further categorisation of
BMI ≥35 kg/m2 and ≥40 kg/m2, however the results did not reach statistical
significance, likely due to insufficient numbers. Other variables found to be
significant confounders were included in the multivariable model. Increasing
recipient age was associated with better graft survival (HR 0.83 per 10 year
increase, 95% CI 0.69, 0.99, p=0.038). Black compared to White recipient
ethnicity adversely affected graft survival, and although this did not quite
reach statistical significance (HR 1.68, 95% CI 0.92, 3.07, p=0.089), the
ethnicity variable was kept in the model due to its clinical significance. Pre-
transplant time on dialysis had a negative effect on graft survival, but this
was only apparent after 3 years on dialysis (> 3 years on dialysis versus pre-
emptive transplant, HR 2.24, 95% CI 1.10, 4.59, p=0.027), hence the variable
was categorised accordingly to reduce the number of degrees of freedom in
the model. A high level of recipient sensitisation (cRF≥85%) increased the risk
of graft failure (HR 2.17, 95% CI 1.28, 3.68, p=0.004). The previous
transplantation variable was univariably significant for worse graft survival
but was not significant in the multivariable model. This can be explained by
its strong correlation with the highly sensitised variable (Cramer’s V
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coefficient=0.499). Adding previous transplantation to the multivariable
model did not reduce the effect of the highly sensitised variable. Increasing
donor age (HR 1.24 per 10 year increase, 95% CI 1.06, 1.45, p=0.009) and
poorer HLA MM level were also associated with worse graft survival. Deceased
donor KO transplants did worse than living donor KO transplants (HR 1.97,
95% CI 1.13, 3.44, p=0.017), whereas SPK transplants showed no significant
difference to living donor transplants. Increasing CIT was univariably
associated with worse graft survival, but adding it to the multivariable model
caused CIT, as well as the transplant type variable to lose significance. This
implies that the worse graft survival among deceased donor transplants
compared with living donor transplants is partly explained by increased CIT
(median CIT 14.5 vs 3.3 hours, respectively). Despite a median CIT of 13.6
hours, SPK transplants did not have significantly worse graft survival than
living donor kidney transplants. Of note, there was no difference in graft
survival for transplants from donors after circulatory death compared with
donors after brain death for deceased KO or SPK transplants, therefore all
deceased donors were considered together for each type of transplant.
Including transplant centre as a random effect in the multivariable model
showed no evidence for a centre effect on graft survival (change in -2 log-
likelihood p=0.404).
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Table 5.9. Multivariable Cox regression analysis of factors affecting 2 year
graft survival
Variables HR [95% CI] p-value
Recipient comorbidities
Peripheral vascular disease 2.77 [1.33, 5.79] 0.007
BMI
Underweight (<18.5) 1.65 [0.50, 5.49] 0.412
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 1.44 [0.89, 2.33] 0.133
Obese (≥30.0) 1.96 [1.18, 3.27] 0.009
Other variables
Recipient age (per 10 yr increase) 0.83 [0.69, 0.99] 0.038
Recipient ethnicity
White 1 [ref]
Asian 0.83 [0.41, 1.67] 0.604
Black 1.68 [0.92, 3.07] 0.089
Other 0.50 [0.07, 3.63] 0.494
Time on dialysis
Pre-emptive 1 [ref]
0 - 3 years 1.24 [0.60, 2.56] 0.559
> 3 years 2.24 [1.10, 4.59] 0.027
Highly sensitised (cRF≥85%) 2.17 [1.28, 3.68] 0.004
Donor age (per 10 year increase) 1.24 [1.06, 1.45] 0.009
Transplant type
Living donor KO 1 [ref]
Deceased donor KO 1.97 [1.13, 3.44] 0.017
SPK 1.07 [0.31, 3.73] 0.920
HLA MM level
1 1 [ref]
2 2.39 [1.02, 5.61] 0.044
3 1.99 [0.88, 4.51] 0.097
4 1.88 [0.69, 5.09] 0.211
CI; confidence interval, HR; hazard ratio, ref; reference
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5.3.3. Impact of recipient comorbidity on 2 year patient survival
Patient survival data were missing for 4 of 2250 kidney transplant recipients
in the study. Of the remaining 2246 patients included in the analysis, 76 (3.4%)
patients died within the 2 year follow up period, (69 of 76 [90.8%] deaths were
with a functioning graft), 268 (11.9%) were censored at last follow-up and
1902 (84.7%) were censored at 2 years. Of the 268 patients censored at last
follow-up, median censoring time was 518.5 days (IQR 244 - 691.5 days).
There were 2 (2.6%) deaths within the first 30 days, 24 (31.6%) between 30
days and 6 months, 15 (19.7%) between 6 months and 1 year and 35 (46.1%)
between 1 and 2 years post-transplantation. Using the Kaplan-Meier method,
overall patient survival was 99.9% (95% CI 99.6 - 99.9) at 30 days, 98.8% (95%
CI 98.3 - 99.2) at 6 months, 98.1% (95% CI 97.5 - 98.6) at 1 year and 96.5% (95%
CI 95.6 - 97.2) at 2 years.
Kaplan-Meier survival plots (unadjusted) demonstrated significantly worse 2
year patient survival for those with diabetes (Figure 5.5.), heart failure (Figure
5.6.), a pacemaker (Figure 5.7.), CVD (Figure 5.8.), PVD (Figure 5.9.) and CLD
(Figure 5.10.), compared to patients without these comorbidities.
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Figure 5.5. Kaplan-Meier survival plot for effect of diabetes on 2 year patient survival
Figure 5.6. Kaplan-Meier survival plot for effect of heart failure (HF) on 2 year
patient survival
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Figure 5.7. Kaplan-Meier survival plot for effect of pacemaker on 2 year patient
survival
Figure 5.8. Kaplan-Meier survival plot for effect of cerebrovascular disease (CVD) on
2 year patient survival
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Figure 5.9. Kaplan-Meier survival plot for effect of peripheral vascular disease (PVD)
on 2 year patient survival
Figure 5.10. Kaplan-Meier survival plot for effect of chronic liver disease (CLD) on 2
year patient survival
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Univariable Cox regression was used to analyse the impact of recipient
comorbidity (Table 5.10) as well as other recipient (Table 5.11), donor and
transplant (Table 5.12) variables on 2 year patient survival after
transplantation. Recipient comorbidities that were significantly associated
with 2 year patient survival on univariable analysis included diabetes, heart
failure, pacemaker, CVD, PVD and CLD. However, all recipient comorbidities
were considered for inclusion in the multivariable model. Other covariates
that were considered in the multivariable modelling process based on the
univariable results and a priori decisions included recipient age, primary
renal disease, time on dialysis, donor age, donor gender, donor BMI, donor
blood group, HLA MM level, transplant type and CIT.
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Table 5.10. Univariable Cox regression analysis of recipient comorbidities
affecting 2 year patient survival
Variables HR [95% CI] p-value
Diabetes 1.72 [1.05, 2.83] 0.032
Ischaemic heart disease 1.43 [0.71, 2.87] 0.315
Heart failure 6.56 [3.38, 12.77] <0.0001
Atrial fibrillation 1.61 [0.40, 6.56] 0.506
Cardiac valve replacement 1.55 [0.22, 11.17] 0.662
Pacemaker 6.45 [2.03, 20.46] 0.002
Cerebrovascular disease 3.86 [2.08, 7.15] <0.0001
Peripheral vascular disease 2.75 [1.20, 6.33] 0.017
Abdominal aortic aneurysm 4.92 [0.69, 35.41] 0.113
Chronic respiratory disease 1.04 [0.45, 2.40] 0.922
Chronic liver disease 3.21 [1.17, 8.79] 0.023
Blood borne viruses 0.59 [0.08, 4.22] 0.596
Malignancy 1.70 [0.82, 3.54] 0.154
Mental illness 1.13 [0.46, 2.79] 0.796
Dementia . . .
BMI
Underweight (<18.5) 0.56 [0.08, 4.07] 0.563
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 0.88 [0.51, 1.50] 0.637
Obese (≥30.0) 0.85 [0.44, 1.62] 0.613
CI; confidence interval, HR; hazard ratio, ref; reference.
(.) number is 0 or too small to calculate
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Table 5.11. Univariable Cox regression analysis of recipient factors
affecting 2 year patient survival
Variables HR [95% CI] p-value
Age (per 10 year increase) 1.76 [1.44, 2.15] <0.0001
Gender
Male 1 [ref]
Female 0.82 [0.51, 1.32] 0.407
Ethnicity
White 1 [ref]
Asian 0.80 [0.35, 1.85] 0.603
Black 0.85 [0.31, 2.33] 0.752
Other . . .
Primary renal disease
Polycystic kidney disease 1 [ref]
Diabetic nephropathy 4.28 [1.61, 11.41] 0.004
Glomerulonephritis 1.96 [0.72, 5.34] 0.190
Pyelonephritis 1.49 [0.45, 4.88] 0.511
Hypertensive nephropathy 3.83 [1.22, 12.07] 0.022
Renal vascular disease 3.57 [0.69, 18.38] 0.129
Other 2.93 [1.06, 8.05] 0.038
Uncertain 1.36 [0.39, 4.69] 0.628
Time on dialysis
Pre-emptive 1 [ref]
0 - 3 years 1.19 [0.52, 2.73] 0.674
> 3 years 3.96 [1.87, 8.36] 0.0003
Smoking status
Non-smoker 1 [ref]
Smoker 1.31 [0.68, 2.55] 0.424
Ex-smoker 0.74 [0.41, 1.32] 0.305
Previous transplant 1.07 [0.55, 2.08] 0.850
Highly sensitised (cRF≥85%) 1.37 [0.7, 2.66] 0.358
Recipient blood group
A 1 [ref]
B 1.15 [0.58, 2.28] 0.694
AB 0.82 [0.25, 2.69] 0.746
O 0.86 [0.52, 1.42] 0.559
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
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Table 5.12. Univariable Cox regression analysis of donor and transplant
factors affecting 2 year patient survival
Variables HR [95% CI] p-value
Donor variables
Donor Age (per 10 year increase) 1.40 [1.18, 1.66] 0.0001
Donor Gender
Male 1 [ref]
Female 1.70 [1.07, 2.71] 0.024
Donor Ethnicity
White 1 [ref]
Asian 0.76 [0.19, 3.11] 0.705
Black 1.71 [0.54, 5.45] 0.361
Other 0.94 [0.13, 6.77] 0.951
Donor BMI (kg/m2)
Underweight (<18.5) . . .
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 1.57 [0.90, 2.75] 0.115
Obese (≥30.0) 2.39 [1.30, 4.39] 0.005
Donor blood group
A 1 [ref]
B 0.71 [0.32, 1.59] 0.405
AB 1.09 [0.34, 3.55] 0.884




2 0.48 [0.22, 1.05] 0.064
3 0.63 [0.33, 1.18] 0.146
4 0.64 [0.30, 1.34] 0.237
Transplant type
Living donor KO 1 [ref]
Deceased donor KO 2.22 [1.27, 3.87] 0.005
SPK 1.72 [0.63, 4.69] 0.291
CIT (per hour) 1.05 [1.02, 1.09] 0.002
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
Recipient comorbidities found to be independent risk factors for patient
death after adjustment for confounding factors in the multivariable model
(Table 5.13) included heart failure (HR 3.37, 95% CI 1.69, 6.72, p=0.0005), CVD
(HR 2.51, 95% CI 1.32, 4.78, p=0.005) and CLD (HR 3.97, 95% CI 1.43, 11.04,
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p=0.008). The diabetes variable which was significant on univariable analysis
was explored in several different ways;
a) any diagnosis of diabetes
b) diabetes as a comorbidity only (excluding diabetes as primary renal
disease)
c) diabetes as primary renal disease only
d) type 1 diabetes
e) type 2 diabetes
Diabetes as a primary renal disease was the only diabetes variable that was
significant after adjustment for all other confounders in the multivariable
model, perhaps suggesting that the severity of the disease is the most
important factor for patient survival. Compared with polycystic kidney
disease, diabetic nephropathy (HR 4.20, 95% CI 1.51, 11.68, p=0.006),
glomerulonephritis (HR 2.78, 95% CI 1.01, 7.62, p=0.048) and hypertensive
nephropathy (HR 4.25, 95% CI 1.34, 13.48, p=0.014) as a primary renal disease
were associated with significantly worse patient survival. Other variables
significant in the multivariable model included recipient age (HR 1.71 per 10
year increase, 95% CI 1.38, 2.13, p<0.0001) and pre-transplant time on dialysis
(> 3 years on dialysis versus pre-emptive transplant, HR 2.88, 95% CI 1.31,
6.33, p=0.009). As with graft survival, the negative effect of dialysis on patient
survival was only significant for over 3 years on dialysis after adjustment for
confounding factors. The type of transplant did not significantly affect
patient survival. There was no evidence for a centre effect on patient survival
(change in -2 log-likelihood p=0.984) upon adding transplant centre as a
random effect in the model.
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Table 5.13. Multivariable Cox regression analysis of factors affecting 2
year patient survival
Variables HR [95% CI] p-value
Recipient comorbidities
Heart failure 3.37 [1.69, 6.72] 0.0005
Cerebrovascular disease 2.51 [1.32, 4.78] 0.005
Chronic liver disease 3.97 [1.43, 11.04] 0.008
Other variables
Recipient age (per 10 yr increase) 1.71 [1.38, 2.13] <0.0001
Primary renal disease
Polycystic kidney disease 1 [ref]
Diabetic nephropathy 4.20 [1.51, 11.68] 0.006
Glomerulonephritis 2.78 [1.01, 7.62] 0.048
Pyelonephritis 2.30 [0.69, 7.62] 0.174
Hypertensive nephropathy 4.25 [1.34, 13.48] 0.014
Renal vascular disease 3.25 [0.62, 16.90] 0.162
Other 4.26 [1.54, 11.82] 0.005
Uncertain 1.41 [0.41, 4.89] 0.589
Time on dialysis
Pre-emptive 1 [ref]
0 - 3 years 1.04 [0.45, 2.40] 0.929
> 3 years 2.88 [1.31, 6.33] 0.009
Transplant type
Living donor KO 1 [ref]
Deceased donor KO 1.10 [0.61, 1.99] 0.755
SPK 1.75 [0.55, 5.57] 0.343
CI; confidence interval, HR; hazard ratio, ref; reference
5.3.4. Impact of recipient comorbidity on 2 year transplant survival
A further analysis of a combined “transplant survival” outcome was
undertaken, where transplant failure was defined as the earliest of graft
failure or patient death. The outcome variable was missing for 5 of 2250
patients, thus the analysis was conducted on a cohort of 2245 patients. There
were 182 (8.1%) transplant failures within the 2 year follow up period (113
graft failures and 69 deaths), 183 (8.2%) patients were censored at last follow-
up and 1880 (83.7%) patients were censored at 2 years. Of the 183 patients
censored at last follow-up, median censoring time was 670 days, interquartile
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range 365 - 707 days. In all, 42 (23.1%) transplant failures occurred within the
first 30 days, 38 (20.9%) between 30 days and 6 months, 30 (16.5%) between
6 months and 1 year and 72 (39.6%) between 1 and 2 years post-
transplantation. Using the Kaplan-Meier method, transplant survival was
98.1% (95%CI 97.5 - 98.6) at 30 days, 96.4% (95%CI 95.5 - 97.1) at 6 months,
95.1% (95%CI 94.1 - 95.9) at 1 year and 91.7% (95%CI 90.5 - 92.8) at 2 years.
Univariable Cox regression analysis for 2 year transplant survival is shown in
Table 5.14, 5.15 and 5.16. Diabetes, heart failure, CVD and PVD were
significantly associated with transplant survival on univariable analysis. All
recipient comorbidities were considered for inclusion in the multivariable
model. Other variables that were also considered for inclusion in the
multivariable model included recipient age, recipient ethnicity, primary renal
disease, time on dialysis, previous transplantation, highly sensitised, donor
age, donor gender, donor BMI, transplant type and CIT.
143
Table 5.14. Univariable Cox regression analysis of recipient comorbidities
affecting 2 year transplant survival
Variables HR [95% CI] p-value
Diabetes 1.47 [1.05-2.05] 0.024
Ischaemic heart disease 1.21 [0.75-1.94] 0.437
Heart failure 3.71 [2.19-6.29] <0.0001
Atrial fibrillation 1.30 [0.48-3.51] 0.602
Cardiac valve replacement 0.63 [0.09-4.47] 0.640
Pacemaker 2.55 [0.81-7.97] 0.108
Cerebrovascular disease 2.46 [1.54-3.91] 0.0001
Peripheral vascular disease 2.18 [1.21-3.91] 0.009
Abdominal aortic aneurysm 1.99 [0.28-14.16] 0.494
Chronic respiratory disease 1.30 [0.80-2.11] 0.291
Chronic liver disease 1.92 [0.85-4.34] 0.115
Blood borne viruses 0.96 [0.36-2.58] 0.933
Malignancy 1.19 [0.69-2.04] 0.542
Mental illness 1.30 [0.75-2.24] 0.348
Dementia . . .
BMI
Underweight (<18.5) 1.10 [0.40-3.03] 0.854
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 1.13 [0.79-1.61] 0.500
Obese (≥30.0) 1.36 [0.92-2.02] 0.124
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
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Table 5.15. Univariable Cox regression analysis of recipient factors
affecting 2 year transplant survival
Variables HR [95% CI] p-value
Age (per 10 year increase) 1.21 [1.08-1.36] 0.0008
Gender
Male 1 [ref]
Female 0.82 [0.60-1.11] 0.199
Ethnicity
White 1 [ref]
Asian 0.95 [0.57-1.58] 0.832
Black 1.86 [1.17-2.97] 0.009
Other 0.35 [0.05-2.48] 0.293
Primary renal disease
Polycystic kidney disease 1 [ref]
Diabetic nephropathy 2.39 [1.33-4.30] 0.004
Glomerulonephritis 1.59 [0.89-2.83] 0.115
Pyelonephritis 1.40 [0.71-2.74] 0.331
Hypertensive nephropathy 2.52 [1.25-5.10] 0.010
Renal vascular disease 2.19 [0.73-6.55] 0.161
Other 2.18 [1.21-3.93] 0.009
Uncertain 1.62 [0.83-3.16] 0.154
Time on dialysis
Pre-emptive 1 [ref]
0 - 3 years 1.18 [0.72-1.95] 0.511
> 3 years 3.12 [1.97-4.94] <0.0001
Smoking status
Non-smoker 1 [ref]
Smoker 1.30 [0.64, 1.65] 0.905
Ex-smoker 0.88 [0.62, 1.25] 0.479
Previous transplant 1.52 [1.04-2.22] 0.030
Highly sensitised (cRF≥85%) 1.86 [1.27-2.73] 0.001
Recipient blood group
A 1 [ref]
B 0.91 [0.56, 1.50] 0.716
AB 0.73 [0.32, 1.68] 0.459
O 1.05 [0.77, 1.44] 0.750
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
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Table 5.16. Univariable Cox regression analysis of donor and transplant
factors affecting 2 year transplant survival
Variables HR [95% CI] p-value
Donor variables
Donor Age (per 10 year increase) 1.26 [1.13-1.40] <0.0001
Donor Gender
Male 1 [ref]
Female 1.28 [0.96-1.70] 0.099
Donor Ethnicity
White 1 [ref]
Asian 0.62 [0.23-1.67] 0.343
Black 1.40 [0.62-3.17] 0.414
Other 1.14 [0.37-3.58] 0.818
Donor BMI (kg/m2)
Underweight (<18.5) . . .
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 1.22 [0.87-1.71] 0.255
Obese (≥30.0) 1.46 [0.99-2.17] 0.059
Donor blood group
A 1 [ref]
B 0.62 [0.35, 1.12] 0.116
AB 1.01 [0.46, 2.42] 0.906




2 1.07 [0.63-1.83] 0.795
3 1.08 [0.67-1.74] 0.763
4 0.84 [0.48-1.47] 0.537
Transplant type
Living donor KO 1 [ref]
Deceased donor KO 2.01 [1.42, 2.85] <0.0001
SPK 1.18 [0.57, 2.42] 0.659
CIT (per hour) 1.05 [1.03, 1.07] <0.0001
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
Recipient comorbidities that independently increased the risk of transplant
failure after adjustment for relevant factors in the multivariable model (Table
5.17) included heart failure (HR 2.32, 95% CI 1.35, 3.99, p=0.002) and CVD (HR
1.65, 95% CI 1.01, 2.70, p=0.044). Other variables significant in the
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multivariable transplant survival model included a primary renal disease of
diabetic nephropathy (HR 2.42, 95% CI 1.29, 4.56, p=0.006) and hypertensive
nephropathy (HR 2.22, 95% CI 1.08, 4.56, p=0.030) compared with polycystic
kidney disease, pre-transplant time on dialysis (> 3 years on dialysis versus
pre-emptive transplant, HR 2.11, 95% CI 1.29, 3.45, p0.003), donor age (HR
1.16 per 10 year increase, 95% CI 1.03, 1.31, p=0.0014) and highly sensitised
(HR 1.54, 95% CI 1.02, 2.32, p=0.041). Recipient age and transplant type were
included in the model but did not show significant effects on transplant
survival. Including transplant centre as a random effect in the model did not
show any evidence for between-centre variation in transplant survival (change
in -2 log likelihood p=0.680).
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Table 5.17. Multivariable Cox regression analysis of factors affecting 2
year transplant survival
Variables HR [95% CI] p-value
Recipient comorbidities
Heart failure 2.32 1.35-3.99] 0.002
Cerebrovascular disease 1.65 [1.01-2.70] 0.044
Other variables
Recipient age (per 10 yr increase) 1.08 [0.95, 1.23] 0.250
Primary renal disease
Polycystic kidney disease 1 [ref]
Diabetic nephropathy 2.42 [1.29, 4.56] 0.006
Glomerulonephritis 1.72 [0.96, 3.08] 0.068
Pyelonephritis 2.45 [0.73, 2.89] 0.286
Hypertensive nephropathy 2.22 [1.08, 4.56] 0.030
Renal vascular disease 2.09 [0.70, 6.25] 0.190
Other 2.32 [1.28, 4.23] 0.006
Uncertain 1.49 [0.76, 2.93] 0.247
Time on dialysis
Pre-emptive 1 [ref]
0 - 3 years 1.01 [0.61, 1.68] 0.969
> 3 years 2.11 [1.29, 3.45] 0.003
Highly sensitised (cRF≥85%) 1.54 [1.02, 2.32] 0.041
Donor age (per 10 year increase) 1.16 [1.03, 1.31] 0.014
Transplant type
Living donor KO 1 [ref]
Deceased donor KO 1.35 [0.92, 1.97] 0.125
SPK 1.11 [0.49, 2.55] 0.801
CI; confidence interval, HR; hazard ratio, ref; reference
Several of the variables that were significant risk factors for graft survival
(PVD, obesity, recipient age, recipient ethnicity, transplant type, HLA MM
level) and patient survival (CLD, recipient age) were not found to be significant
in the model for transplant survival. A comparison of the multivariable
models for graft, patient and transplant survival is shown in Table 5.18.
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Table 5.18. Comparison of multivariable models for 2 year graft, patient and
transplant survival
Graft survival model Patient survival model Transplant survival model
PVD Heart failure Heart failure
Obesity Cerebrovascular disease Cerebrovascular disease
Chronic liver disease
Recipient age Recipient age Recipient age*
Transplant type Transplant type* Transplant type*
Time on dialysis Time on dialysis Time on dialysis
Recipient ethnicity* Primary renal disease Primary renal disease
Highly sensitised Highly sensitised
Donor age Donor age
HLA MM level
*p>0.05
A decision was made a priori to retain recipient age and transplant type in all models due to
clinical significance and as such these factors were not necessarily statistically significant
(p<0.05) in all models; where this is the case it is marked with an Asterix. Similarly, the ethnicity
variable did not quite reach statistical significance (p=0.089) but was retained in the model
due to clinical significance.
5.3.5. Sensitivity analyses
The same multivariable modelling techniques were employed to run a series
of sensitivity analyses, in order to test the robustness of the results. Sub-
cohorts of kidney only transplant recipients (n=2100), first transplant
recipients (n=1946) and deceased donor transplant recipients (n=1438) were
modelled using multivariable Cox regression for 2 year graft survival (Table
5.19), patient survival (Table 5.20) and transplant survival (Table 5.21). The
results in all sub-cohorts were largely comparable to the models for the full
study cohort.
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Table 5.19. 2 year graft survival multivariable models for sub-cohorts
Variables
Kidney only recipients [n=2100] First transplant recipients [n=1946] Deceased donor recipients [n=1438]
HR [95% CI] p-value HR [95% CI] p-value HR [95% CI] p-value
Peripheral vascular disease 2.66 [1.22, 5.80] 0.014 2.63 [1.12, 6.18] 0.026 3.09 [1.46, 6.52] 0.003
BMI
Underweight (<18.5) 1.71 [0.51, 5.69] 0.383 1.25 [0.29, 5.41] 0.764 0.82 [0.11, 6.17] 0.850
Normal (18.5 - 24.9) 1 [ref] 1 [ref] 1 [ref]
Overweight (25.0 - 29.9) 1.50 [0.92, 2.45] 0.102 1.14 [0.66, 1.99] 0.639 1.48 [0.86, 2.56] 0.162
Obese (≥30.0) 1.94 [1.15, 3.27] 0.013 1.83 [1.03, 3.23] 0.039 2.34 [1.34, 4.11] 0.003
Recipient age (per 10 years) 0.84 [0.70, 1.00] 0.052 0.81 [0.67, 0.99] 0.041 0.84 [0.68, 1.03] 0.098
Recipient ethnicity
White 1 [ref] 1 [ref] 1 [ref]
Asian 0.74 [0.35, 1.54] 0.422 0.90 [0.42, 1.90] 0.773 0.84 [0.40, 1.78] 0.654
Black 1.71 [0.94, 3.11] 0.082 1.45 [0.73, 2.89] 0.288 1.55 [0.81, 2.98] 0.189
Other 0.50 [0.07, 3.62] 0.491 0.71 [0.10, 5.23] 0.737 0.61 [0.08, 4.40] 0.617
Time on dialysis
Pre-emptive 1 [ref] 1 [ref] 1 [ref]
0 - 3 years 1.18 [0.57, 2.45] 0.661 1.18 [0.57, 2.46] 0.663 1.73 [0.60, 4.98] 0.311
> 3 years 2.12 [1.03, 4.36] 0.040 2.13 [1.01, 4.50] 0.046 2.94 [1.05, 8.27] 0.041
Highly sensitised (cRF≥85%) 2.27 [1.33, 3.85] 0.003 0.62 [0.15, 2.56] 0.510 2.10 [1.13, 3.90] 0.019
Transplant type
Living donor KO 1 [ref] 1 [ref] . . .
Deceased donor KO 1.93 [1.10, 3.37] 0.022 2.10 [1.08, 4.07] 0.029 1 [ref]
SPK . . . 1.30 [0.35, 4.77] 0.696 0.47 [0.13, 1.70] 0.251
Donor age (per 10 years) 1.23 [1.05, 1.42] 0.012 1.26 [1.05, 1.51] 0.013 1.26 [1.05, 1.51] 0.011
HLA MM group
1 1 [ref] 1 [ref] 1 [ref]
2 2.48 [1.06, 5.80] 0.037 4.33 [1.02, 18.42] 0.047 2.89 [1.07, 7.81] 0.036
3 2.06 [0.91, 4.65] 0.084 2.86 [0.68, 11.95] 0.151 2.19 [0.83, 5.76] 0.113
4 1.64 [0.58, 4.61] 0.352 3.29 [0.72, 15.10] 0.126 3.12 [0.96, 10.10] 0.058
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Table 5.20. 2 year patient survival multivariable models for sub-cohorts
Variables
Kidney only recipients [n=2100] First transplant recipients [n=1946] Deceased donor recipients [n=1438]
HR [95% CI] p-value HR [95% CI] p-value HR [95% CI] p-value
Heart failure 3.45 [1.72, 6.90] 0.0005 4.05 [1.98, 8.26] 0.0001 3.43 [1.63, 7.21] 0.001
Cerebrovascular disease 2.72 [1.42, 5.23] 0.003 2.01 [0.96, 4.22] 0.064 3.14 [1.57, 6.29] 0.001
Chronic liver disease 4.22 [1.51, 11.77] 0.006 4.12 [1.45, 11.70] 0.008 5.14 [1.80, 14.67] 0.002
Recipient age (per 10 years) 1.77 [1.42, 2.22] <0.0001 1.73 [1.06, 1.08] <0.0001 1.67 [1.29, 2.16] 0.0001
Primary renal disease
Polycystic kidney disease 1 [ref] 1 [ref] 1 [ref]
Diabetic nephropathy 4.10 [1.47, 11.43] 0.006 3.77 [1.35, 10.64] 0.012 2.74 [0.94, 7.96] 0.064
Glomerulonephritis 2.81 [1.02, 7.72] 0.045 2.87 [1.02, 8.04] 0.045 2.53 [0.90, 7.07] 0.077
Pyelonephritis 2.38 [0.72, 7.90] 0.156 2.08 [0.55, 7.83] 0.280 1.82 [0.48, 6.89] 0.377
Hypertensive nephropathy 4.35 [1.37, 13.82] 0.013 4.29 [1.29, 14.21] 0.017 4.33 [1.36, 13.81] 0.013
Renal vascular disease 3.30 [0.63, 17.20] 0.156 3.00 [0.58, 15.67] 0.193 3.36 [0.64, 17.57] 0.152
Other 4.36 [1.57, 12.10] 0.005 3.79 [1.30, 11.01] 0.014 2.12 [0.67, 6.75] 0.204
Uncertain 1.45 [0.42, 5.03] 0.156 1.46 [0.42, 5.06] 0.554 1.28 [0.37, 4.46] 0.699
Time on dialysis
Pre-emptive 1 [ref] 1 [ref] 1 [ref]
0 - 3 years 1.41 [0.55, 3.57] 0.475 0.86 [0.36, 2.05] 0.726 0.62 [0.23, 1.68] 0.350
> 3 years 3.25 [1.34, 7.91] 0.009 2.97 [1.32, 6.70] 0.009 1.96 [0.80, 4.77] 0.139
Transplant type
Living donor KO 1 [ref] 1 [ref] . . .
Deceased donor KO 1.08 [0.60, 1.96] 0.792 1.09 [0.55, 2.16] 0.801 1 [ref]
SPK . . . . . . 1.79 [0.56, 5.77] 0.329
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Table 5.21. 2 year transplant survival multivariable models for subcohorts
Variables
Kidney only recipients [n=2100] First transplant recipients [n=1946] Deceased donor recipients [n=1438]
HR [95% CI] p-value HR [95% CI] p-value HR [95% CI] p-value
Heart failure 2.37 [1.38, 4.07] 0.002 3.17 [1.81, 5.54] <0.0001 2.21 [1.20, 4.05] 0.011
Cerebrovascular disease 1.82 [1.10, 2.97] 0.018 1.48 [0.85, 2.56] 0.166 1.76 [1.04, 2.97] 0.035
Recipient age (per 10 years) 1.10 [0.97, 1.26] 0.151 1.07 [0.93, 1.24] 0.345 1.07 [0.91, 1.26] 0.425
Primary renal disease
Polycystic kidney disease 1 [ref] 1 [ref] 1 [ref]
Diabetic nephropathy 2.37 [1.26, 4.46] 0.007 2.47 [1.28, 4.80] 0.007 1.96 [0.99, 3.88] 0.053
Glomerulonephritis 1.73 [0.97, 3.09] 0.065 2.06 [1.11, 3.84] 0.023 1.58 [0.84, 2.98] 0.160
Pyelonephritis 1.47 [0.74, 2.92] 0.273 1.40 [0.62, 3.16] 0.425 1.44 [0.67, 3.12] 0.352
Hypertensive nephropathy 2.24 [1.09, 4.60] 0.028 2.42 [1.11, 5.24] 0.026 2.09 [0.96, 4.52] 0.063
Renal vascular disease 2.11 [0.70, 6.32] 0.182 2.12 [0.70, 6.46] 0.186 2.23 [0.73, 6.79] 0.157
Other 2.34 [1.28, 4.26] 0.006 2.43 [1.26, 4.66] 0.008 1.68 [0.85, 3.34] 0.138
Uncertain 1.50 [0.76, 2.95] 0.243 1.48 [0.72, 3.08] 0.290 1.34 [0.65, 2.18] 0.429
Time on dialysis
Pre-emptive 1 [ref] 1 [ref] 1 [ref]
0 - 3 years 1.06 [0.63, 1.81] 0.819 0.96 [0.57, 1.62] 0.962 1.08 [0.53, 2.18] 0.838
> 3 years 2.09 [1.25, 3.50] 0.005 2.21 [1.32, 3.69] 0.0003 2.28 [1.17, 4.45] 0.016
Highly sensitised 1.60 [1.06, 2.44] 0.027 0.80 [0.33, 1.96] 0.625 1.41 [0.86, 2.32] 0.177
Donor age (per 10 years) 1.13 [1.00, 1.27] 0.046 1.14 [1.01, 1.30] 0.047 1.20 [1.04, 1.37] 0.008
Transplant type
Living donor KO 1 [ref] 1 [ref] . . .
Deceased donor KO 1.36 [0.93, 1.99] 0.115 1.29 [0.84, 1.99] 0.249 1 [ref]
SPK . . . 0.99 [0.39, 2.50] 0.987 0.94 [0.41, 2.17] 0.881
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5.4. Discussion
In this national prospective cohort study, the key recipient comorbid
conditions that predict poorer survival outcomes within two years after
kidney transplantation have been identified. PVD and obesity were associated
with a two- to three- fold increased risk of graft failure within two years of
transplantation. Different comorbidities impacted on patient survival, and the
risk of death within two years of transplantation was approximately doubled
for CVD, tripled for heart failure and quadrupled for CLD. With
comprehensive adjustment for comorbidity and case-mix in this national
analysis, it was also possible to demonstrate no differences in survival
outcomes between the 23 transplant centres in the UK.
As well as analysing graft and patient survival separately, we also investigated
a combined transplant survival outcome defined as the earliest of graft failure
or patient death. This definition of transplant survival which incorporates
death with a functioning graft is often used in the transplant literature as it
demonstrates the overall success of the transplant.183, 185 However, we found
that this method failed to demonstrate the importance of several comorbidity
risk factors that were significant for graft survival (PVD, obesity) and patient
survival (CLD) separately. This is because the comorbidities affecting graft
and patient survival are different, therefore their effects are blunted when
analysing the composite end-point of transplant survival. This was also
apparent when considering confounding factors, where the effects of several
factors which influenced graft survival but not patient survival (recipient
ethnicity, transplant type, HLA MM level) were lost in the transplant survival
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model. A further problematic scenario was encountered with recipient age.
We found that while recipient age significantly increased the risk of patient
death, it actually reduced the risk of graft failure - a finding that is well
documented throughout the literature and is due to the decreased
immunocompetence of older age.186-188 Thus, the opposite effects of age on
graft and patient survival caused the effects to be essentially cancelled out in
the transplant survival analysis. This demonstrates the importance of
distinguishing between graft and patient survival when investigating factors
which impact on survival outcomes after kidney transplantation.
Graft survival rates for kidney transplantation have progressively improved
over time, largely due to advances in immunosuppressive therapies leading
to a reduction in the rate of rejection.13 Our results confirmed excellent overall
2 year graft survival rates of 94.8%, which is in keeping with national UK
transplant registry data for the period of the study.13 Previous research has
focussed on the influence of immunological, donor and transplant related
factors on graft survival,61, 184, 189 however the impact of recipient factors such
as comorbidity on the risk of graft failure have not been widely studied.
In this study, a history of PVD at the time of transplantation was found to
significantly increase the risk of graft failure by a factor of 2.77, after
adjustment for confounding factors. PVD is typically diagnosed clinically by
measuring the ankle-brachial pressure index (ABPI), and our results are in
agreement with a US study of 819 patients which reported a 2.77 fold increase
in the risk of graft failure for patients with a low ABPI (<0.9).190 Previous
studies have reported inferior transplant survival (uncensored for death)
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among PVD patients, largely due to death from cardiovascular causes.191-193
Our results contradict these findings, as we found PVD to be a risk factor for
death censored graft survival and not for patient survival or transplant
survival, after adjustment for other factors. However, these studies were
performed in earlier US patient cohorts. Improved management of
cardiovascular risk factors among the PVD patients in our more
contemporary UK cohort may explain why PVD patients were not at increased
risk of death in our study, and instead survived to demonstrate the intrinsic
negative effect of PVD on the graft. We were unable to confirm the mechanism
of graft loss among the patients with PVD in our study. However, there are a
number of means by which PVD may impact the success of a kidney
transplant. Pre-existing PVD of the aorta or iliac arteries may complicate the
positioning of the kidney graft, resulting in difficult anastomoses, cholesterol
emboli or hypoperfusion of the graft, and subsequent failure in the early post-
operative period.194, 195 In the longer term, de novo atherosclerotic lesions of
the transplant renal artery or proximal iliac artery can lead to transplant renal
artery stenosis, which if not recognised and treated promptly can have
devastating consequences including graft loss, refractory hypertension,
pulmonary oedema and ultimately patient death.196, 197 The majority of graft
failures among PVD patients in our study were early (within the first 30 days
post-transplantation), thus implying that graft loss was related to pre-existing
rather than de novo PVD. Patients with ESRD are at increased risk of
developing PVD, as renal impairment is a significant risk factor for the
disease.198 However, the impact of transplantation on the progression of pre-
existing PVD is not clear. There is some evidence that transplantation may
reduce the incidence of de novo PVD, when compared with patients remaining
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on the transplant waiting list.199 On the other hand, transplant recipients are
exposed to immunosuppressive drugs in the post-operative period which
often lead to hyperglycaemia, hypertension and hyperlipidaemia; all of which
are potent atherogenic factors which may lead to the development or
exacerbation of PVD.200-202 Despite being a high risk group, patients with PVD
still derive a significant survival benefit from transplantation over dialysis.203-
205 As such PVD should not preclude transplantation, but efforts should focus
on minimising cardiovascular risk factors, careful pre-operative planning,
maintaining a high index of suspicion to enable early detection of
complications in the graft and fully informed discussion with patients about
the increased risks of graft loss.
Obesity is a major public health issue.206 It was the most prevalent
comorbidity among the patients in this study, with 20.6% patients obese at
the time of transplantation. Obesity is an ongoing topic of controversy with
regard to patient suitability for kidney transplantation. Some centres do not
exclude patients with obesity from transplantation, while others restrict
access to the waiting list on the basis of specific BMI thresholds, which may
differ considerably between centres, and even between clinicians within the
same centre.6 This variability is not surprising given that current best practice
guidelines do not offer clear advice on the topic. UK Renal Association
guidelines suggest that obesity (BMI >30 kg/m2) is not an absolute
contraindication to transplantation, but that patients be screened rigorously
for cardiovascular disease, each case considered individually, and individuals
with a BMI >40 kg/m2 are less likely to benefit.125 The Kidney Health Australia
- Caring for Australasians with Renal Impairment (KHA-CARI) guidelines give
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similar recommendations.207 European renal best practice guidelines state that
patients with a BMI >30 kg/m2 should reduce weight before transplantation.208
Canadian society of transplantation guidelines recommend supervised
weight-loss for obese candidates, with target BMI < 30 kg/m2 but state that
whether a patient should be denied kidney transplantation solely on the basis
of obesity is a matter of debate.209 American guidelines do not offer specific
recommendations on obesity, and advise clinicians to refer to their specific
centre policy.210, 211 Although early single centre studies failed to show any
impact of obesity on graft survival,55, 212, 213 more recent multicentre analyses
and systematic reviews have confirmed that obesity does significantly reduce
graft survival.53, 214-217 Our results are in keeping with this evidence as we found
that obesity conferred a 1.96 fold increase in the risk of graft loss within 2
years. Obesity is a strong risk factor for the development of chronic kidney
disease (CKD) and ESRD,218 and there is growing evidence for the mechanisms
by which obesity leads to a decline in renal function in native kidneys. Obesity
induces glomerular hyperfiltration, hypertension, proteinuria,
glomerulomegaly and glomerulosclerosis, resulting in progressive renal
impairment.219-221 As well as changing renal haemodynamics, excess adipose
tissue produces adipokines that promote inflammation and glomerular
injury.222 Lipid accumulation in the kidney causing essentially a “fatty kidney”
also increases insulin resistance and further mediates glomerular damage via
cell dysfunction.223 It is not yet clear whether these same mechanisms could
explain the deleterious effect of obesity on transplanted kidneys. The fact
that the greater risk of graft loss for obese patients in our study was not
apparent until over a year post-transplantation, may support the theory of a
progressive pathological process. A study of 838 transplant recipients found
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that at 1 year post-transplant, higher BMI was associated with hyperfiltration
in the graft, which in turn was associated with graft loss.224 Another possible
explanation for inferior graft survival among obese transplant recipients, is
difficulties in achieving and maintaining the narrow therapeutic target
concentrations of immunosuppressive drugs.225 For obese CKD patients (not
receiving renal replacement therapy), there is some evidence that weight loss
significantly reduces proteinuria and may halt the progression of renal
impairment.226, 227 However, these findings have not been able to be reproduced
among patients undergoing transplantation. A large registry analysis of
kidney transplant recipients in the US found no benefit for pre-transplant
weight loss on graft or patient survival.228 Although, the study was limited by
the inability to determine whether weight loss was intentional or the result of
declining clinical  condition. The latter would of course confound survival
results. While we found that obesity was a risk factor for graft loss, we did
not find any significant effect for obesity on patient survival. This is
consistent with the results of a recent systematic review and meta-analysis
including 17 studies and 138,081 patients.215 This finding may be related to
the well-recognised obesity paradox in patients undergoing maintenance
dialysis, whereby increasing BMI is paradoxically associated with decreasing
mortality risk.229, 230 It is possible that obese patients on dialysis are in a better
clinical and nutritional state at the point of transplantation compared with
their non-obese counterparts,231 allowing them to cope better with the stresses
of transplantation. Hence, this may offset any negative association of obesity
on patient survival after transplantation. Despite the obesity paradox of
dialysis, obese patients still derive a significant survival benefit from
transplantation.54, 232, 233 A registry study in the UK showed a clear survival
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benefit for patients undergoing transplantation over those who remained on
the waiting list across all BMI bands, with a fivefold increase in survival for
transplanted patients.233 As well as being at higher risk of graft loss, obese
patients are also known to have higher rates of delayed graft function (DGF),
surgical site infection, wound dehiscence and incisional hernia following
transplantation.216, 234, 235 Obesity is a potentially reversible condition. However,
with worse outcomes after transplantation but better outcomes on dialysis,
there are complex and controversial questions surrounding the optimal
management of obese patients with ESRD. The results of the present study
can be used to carefully counsel patients with obesity about the increased
risks of graft loss. Further prospective studies are required to assess whether
pre-transplant weight loss can improve outcomes.
Patients with ESRD have a significantly elevated risk of cardiovascular disease
compared with the general population.171, 236 Although this risk is somewhat
alleviated by transplantation, cardiovascular events remain the leading cause
of post-transplant mortality.237 Thus, it was not unexpected that a number of
cardiovascular comorbidities were found to be significant risk factors for
patient death in the present study. Nevertheless, identifying and quantifying
these risks is vital for evidence-based decision making and patient
counselling. Heart failure led to a 3.37 increased risk of mortality within 2
years after kidney transplantation in the study. With the acknowledgement
that it can be difficult to make a clear distinction between heart failure and
fluid overload in patients on dialysis; the findings demonstrate that a
diagnosis of heart failure in the patient’s record predicts poorer survival,
irrespective of how the diagnosis was made or the exact pathophysiology. It
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is noteworthy that despite the significant detrimental effect of heart failure
on post-transplant survival, no effect was observed for ischaemic heart
disease. Cardiac risk factors are often pooled together in observational
studies, with a tendency to think of cardiac disease as denoting ischaemic
atherosclerotic disease only.238 This study is one of very few to examine the
distinct diagnoses separately. The findings support the results of a single
centre study which found that patients with pre-existing impaired left
ventricular systolic function were at significantly higher risk of both cardiac
mortality and all-cause mortality after transplantation, while cardiac
ischaemia was not.239 These results mirror the finding that among dialysis
patients, heart failure is a more potent predictor of death than ischaemic
heart disease.240 They could also signify that the current risk stratification of
patients with ischaemic heart disease in the context of renal transplantation
in the UK is effective. Previous research has shown that kidney
transplantation can improve the morphological and functional abnormalities
of heart failure.241, 242 However, such improvement is impeded by a longer
duration on dialysis pre-transplantation.242, 243 It is thought that this is the
result of a more prolonged exposure to uraemic toxins that are detrimental
to myocardial contractility.238, 244 This would suggest that patients with heart
failure would benefit from minimising time spent on dialysis and pursuing
early transplantation. Given the current deceased donor shortage and length
of the waiting list, it is likely that living donor kidney transplantation would
provide the best option for these patients.
CVD was identified as another significant risk factor for mortality, conferring
a 2.51 elevated risk of death within 2 years post-transplantation. It is known
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that patients with ESRD and kidney transplant recipients have more severe
carotid atherosclerosis than the general population and are at substantially
greater risk of stroke.245-248 A large US registry analysis demonstrated that
transplantation reduced the risk of cerebrovascular events from 11.8% to 6.8%
compared to patients remaining on the waiting list.249 However, previous CVD
remains a strong risk factor for further post-transplantation events and
mortality.247, 250, 251 Post-transplantation cerebrovascular events are associated
with high mortality,252 which is worse for haemorrhagic strokes (48%)
compared with ischaemic strokes (6%).251 In a prospective randomised
controlled trial including 1652 kidney transplant recipients (ALERT trial), the
use of Fluvastatin did not reduce the incidence cerebrovascular events or
mortality.251 Further trials are needed to assess the ability of therapies to
reduce the risk of further cerebrovascular events and mortality in this high
risk population.
CLD was associated with a 3.97 times greater risk of mortality in this study.
There is a paucity of published research regarding CLD and kidney transplant
outcomes. Previous studies have focussed on the role of hepatitis B and C
related liver disease as predictors of increased mortality after kidney
transplantation.253-255 To our knowledge, this is the first study to demonstrate
that CLD of any aetiology leads to reduced survival after kidney
transplantation. Further research is required to understand the underlying
mechanisms. A national survey of transplant surgeons demonstrated
substantial heterogeneity of opinion and current practices with regards to the
management of patients with compensated liver cirrhosis and ESRD.256 The
majority of respondents (69.5%) stated they would consider these patients for
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renal transplantation alone, 26.9% believed they could only be considered for
simultaneous liver-kidney transplantation, and 3.6% believed that this
population of patients were not suitable for kidney transplantation. The
results of our study can be used to quantify the risks of kidney
transplantation in patients with CLD in order to aid decision making and
discussion with patients.
Diabetes has long been recognised as a risk factor for mortality after
transplantation, primarily due to elevated cardiovascular risk.257 The survival
advantage of renal transplantation over dialysis for diabetic patients is also
well documented.7, 8, 258 However, more recently several studies have shown a
decrease in the post-transplant mortality of diabetic patients over time,
resulting in a narrowing of the mortality difference between diabetics and
non-diabetics to the point of largely eliminating it.259, 260 This has been
attributed to enhanced management of glycaemic control, increased use of
cardioprotective medications and improvement in post-operative care. This
may explain the finding in our study that having a diagnosis of diabetes was
only associated with inferior patient survival after transplantation if diabetes
was the cause of renal failure, and that there was no survival disadvantage
for patients with uncomplicated diabetes.
Pre-transplant time on dialysis is a well-recognised risk factor for inferior
graft and patient survival after transplantation.20 Compared with kidney
transplantation, dialysis is a less effective renal replacement therapy and
results in the accumulation of uraemia-related risk factors such as
inflammation, oxidative stress, malnutrition and hyperhomocysteinaemia,
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leading to increased cardiovascular risk.261 In a paired donor kidney analysis
in the US, Meier-Kriesche et al. demonstrated that the detrimental dose effect
of dialysis on graft loss and patient death after transplantation was evident
even after just 6 months on dialysis.19 This was confirmed in subsequent US
studies.262, 263 In our study, dialysis was only associated with inferior graft and
patient survival after a period of 3 years. It is known that mortality on dialysis
is significantly higher in the US than in the UK,114, 264 and this may explain some
of the difference between our results and those of the US studies.
Furthermore, improvements in dialysis care and outcomes over time may
account for the reduced effect of dialysis on survival in our more
contemporary cohort.265 This is supported by more recent analyses in
European cohorts showing a reduction in the influence of dialysis vintage on
transplantation outcomes in the current era.266, 267
It is long established that living donor kidney transplants provide superior
survival outcomes compared to deceased donor kidney transplants.18, 122
Despite this, there are few studies comparing outcomes of living and
deceased donor kidney transplant outcomes with adjustment for
comorbidity. In the present analysis we were able to account for significant
comorbidity variables in a fully adjusted multivariable model. This
demonstrated that 2 year graft survival was significantly better for living
donor versus deceased donor transplantation, however no significant
differences in patient survival were found. Of note, in the graft survival
model, the addition of the CIT variable caused the transplant type variable to
lose significance, indicating that the difference in graft survival between living
and deceased donor transplants can largely be explained by the difference in
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CIT. The lack of difference in patient survival suggests that recipient variables
including comorbidity may be more important for patient survival outcomes
within 2 years than the type of donor. These findings are in keeping with a
study which assessed the ability of a number of comorbidity indices in
predicting mortality after kidney transplantation in a cohort of UK transplant
recipients.268 In all multivariable models, comorbidity score and age were
significant, while donor type was not.
An important outcome of this study was that we did not find any evidence of
inter-centre variation in survival outcomes between the 23 UK transplant
centres. Reports from the UK Transplant Registry have identified several
centres in the UK with graft and patient survival rates lower than the national
rate,269 however, these registry analyses are not adjusted for recipient
comorbidity. Thus, our results would suggest that any centre disparities in
survival outcomes are due to variations in patient case-mix and comorbidity
and provide a strong argument for including prospectively collected
comorbidity data in future registry analyses. Our findings are in keeping with
a previous study of patients on renal replacement therapy (including dialysis
and transplant patients) in England, where nearly all variation in survival
between centres was explained by demographic and comorbidity variables
obtained by linkage to the Hospital Episode Statistics database.270 In contrast,
studies in the US and Canada have demonstrated persistent centre differences
in survival outcomes after transplantation despite adjustment for recipient
comorbidity and other prognostic factors.169, 271
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A major strength of the present study is that it is a prospective and
comprehensive analysis of a large cohort of transplant recipients from all UK
transplant centres. There are a number of limitations. We used relatively
broad definitions for each comorbidity and were unable to distinguish
between differing levels of severity or duration for each condition. All
comorbidity data were collected at the time of transplantation when patients
were recruited to the study. Therefore, we were unable to assess the
progression or improvement of each condition after transplantation, and
whether this impacted on outcomes. These limitations were compromises
that allowed us to prospectively collect data on a wide range of comorbid
conditions in a national cohort of transplant recipients. As it was not possible
to recruit the entire kidney transplant population, the study is at risk of
selection bias. It is reassuring that the distribution of age, gender and type of
transplant is similar in the study population versus the national kidney
transplant population. However, the study did include a significantly higher
proportion of White patients compared with the national kidney transplant
population. Therefore, the conclusions within this analysis are less certain for
patients from Black, Asian and other ethnic backgrounds. Finally, the results
from this observational study describe associations only and no causation
can be inferred.
The increasing prevalence of comorbidities in the ESRD population poses a
significant challenge for the assessment of patient suitability for kidney
transplantation as well as predicting the risks and outcomes of individual
patients. This study identifies several comorbidities that negatively impact on
2 year graft and patient survival after kidney transplantation. Obesity and
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PVD compromise graft survival, while heart failure, CVD and CLD increase
patient mortality. Interestingly, the identified comorbidities share common
risk factors that link them all to the so called metabolic syndrome. This global
epidemic is estimated to affect around a quarter of the world’s population,
and prevalence is increasing rapidly. Together with the ageing population,
this will lead to growing numbers of high risk patients being referred for
transplantation. The risk-benefit ratio of transplantation should be carefully
considered in these populations. With the recent landmark Montgomery
case,272 awareness and communication of risks to patients are increasingly
important. Our study provides up to date evidence that can be used during
the informed consent process, to correctly portray the risks conferred by
specific comorbidities on kidney transplantation. Further research is needed
to determine whether optimisation of these comorbid conditions can improve
graft and patient survival. Needless to say, prevention is better than cure, and
there should be increased efforts to address risk factors early in order to




Patient Reported Outcome Measures of Living Donor
and Deceased Donor Kidney Transplantation
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6.1. Introduction
Clinicians have a limited understanding of the impact a health condition or
treatment may have on patients’ daily lives.273 For this reason, patient
reported outcome measures (PROMS) are increasingly recognised as
important indicators in healthcare. PROMS allow patients to express their
assessment of their health and quality of life (QoL). PROMS is an umbrella
term that encompasses a wide variety of different outcomes including health
status, well-being, QoL and treatment satisfaction. The most widely used
instruments are those that measure patient reported health status, otherwise
known as health-related quality of life (HRQoL). PROMS may also be general
or condition-specific. While general PROMS are applicable for any condition
and allow comparison between different patient populations or with the
general population, condition-specific instruments are increasingly used to
provide more detailed information about patients’ experiences in the context
of a particular health condition.274, 275
With continued improvements in the life expectancy after kidney
transplantation, quality of life is an increasingly important issue for kidney
transplant recipients. Despite this, PROMS research in this population is
limited. Most studies have focussed on HRQoL in kidney transplant recipients
relative to patients on dialysis, and several meta-analyses have shown results
in favour of kidney transplantation.63, 103, 276 However, HRQoL only measures
patients’ perceived general health status, and there is lack of data for other
non-health related aspects of life (e.g. wellbeing) as well as domains which are
specific to having a renal condition (e.g. dietary restrictions). Furthermore,
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while it is widely acknowledged that living donor kidney transplantation
(LDKT) provides superior survival outcomes compared with deceased donor
kidney transplantation (DDKT), very few studies have explored whether any
differences in PROMS exist between the two recipient groups. It is known that
transplantation results in considerable psychological implications for
transplant recipients and that appropriate support is important to aid
adjustment and avoid issues which may undermine the success of the
transplant. However, the needs of LDKT and DDKT recipients may differ
considerably.277 In DDKT, the recipient’s transplant depends on the death of
another human being, while in the case of LDKT, donors are usually close
family members  who undergo a major operation with its own risks. Each of
these scenarios may lead to distinct psychosocial issues and consequences
on the recipient’s quality of life.278
This aim of this analysis was to compare a range of PROMS in LDKT and DDKT
recipients 1 year post-transplantation, adjusting for relevant




A subset of 262 kidney-only transplant recipients from the ATTOM incident
transplant cohort (n=2262) were invited to complete PROMS questionnaires
at 1 year post-transplantation. The subset was recruited in a quasi-random
manner (the first patient to be recruited to the incident transplant cohort each
month in each transplant centre). In each centre, recruitment took place over
a 12-month period, between 1st November 2011 and 31st March 2013 and
patients aged 18 – 75 years were eligible for recruitment. The subset included
both LDKT (n=118) and DDKT (n=144) recipients. For the purposes of this
analysis, multi-organ transplant recipients were excluded. A total of 214
(81.7%) patients responded and returned the questionnaires (Figure 6.1), all
of whom had a functioning graft at 1 year.
6.2.2. Data variables
The primary outcome measures were patients’ self-reported health status,
well-being, general quality of life, renal-dependent quality of life and
treatment satisfaction. These measures were assessed by the following
questionnaires (Table 6.1); EuroQol five dimensions (EQ-5D) including the
EuroQol visual analogue scale (VAS),279 the 12-item well-being questionnaire
(W-BQ12),280, 281 renal-dependent quality of life (RDQoL) which includes a
general quality of life measure,282 renal treatment satisfaction (RTSQs)283 and
renal treatment satisfaction change version (RTSQc)283. Questionnaires were
either posted to patients or were completed online, and were provided in
other languages if required.
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Figure 6.1. Study population
Table 6.1. PROMS questionnaires





 General health status




o Pain / Discomfort
o Anxiety / Depression








 Converted to weighted index score
using the value set for England275




 General health status
 Rating of health (today) on visual
analogue scale
 0 = worst health you can imagine


















 Single item question rated from -3




 17 aspects of life
 Rating of impact of renal condition
 Rating of importance of each aspect of
life
 Combined to give an average weighted
impact score







 Satisfaction with current renal treatment
 Rated from 6 (very satisfied) to 0 (very
dissatisfied) on 13 items







 Satisfaction with current renal treatment
compared with satisfaction with
previous renal treatment
 Rated from +3 (much more satisfied
now) to -3 (much less satisfied now) on
13 items
 Higher score indicates greater




Baseline demographic, socioeconomic and clinical variables were collected at
the time of transplantation (Appendix A.2). Variables of interest included:
(a) demographic variables: age, gender, ethnicity
(b) socioeconomic variables: civil status, highest qualification, employment
status, car ownership, home ownership, health literacy
(c) clinical variables: transplant type, primary renal disease, modified
Charlson Comorbidity Index (CCI), mental illness, body mass index (BMI),
smoking status, previous transplantation, pre-emptive transplantation
Variable definitions are given in Appendix A.3. A modified Charlson
Comorbidity Index (CCI) designed specifically for patients with ESRD was
calculated for each patient using the methods described in Chapter 2. In order
to reduce the number of degrees of freedom, the modified CCI was used
during modelling rather than considering each comorbidity variable
separately. The modified CCI was divided into 4 groups; 0, 1, 2 and ≥3. Mental
illness was included separately as this is not part of the modified CCI score,
but was hypothesised to be an important variable when analysing PROMS. BMI
was grouped in accordance with the World Health Organisation (WHO) BMI
classifications of Underweight (<18.5 kg/m2), Normal (18.5 - 24.9 kg/m2),
Overweight (25.0 - 29.9 kg/m2) and Obese (≥30.0 kg/m2).126
6.2.3. Statistical methods
Baseline characteristics of LDKT and DDKT recipients were presented as
numbers with percentages (%) and compared by chi-squared tests for
categorical data. The effect of the type of transplant received (LDKT vs DDKT)
on PROMS was analysed using generalised linear regression models adjusted
173
for all demographic, socioeconomic and clinical variables. The proportion of
missing data is shown in Table 6.2. In the PROMS subset, data could not be
assumed to be missing at random, and as such it was not appropriate to
undertake multiple imputation. Therefore, patients with missing data were
excluded and complete case analysis was performed. All data were analysed
using SAS®9.4 (SAS Institute Inc, Cary, USA).





Civil status 4 [1.9]
Qualifications 4 [1.9]
Employment status 4 [1.9]
Car ownership 4 [1.9]
Home ownership 4 [1.9]
Health Literacy 4 [1.9]
Primary renal disease 0 [0]
Modified CCI 0 [0]
Mental illness 0 [0]
BMI 18 [8.4]
Smoking status 28 [13.1]
Previous transplant 1 [0.5]
Pre-emptive transplant 0 [0]
EQ-5D 5 [2.3]








6.3.1. Study population characteristics
A comparison of baseline characteristics between LDKT and DDKT recipients
in the PROMS subset is displayed in Table 6.3. Compared to DDKT recipients,
a significantly higher proportion of LDKT recipients were younger, married
or living with a partner, had obtained qualifications, were employed, were car
and home owners, had normal health literacy, had mental illness and
underwent pre-emptive transplantation.







18 – 34 12 [10.0] 22 [23.4]
35 – 49 35 [29.2] 34 [36.2]
50 – 64 50 [41.7] 31 [33.0]
65 – 75 23 [19.2] 7 [7.5]
Gender 0.532
Male 79 [65.8] 58 [61.7]
Female 41 [34.2] 36 [38.3]
Ethnicity 0.073
White 100 [83.3] 89 [94.7]
Asian 10 [8.3] 3 [3.2]
Black 8 [6.7] 2 [2.1]
Other 2 [1.7] 0 [0]
Civil status 0.034
Married / Living with partner 65 [55.6] 61 [65.6]
Divorced / Separated / Widowed 29 [24.8] 10 [10.8]
Single 23 [19.7] 22 [23.7]
Qualifications 0.004
Higher education level 35 [29.9] 29 [31.2]
Secondary education level 63 [53.9] 59 [63.4]
No qualifications 19 [16.2] 5 [5.4]
Employment status 0.032
Employed 45 [38.5] 48 [51.6]
Unemployed 6 [5.1] 4 [4.3]
Long term sick / disability 29 [24.8] 21 [22.6]
Retired 32 [27.4] 11 [11.8]
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Other 5 [4.3] 9 [9.7]
Car ownership 101 [86.3] 89 [95.7] 0.022
Home ownership 71 [60.7] 69 [74.2] 0.039
Health literacy 0.049
Normal 105 [89.7] 90 [96.8]
Limited 12 [10.3] 3 [3.2]
Primary renal disease 0.069
Diabetic nephropathy 11 [9.2] 3 [3.2]
Glomerulonephritis 29 [24.2] 36 [38.3]
Polycystic kidney disease 24 [20.0] 13 [13.8]
Pyelonephritis 12 [10.0] 15 [16.0]
Hypertensive nephropathy 7 [5.8] 2 [2.1]
Renal vascular disease 3 [2.5] 0 [0]
Other 21 [17.5] 16 [17]
Uncertain 13 [10.8] 9 [9.6]
Modified CCI 0.534
0 93 [77.5] 78 [83.0]
1 10 [8.3] 8 [8.5]
2 10 [8.3] 6 [6.4]
≥3 7 [5.8] 2 [2.1]
Mental illness 2 [1.7] 7 [7.5] 0.037
BMI (kg/m2) 0.873
<18.5 (underweight) 3 [2.8] 2 [2.3]
18.5 – 24.9 (normal) 40 [36.7] 37 [42.5]
25.0 – 29.9 (overweight) 45 [41.3] 33 [37.9]
>=30 (obese) 21 [19.3] 15 [17.2]
Smoking status 0.353
Non-smoker 68 [66.0] 48 [57.8]
Smoker 9 [8.7] 6 [7.2]
Ex-smoker 26 [25.2] 29 [34.9]
Previous transplant 15 [12.6] 15 [16.0] 0.485
Pre-emptive transplantation 14 [11.7] 38 [40.4] <0.0001
Data are number [%]. P-values are for chi-squared test.
Data are missing for some participants and excluded from percentage calculations. Numbers
of missing data are shown in Table 6.2.
6.3.2. PROMS of LDKT vs DDKT
Median values for each PROMs outcome is shown for DDKT and LDKT
recipients in Table 6.4. Univariable differences in PROMS between LDKT and
DDKT recipients are shown in Table 6.5 with their 95% confidence intervals
(95% CI). Compared to DDKT recipients, LDKT recipients had significantly
higher scores for the EQ-5D VAS, general QoL, RDQoL and RTSQs (e.g. for
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LDKT recipients the predicted EQ-5D VAS score was 4.51 units higher than
for DDKT recipients, p=0.040).
Table 6.4. Median values for PROMS
Variable DDKT LDKT





117 0.90 (0.79–1.00) 92 0.94 (0.83–1.00)
EQ-5D VAS 0-100 119 80 (70-90) 93 85 (80-90)
WBQ12 0-36 120 27 (21-30.5) 93 28 (24-32)
General
QoL
-3 to +3 120 1 (1-2) 94 2 (1-2)




RTSQs 0-78 120 70.5 (64–77) 93 74 (68-77)
RTSQc -39 to +39 113 33 (27–39) 93 35 (27–38)






EQ-5D Utility 0.04 [-0.11, 0.09] 0.121
EQ-5D VAS 4.51 [0.20, 8.82] 0.040
WBQ12 1.40 [-0.45, 3.26] 0.138
General QoL 0.42 [0.14, 0.69] 0.003
RDQoL 0.77 [0.25, 1.30] 0.004
RTSQs 3.51 [1.01, 6.01] 0.006
RTSQc 0.05 [-3.23, 3.14] 0.975
Multivariable generalised linear regression models were created for each of
the PROMS outcomes. Each model included transplant type as the variable of
interest and was adjusted for recipient age, gender, ethnicity, civil status,
qualifications, employment status, car ownership, home ownership, health
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literacy, primary renal disease, modified CCI, mental illness, BMI, smoking
status, previous transplantation and pre-emptive transplantation.
There was no significant difference in EQ-5D utility scores between LDKT and
DDKT recipients in the adjusted multivariable model (parameter estimate
0.04, 95% CI -0.02, 0.10, p=0.231) (Table 6.6). The model showed that
significantly higher EQ-5D utility scores were reported by single patients
(compared with married patients or patients living with a partner) and
patients with a primary renal disease of glomerulonephritis, polycystic kidney
disease or pyelonephritis (compared with diabetic nephropathy as a primary
renal disease). Unemployed patients and those on long term sick leave or off
work due to disability reported significantly lower EQ-5D utility scores
compared with employed patients.
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LDKT 0.04 -0.02 0.10 0.231
Age group
18 – 34 [REF]
35 – 49 0.01 -0.09 0.10 0.886
50 – 64 0.04 -0.07 0.14 0.486
65 – 75 0.04 -0.09 0.18 0.544
Gender
Male [REF]
Female -0.04 -0.09 0.02 0.236
Ethnicity
White [REF]
Asian -0.10 -0.20 0.003 0.058
Black 0.07 -0.07 0.20 0.340
Other 0.02 -0.22 0.25 0.885
Civil status
Married / Living with partner [REF]
Divorced / Separated /
Widowed
0.04 -0.04 0.12 0.286
Single 0.13 0.04 0.22 0.005
Qualifications
Higher education level [REF]
Secondary education level 0.01 -0.06 0.07 0.862
No qualifications 0.06 -0.04 0.17 0.244
Employment status
Employed [REF]
Unemployed -0.18 -0.33 -0.02 0.025
Long term sick / disability -0.12 -0.19 -0.04 0.004
Retired 0.01 -0.08 0.10 0.832
Other 0.004 -0.10 0.11 0.943
Car ownership
Yes [REF]
No 0.05 -0.06 0.15 0.375
Home ownership
Yes [REF]
No -0.02 -0.10 0.05 0.570
Health literacy
Normal [REF]
Limited -0.08 -0.21 0.05 0.221
Primary renal disease
Diabetic nephropathy [REF]
Glomerulonephritis 0.22 0.08 0.36 0.002
Polycystic kidney disease 0.23 0.09 0.37 0.001
Pyelonephritis 0.25 0.10 0.40 0.001
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Hypertensive nephropathy 0.16 -0.01 0.33 0.072
Renal vascular disease -0.05 -0.32 0.22 0.717
Other 0.23 0.09 0.37 0.001
Uncertain 0.09 -0.07 0.24 0.262
Modified CCI
0 [REF]
1 0.10 -0.01 0.20 0.076
2 -0.01 -0.11 0.09 0.795
≥3 -0.06 -0.21 0.08 0.406
Mental illness
No [REF]
Yes -0.10 -0.22 0.01 0.076
BMI (kg/m2)
<18.5 (underweight) 0.05 -0.12 0.22 0.557
18.5 – 24.9 (normal) [REF]
25.0 – 29.9 (overweight) 0.005 -0.06 0.07 0.880
>=30 (obese) 0.003 -0.08 0.08 0.948
Smoking status
Non-smoker [REF]
Smoker -0.06 -0.17 0.04 0.205
Ex-smoker 0.04 -0.02 0.10 0.230
Previous transplant
No [REF]
Yes 0.04 -0.04 0.12 0.320
Pre-emptive transplantation
No [REF]
Yes 0.03 -0.04 0.10 0.420
Table 6.7 shows the multivariable model for EQ-5D VAS scores. With all other
variables held constant, EQ-5D VAS scores were predicted to be 6.75 units
higher for LDKT recipients than DDKT recipients on a scale of 0-100 (95% CI
1.21, 12.30, p=0.017). The R2 value for the model was 0.375, meaning the
model explained 37.5% of variance in scores. Older patients (compared with
younger patients), single patients (compared with married patients), patients
with polycystic kidney disease (compared with diabetic nephropathy patients)
and patients with a modified CCI score of 1 (compared to 0) reported
significantly better EQ-5D VAS scores. Patients on long term sick leave and
smokers reported significantly lower EQ-5D VAS scores.
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LDKT 6.75 1.21 12.30 0.017
Age group
18 – 34 [REF]
35 – 49 8.64 0.16 17.12 0.046
50 – 64 10.60 1.15 20.06 0.028
65 – 75 10.76 -1.66 23.19 0.089
Gender
Male [REF]
Female -3.13 -8.49 2.22 0.249
Ethnicity
White [REF]
Asian -8.15 -17.89 1.59 0.100
Black 3.54 -9.51 16.60 0.592
Other -1.40 -23.42 20.62 0.900
Civil status
Married / Living with partner [REF]
Divorced / Separated /
Widowed
2.56 -4.44 9.56 0.471
Single 9.06 0.81 17.31 0.032
Qualifications
Higher education level [REF]
Secondary education level -0.86 -6.54 4.83 0.766
No qualifications -2.16 -11.97 7.65 0.664
Employment status
Employed [REF]
Unemployed -7.72 -22.32 6.87 0.297
Long term sick / disability -9.31 -16.39 -2.23 0.010
Retired -2.77 -11.17 5.62 0.515
Other 4.25 -5.68 14.18 0.398
Car ownership
Yes [REF]
No -1.55 -11.23 8.12 0.751
Home ownership
Yes [REF]
No 6.27 -0.86 13.40 0.084
Health literacy
Normal [REF]
Limited -2.47 -13.75 8.80 0.665
Primary renal disease
Diabetic nephropathy [REF]
Glomerulonephritis 8.99 -3.84 21.81 0.168
Polycystic kidney disease 14.86 2.04 27.68 0.023
Pyelonephritis 13.67 -0.17 27.52 0.053
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Hypertensive nephropathy 14.42 -1.83 30.68 0.082
Renal vascular disease -17.57 -42.71 7.58 0.169
Other 12.55 -0.20 25.29 0.054
Uncertain 3.19 -11.37 17.75 0.665
Modified CCI
0 [REF]
1 11.17 1.25 21.09 0.028
2 1.30 -7.77 10.37 0.777
≥3 -4.96 -18.77 8.85 0.479
Mental illness
No [REF]
Yes -8.48 -19.24 2.28 0.122
BMI (kg/m2)
<18.5 (underweight) -3.65 -19.42 12.12 0.648
18.5 – 24.9 (normal) [REF]
25.0 – 29.9 (overweight) 0.55 -5.14 6.25 0.848
>=30 (obese) -1.86 -9.28 5.57 0.622
Smoking status
Non-smoker [REF]
Smoker -9.58 -18.72 -0.45 0.040
Ex-smoker -3.86 -9.72 2.00 0.195
Previous transplant
No [REF]
Yes -0.07 -7.77 7.63 0.986
Pre-emptive transplantation
No [REF]
Yes -3.74 -10.09 2.61 0.246
The multivariable model for WBQ12 scores is shown in Table 6.8. WBQ12
scores were 2.58 units higher for LDKT recipients than DDKT recipients on a
scale of 0 to 36 (95% CI 0.22, 4.95, p=0.033) with adjustment for all other
factors in the model. The R2 value for the model was 0.424. The model also
showed that wellbeing scores were significantly worse for females, Asian
patients and patients with mental illness.  Patients with glomerulonephritis,
polycystic kidney disease, pyelonephritis and hypertensive nephropathy
reported significantly better wellbeing than patients with diabetic
nephropathy as the primary renal disease.
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LDKT 2.58 0.22 4.95 0.033
Age group
18 – 34 [REF]
35 – 49 -0.12 -3.74 3.50 0.946
50 – 64 -0.03 -4.07 4.01 0.988
65 – 75 1.45 -3.86 6.76 0.590
Gender
Male [REF]
Female -2.70 -4.99 -0.42 0.021
Ethnicity
White [REF]
Asian -4.20 -8.36 -0.04 0.048
Black 3.93 -1.65 9.50 0.166
Other 2.08 -7.32 11.49 0.662
Civil status
Married / Living with partner [REF]
Divorced / Separated /
Widowed
0.75 -2.24 3.74 0.622
Single 2.78 -0.74 6.30 0.121
Qualifications
Higher education level [REF]
Secondary education level 0.73 -1.70 3.15 0.553
No qualifications 1.25 -2.94 5.44 0.555
Employment status
Employed [REF]
Unemployed -3.85 -10.08 2.39 0.225
Long term sick / disability -0.81 -3.83 2.21 0.596
Retired 1.84 -1.74 5.43 0.311
Other 0.73 -3.51 4.97 0.733
Car ownership
Yes [REF]
No 3.69 -0.44 7.83 0.079
Home ownership
Yes [REF]
No -1.66 -4.70 1.39 0.284
Health literacy
Normal [REF]
Limited -0.90 -5.72 3.91 0.712
Primary renal disease
Diabetic nephropathy [REF]
Glomerulonephritis 7.89 2.41 13.37 0.005
Polycystic kidney disease 8.07 2.60 13.55 0.004
Pyelonephritis 8.90 2.99 14.82 0.004
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Hypertensive nephropathy 8.08 1.14 15.02 0.023
Renal vascular disease 2.20 -8.54 12.94 0.686
Other 9.11 3.66 14.55 0.001
Uncertain 2.65 -3.57 8.86 0.401
Modified CCI
0 [REF]
1 4.02 -0.22 8.25 0.063
2 1.13 -2.75 5.00 0.565
≥3 -0.89 -6.79 5.00 0.765
Mental illness
No [REF]
Yes -9.32 -13.91 -4.72 0.0001
BMI (kg/m2)
<18.5 (underweight) 3.13 -3.61 9.86 0.360
18.5 – 24.9 (normal) [REF]
25.0 – 29.9 (overweight) 1.60 -0.84 4.03 0.196
>=30 (obese) 0.20 -2.97 3.37 0.900
Smoking status
Non-smoker [REF]
Smoker -1.98 -5.89 1.92 0.316
Ex-smoker -0.51 -3.02 1.99 0.685
Previous transplant
No [REF]
Yes 2.71 -0.57 6.00 0.105
Pre-emptive transplantation
No [REF]
Yes -0.27 -2.98 2.44 0.844
Table 6.9 shows the multivariable analysis of factors associated with general
QoL. With all other variables held constant, general QoL scores were 0.41 units
higher for LDKT recipients than DDKT recipients on a scale of -3 to +3 (95%
CI 0.06, 0.75, p=0.022). The R2 value for the model was 0.415. General QoL
was significantly worse for unemployed patients, patients on long term sick
leave or not working due to disability, those with a higher CCI score and
patients with mental illness. Single patients reported significantly better
general QoL than married or cohabiting patients.
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LDKT 0.41 0.06 0.75 0.022
Age group
18 – 34 [REF]
35 – 49 -0.08 -0.60 0.44 0.764
50 – 64 -0.39 -0.96 0.19 0.187
65 – 75 -0.17 -0.94 0.60 0.660
Gender
Male [REF]
Female -0.21 -0.55 0.12 0.204
Ethnicity
White [REF]
Asian -0.38 -0.99 0.23 0.218
Black 0.48 -0.34 1.29 0.247
Other -0.06 -1.44 1.31 0.931
Civil status
Married / Living with partner [REF]
Divorced / Separated /
Widowed
0.32 -0.12 0.76 0.149
Single 0.52 0.01 1.03 0.045
Qualifications
Higher education level [REF]
Secondary education level -0.05 -0.40 0.31 0.794
No qualifications 0.46 -0.15 1.07 0.137
Employment status
Employed [REF]
Unemployed -1.08 -1.99 -0.16 0.021
Long term sick / disability -0.50 -0.94 -0.06 0.027
Retired 0.35 -0.18 0.87 0.194
Other 0.43 -0.18 1.03 0.164
Car ownership
Yes [REF]
No -0.21 -0.81 0.40 0.501
Home ownership
Yes [REF]
No -0.24 -0.68 0.21 0.291
Health literacy
Normal [REF]
Limited 0.14 -0.57 0.84 0.703
Primary renal disease
Diabetic nephropathy [REF]
Glomerulonephritis 0.44 -0.37 1.24 0.284
Polycystic kidney disease 0.47 -0.33 1.27 0.245
Pyelonephritis 0.005 -0.86 0.87 0.991
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Hypertensive nephropathy 0.80 -0.22 1.81 0.123
Renal vascular disease -1.07 -2.64 0.50 0.180
Other 0.48 -0.31 1.28 0.234
Uncertain -0.04 -0.95 0.87 0.929
Modified CCI
0 [REF]
1 0.33 -0.29 0.95 0.295
2 -0.62 -1.18 -0.05 0.033
≥3 -0.44 -1.31 0.42 0.310
Mental illness
No [REF]
Yes -0.86 -1.53 -0.19 0.013
BMI (kg/m2)
<18.5 (underweight) 0.25 -0.73 1.24 0.615
18.5 – 24.9 (normal) [REF]
25.0 – 29.9 (overweight) 0.08 -0.27 0.44 0.654
>=30 (obese) -0.12 -0.58 0.35 0.613
Smoking status
Non-smoker [REF]
Smoker -0.25 -0.82 0.32 0.383
Ex-smoker 0.01 -0.36 0.37 0.964
Previous transplant
No [REF]
Yes 0.31 -0.18 0.79 0.211
Pre-emptive transplantation
No [REF]
Yes 0.33 -0.06 0.72 0.101
Table 6.10 shows the multivariable model for RDQoL. With adjustment for all
other variables, RDQoL scores were predicted to be 0.95 units higher for LDKT
recipients than DDKT recipients on a scale of -9 to +3 (95% CI 0.29, 1.61,
p=0.005). The R2 value for the model was 0.444. Asian patients and patients
with mental illness reported significantly worse renal dependent QoL, while
overweight and obese patients reported significantly better RDQoL scores.
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LDKT 0.95 0.29 1.61 0.005
Age group
18 – 34 [REF]
35 – 49 -0.30 -1.29 0.69 0.552
50 – 64 -0.14 -1.25 0.96 0.795
65 – 75 0.08 -1.39 1.55 0.916
Gender
Male [REF]
Female -0.14 -0.78 0.49 0.654
Ethnicity
White [REF]
Asian -3.06 -4.22 -1.90 <0.0001
Black -1.04 -2.59 0.51 0.188
Other -0.13 -2.75 2.49 0.922
Civil status
Married / Living with partner [REF]
Divorced / Separated /
Widowed
-0.03 -0.86 0.80 0.944
Single 0.94 -0.04 1.91 0.059
Qualifications
Higher education level [REF]
Secondary education level -0.48 -1.15 0.19 0.162
No qualifications 0.25 -0.92 1.41 0.677
Employment status
Employed [REF]
Unemployed 0.18 -1.56 1.91 0.842
Long term sick / disability 0.19 -0.65 1.04 0.650
Retired 0.79 -0.21 1.79 0.118
Other 1.14 -0.01 2.30 0.052
Car ownership
Yes [REF]
No 1.15 0.003 2.30 0.051
Home ownership
Yes [REF]
No -0.15 -1.00 0.70 0.723
Health literacy
Normal [REF]
Limited -0.33 -1.68 1.01 0.624
Primary renal disease
Diabetic nephropathy [REF]
Glomerulonephritis 0.16 -1.37 1.69 0.837
Polycystic kidney disease 0.32 -1.20 1.85 0.675
Pyelonephritis 0.72 -0.93 2.37 0.387
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Hypertensive nephropathy -0.24 -2.18 1.69 0.803
Renal vascular disease 0.11 -2.89 3.10 0.945
Other 1.01 -0.51 2.52 0.192
Uncertain 0.02 -1.71 1.76 0.977
Modified CCI
0 [REF]
1 0.26 -0.92 1.44 0.666
2 0.50 -0.58 1.58 0.365
≥3 0.68 -0.97 2.32 0.417
Mental illness
No [REF]
Yes -2.47 -3.75 -1.19 0.0002
BMI (kg/m2)
<18.5 (underweight) 0.51 -1.37 2.39 0.593
18.5 – 24.9 (normal) [REF]
25.0 – 29.9 (overweight) 0.84 0.16 1.52 0.016
>=30 (obese) 1.05 0.16 1.93 0.021
Smoking status
Non-smoker [REF]
Smoker -0.41 -1.50 0.67 0.453
Ex-smoker -0.26 -0.96 0.44 0.468
Previous transplant
No [REF]
Yes -0.36 -1.28 0.55 0.436
Pre-emptive transplantation
No [REF]
Yes 0.04 -0.71 0.79 0.909
The multivariable model for RTSQs is shown in Table 6.11. RTSQs scores were
7.06 units higher for LDKT recipients than DDKT recipients on a scale of 0 to
78 (95% CI 3.96, 10.16, p<0.0001), after adjustment for all other variables. The
R2 value for the model was 0.429. Patients with no qualifications and limited
health literacy reported significantly better RTSQs scores. Patients with a
modified CCI score of 2, patients with mental illness and those who received
a pre-emptive transplant (borderline significance p=0.051) reported worse
satisfaction with their transplant.
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LDKT 7.06 3.96 10.16 <0.0001
Age group
18 – 34 [REF]
35 – 49 0.80 -3.95 5.54 0.740
50 – 64 2.98 -2.30 8.27 0.266
65 – 75 5.78 -1.17 12.74 0.102
Gender
Male [REF]
Female -0.15 -3.14 2.85 0.922
Ethnicity
White [REF]
Asian -5.27 -10.72 0.17 0.058
Black 3.86 -3.45 11.16 0.298
Other -1.94 -14.25 10.38 0.756
Civil status
Married / Living with partner [REF]
Divorced / Separated /
Widowed
2.88 -1.04 6.79 0.149
Single 2.15 -2.47 6.76 0.359
Qualifications
Higher education level [REF]
Secondary education level 0.77 -2.41 3.95 0.633
No qualifications 8.44 2.95 13.93 0.003
Employment status
Employed [REF]
Unemployed -7.80 -15.97 0.36 0.061
Long term sick / disability -3.18 -7.14 0.78 0.115
Retired -2.42 -7.12 2.28 0.310
Other 2.70 -2.85 8.26 0.338
Car ownership
Yes [REF]
No -1.71 -7.12 3.71 0.534
Home ownership
Yes [REF]
No 0.50 -3.49 4.49 0.805
Health literacy
Normal [REF]
Limited 7.18 0.87 13.48 0.026
Primary renal disease
Diabetic nephropathy [REF]
Glomerulonephritis 2.94 -4.23 10.12 0.418
Polycystic kidney disease 1.20 -5.97 8.37 0.742
Pyelonephritis 1.87 -5.88 9.62 0.634
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Hypertensive nephropathy 4.74 -4.36 13.83 0.305
Renal vascular disease -1.77 -15.83 12.30 0.804
Other 5.98 -1.15 13.11 0.100
Uncertain -1.14 -9.29 7.00 0.782
Modified CCI
0 [REF]
1 5.10 -0.45 10.65 0.071
2 -6.56 -11.64 -1.49 0.012
≥3 4.03 -3.69 11.75 0.304
Mental illness
No [REF]
Yes -8.02 -14.04 -2.00 0.009
BMI (kg/m2)
<18.5 (underweight) -8.72 -17.54 0.10 0.053
18.5 – 24.9 (normal) [REF]
25.0 – 29.9 (overweight) 2.19 -0.99 5.38 0.176
>=30 (obese) 1.17 -2.98 5.32 0.578
Smoking status
Non-smoker [REF]
Smoker -4.92 -10.03 0.19 0.059
Ex-smoker -1.90 -5.18 1.37 0.253
Previous transplant
No [REF]
Yes -0.16 -4.47 4.15 0.942
Pre-emptive transplantation
No [REF]
Yes -3.54 -7.10 0.01 0.051
Table 6.12 shows the results of the multivariable model for RTSQc. With all
other variables held constant, RTSQc scores were 6.40 units higher for LDKT
recipients than DDKT recipients on a scale of -39 to +39 (95% CI 2.44, 10.36,
p=0.0002). The R2 value for the model was 0.430. Unemployed patients, those
with a modified CCI score of 2, underweight patients and patients who
underwent pre-emptive transplantation reported significantly worse RTSQc
scores, while patients with limited health literacy and hypertensive
nephropathy reported significantly better scores.
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LDKT 6.40 2.44 10.36 0.002
Age group
18 – 34 [REF]
35 – 49 1.97 -4.04 7.97 0.518
50 – 64 5.26 -1.37 11.88 0.119
65 – 75 3.97 -4.78 12.73 0.371
Gender
Male [REF]
Female 0.47 -3.39 4.33 0.810
Ethnicity
White [REF]
Asian -0.86 -7.66 5.95 0.804
Black 3.19 -5.93 12.31 0.490
Other -2.35 -17.77 13.07 0.764
Civil status
Married / Living with partner [REF]
Divorced / Separated /
Widowed
5.00 -0.13 10.12 0.056
Single 4.50 -1.34 10.34 0.130
Qualifications
Higher education level [REF]
Secondary education level -0.02 -4.09 4.05 0.991
No qualifications 3.90 -3.11 10.90 0.273
Employment status
Employed [REF]
Unemployed -13.49 -24.70 -2.28 0.019
Long term sick / disability -4.71 -9.76 0.34 0.068
Retired -2.94 -8.86 2.98 0.328
Other 2.90 -4.02 9.82 0.408
Car ownership
Yes [REF]
No -5.04 -12.17 2.10 0.165
Home ownership
Yes [REF]
No -0.32 -5.34 4.71 0.901
Health literacy
Normal [REF]
Limited 10.20 1.81 18.59 0.018
Primary renal disease
Diabetic nephropathy [REF]
Glomerulonephritis 4.21 -4.82 13.24 0.358
Polycystic kidney disease 0.43 -8.65 9.50 0.926
Pyelonephritis 0.20 -9.58 9.98 0.968
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Hypertensive nephropathy 11.94 0.54 23.35 0.040
Renal vascular disease 1.78 -16.00 19.55 0.844
Other 7.76 -1.14 16.66 0.087
Uncertain 2.39 -7.94 12.72 0.648
Modified CCI
0 [REF]
1 4.58 -2.37 11.53 0.195
2 -10.59 -16.93 -4.25 0.001
≥3 4.95 -4.77 14.67 0.315
Mental illness
No [REF]
Yes -6.45 -13.97 1.07 0.092
BMI (kg/m2)
<18.5 (underweight) -12.79 -23.79 -1.80 0.023
18.5 – 24.9 (normal) [REF]
25.0 – 29.9 (overweight) 1.95 -2.16 6.06 0.349
>=30 (obese) 3.41 -1.86 8.68 0.203
Smoking status
Non-smoker [REF]
Smoker 1.11 -5.32 7.55 0.733
Ex-smoker -3.90 -8.07 0.28 0.067
Previous transplant
No [REF]
Yes 0.43 -5.01 5.87 0.876
Pre-emptive transplantation
No [REF]
Yes -10.43 -15.02 -5.84 <0.0001
A summary of PROMS outcomes for LDKT vs DDKT recipients from the
multivariable models is shown in Table 6.13. Except for the EQ-5D utility
questionnaire, all other PROMS questionnaires demonstrated better outcomes
for LDKT compared with DDKT recipients in adjusted multivariable models.
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EQ-5D Utility 0.04 [-0.02, 0.10] 0.231
EQ-5D VAS 6.75 [1.21, 12.30] 0.017
WBQ12 2.58 [0.22, 4.95] 0.033
General QoL 0.41 [0.06, 0.75] 0.022
RDQoL 0.95 [0.29, 1.61] 0.005
RTSQs 7.06 [3.96, 10.16] <0.0001
RTSQc 6.40 [2.44, 10.36] 0.002
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6.4. Discussion
In this study, a wide range of general and condition-specific PROMS were
assessed in a cohort of kidney transplant recipients. At 1 year post-
transplantation, LDKT recipients reported significantly better health status,
wellbeing, general quality of life, renal-dependent quality of life and renal
treatment satisfaction compared with DDKT recipients, after adjustment for
demographic, socioeconomic and clinical variables.
Previous research on PROMS in patients with ESRD has focussed heavily
patient health status, otherwise known as health-related quality of life or
health utilities. Health status measures the patient’s perceived impact of their
health on a number of domains including physical, social and emotional
functions. Health status is often the measure of choice as it enables the
calculation of quality-adjusted life years for cost-effectiveness analyses,
which in turn leads to the potential to influence resource allocation.284 The
most widely used health status questionnaires include the EQ-5D and the 36-
Item Short Form Health Survey (SF-36). In this study we chose to use the EQ-
5D as it is recommended as the preferred instrument for measuring health
status by the National Institute for Health and Care Excellence (NICE)285 and
has been validated in renal transplant recipients.286 The benefits of
transplantation over dialysis on patient reported health status are widely
acknowledged.63, 103, 276 While dialysis patients demonstrate substantially worse
health status compared with the general population, transplantation seems
to restore health status to a level comparable to the general population.287
However, only few studies have compared the health status of patients
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receiving kidney transplants from different donor types. De Groot et al.
examined health status among LDKT and DDKT recipients in Leiden using the
SF-36 and found that LDKT recipients had better health status than DDKT
recipients, but only for the physical component score (not the mental
component score).288 Griva et al. also used the SF-36 to compare health status
between LDKT and DDKT recipients in London, but found no differences
between the two groups.104 In the present study, there were no significant
differences in health status between LDKT and DDKT recipients when
measured by the EQ-5D questionnaire, however LDKT recipients did report
higher EQ-5D VAS scores. The finding that EQ-5D VAS scores were better for
LDKT than DDKT recipients cannot be explained by a higher rate of graft
failure within the DDKT group as no patients within the entire subset
experienced graft failure within the first year. Furthermore, the multivariable
analyses were corrected for sociodemographic and comorbidity differences
between the two groups to minimise the risk of confounding. Patient reported
health status has been shown to be an independent predictor of mortality in
kidney transplant recipients, even after adjustment for clinical variables.289, 290
It has been suggested that a patient’s own subjective assessment of their
health status may reflect their real health situation better than objective
parameters, and as such should be considered as an important factor when
assessing patient prognosis.289
Health status questionnaires in isolation may not be a reliable indicator of a
patient’s overall quality of life as they do not capture many other non-health
related aspects of life which may be important to patients. Therefore, in this
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study we also considered other PROMS to ensure a multi-dimensional
approach.
Poor psychological well-being has been reported to be an important predictor
of compliance to post-transplantation immunosuppressive therapy, renal
function and graft rejection.96, 291 We used the WBQ-12 questionnaire to assess
well-being as it has previously been shown to be a reliable and valid measure
of psychological well-being in various popultions280, 281, 292, 293 including patients
with ESRD.294 Well-being scores were significantly higher at 1 year post-
transplantation for LDKT versus DDKT recipients. This is consistent with a
previous study by Gozdowska et al. which showed that LDKT recipients
reported a better sense of happiness, better social life involvement and were
more satisfied with their interpersonal relationships compared with DDKT
recipients.295 The authors surmised that a greater level of social support
improved recipients ability to adapt to post-transplantation life and increased
the recipients’ level of happiness.295 Other research has also linked having
better social support with an enhanced ability to recover and adapt after
transplantation.96, 296, 297 One study described higher levels of guilt towards the
donor among LDKT compared with DDKT recipients, when measured with the
Transplant Effects Questionnaire.104 However the study did not assess
whether this translated into a detrimental effect on overall well-being.
Lumsdaine et al. analysed levels of anxiety towards the donor among LDKT
recipients at different time points.105 Pre-operatively LDKT recipients did
express a high level of concern about their donor, but this significantly
decreased at 6 weeks and 1 year post-transplantation. Furthermore, despite
their anxiety about the donor, LDKT recipients had excellent overall
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psychological well-being at 6 weeks and 1 year post-transplantation, with
scores that were significantly higher than the UK normative value. The same
study also reported that both donors and recipients experienced significant
improvements in their mutual relationship after LDKT.105 It is important not
to forget about the potential psychological effects of LDKT on the donor. A
systematic review of over 5000 living kidney donors found that the large
majority of donors derived positive psychological benefits, felt happier after
donation and would choose to donate again.298 Our study supports the theory
that LDKT recipients may gain greater psychosocial benefits from
transplantation than DDKT recipients, due to the process of receiving an
organ from a person within their social support network, strengthening their
interpersonal relationships, coping strategies and psychological well-being.
Both general QoL and renal-dependent QoL were found to be significantly
higher for LDKT versus DDKT recipients after adjustment for confounding
variables. As previously mentioned, most publications that state they have
measured QOL have actually used tools that measure health status. There is
a lack of evidence in the transplant literature for true QoL outcomes that
encompass the multi-dimensional aspects of QoL. One study investigated QoL
among transplant recipients using the World Health Organisation Quality of
Life abbreviated version (WHOQOL-BREF), which assesses generic QoL in the
four domains of physical health, psychological health, social relationships
and environment. LDKT recipients reported significantly higher scores in the
psychological and environmental domains compared with DDKT recipients.295
Disease specific PROMS can provide more detailed and relevant outcomes for
the intended study population. In this study we utilised the RDQoL which
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assesses the impact of renal disease on various aspects of a patient’s life
relevant to their disease such as dietary and fluid restrictions, physical
appearance, work, future, family life, physical capability, travel, holidays, sex
life, confidence, social life, dependence etc.282 We did not find any other
published studies that have compared disease-specific QoL outcomes
between LDKT and DDKT recipients and were therefore unable to compare
our results with other research. This highlights the great need for more
research in this area.
Another important aim in the care of patients with ESRD is treatment
satisfaction. This gives an idea of the patient’s overall experience of their
treatment and thus is an important tool for identifying ways in which to
improve patient care. The RTSQs and RTSQc assess ESRD patients’
satisfaction with various aspects of their treatment including convenience,
flexibility, freedom and satisfaction to continue with the treatment.283
Treatment satisfaction has previously been shown to be significantly better
for transplant recipients compared with patients on dialysis.101, 283 However, to
our knowledge this is the first study to show that LDKT recipients express
significantly greater satisfaction with their treatment compared with DDKT
recipients. Patient satisfaction with their treatment is vital to ensure optimal
adherence to the treatment regimen including immunosuppressive
medications and has been shown to have a direct association with the success
of the graft.97, 299 Investigating the reasons why LDKT recipients report better
treatment satisfaction then DDKT recipients was beyond the scope of this
study. However, the more timely access to transplantation, avoidance or
minimisation of dialysis, the planned elective operation, higher quality graft,
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reduced cold ischaemic time and superior graft and patient survival outcomes
would all be plausible reasons for a better patient treatment experience in
LDKT. The analysis also demonstrated that patients who underwent pre-
emptive transplantation reported worse treatment satisfaction compared
with patients who underwent transplantation after a period of dialysis,
particularly for the RTSQc questionnaire (satisfaction with current versus
previous treatment). This finding is unsurprising, given the fact that pre-
emptive recipients have proceeded from having no treatment to undergoing
a major operation, immunosuppression and experiencing the associated
potential complications. Studies have consistently shown that transplantation
results in better PROMS than dialysis, due to lower levels of physical and
psychological morbidity and improved lifestyle.9, 10, 63 However, pre-emptive
transplant recipients have not experienced the burdens of dialysis and thus
cannot appreciate the benefits of transplantation over dialysis. This is
concerning because in most countries including the UK, pre-emptive
transplantation is accepted as the preferred treatment option due to its
superior graft and patient survival rates.21, 300-302 These findings highlight the
need for improved efforts to educate patients about the benefits of pre-
emptive transplantation, to manage patient expectations and to provide
psychological support throughout the whole treatment journey. It is
encouraging however, that pre-emptive transplantation did not appear to be
detrimental to patients’ health status, psychological well-being and quality of
life, compared with other transplant recipients.
The results of this study should be interpreted within the context of some
limitations. First, the PROMS data were from a fixed time point of 1 year post-
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transplantation, and we were unable to consider changes in PROMS over time.
Thus, the results must be verified in a longitudinal study. Second, all of the
patients who returned the questionnaires had a functioning graft, and as such
the results of the study may not be representative for patients who
experienced graft failure. Response bias is a recognised limitation of PROMS,
because patients with poorer outcomes are less likely to engage and
respond.303 This must be taken into account when interpreting the results, as
outcomes may have been overestimated in both groups. Third, we were
unable to explore the reasons for differences in PROMS between the two
recipient groups within the limits of this study. One of the potential reasons
for better PROMS in LDKT could be superior graft function. Unfortunately, we
were not able to correct the analyses for graft function as we did not have
access to graft function data. If correcting for graft function eliminates the
differences in PROMS between LDKT and DDKT, this implies that the better
outcomes are due to better graft function. If differences were to remain
despite adjusting for graft function, then other parts of the transplantation
pathway may be implicated in determining PROMS. This should be addressed
in future work. The strengths of this study are that we included patients from
all transplant units in the UK, there was a high questionnaire response rate
(81.7%) and all analyses were adjusted for an extensive set of variables.
The results of this study support the promotion of LDKT as an excellent
treatment option for patients with ESRD. LDKT is associated with superior
PROMS compared with DDKT recipients at 1 year post transplantation.
Further work is needed to determine the reasons for these differences, and
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Prediction of Survival on Dialysis
202
7.1. Introduction
Patients on long-term dialysis for the treatment of end-stage renal disease
(ESRD) experience drastically reduced life expectancy, but there is wide
variation in the prognosis of individual patients. In the UK, the median life
expectancy for incident dialysis patients aged 25-29 years is approximately
18.5 years, while for patients over 75 years it is just 2.4. years.304 The presence
of comorbidity, and in particular complex and multimorbidity is an
increasingly common problem in the dialysis population.305 Previous studies
have shown that comorbidity is major risk factor for mortality on dialysis and
significantly contributes to the variability in patient survival.90, 109, 306
Risk stratification of patients on dialysis using predictive models can offer
patients valuable prognostic information, as well as allowing clinicians to
tailor clinical care and therapeutic decisions to individual patients. Risk
scores can also guide research on targeted interventions for high risk patients
and provide a useful method of adjusting for case-mix in research studies.
Various models aimed at predicting survival on dialysis have been developed,
but few are utilised in clinical practice. Many studies have developed models
using variables that are not readily available to clinicians e.g. peritoneal
equilibration test and specific biomarkers such as plasma S100A12, or are
restricted to patients on one type of dialysis therapy e.g. haemodialysis (HD)
or peritoneal dialysis (PD) only and therefore unable to be applied to the
entire incident dialysis population.307-311 It is well recognised that dialysis
outcomes vary significantly between different countries, and so models
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developed in one dialysis population may not be applicable to other dialysis
populations.114 Furthermore, although comorbidity is included in most
predictive models due to its strong effect on dialysis survival, collecting
accurate comorbidity data at a population level is challenging and as such the
majority of studies have used retrospective data, data obtained from
administrative datasets or single centre data, resulting in loss of reliability.92,
312-314
Currently the average waiting time from activation on the transplant waiting
list to transplantation is 2 years.13 However, many patients will suffer clinical
deterioration or death during the wait. A risk index that predicts which
patients are likely to survive the first 2 years on dialysis would not only
provide important prognostic information, but could also be used as a useful
tool to inform decisions regarding access to the waiting list. If adopted
nationally, this would essentially standardise the referral process for
transplantation, thereby reducing well documented disparities in access to
transplantation in the UK.3-5, 315 The aim of this analysis was to develop and
validate a risk index to predict 2 year survival for incident dialysis patients in
the UK, using prospective national data collected as part of the Access to





The ATTOM incident dialysis cohort formed the study population for this
analysis. This comprised of 2623 patients recruited within 90 days of starting
dialysis, from all 72 renal units in the UK. Patients aged between 18 - 75 years
were eligible for recruitment. Full recruitment methods are detailed in
Chapter 2. The total recruitment period lasted from 1st November 2011 to
31st March 2013. However, in each centre, recruitment took place over a 12-
month period at any point during the total recruitment period. Because of
this, the true proportion of patients recruited to the study is difficult to
quantify due to differing start and end recruitment dates in each centre. To
provide an approximation, we have calculated the study population as a
proportion of the number of patients aged 18-75 years starting dialysis in the
UK during the total recruitment period (48.6%), with the acknowledgement
that this is an underestimation of the true figure (Figure 7.1). For the purposes
of this analysis, patients whose renal function recovered so that they no
longer required dialysis (n=63) or who died or were transplanted within the
first 90 days (n=51) were excluded, leaving 2509 patients included in the final
analysis.
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Figure 7.1. Study population
7.2.2. Study design and data variables
This was a prospective cohort study investigating the factors associated with
survival on dialysis. Baseline demographic, clinical and comorbidity data were
collected at the time of recruitment to the study (Appendix A.2.). Patients
were followed up for 2 years from the start of dialysis.
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The exposure variables of interest in this study were comorbidities present at
the time of starting dialysis including diabetes, ischaemic heart disease, heart
failure, atrial fibrillation, cardiac valve replacement, pacemaker,
cerebrovascular disease, peripheral vascular disease, abdominal aortic
aneurysm, chronic respiratory disease, chronic liver disease, blood borne
viruses, malignancy, mental illness, dementia and body mass index (BMI)
(definitions given in Appendix A.3.). BMI (kg/m2) was grouped in accordance
with the World Health Organisation (WHO) BMI classifications.126 Other patient
variables of interest included age, gender, ethnicity, primary renal disease,
smoking status, previous transplantation, type of dialysis and albumin (g/L)
(definitions in Appendix A.3.). Type of dialysis was categorised as HD
(including haemodialysis and haemodiafiltration) and PD (including
continuous ambulatory peritoneal dialysis and automated peritoneal
dialysis).
The primary outcome measure was patient survival which was defined as the
time from 90 days after starting dialysis to death, with censoring at the time
of transplantation if a patient received a transplant, or at 2 years. This method
for calculating survival on dialysis is designed to minimise the risk of
including patients with acute renal failure, and is the method used by renal
registries in most countries.316 A secondary outcome measure was activation
on the transplant waiting list. Time to listing was defined from the start of
dialysis to the date of activation on the waiting list. Patients who were listed
prior to the start of dialysis were given a time to listing of 0 days.
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7.2.3. Statistical methods
Baseline characteristics were presented as numbers with percentages (%) and
medians with interquartile ranges (IQR). Categorical data were compared by
chi-squared tests and non-parametric continuous data were compared by
Wilcoxon tests. The dataset was split evenly into derivation and validation
datasets using Bernoulli trials, with each patient having a probability of 0.5
of being assigned to either dataset. The derivation dataset was used to
identify patient level risk factors for survival on dialysis using univariable and
multivariable Cox proportional hazards regression. The multivariable model
was built using a manual backward elimination method, with all variables
considered for inclusion in the model. The importance of each variable in the
model was tested using the likelihood ratio test and variables with p-values
<0.1 were retained in the model. Interaction terms were also considered for
selection. Continuous variables were explored as linear, logarithmic,
fractional polynomials and categorical variables. The proportional hazards
assumption was tested using log cumulative hazards plots and Schoenfeld
residuals and found to be satisfied for all variables. The presence of a renal
unit effect was investigated by considering renal unit as a frailty effect. The
proportion of missing data varied between 0% - 16% for all variables (Table
7.1). Missing data were imputed using the fully conditional specification
logistic regression multiple imputation method to produce ten imputed
datasets. Each imputed dataset was modelled separately, and parameter
estimates were combined to create the final risk index. Two sensitivity
analyses were conducted. The first used the same modelling methods as
above in a sub-cohort of patients with no previous transplants. The second
used a Fine and Gray model317 to incorporate transplantation as a competing
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risk when modelling time to patient death. The validation dataset was
subsequently used to test the predictive ability of the derived model. The
discrimination of the model was summarised using Harrell’s c-statistic as well
as plotting Kaplan-Meier (KM) survival estimates stratified by risk index
quartile. Calibration of the model was assessed using the calibration-in-the-
large and the calibration slope.318 KM analysis was used to analyse the
cumulative incidence of listing for each risk index quartile and to analyse the
survival of listed versus non-listed patients. All analyses were conducted
using SAS (version 9.4).





Primary renal disease 25 [1.0]
Smoking status 380 [15.1]
Previous transplant 5 [0.2]
Type of dialysis 6 [0.2]
Albumin 285 [11.4]
Diabetes 20 [0.8]
Ischaemic heart disease 25 [1.0]
Heart failure 27 [1.1]
Atrial fibrillation 28 [1.1]
Cardiac valve replacement 28 [1.1]
Pacemaker 27 [1.1]
Cerebrovascular disease 27 [1.1]
Peripheral vascular disease 28 [1.1]
Abdominal aortic aneurysm 29 [1.2]
Chronic respiratory disease 27 [1.1]
Chronic liver disease 26 [1.1]
Blood borne viruses 26 [1.1]
Malignancy 23 [0.9]





7.3.1. Study population characteristics
The demographics of the study population were compared to those of all
patients aged 18-75 years starting dialysis in the UK during the entire
recruitment period using the one sample chi-square goodness of fit test
(Table 7.2). Compared to the national incident dialysis population, the study
population were younger and comprised a higher proportion of males,
patients of White ethnicity and HD patients.
Table 7.2. Demographics of incident dialysis recipients – national









18 – 34 8.2 9.3
35 – 49 19.8 20.5
50 – 60 22.6 24.3
60 – 70 31.5 29.8












The study population was split evenly into derivation (50%) and validation
(50%) datasets. The baseline prevalence of comorbidity (Table 7.3) and
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baseline patient characteristics (Table 7.4) were compared between the
derivation and validation datasets. Comorbidity prevalence was similar
between the two datasets, with the most prevalent comorbidity being
diabetes, followed by obesity, ischaemic heart disease and malignancy. There
was a higher proportion of patients with abdominal aortic aneurysms in the
derivation dataset. In both datasets, the median age was 58-59 years, and the
majority of patients were male, of White ethnicity, had diabetes as the primary
renal disease, were non-smokers and received HD as the modality of dialysis.






Diabetes 535 [42.7] 499 [40.3] 0.226
Ischaemic heart disease 258 [20.7] 256 [20.7] 0.965
Heart failure 85 [6.8] 97 [7.9] 0.316
Atrial fibrillation 53 [4.3] 55 [4.5] 0.794
Cardiac valve replacement 14 [1.1] 17 [1.4] 0.568
Pacemaker 22 [1.8] 17 [1.4] 0.440
Cerebrovascular disease 108 [8.7] 121 [9.8] 0.322
Peripheral vascular disease 122 [9.8] 101 [8.2] 0.164
Abdominal aortic aneurysm 30 [2.4] 12 [1.0] 0.006
Chronic respiratory disease 137 [11.0] 163 [13.2] 0.091
Chronic liver disease 23 [1.8] 36 [2.9] 0.080
Blood borne viruses 36 [2.9] 32 [2.6] 0.654
Malignancy 153 [12.3] 177 [14.3] 0.134
Mental illness 108 [8.7] 110 [8.9] 0.819
Dementia 6 [0.5] 2 [0.2] 0.162
BMI, kg/m2 0.060
Underweight (<18.5) 30 [2.8] 41[3.9]
Normal (18.5 - 24.9) 353 [33.2] 371 [35.3]
Overweight (25.0 - 29.9) 340 [32.0] 284 [27.0]
Obese (≥30.0) 340 [32.0] 355 [33.8]
Data are number [%].
Data are missing for some participants and excluded from percentage calculations.
Number of missing data are shown in Table 7.1.
p-value is for chi-square test.
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7.3.2. Derivation of the ATTOM risk index
Two year follow-up data were available for all patients. In the derivation
dataset, 179 (14.2%) patients died, 203 (16.1%) were censored at the time of
transplantation and 881 (69.8%) were still alive at 2 years. Overall 2 year







Age 58.2 [47.2 – 66.7] 58.7 [47.8 – 67.5] 0.418
Gender 0.195
Male 835 [66.1] 793 [63.6]
Female 428 [33.9] 453 [36.4]
Ethnicity 0.090
White 995 [79.0] 1007 [81.2]
Asian 156 [12.4] 128 [10.3]
Black 85 [6.8] 93 [7.5]
Other 23 [1.8] 12 [1.0]
Primary renal disease 0.241
Polycystic kidney disease 91 [7.3] 107 [8.7]
Diabetic nephropathy 353 [28.3] 337 [27.2]
Glomerulonephritis 213 [17.1] 201 [16.3]
Pyelonephritis 84 [6.7] 97 [7.8]
Hypertensive nephropathy 82 [6.6] 82 [6.6]
Renal vascular disease 55 [4.4] 33 [2.7]
Other 177 [14.2] 193 [15.6]
Uncertain 192 [15.4] 187 [15.1]
Smoking status 0.108
Non-smoker 538 [50.0] 497 [47.2]
Smoker 205 [19.1] 185 [17.6]
Ex-smoker 333 [31.0] 371 [35.2]
Previous transplant 139 [11.0] 130 [10.4] 0.629
Type of dialysis 0.169
HD 995 [79.0] 973 [78.2]
PD 264 [21.0] 271 [21.8]
Albumin 34 [30 – 38] 34.5 [30-38] 0.739
Data are median [IQR] or number [%].
Data are missing for some participants and excluded from percentage calculations.
Number of missing data are shown in Table 7.1.
Wilcoxon test for age and albumin, all others chi-square test.
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survival calculated with the Kaplan-Meier method was 84.4% (95% confidence
interval [CI] 82.2, 86.4). The impact of comorbidity and patient factors on 2
year survival were investigated in the derivation dataset with univariable
analysis (Table 7.5 and Table 7.6), multivariable Cox regression using
complete case data and subsequently multivariable Cox regression using
imputed data in order to account for missing data and derive the risk index
(Table 7.7). Through building the models on the 10 imputed datasets, it was
observed that the models overall reflected the model derived from complete
case analysis and the same terms were included in the final model combining
all imputed datasets (Table 7.7).
Table 7.5. Univariable Cox regression analysis of comorbidities affecting
2 year patient survival on dialysis
Variables HR [95% CI] p-value
Diabetes 1.55 [1.16, 2.09] 0.003
Ischaemic heart disease 1.69 [1.23, 2.32] 0.001
Heart failure 2.06 [1.33, 3.20] 0.001
Atrial fibrillation 2.39 [1.43, 3.99] 0.0009
Cardiac valve replacement 2.02 [0.75, 5.45] 0.163
Pacemaker 2.32 [1.09, 4.93] 0.029
Cerebrovascular disease 1.60 [1.04, 2.46] 0.032
Peripheral vascular disease 1.68 [1.12, 2.52] 0.012
Abdominal aortic aneurysm 1.11 [0.46, 2.70] 0.818
Chronic respiratory disease 1.93 [1.33, 2.81] 0.0006
Chronic liver disease 3.49 [1.84, 6.60] 0.0001
Blood borne viruses 0.72 [0.27, 1.95] 0.520
Malignancy 2.18 [1.54, 3.09] <0.0001
Mental illness 1.70 [1.11, 2.61] 0.016
Dementia . . .
BMI, kg/m2 1
Underweight (<18.5) 2.30 [1.13, 4.67] 0.021
Normal (18.5 - 24.9) 1 [ref]
Overweight (25.0 - 29.9) 0.53 [0.34, 0.84] 0.007
Obese (≥30.0) 1.02 [0.70, 1.49] 0.927
CI; confidence interval, HR; hazard ratio, ref; reference
(.) number is 0 or too small to calculate
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Table 7.6. Univariable Cox regression analysis of patient factors affecting
2 year patient survival on dialysis
Variables HR [95% CI] p-value
Age (per 10 years) 1.34 [1.18, 1.52] <0.0001
Gender
Male 1 [ref]
Female 1.37 [1.02, 1.85] 0.037
Ethnicity
White 1 [ref]
Asian 0.71 [0.43, 1.16] 0.166
Black 0.36 [0.15, 0.87] 0.024
Other 0.61 [0.15, 2.45] 0.483
Primary renal disease
Polycystic kidney disease 1 [ref]
Diabetic nephropathy 3.17 [1.28, 7.87] 0.013
Glomerulonephritis 1.49 [0.56, 3.99] 0.427
Pyelonephritis 2.21 [0.77, 6.35] 0.142
Hypertensive nephropathy 1.76 [0.59, 5.24] 0.313
Renal vascular disease 3.40 [1.18, 9.79] 0.023
Other 2.73 [1.06, 7.05] 0.038
Uncertain 2.17 [0.83, 5.65] 0.113
Smoking status
Non-smoker 1 [ref]
Smoker 1.46 [0.98, 2.18] 0.064
Ex-smoker 1.09 [0.75, 1.59] 0.640
Previous transplant 0.82 [0.50, 1.35] 0.438
Type of dialysis
HD 1 [ref]
PD 0.70 [0.47, 1.06] 0.090
Albumin, g/L (per unit increase) 0.92 [0.90, 0.94] <0.0001
CI; confidence interval, HR; hazard ratio, ref; reference
During the multivariable modelling process (Table 7.7) the diabetes variable
was explored in the following ways: any diagnosis of diabetes, diabetic
nephropathy, diabetes as comorbidity only (excluding diabetic nephropathy),
type 1 diabetes and type 2 diabetes. Diabetic nephropathy provided the best
fit in the model after adjustment for all other factors. An interaction between
age and diabetic nephropathy was also noted to be significant and was
included in the model. This showed that the negative effect of increasing age
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on survival was only significant for patients without diabetic nephropathy.
For patients with diabetic nephropathy, there was little additional impact of
age on survival, over and above the effect of diabetes. The albumin variable
was found to fit best within the model using a natural logarithmic scale. The
BMI variable was explored as a linear variable and as a categorical variable.
Being underweight was noted to cause a negative effect on survival, whereas
there was no difference in survival between normal, overweight and obese
patients. Therefore, the best fit in the model was obtained using a binary
variable for being underweight. Adding renal unit as a frailty effect in the
model did not show any significant difference in patient survival between
units (change in -2 log-likelihood p=0.987).
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Table 7.7. Multivariable Cox regression analysis of factors affecting 2 year
patient survival on dialysis
Variables HR [95% CI] p-value
Age (per 10 years) . . <0.0001
Gender
Male 1 [ref]
Female 1.46 [1.07, 2.00] 0.017
Diabetic nephropathy
No .
Yes . . 0.0002
Age*Diabetic nephropathy 0.013
Diabetic nephropathy Yes vs No at
age=56
1.98 [1.39, 2.82]
10 year increase in age when
Diabetic nephropathy=No
1.46 [1.21, 1.75]
10 year increase in age when
Diabetic nephropathy=Yes
0.90 [0.73, 1.12]
Log albumin, g/L (per unit) 0.20 [0.11, 0.36] <0.0001
Heart failure
No 1 [ref]
Yes 1.72 [1.07, 2.77] 0.025
Atrial fibrillation
No 1 [ref]
Yes 1.65 [0.95, 2.87] 0.074
Chronic respiratory disease
No 1 [ref]
Yes 1.61 [1.09, 2.39] 0.017
Chronic liver disease
No 1 [ref]
Yes 2.57 [1.25, 5.27] 0.010
Malignancy
No 1 [ref]
Yes 2.01 [1.37, 2.93] 0.0003
Underweight (BMI<18.5kg/m2)
No 1 [ref]
Yes 2.13 [1.00, 4.53] 0.050
CI; confidence interval, HR; hazard ratio, ref; reference
Sensitivity analysis omitting patients with previous transplants had no effect
on the terms included in the model. Similarly, using a competing risk model
with transplantation as a competing risk had little effect on the resulting
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parameter estimates. Therefore, the model developed in Table 7.7 was used
to derive the equation for the ATTOM risk index (Table 7.8).
Table 7.8. ATTOM risk index for prediction of survival on dialysis
Risk index = Age/10 x 0.376
+Female x 0.381
+Diabetic nephropathy x 3.169
-Age/10 x Diabetic nephropathy x 0.452
-ln(albumin) x 1.597
+Heart failure x 0.543
+Atrial fibrillation x 0.503
+Chronic respiratory disease x 0.479
+Chronic liver disease x 0.943
+Malignancy x 0.696
+Underweight x 0.756
In order to use the risk index to predict 2 year survival on dialysis for a
specific individual the following equation is used:
Where S0(t) is the baseline survival at t=2 years, ∑ßX is the risk index for the
individual and ∑ß is the baseline risk index (calculated using mean values
for continuous variables and 0 values for categorical variables). Using the
derivation dataset, the baseline survival is calculated as 0.916 at 2 years and
the baseline risk index is calculated as -3.487. A theoretical patient is
provided as an example of calculating the predicted survival for a specific
individual at the time of starting dialysis. The example patient is aged 63
years, male, with diabetic nephropathy, an albumin of 31g/L and heart failure,
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but no other comorbidities and is overweight. The risk index for this patient
is calculated using the equation in Table 7.8 as follows:
Risk index = (Age (63)/10 x 0.376) + (Female (0) x 0.381) + (Diabetic
nephropathy (1) x 3.169) – (Age (63)/10 x Diabetic nephropathy (1) x 0.452)
– (ln(albumin) (3.434) x 1.597) + (Heart failure (1) x 0.543) + (Atrial
fibrillation (0) x 0.503) + (Chronic respiratory disease (0) x 0.479) +
(Chronic liver disease (0) x 0.943) + (Malignancy x (0) 0.696) +
(Underweight x (0) 0.756) = -2.251
Therefore the predicted survival is calculated as:
0.916 exp (-2.251 - -3.487) = 0.739 (or 73.9%)
7.3.3. Validation of the ATTOM risk index
In the validation dataset, survival data were available for all patients. Over the
2 year follow up period, 188 (15.1%) patients died, 185 (14.8%) were censored
at the time of transplantation and 873 (70.1%) were still alive at 2 years.
Overall 2 year survival calculated with the KM estimator was 83.5% (95% CI
81.2, 85.5). The risk index (Table 7.8) was calculated for all patients in the
validation dataset. Using the risk index to predict survival demonstrated a HR
of 2.31 (95% 1.93, 2.77, p<0.0001) and c-statistic of 0.72, confirming
reasonable discrimination of the model. The risk index values were then split
into quartiles, with quartile 1 containing the lowest risk patients and quartile
4 containing the highest risk patients. KM survival estimates of survival
stratified by risk index quartiles were compared (Figure 7.2). This confirmed
good ability of the risk index to discriminate between patients with a low and
high risk of mortality (p<0.0001). Calibration of the model was good with a
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calibration-in-the-large of 18.2% vs 16.5% for predicted vs observed risk of
death, and a calibration slope of 0.84 (standard error [SE] 0.09).
Figure 7.2. KM survival plot for effect of the risk index on 2 year patient survival on
dialysis
7.3.4. Comparison of the risk index to the Charlson Comorbidity Index
In order to further assess the ability of the developed risk index to predict
patient survival, it was compared to the most commonly used risk index in
studies of dialysis patients – the Charlson Comorbidity Index (CCI). The CCI
was originally developed to predict survival among general medical
patients,107 but has since been modified for use among dialysis patients.106
Details on the calculation of the modified CCI score are given in Chapter 2
(Table 2.2.) and definitions of the variables used in the score are given in
Appendix A.4.
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Using the modified CCI to predict survival in the validation dataset gave a HR
of 1.21 (95% CI 1.14, 1.28, p<0.0001) and c-statistic 0.63, which is significantly
lower than that observed for the ATTOM risk index (0.72). The calibration
slope was also much poorer (0.19, SE 0.03). Calibration-in-the-large could not
be calculated as the equation for predicting survival from the modified CCI
was not provided in the paper by Hemmelgarn et al.106
7.3.5. Listing status by ATTOM risk index
In the validation dataset, listing data were available for 1245 of 1246 patients.
A total of 514 (41.3%) patients were activated on the transplant waiting list
within 2 years of starting dialysis. Of these, 154 (30.0%) were listed prior to
the start of dialysis. Table 7.9 and Figure 7.3 show the proportion of patients
in the validation dataset who were listed within 2 years, stratified by ATTOM
risk index quartile. This shows that lower risk index quartiles were associated
with a higher rate of listing.
Table 7.9. 2 year listing rate by ATTOM risk index quartile
Quartile 1 Quartile 2 Quartile 3 Quartile 4
% listed 69.3 48.1 29.3 19.6
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Figure 7.3. Cumulative incidence plot of listing within 2 years of starting dialysis by
ATTOM risk index quartile. Patients who were listed prior to the start of dialysis
were assigned a listing time of 0.
Surprisingly, 30.7% of the patients in risk quartile 1 and 51.9% of the patients
in risk quartile 2 were not listed, despite having a high probability of surviving
to 2 years (95.5% and 91.5% respectively, Figure 7.2). This was explored
further by analysing the survival of patients in risk quartile 1 (Figure 7.4) and
risk quartile 2 (Figure 7.5) stratified by listing status.
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Figure 7.4. KM survival plot of risk quartile 1 patients stratified by listing status
Figure 7.5. KM survival plot of risk quartile 2 patients stratified by listing status
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Among the patients in risk quartile 1, there was no significant difference in
survival between patients who were listed and patients who were not listed
within 2 years of starting dialysis (p=0.169).  Both groups experienced good
survival at 2 years, thus suggesting that the 30.7% of patients in this quartile
who were not listed, may represent a group of patients who are suitable for
listing but may be experiencing barriers or inequity in access to
transplantation. This is explored in more detail below. Among the patients in
risk quartile 2, patients who were not listed (51.9%) did experience
significantly worse survival compared to those who were listed (p=0.0009).
This difference may be due to factors not included in the model, or it may be
accounted for by the ability of clinicians to make an overall assessment of the
patient’s general fitness, which may not necessarily be quantifiable by specific
factors. However the patients in risk quartile 2 who were not listed still
experienced reasonable survival at 2 years (86%), and may also represent a
group of patients who should be considered for transplant listing.
In order to explore the potential reasons for non-listing among the patients
in risk quartile 1, a comparison of comorbidity (Table 7.10) and
sociodemographic factors (Table 7.11) between listed and non-listed patients
in this quartile was undertaken. This showed a significantly higher prevalence
of ischaemic heart disease, mental illness and obesity among non-listed
patients. Furthermore, significant sociodemographic barriers to listing were
identified, including Black ethnicity, non car-ownership, non home-
ownership, unemployment and not being able to work due to long term illness
or disability.
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Diabetes 13 [8.1] 8 [11.3] 0.443
Ischaemic heart disease 2 [1.3] 6 [8.5] 0.006
Heart failure 1 [0.6] 3 [4.2] 0.053
Atrial fibrillation 0 0 .
Cardiac valve replacement 0 0 .
Pacemaker 1 [0.6] 1 [1.4] 0.553
Cerebrovascular disease 2 [1.3] 4 [5.6] 0.053
Peripheral vascular disease 1 [0.6] 1 [1.4] 0.553
Abdominal aortic aneurysm 0 0 .
Chronic respiratory disease 9 [5.6] 2 [2.8] 0.355
Chronic liver disease 0 0 .
Blood borne viruses 2 [1.3] 3 [4.2] 0.152
Malignancy 2 [1.3] 3 [4.2] 0.152
Mental illness 8 [5.0] 10 [14.1] 0.018
Dementia 0 0 .
BMI, kg/m2 0.0005
Underweight (<18.5) 4 [2.5] 1 [1.4]
Normal (18.5 - 24.9) 72 [45.0] 25 [35.2]
Overweight (25.0 - 29.9) 50 [31.3] 11 [15.5]
Obese (≥30.0) 34 [21.3] 34 [47.9]
Data are number [%].
p-value is for chi-square test.
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Table 7.11. Sociodemographic characteristics of listed and non-listed patients in






Age 42.8 [31.6 – 50.3] 45.0 [34.1 – 51.5] 0.524
Gender 0.252
Male 126 [78.8] 51 [71.8]
Female 34 [21.3] 20 [28.2]
Ethnicity 0.002
White 125 [79.1] 53 [75.7]
Asian 16 [10.1] 1 [1.4]
Black 13 [8.2] 16 [22.9]
Other 4 [2.5] 0
Car ownership 117 [76.5] 40 [58.0] 0.005
Home ownership 69 [45.1] 16 [23.2] 0.002
Qualifications 0.547
Higher education level 33 [21.6] 13 [18.8]
Secondary education level 88 [57.5] 37 [53.6]
No qualifications 32 [20.9] 19 [27.5]
Employment status <0.0001
Employed 85 [55.6] 11 [15.9]
Unemployed 20 [13.1] 10 [14.5]
Long term sick / disability 35 [22.9] 43 [62.3]
Retired 4 [2.6] 1 [1.5]
Other 6 [14.0] 3 [1.7]
Data are median [IQR] or number [%].
Wilcoxon test for age, all others chi-square test.
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7.4. Discussion
In this national prospective cohort study, we have created and internally
validated a novel risk index for the prediction of 2 year survival on dialysis in
the UK. Variables in the risk index included age, gender, diabetic nephropathy,
serum albumin, heart failure, atrial fibrillation, chronic respiratory disease,
chronic liver disease, malignancy and underweight BMI, as measured at the
time of starting dialysis. The majority of the variables that were found to be
important predictors of mortality in the risk index were comorbidities. This
is unsurprising as the impact of comorbid disease on survival on dialysis is
well established.90-93, 310, 319-321 The additional negative impact of increasing age,
low serum albumin and low BMI in the risk index is also consistent with the
published literature.93, 114, 322-326 The predictors that were used in the risk index
are all readily available variables, and as such it could be easily implemented
into routine clinical practice. The risk index is applicable to both HD and PD
patients, in contrast to previous studies.310, 311, 319
We found that the ATTOM risk index had better performance characteristics
compared with the frequently used CCI score. The CCI was originally
developed in general medical patients in the US and subsequently adapted to
predict survival in incident dialysis patients in Canada.106 The marked
international differences in survival on dialysis means that any risk scores
developed using patients from other countries are unlikely to be applicable
to UK dialysis patients,114 and may account for the superior performance of
the ATTOM risk index compared with the modified CCI. Two other studies to
date have reported on the patient and comorbidity factors increasing
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mortality among incident dialysis patients in the UK. Cherukuri et al. showed
that several comorbidities in addition to older age and high calcium
phosphate product were associated with overall mortality at 5 years.
However, the study only performed univariable analyses, and was conducted
in a single UK centre with a small number of patients (n=94), and as such the
results do not have sufficient reliability or generalisability for the entire UK
dialysis population.327 Wagner et al. conducted a national multicentre study in
the UK and developed a model for prediction of 3 year mortality on dialysis
that included age, ethnicity, primary kidney disease, treatment modality,
diabetes, cardiovascular disease, smoking, haemoglobin, serum albumin,
creatinine and calcium.92 The model reached a c-statistic of 0.73, which is very
similar to the performance of the ATTOM risk index. However, the model was
developed using UK renal registry data which only collects data on a limited
number of comorbidities and is known to have a high level of missing data
(particularly missing comorbidity data); this resulted in 50% of the study
population being excluded. The ATTOM dataset benefits from good data
completeness and the inclusion of data on an extensive range of
comorbidities that were collected on a national basis in a prospective study,
providing better reliability than registry data. Furthermore, the study by
Wagner et al. was conducted using a more historical cohort of dialysis
patients (2002-2004), and thus the risk index developed from our more
contemporary cohort (2011-2013) is more applicable to current dialysis
patients.
There are a number of ways in which the ATTOM risk index could be
implemented into clinical practice. It can provide both patients and clinicians
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with valuable quantifiable prognostic information, thereby enabling
treatment decisions and planning to be tailored to individual patients. The
model can also be utilised in future research targeted at patients with specific
risk-profiles, or to provide adjustment for case-mix in clinical studies. For
many patients with ESRD, dialysis is not the most effective renal replacement
therapy, and the ultimate goal is for a better life expectancy and quality of
life through the option of kidney transplantation.7, 8, 10 However, the number
of patients who actually achieve transplantation is greatly restricted by the
vastly insufficient number of donor organs. In 2018 there were 5033 patients
on the waiting list for a deceased donor kidney transplant in the UK. Although
this number has begun to fall in recent years, this still equates to a lengthy
median waiting time of 2 years.13 Not being able to survive the wait is a real
risk for many patients with ESRD. Between 2017-2018, 245 patients died
whilst waiting for a kidney transplant and 439 patients were removed from
the list (typically due to clinical deterioration resulting in becoming
unsuitable for transplantation).13 Moreover, it is well recognised that many
ESRD patients experience inequity in access to transplantation or delayed
referral for transplant assessment. Previous research has shown that various
patient factors such as older age, non-White ethnicity and social deprivation,
disadvantage patients in accessing transplantation.3-5 Yet, perhaps the most
concerning finding is that there is consistent evidence for significant variation
in access to transplantation between centres in the UK, that cannot be
explained by differences in patient factors or case-mix.3-5, 315 Discrepancies in
centres’ assessment processes for determining patient suitability for
transplantation and differences in clinicians’ views towards patient selection
are likely to be major contributing factors to the observed inconsistencies in
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listing and transplantation across the UK.6, 49 In this study, almost a third of
patients with the greatest predicted survival (patients in risk quartile 1), were
not listed for transplantation within 2 years. Non-listed patients were
significantly more likely to have obesity, ischaemic heart disease or mental
illness. It is likely that in many centres, patients who would otherwise have
good predicted survival are being declined for transplant listing due to these
factors. It is also clear that sociodemographic factors including ethnicity and
social deprivation act as barriers to transplant listing in patients who have
good predicted survival outcomes. The ATTOM risk index provides an
objective and evidence-based means of predicting patient survival on dialysis.
We propose that this tool could be used to inform a nationally agreed
threshold at which patients are deemed to have a high likelihood of surviving
a 2 year period on dialysis, and as such should be considered for referral for
transplantation or activation on the waiting list. This would provide a
transparent means of risk-stratification that ensures that those listed have a
reasonable expectation of surviving the wait for transplantation.
Furthermore, it would likely result in a reduction in the size of the waiting
list, as well as greatly improved equity in access to transplantation across the
UK. The proposed listing tool does however bring an important question to
the fore; what is an acceptable survival probability at which patients should
be considered for listing? Currently, the UK listing policy states that any
condition with a predicted life expectancy of <2 years is an absolute
contraindication to listing.40 This is in line with European best practice
guidelines that also that recommend exclusion of patients with a life
expectancy of less than 2 years.328 However, these guidelines do not give
explicit details on the method that should be used to predict 2 year life
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expectancy. In contrast, in New Zealand an estimated 5 year post-
transplantation survival of over 80% is a requirement for entry to the waiting
list.329 Estimates are calculated from a survival prediction tool, based on an
index derived and validated in a US dataset of  170 000 patients.330 Patients
are rescored annually or at the time of any change in their health status, and
removed from the waiting list if their score falls below 70%.331 While these
criteria are relatively strict in comparison to UK and European guidelines, they
do provide a clear, objective and standardised means of determining access
to the waiting list. If a listing tool were to be adopted in the UK, the survival
probability threshold for listing would need to be agreed on a national basis,
with input from all stakeholders, including patients. The policy would also
require continued re-evaluation and a robust and transparent framework of
oversight. A similar concept is already in operation in the UK for liver
transplantation. Access to the waiting list is based on predicted survival
without a transplant, as estimated by the United Kingdom Model for End-
Stage Liver Disease (UKELD) score.332 Once on the waiting list, the organ
offering scheme is based on a transplant benefit score i.e. the difference
between the patient’s predicted survival without a transplant and their
predicted survival with a transplant from a given donor liver. The transplant
benefit score is calculated using 21 recipient and 7 donor characteristics.333
The patient with the greatest predicted survival benefit from a given donor
liver is prioritised for that donor. With longer follow up of patients in the
ATTOM study, it is anticipated that future analyses will be able to provide a
similar scoring system for prediction of post kidney transplant survival.
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There are a number of limitations to the study. First, we were unable to recruit
the entire UK dialysis population, and as such the risk index may not be as
reliable in certain patient groups who were underrepresented in the sample.
This limitation was a compromise that was taken in order to be able to
prospectively collect extensive and detailed data on a national sample of
patients with good data completeness. We sought to reduce bias by including
patients from all 72 renal units in the UK. Secondly, again for practical
reasons, we were only able to collect data on risk factors at a single point in
time (at the start of dialysis), and therefore were unable to assess the impact
of the development of new risk factors or worsening of existing risk factors
over time. Third, although the risk index performed well on internal
validation, it requires further external validation in independent datasets to
provide further information about the robustness of the model.
The ATTOM risk index uses a small number of readily available basic patient
variables to provide prediction of 2 year survival on dialysis with good
accuracy. Further research is required to externally validate the risk index and






Like elsewhere in the world, kidney transplantation in the UK has seen
incredible progress and development since its inception less than half a
century ago. Kidney transplantation is now established as the optimal
treatment strategy for ESRD due its superior survival benefits, quality of life
and cost-effectiveness when compared with dialysis. The fact that survival
rates from transplantation continue to improve year on year, despite the
growing pressures on the NHS is a remarkable achievement and a testament
to the relentless hard work and dedication of the transplant community.
While there has been great success in increasing the number of donor organs
and reducing the size of the waiting list in the UK, there is still a long way to
go. The ongoing shortfall between supply and demand means that disparities
in access to transplantation have become a major issue. This is particularly
pronounced for certain disadvantaged groups in society. The incidence of
patients requiring RRT in the UK continues to rise, alongside an increase in
the age of the population and causal factors such as type 2 diabetes mellitus
and hypertension.334 Multimorbidity among potential transplant recipients
has become increasingly common. This has resulted in uncertainty and
variability across the UK in the evaluation of risk and benefit in the context
of kidney transplantation.
There was limited research on these issues in the UK, and studies to date were
generally retrospective or single centre analyses. Therefore, this thesis set out
to address the concerns related to access to and outcomes from renal
transplantation in the UK as part of a national prospective cohort study:
Access to Transplantation and Transplant Outcome Measures (ATTOM). This
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was the first study to include ESRD patients from all 72 renal units in the UK.
The aims were to explore the following questions:
1) What factors may be contributing to inequity in access to transplantation in
the UK?
2) How do patient factors including comorbidity affect graft and patient
survival after renal transplantation, and do survival rates differ between
centres in the UK?
3) Do patient reported outcome measures differ after living and deceased
donor kidney transplantation?
4) What factors affect the survival of patients on dialysis, and can these risk
factors be quantified in a survival prediction score aimed at reducing inequity
and standardising access to the waiting list?
Each of these questions are discussed individually below.
1) What factors may be contributing to inequity in access to transplantation in
the UK?
The study performed in Chapter 3 demonstrated significant differences in the
comorbidity burden of listed and transplanted patients between centres in
the UK. The findings suggest that some centres are listing and transplanting
patients with significantly higher comorbidity than others, and thus centre
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differences in selection criteria and assessment of risk may be contributing
to inequity in access to transplantation in the UK.
Striking differences in patient factors between dialysis, waiting list and
transplant patients were also highlighted in Chapter 3. The analysis showed
that there were two levels at which patients are disadvantaged in accessing
transplantation. Patients on dialysis were more likely to be older, have lower
educational attainment and have greater socioeconomic deprivation
compared with patients who made it to the waiting list or to transplantation.
Interestingly, previously documented ethnicity differences at this level were
not found in this study and may reflect an improvement in access to the
waiting list for patients from ethnic minorities. Additional differences were
noted between patients on the waiting list and those who achieved
transplantation. Females, ethnic minorities, patients with lower educational
attainment and greater socioeconomic deprivation were underrepresented in
the transplant group compared with the waiting list group. As the national
allocation system should not be affected by socioeconomic factors, this led
us to explore whether the disparities could be explained by differences
between patients undergoing DDKT and LDKT in Chapter 4.
In Chapter 4, older age, Black and Asian ethnicity, being divorced, separated,
widowed or single, lower educational attainment and greater socioeconomic
deprivation were found to significantly lower the likelihood of LDKT versus
DDKT. Geographic factors were also identified as contributing to disparities
in access to LDKT. We also investigated whether similar factors could act as
barriers to pre-emptive transplantation. Asian ethnicity, unemployment and
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greater socioeconomic deprivation were associated with a lower likelihood of
pre-emptive LDKT versus LDKT after the initiation of dialysis. These findings
demonstrate the strength of social factors in influencing access to
transplantation. In the context of recent initiatives to increase the rate of
LDKT in the UK, the results are important for identifying disadvantaged
patient groups and developing targeted interventions. These results were
presented to Parliament at the living donor transplant summit (22nd
November 2017) hosted by the all-party parliamentary kidney group, as part
of a manifesto to increase LDKT in the UK. Several interventions are now
underway, using culturally sensitive and tailored home education
programmes to target disadvantaged patient groups.
2) How do patient factors including comorbidity affect graft and patient
survival after renal transplantation, and do survival rates differ between
centres in the UK?
The analysis in Chapter 5 identified the key comorbid conditions that predict
poorer two year graft and patient survival after kidney transplantation.
Peripheral vascular disease and obesity were associated with a two- to three-
fold increased risk of graft failure, while the risk of death was approximately
doubled for cerebrovascular disease, tripled for heart failure and quadrupled
for chronic liver disease. The study also yielded some interesting findings
with regards to other patient factors. Previous US studies have shown that the
negative effect of pre-transplant dialysis on survival outcomes after
transplantation is evident after just 6 months on dialysis.19 In this study, the
detrimental effect of dialysis was only associated with poorer outcomes after
a period of 3 years on dialysis. This may reflect the superior survival of
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patients on dialysis in the UK compared with the US, as well as improvements
dialysis care over time. The superior graft survival of LDKT over DDKT, was
confirmed in the fully adjusted model accounting for significant comorbidity
variables. The lack of difference in patient survival between LDKT and DDKT
suggests that recipient variables including comorbidity may be more
important for patient survival outcomes within 2 years than the type of
donor. The risk associated with these important patient factors were
quantified in this analysis and can be used to fully inform patients of their
individual risks of transplantation, thereby facilitating shared decision-
making and informed consent.
Contrary to previous registry reports, there was no evidence of inter-centre
variation in the survival outcomes of transplant patients in the fully adjusted
multivariable models. This work provides a strong argument for the inclusion
of comorbidity factors in future registry analyses to avoid inappropriate
labelling of centres as poor performers without adequate risk adjustment.
Due to the excellent survival outcomes of transplant recipients in the current
era and the relatively short period of follow up of 2 years, there were
insufficient events to allow development of a post-transplant survival risk
score. At 5 years post-transplantation we plan to revisit this analysis, as the
higher number of deaths and graft failures at this time point will allow
splitting of the cohort into derivation and validation datasets for
development of a risk index.
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Part of the original research plan was to explore how patient factors and
comorbidity affected the survival benefit of transplantation over dialysis in
order to determine which patients would benefit most and which the least
from transplantation. This was the reason for recruiting a matched control
cohort of patients on the waiting list, as it would not have been appropriate
to directly compare incident dialysis patients to incident transplant patients
due to the bias introduced by the selection process for transplantation.
However, we were unable to conduct this analysis as a significantly higher
than expected proportion of the waiting list cohort (~50%) were transplanted
within the 2 year follow up period. This reflects the increase in the number
of donors and transplants and the decrease in the waiting list that happened
over the follow up period of the study. During the planning of the study, the
number of available donors was significantly lower and was static, and the
waiting list had reached an all-time high. Therefore, we did not anticipate that
such a high proportion of the waiting list cohort would be transplanted. After
discussion with the statistics team at NHSBT, it was decided that we would be
unable to conduct a robust analysis with the available data.
3) Do patient reported outcome measures differ after living and deceased
donor kidney transplantation?
The study performed in Chapter 6 demonstrated significantly better patient
reported health status, wellbeing, general quality of life, renal-dependent
quality of life and renal treatment satisfaction for living versus deceased
donor kidney transplantation at 1 year. The findings therefore enhance the
recognised clinical benefits of LDKT and support the promotion of LDKT as
the optimal form of transplantation. A concerning but understandable finding
238
of the study was that patients who underwent pre-emptive transplantation
reported significantly worse treatment satisfaction than patients who
received a period of dialysis prior to transplantation. This highlights the need
for improved efforts to educate patients about the benefits of pre-emptive
transplantation, to manage patient expectations and to provide psychological
support throughout the whole treatment journey. Reassuringly, pre-emptive
transplant recipients did not report inferior health status, psychological well-
being and quality of life, compared with other transplant recipients.
4) What factors affect the survival of patients on dialysis, and can these risk
factors be quantified in a survival prediction score aimed at reducing inequity
and standardising access to the waiting list?
In Chapter 7, a comprehensive analysis of patients on dialysis showed that
older age, female gender, lower serum albumin, being underweight or having
diabetes, heart failure, atrial fibrillation, chronic respiratory disease, chronic
liver disease or malignancy were important independent predictors of
mortality within two years of starting dialysis. The results were developed
into a novel survival prediction score that was internally validated, with good
performance statistics. Further research is required to externally validate the
score. The score could be easily implemented in the clinical setting to provide
patients with individual survival prediction. We also propose that it could be
used as a tool to aid listing decisions, thereby providing an objective and
evidence based means of standardising access to the waiting list and
improving equity of access to transplantation. However, the predicted
survival probability at which patients should be considered for listing would
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need to be agreed on a national basis with input from all relevant
stakeholders, and most importantly patients.
The findings of this thesis have the ability to positively impact the care of
patients with ESRD in the UK by driving initiatives to reduce inequity in access
to transplantation, targeting disadvantaged patient groups, providing
individual survival prediction for patients, informing national guidelines for
fairer transplant listing and allocation and guiding future research into
improving outcomes for all patients.
The work described in this thesis was part of the scientific evidence presented
to and considered by a working group involved in the design of a new national
kidney offering scheme in the UK. The terms of reference of the working
group were to determine the criteria for listing for a kidney transplant, to
evaluate the key principles of allocation, to consider whether priorities should
differ at the extremes of age, to determine how best to maximise the benefit
of each donor-recipient combination to include consideration of measures of
organ quality and to determine the contribution of time spent on the waiting
list to allocation priority. The recommendations from the working group were
used in the development of the new national kidney offering scheme, which
is currently being finalised.
Further work is required. A number of targeted interventions for improving
access to transplantation are already underway in some pilot sites in the UK,
and if successful could be rolled out across all centres. The importance of
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comorbidity in the survival outcomes of ESRD patients has been highlighted
in this work, and provides a case for exploring methods in which accurate
comorbidity variables could be routinely collected by the UK transplant
registry and UK renal registry. This would significantly enhance the national
analyses produced by the registries and open up new insights into how the
outcomes of ESRD patients could be further improved.  Further research is
needed to determine whether optimisation of specific comorbidity risk
factors can improve survival outcomes. The patients enrolled in the study will
continue to be followed up so that longer term outcomes can be analysed. We
plan to update our analyses at 5 and 10 years. In addition to the risk index
for dialysis patients, a risk index for post-transplant survival will be explored.
Additional work is required to investigate whether interventions can improve
the patient reported outcomes of transplant recipients, particularly DDKT
recipients. We also intend to take forward the work done on the survival
prediction score for patients on dialysis, by incorporating it into a user
friendly mobile app tool, and assessing ways in which it could be integrated
into the listing process in the UK.
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A.2. Data proforma
Demographic variables – collected for all patients
Variable Options















Date first seen by nephrologist























Heath literacy: how often do you need
help to read instructions, leaflets or













Were you born in the UK? No
Yes
Clinical variables – collected for all patients
Variable Options





































Peripheral vascular disease No
Yes:
Claudication
Radiological or surgical intervention
Amputation
Abdominal aortic aneurysm No
Yes:
Surveillance
Radiological or surgical repair




























Number of cigarettes per day
Previous transplant No
Yes
Number of previous transplants
Dialysis variables – collected for incident dialysis cohort
Variable Options
Start of dialysis date









Transplant variables – collected for incident transplant cohort
Variable Options
Date of transplant
Type of transplant Kidney only
Kidney + pancreas



















Start of dialysis date




Date of activation on waiting list
Recipient calculated reaction frequency
(%)








































Waiting list variables – collected for waiting list cohort
Variable Options
Date of activation on waiting list
Type of transplant listed for Kidney only
Kidney + pancreas
Kidney + other organ









Start of dialysis date

























White – British, Irish, European, other White background
Black – Caribbean, African, other Black background
Asian – Indian, Pakistani, Bangladeshi, Indian subcontinent, other Asian
background
Other – Any other background including Chinese and mixed backgrounds
Highest qualification
No qualifications
Secondary education level – Ordinary level (O-level), General Certificate of
Secondary Education (GSCE), General Certificate of Education Advanced level
(A-level), National Vocational Qualification (NVQ) 1-3
Higher education level - Bachelor’s Degree (e.g. BA/BSc), Higher Degree
(e.g. MSc/PhD), NVQ 4-5
Employment status
Employed – full-time and part-time included
Unemployed
Long term sick/ disabled
Retired
Other - looking after the family home, not in work for some other reason,
students
Primary renal diagnosis
Coded as per UK renal registry definitions (which are based on ERA-EDTA
definitions). These can be found at: https://www.renalreg.org/wp-
content/uploads/2018/06/19-AppH.pdf
Diabetes
Any cause of diabetes
Type I diabetes – Insulin required from time of diagnosis




Angina – chest pain on exertion, relieved by rest / GTN. As reported by
patient or as documented on case notes with or without ECG changes,
exercise tolerance testing or other imaging
NSTEMI – troponin rise and non-ST segment elevation ischaemic ECG
changes such as ST depression, T-wave inversion or no ECG changes.
STEMI – troponin rise and ST segment elevation on ECG
PCI – coronary angioplasty with or without stent insertion
CABG - coronary artery bypass graft operation
Heart failure




Left or right ventricular dysfunction on cardiac echo
Ejection fraction <30% on cardiac echo
Atrial fibrillation
Only includes patients in chronic atrial fibrillation at the time of recruitment,
previous isolated episodes not included
Cardiac valve replacement
Any kind of cardiac valve replacement or repair
Permanent pacemaker
Currently has permanent pacemaker in situ
Cerebrovascular disease
Transient Ischaemic Attack (TIA) – also known as “mini-stroke”. Transient
episode of neurologic dysfunction caused by ischaemia without infarction.
Symptoms typically lasting less than 24 hours
Cerebrovascular accident (CVA) – includes Ischaemic stroke, cerebral
haemorrhage, subarachnoid haemorrhage or subdural haemorrhage
confirmed on imaging




Claudication – lower limb pain on walking as reported by the patient, with or
without doppler or angiographic evidence
Radiological or surgical intervention – includes angioplasty, endarterectomy,
bypass graft
Amputation – amputation of any part of the limb
Abdominal aortic aneurysm
Surveillance – radiological diagnosis under surveillance
Radiological or surgical repair – previous endovascular or open surgical
repair
Chronic respiratory disease
Asthma – inflammatory condition of the lungs causing recurrent attacks of
breathlessness and wheezing, differs in severity and occurs in all age groups
Chronic obstructive pulmonary disease (COPD) – chronic and progressive
airflow obstruction that is not fully reversible. FEV1/FVC ratio <0.7 and FEV1
< 80% predicted
Bronchiectasis – abnormal and irreversible dilatation of the bronchi due to
destruction of elastic and muscular tissue by acute or chronic inflammation
and infection. Results in chronic infections and airway obstruction
Chronic liver disease
Persistent enzyme evidence of hepatic dysfunction with imaging or biopsy
evidence of cirrhotic or non-cirrhotic liver disease
Blood borne viruses
Evidence of Hepatitis C or B or HIV PCR or antibody positive results
Malignancy
Diagnosis of any malignancy in the past or in the present. Does not include
benign tumours such as breast adenoma, colon polyp, actinic keratosis etc.
Mental illness
Includes any kind of mental illness such as depression, psychosis, bipolar
disorder, substance abuse, deliberate self-harm, schizophrenia
Dementia
Any form of dementia including vascular dementia and Alzhemier’s disease
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Type of dialysis
If the patient has been on more than one type of dialysis, this is the
modality that the patient has spent most time on
Recipient calculated reaction frequency (cRF)
The cRF is a measure of recipient HLA sensitisation and is calculated as the
percentage of 10,000 recent donors to which the recipient has pre-formed
HLA antibodies
HLA mismatch group
HLA mismatches were classified into 4 levels as defined by the current UK
deceased donor kidney allocation scheme: level 1 (000 HLA-A, B, DR MM),
level 2 (0DR + 0/1B MM), level 3 (0DR + 2B MM) or (1DR + 0/1B MM) and
level 4 (1DR + 2B MM) or (2DR MM)
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Appendix A.4. Modified Charlson Comorbidity Index
definitions
Myocardial infarction
ATTOM ischaemic heart disease variable = NSTEMI or STEMI
Congestive heart failure
ATTOM heart failure variable = YES
Peripheral vascular disease
ATTOM peripheral vascular disease variable = YES (all options included)
ATTOM abdominal aortic aneurysm variable = RADIOLOGICAL OR SURGICAL
REPAIR
Cerebrovascular disease
ATTOM cerebrovascular disease variable = YES (all options included)
Dementia
ATTOM dementia variable = YES
Chronic pulmonary disease
ATTOM chronic respiratory disease = YES (all options included)
Diabetes without complications
ATTOM diabetes variable = YES
(ATTOM primary renal disease variable ≠ DIABETIC NEPHROPATHY)
Diabetes with complications
ATTOM primary renal disease variable = DIABETIC NEPHROPATHY
Moderate-severe liver disease
ATTOM chronic liver disease variable = CIRRHOTIC
Leukaemia
ATTOM malignancy variable = LEUKAEMIA, MYELOGENOUS LEUKAEMIA,
LYMPHOCYTIC LEUKAEMIA, POLYCYTHEMIA VERA
Lymphoma
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ATTOM malignancy variable = LYMPHOMA, HODGKIN’S, LYMPHOSARCOMA,
WALDENSTROMS MACROGLOBULINAEMIA, MYELOMA, NON-HODGKIN’S
Metastatic disease
ATTOM malignancy variable = METASTATIC, METASTASES, METS
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A.5. PROMs questionnaires





 General health status




o Pain / Discomfort
o Anxiety / Depression






 Converted to weighted index score
using the value set for England*





 General health status
 Rating of health (today) on visual
analogue scale
 0 = worst health you can imagine






 Calculated by combining scores from











 Single item question rated from -3




 17 aspects of life
 Rating of impact of renal condition
-9 to +3
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 Rating of importance of each aspect
of life
 Combined to give an average
weighted impact score






 Satisfaction with current renal
treatment
 Rated from 6 (very satisfied) to 0 (very
dissatisfied) on 13 items







 Satisfaction with current renal
treatment compared with satisfaction
with previous renal treatment
 Rated from +3 (much more satisfied
now) to -3 (much less satisfied now)
on 13 items
 Higher score indicates greater
satisfaction with current compared
with previous treatment
-39 to +39
* Devlin N, Shah K, Feng Y, Mulhern B, Van Hout B. Valuing Health-Related Quality of Life: An EQ-5D-5L
Value Set for England. London: Office of Health Economics, January 2016. Available from
https://www.ohe.org/publications/valuing-health-related-quality-life-eq-5d-5l-value-set-england.
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Worldwide, the number of patients able to benefit from
kidney transplantation is greatly restricted by the severe
shortage of deceased donor organs. Allocation of this
scarce resource is increasingly challenging and complex.
Striking an acceptable balance between efficient use of
(utility) and fair access to (equity) the limited supply of
donated kidneys raises controversial but important
debates at ethical, medical, and social levels. There is no
international consensus on the recipient and donor factors
that should be considered in the kidney allocation process.
There is a general trend toward a reduction in the influence
of human leukocyte antigen mismatch and an increase in
the importance of other factors shown to affect
posttransplant outcomes, such as cold ischemia, duration
of dialysis, donor and recipient age, and comorbidity.
Increased consideration of equity has led to improved
access to transplantation for disadvantaged patient groups.
There has been an overall improvement in the
transparency and accountability of allocation policies.
Novel and contentious approaches in kidney allocation
include the use of survival prediction scores as a criterion
for accessing the waiting list and at the point of organ
offering with matching of predicted graft and recipient
survival. This review compares the diverse international
approaches to deceased donor kidney allocation and their
evolution over the last decade.
Kidney International (2017) 91, 1287–1299; http://dx.doi.org/10.1016/
j.kint.2016.09.054
KEYWORDS: deceased donor; equity of access; kidney allocation; kidney
transplantation; longevity matching; survival prediction
Copyright ª 2017, International Society of Nephrology. Published by
Elsevier Inc. All rights reserved.
T he superior outcomes of kidney transplantation overdialysis and the growing incidence of end-stage renaldisease have led to an exponential increase in the
need for kidney transplantation worldwide.1 In contrast, the
number of deceased donors has changed little and is vastly
insufficient.2 Consequently, patients face longer waiting
times, as well as a higher risk for morbidity and mortality
while on the waiting list. In the US alone, the number of
patients on the waiting list has doubled over the past decade,
reaching around 100,000 patients, median waiting time has
increased to over 4.5 years, and nearly 5000 patients die while
waiting for a deceased donor kidney transplant every year.3
Similar trends have been noted in other countries (Figure 1
and Table 1).
While living donors usually donate to a specified recipient,
in most countries, deceased organ donation is non-directed
and organs are offered to patients on a waiting list via an
allocation scheme. Allocation schemes are generally governed
by appointed transplant organizations that may operate at a
regional, national, or even international level. Ownership of
deceased donor organs is a controversial matter; in some
countries, they are considered a national resource, whereas in
others, they are retained within the donor region, and sharing
among regions may be limited to payback requirements.
Thus, allocation schemes vary from simple local programs to
complex national algorithms. Furthermore, there is no uni-
versal consensus on the factors that should be considered in
the allocation process, leading to considerable variation in the
way patients are prioritized within different schemes.
The major debate in the allocation of scarce donor organs
centers on the competing ethical values of utility (maximum
outcomes) and equity (fairness). Consideration must be given
to the efficient use of organs to optimize outcomes and the
overall benefits to society, as well as to the welfare of individual
patients and fair access to transplantation.4 Utility-based allo-
cation prioritizes patients with the best chance of a favorable
outcome, aiming to achieve the maximum benefit from every
transplanted organ. Inevitably, this gives rise to a debate over
how benefit should be measured, that is whether by graft sur-
vival, patient survival, life years gained from transplant, or
quality of life. Furthermore, it disadvantages patients who are
less likely to experience a good outcome, such as those who are
older, have diabetes, have more comorbidity, or have been on
dialysis for a longer period of time.5–9 Although an increasing
Correspondence: G.C. Oniscu, Transplant Unit, Royal Infirmary of Edinburgh,
51 Little France Crescent, Edinburgh, EH16 4SA, UK. E-mail: gabriel.
oniscu@ed.ac.uk
Received 19 July 2016; revised 12 September 2016; accepted 28
September 2016; published online 18 March 2017
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proportion of patients on the waiting list fall into the above
categories, they still derive a significant survival benefit from
transplantation.1,10–12 The principle of equity necessitates
fairness in organ allocation; however, this may be interpreted in
various ways. Equity is commonly conceived as “equal oppor-
tunity,” that is, every person who may benefit from a transplant
should have an equal opportunity of receiving one.13 It is
important not tomisinterpret this as equality; although equality
involves treating all patients exactly the same (i.e., allocation by
lottery), it neglects the fact that patients do not start from equal
circumstances.14 The discovery of human leukocyte antigen
(HLA) matching as a major determinant of graft survival led to
its principal role in the first formal allocation schemes.15–17
However, it became apparent that such schemes resulted in
inequitable access to transplantation for difficult-to-match
patients.18–20 Consequently, most schemes now award extra
priority to highly sensitized patients and patients with rare HLA
types (most commonly from ethnic minorities) who are bio-
logically disadvantaged in finding a compatible donor, to
equalize their opportunity for transplantation. “Queuing” (first
come, first served) is another concept of equity that has been
widely accepted in kidney allocation. However, with the
increasing age and morbidity of patients on the waiting list, this
approach has been challenged for favoring those who are able to
survive the ever-increasing wait. Furthermore, with growing
evidence for disparities in access to the waiting list, many
schemes now measure the waiting time from the start date of
dialysis as opposed to the listing date, although some countries
are yet to adopt this approach. Priority for pediatric patients is
universally acknowledged in view of the detrimental impact of
renal failure and prolonged dialysis on growth and develop-
ment (although the age cutoff and priority level substantially
varies among different schemes). In contrast, the prioritization
of younger adults over older ones is widely disputed. While
advocates of the “fair innings” concept believe that equity
should be measured by the opportunity to reach a normal life
expectancy, critics argue that preferential allocation to younger
patients is age discrimination.21 The “prudential lifespan”
provides an alternative concept of equity through the allocation
of kidneys by age matching. This justifies the allocation of
younger (and therefore “higher quality” kidneys) to younger
recipients and the allocation of older kidneys to older recipients
because all patients are treated similarly at a particular stage of
life.22 However, this approach becomes problematic if there is a
discrepancy in the age distribution of donor and recipient
pools. Moreover, age is just one of the many factors that in-
fluence the outcome of transplanted kidneys. A range of sur-
vival predictors are utilized in the emerging concept of
longevity matching, where kidneys are allocated on the basis
of matching estimated graft and recipient survival. This
approach remains controversial, reflecting the enduring diffi-
culties in achieving an acceptable balance between utility and
equity.
This review compares the allocation schemes of several
























































Figure 1 | Patients on kidney transplant waiting list 2003 versus 2013. Eurotransplant 2003: Austria, Belgium, Germany, the Netherlands,
Luxembourg, and Slovenia. Eurotransplant 2013: Austria, Belgium, Croatia, Germany, Hungary, the Netherlands, Luxembourg, and Slovenia.
Scandiatransplant: Denmark, Finland, Iceland, Norway, and Sweden. Data sources: UK,87–89 US,3,90,91 Australia,92,93 New Zealand,92,93
Eurotransplant,94,95 Scandiatransplant,96,97 Israel,98,99 Spain,98,99 and France.98–100 Population data from United Nations. Department of
Economic and Social Affairs Population Division. World Population Prospects: The 2015 Revision. Total Population – Both Sexes. Available at:
https://esa.un.org/unpd/wpp/Download/Standard/Population/. Accessed April 11, 2016.
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United Kingdom
The first UK national kidney allocation scheme was a simple
HLA-matching scheme that was introduced in 1989.23 One
kidney from each donor was allocated nationally to a
“beneficially mismatched recipient” (defined as HLA-A, -B,
and -DR mismatch 000, 100, or 010), whereas the paired
donor kidney was allocated locally according to individual
center policies.17,23
A revised scheme was implemented in 1998, after 3 distinct
tiers of HLA mismatch were identified as major influences on
graft outcome.24 Allocation was prioritized on a national basis
for tier 1 (000 mismatch) followed by tier 2 (100, 010, and
110 mismatch) patients; allocation was on a local basis for tier
3 patients (all other HLA-mismatch grades). Within tiers 1
and 2, priority was given to pediatric patients (<18 years),
patients disadvantaged in finding a compatible donor (who
are highly sensitized [panel reactive antibody, {PRA} $85%],
are HLA-DR homozygous, or have blood group B), and local
patients. A points score differentiated equally eligible patients
within the tiers on the basis of recipient’s age, donor-recipient
age difference, waiting time (from listing date), matchability
score, sensitization level, and balance of organ exchange
among centers. Matchability was a measure of the likelihood
of being offered a well-matched kidney (tier 1 or 2), with the
aim being to improve access for difficult-to-match patients.
However, because the points score was employed to only
differentiate among equally HLA-matched patients, the
overall effect of the point-scoring factors proved to be mini-
mal. Although the 1998 scheme improved the level of HLA
matching of allocated kidneys, the inequity of access
remained a significant issue.24
In 2006, a new scheme was implemented, and this re-
mains in place to date, albeit with minor modifications.25
Previously deemed non-favorable levels of HLA mismatch
were shown to achieve good outcomes; therefore, the new
scheme places less emphasis on HLA matching, and except
for zero HLA mismatches, HLA-A matching is no longer
considered.8 Zero HLA-mismatched patients retain top
priority along with well-matched (100, 010, and 110) pe-
diatric patients, HLA-DR homozygous patients, and highly
sensitized patients (now measured as calculated reaction
frequency, $85%). The calculated reaction frequency is the
percentage of 10,000 recent donors to which the patient has
pre-formed antibodies. The points score was also revised;
where previously waiting time contributed the least points,
it now has potentially the greatest influence (although it
continues to be defined as the time from listing). Points for
the recipient’s age are combined with HLA mismatch in a
novel approach to prioritize younger patients for well-
matched grafts. This minimizes HLA sensitization and
improves the likelihood of retransplantation, which is
particularly crucial for younger recipients who are likely to
require more than 1 graft in their lifetime. Other point-
scoring factors include the proximity of the donor to the
recipient center (to minimize ischemia), donor-recipient age
difference, HLA-DR and -B homozygosity and blood group
(to address imbalances of distribution between donor and
recipient pools). Because the matchability score proved to be
unsuccessful in improving equity, the 2006 scheme utilizes a
different approach whereby rare HLA types are defaulted to
more common related HLA types against which cross-
reacting antibodies seldom form. In September 2014, the
national scheme was extended to include allocation from
donors after circulatory death. In the phase-in period, this
allocation is only applicable to one kidney from donors after
circulatory death who are aged 5 to 50 years.26
The 2006 scheme has successfully increased the number of
transplants for highly sensitized, long-waiting, difficult-to-
match and Black, Asian, and minority ethnic patients, without
compromising graft or patient survival (Table 2). Nevertheless,
the past decade has also seen an overall increase in the size of the
waiting list, median waiting time (Table 1), and number of
discarded kidneys.27 This raises concerns regarding the effi-
ciency and suitability of the allocation systemwithin the context
of an older and higher risk population of donors and recipients.
United States
The first US kidney allocation scheme was introduced in
1987, and a completely revised scheme was implemented for
the first time in 2014.28 Under the former system, the country
was divided into 58 donor service areas (DSAs), responsible
for local procurement and allocation of deceased donor or-
gans.29 Although there was mandatory national sharing of
zero HLA-mismatched kidneys, these were required to be
paid back to the procuring DSA. The large majority of organs
were retained within and allocated by individual DSAs. Given
that local organ supply relative to the demand varied widely
among DSAs, substantial disparities were observed in the
waiting time across the country.30 In March 2000, the
Department of Health and Human Services issued “The Final
Rule” to establish a national framework for organ allocation
and to reduce geographical inequities.31 Following this, all
kidneys were allocated via one of 4 sequences, according to
the category of the donor:
 Standard criteria donors <35 years
 Standard criteria donors $35 years
 Expanded criteria donors (ECD)
 Donors after circulatory death
ECD kidneys were defined by an estimated risk for
graft failure of $70% higher than standard criteria donor
kidneys and were offered to specifically consenting
recipients.32 Within each sequence, priority was given to zero
HLA-mismatched patients, blood group-identical patients,
highly sensitized patients (calculated PRA, $80%), pediatric
patients (<18 years), prior live organ donors, local patients,
and DSAs owed a payback. A points score was used to rank
individual patients (recipients of ECD or donor after circu-
latory death kidneys were ranked by waiting time only).33 The
points score was extensively modified over time toward fewer
points for HLA matching (except for zero HLA mismatches,
HLA-A matching was eliminated in 1995 and HLA-B
matching was eliminated in 2003) and more points for
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waiting time, reflecting efforts to achieve a more equitable
system.34,35 The “Share 35” scheme was implemented in
2005, which awarded extra priority to pediatric recipients for
donors under 35 years and zero HLA-mismatched donors of
all ages, but it was unexpectedly associated with a decline in
pediatric living donor transplants.36,37
Despite repeated efforts to improve the former system, it
was perceived as inefficient and inequitable. Over the last
decade, the waiting list numbers have doubled, death on the
waiting list has increased (Table 1), and average post-
transplant survival has deteriorated.38 By 2011, 39 of 58
DSAs were operating with at least one variance to the national
system, resulting in inconsistent allocation across the coun-
try.39 Because waiting time had become the dominant factor
of allocation owing to the efforts to improve equity, a system
that was essentially a queue was created, with minimal regard
for outcomes. As such, kidneys with a long predicted lifespan
were often allocated to patients with significantly shorter life
expectancy, leading to high rates of death with a functioning
graft and unrealized graft benefit. Similarly, younger patients
were frequently allocated kidneys with a much shorter life
span, resulting in high discard rates, retransplantation rates,
and HLA sensitization.40
The key concept of the new system is longevity matching,
whereby 20% of listed patients with the longest estimated
posttransplant survival are prioritized for 20% of the kidneys
with the longest estimated graft survival.28 The estimated
posttransplant survival score predicts patient survival on the
basis of age, time of dialysis, diabetes status, and prior
transplantation. Graft survival is estimated by the kidney
donor profile index (KDPI), a continuous measure based on
10 donor characteristics (Table 3). This replaces the previous
dichotomous ECD/standard criteria donor stratification of
donor kidneys, which inadequately reflected the risk for graft
failure.41 As before, kidneys are allocated through 4 se-
quences, now defined by the KDPI score of the donor kidney
(KDPI #20%, 20% > KDPI < 35%, 35% $ KDPI # 85%,
KDPI > 85%). Pediatric patients retain priority for zero
HLA-mismatched kidneys and for kidneys with KDPI <35%.
Local priority is also retained, but paybacks and local vari-
ances are no longer permitted. Changes to the points system
include calculating the waiting time from the start of dialysis
instead of listing and using a sliding scale of points for the
sensitization level.
It is expected that the new scheme will enhance utility by
an additional 9000 life years annually and improve trans-
plantation rates for highly sensitized, ethnic minority and
patients aged 18 to 49 years. However it is acknowledged that
the scheme will likely decrease access to transplantation for
patients older than 50 years.39
Australia
Previously low donation and transplantation rates in Australia
have significantly increased since implementation of the na-
tional Organ and Tissue Authority in 2008.2,42 Remarkably,
Australia is now one of few countries where waiting list
numbers and median waiting time have decreased over the
past decade (Table 1). The decline may be linked to the
introduction of national listing criteria that restrict access to
the kidney transplant waiting list to patients with an esti-
mated 5-year posttransplant survival of over 80%.43 These
criteria are relatively strict compared with current European
Table 1 | Kidney transplant and waiting list figures 2003 versus 2013
Year
UK US Australia New Zealand
2003 2013 2003 2013 2003 2013 2003 2013
Population (million)c 59.5 64.0 291.0 317.1 19.7 23.3 4.0 4.5
Total kidney transplants
n 1836 3256 15138 16895 543 882 111 115
pmp 30.9 50.9 52 53.3 27.6 37.9 27.8 25.6
DD transplants
n 1386 2142 8668 11163 325 630 67 57
pmp 23.3 33.5 29.8 35.2 16.5 27 16.8 12.7
LD transplants
n 450 1114 6470 5732 218 252 44 58
pmp 7.6 17.4 22.2 18.1 11.2 10.8 11 12.9
Patients on waiting list at year end
n 5074 5881d 56514 99253 1591 1056 318 438
pmp 85.3 91.9 194.2 313 80.8 45.3 79.5 97.3
Died on waiting list
n 298 279 3895 4644 45 3 x x
pmp 5 4.4 13.4 14.6 2.3 0.1 x x
Median waiting time, yr 2.3 2.7 3.2 4.5 3.7 2.7 x x
DD, deceased donor; LD, living donor; pmp, per million population; x, data not available.
aEurotransplant 2003: Austria, Belgium, Germany, the Netherlands, Luxembourg and Slovenia. Eurotransplant 2013 ¼ Austria, Belgium, Croatia, Germany, Hungary, the
Netherlands, Luxembourg, and Slovenia.
bScandiatransplant: Denmark, Finland, Iceland, Norway, and Sweden.
cData from United Nations. Department of Economic and Social Affairs Population Division. World Population Prospects: The 2015 Revision. Total Population – Both Sexes.
Available at: https://esa.un.org/unpd/wpp/Download/Standard/Population/. Accessed April 11, 2016.
dNote this number represents a downward trend since 2009.
Data sources: UK,87–89 US,3,90,91 Australia,92,93 New Zealand,92,93 Eurotransplant,94,95 Scandiatransplant,96,97 Israel,98,99 Spain,98,99 and France.98–100
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guidelines that recommend the exclusion of patients with a
life expectancy of less than 2 years.44
The national allocation system was introduced in 2011.43
Only well-matched grafts are allocated nationally (maximum
2 HLA mismatches at HLA-A, -B, or -DR if PRA >80% and at
HLA-A or -B only if PRA <80%). Around 20% of kidneys
achieve this level of matching, whereas the remaining 80% are
allocated locally via state-based algorithms. The national algo-
rithm is based on a points system that starts with a base score
from which points are deducted or gained. Priority is given to
zero HLA mismatches, sensitized patients at 2 levels (PRA
>50% and>80%), pediatric patients (<18 years), waiting time
(from start of dialysis), and local patients. Balance of exchange is
also considered. Although state-based algorithms differ, all are
required to allocate a minimum of 30% of kidneys on waiting
time alone to improve equity for difficult-to-match patients.43
New Zealand
New Zealand’s organ donation and transplantation rates have
remained inferior to those of other western countries (Table 1).
The donor population inNewZealand is predominantlyWhite,
while the ESRD population consists of a high proportion of
Maori and Pacific Island nation people. This has led to inequity
issues for difficult-to-match patients similar to those observed
in the United Kingdom, United States, and Australia.45
Access to the waiting list is determined by the same listing
criteria used by Australia (estimated 5-year posttransplant
survival of >80%), but estimates are calculated using a sur-
vival prediction tool based on an index derived and validated in
a US dataset of 170,000 patients.46 Patients are rescored
annually or at the time of any change in their health status and
are removed from thewaiting list if their score falls below70%.47
The structure of the allocation protocol is also similar to
the Australian system, whereby patients start with a baseline
score from which points are deducted for HLA mismatches
and are gained for pediatric status (age <15 years) and
waiting time (from start of dialysis).48 Unlike most other
allocation systems, points are not awarded for HLA sensiti-
zation because waiting time is considered a good enough
surrogate for this. There are 2 levels of allocation: level 1 aims
to allocate to well-matched patients (maximum of 2 HLA-A
or -B mismatches) and level 2 to long-waiting patients.49
The structure of the protocol has remained largely un-
changed over the past decade, with minor modifications
implemented on the basis of audit data. HLA-DR mismatches
were excluded from level 1 in 2013 to reduce the percentage
of kidneys allocated to this level; age matching was abolished
as it became apparent that younger patients were being
disadvantaged by the predominantly older donor population;
and waiting time was given increased weighting in the points
score (personal communication Ian Dittmer). A novel feature
of the New Zealand kidney allocation scheme is that all ECD
kidneys are biopsied, reviewed by an on-call pathologist, and
scored according to the Remuzzi classification. Kidneys
scoring 4 to 6 are offered as dual transplants, and those
scoring $7 are discarded.49
Eurotransplant
Eurotransplant was created in 1967 as an international
collaboration among Austria, Germany, Belgium,
Luxembourg, and the Netherlands and was later joined by
Slovenia in 1999, Croatia in 2007, and Hungary in 2013.50
The vision was to pool together the donor organs and
create a centralized waiting list to optimize HLA matching
and improve transplant outcomes. However, the early HLA-
based kidney allocation system led to a high percentage of
highly sensitized, long-waiting, rare HLA phenotype, and
HLA-homozygous patients on the waiting list, as well as large
imbalances of exchange among the countries.51
In 1996, the new Eurotransplant Kidney Allocation System
(ETKAS) was introduced to address these issues.52 This was a
points-scoring system based on HLA mismatch, mismatch
probability, waiting time, distance between donor and
transplant center, national balance of exchange, medical
Table 1 | (Continued) Kidney transplant and waiting list figures 2003 versus 2013
Eurotransplanta Scandiatransplantb Israel Spain France
2003 2013 2003 2013 2003 2013 2003 2013 2003 2013
118.8 133.8 24.4 26.1 6.4 7.8 42.5 46.5 60.5 63.8
3991 4586 926 1103 126 264 2051 2552 2127 3074
33.6 34.3 38 42.3 19.7 33.8 48.3 54.9 35.2 48.2
3345 3183 654 756 55 128 1991 2170 1991 2673
28.1 23.8 26.8 29 8.6 16.4 46.8 46.7 32.9 41.9
646 1403 272 347 71 136 60 382 136 401
5.4 10.5 11.1 13.3 11.1 17.4 1.4 8.2 2.2 6.3
12382 11120 1231 1333 469 762 4026 4328 5380 10736
104.2 83.1 50.5 51.1 73.3 97.7 94.7 93.1 88.9 168.3
646 593 20 74 16 30 x x 113 252
5.4 4.4 0.8 2.8 2.5 3.8 x x 1.9 3.9
3.3 3.7 1.1 1.2 x x x x 1.4 2.4
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Table 2 | Transplant characteristics for kidney-only transplants from donors after brain death in the UK 2003 versus 2013
Actual DBD kidney-only transplants in the UK
Jan 1, 2003–Dec 31, 2003 Jan 1, 2013–Dec 31, 2013
n % n %
Number of transplants 1133 1161
HLA mismatches
Level 1 (000 MM) 193 17.0 216 18.6
Level 2 (0DRþ0/1B MM) 588 51.9 437 37.6
Level 3 (0DRþ2B or 1DRþ0/1B MM) 270 23.8 477 41.1
Level 4 (2Bþ1DR or 2DR MM) 82 7.2 31 2.7
Matchability
Easy (1–3) 538 47.5 441 38.0
Moderate (4–7) 429 37.9 512 44.1
Difficult (8–10) 165 14.6 207 17.8
Highly sensitized (cRF >85%) 53 4.7 195 16.8
Waiting time
<1 yr 497 43.9 236 20.3
1–3 yr 392 34.6 370 31.9
3–5 yr 143 12.6 326 28.1
5–7 yr 48 4.2 159 13.7
$7 yr 53 4.7 70 6.0
Recipient age
0–5 yr 10 0.9 7 0.6
6–11 yr 21 1.9 17 1.5
12–17 yr 52 4.6 34 2.9
18–29 yr 122 10.8 107 9.2
30–39 yr 200 17.7 171 14.7
40–49 yr 273 24.1 278 23.9
50–59 yr 266 23.5 269 23.2
60–69 yr 163 14.4 209 18
$70 yr 26 2.3 69 5.9
Donor-recipient age difference
<15 yr 688 60.7 732 63.0
15–25 yr 260 22.9 299 25.8
>25 yr 185 16.3 130 11.2
Recipient blood group
O 467 41.2 512 44.1
A 460 40.6 423 36.4
B 150 13.2 166 14.3
AB 56 4.9 60 5.2
Homozygosity
HLA-A 161 14.2 148 12.7
HLA-B 90 7.9 84 7.2
HLA-DR 103 9.1 146 12.6
HLA-A,B,DR 16 1.4 29 2.5
Graft number
1 954 84.2 939 80.9
2 149 13.2 186 16.0
3 24 2.1 31 2.7
4 6 0.5 5 0.4
Diabetic 74 6.5 75 6.5
Gender (male) 697 61.5 717 61.8
Ethnicity
White 981 86.6 824 71.0
Asian 96 8.5 205 17.7
Black 43 3.8 95 8.2
Other 11 1.0 31 2.7
Not reported 2 0.2 6 0.5
Exchange
Local center 402 35.5 189 16.3
Local area 399 35.2 604 52.0
Other 332 29.3 368 31.7
Median CIT 18.5 h (IQR: 15.9–22.4) 14.5 h (IQR: 11.4–17.9)
1-year graft survival 91.2% (95% CI: 89.3–92.7) 94.1% (95% CI: 92.4–95.4)
1-year patient survival 95.5% (95% CI: 93.9–96.7) 95.9% (95% CI: 94.2–97.1)
CIT, cold ischemia time; cRF, calculated reaction frequency; DBD, donor after brain death; HLA, human leukocyte antigen; IQR, interquartile range; MM. mismatch.
Data source: NHSBT Data Request. Based on data as of January 20, 2015.89
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urgency, and pediatric age. The Eurotransplant Kidney Allo-
cation System remains in place to date.50 Points are awarded
according to the number of HLA mismatches (0–6), and a
unique feature is that equal weighting is given to HLA-A, -B,
and -DR loci. Mismatch probability is a measure of the
likelihood of finding a 0 or 1 HLA-mismatched donor on the
basis of the frequencies of HLA antigens in the Eurotransplant
donor pool. Until April 2000, waiting time was counted from
the date of registration and thereafter from the date of first
dialysis.51 Pediatric status was previously defined as aged <16
years, but since 2010, those aged >16 years with growth
potential proven by an X-ray of the hand are granted pediatric
status. Pediatric patients are assigned additional waiting
points according to the age of listing, are given double points
for zero HLA-mismatched donors, and since 2010, are given
priority for donors aged <16 years.53 Since 2013, previous
kidney donors are given a one-off bonus of 500 extra points
on registration to the waiting list. A distinctive feature of the
Eurotransplant Kidney Allocation System is the inclusion of
medical urgency in the allocation score. The Eurotransplant
Kidney Allocation System has been successful in transplanting
a higher percentage of long-waiting, highly sensitized, rare
HLA phenotype, pediatric patients and in equalizing the in-
ternational imbalances in organ exchange.54,55
Eurotransplant was the first organization to develop special
allocation programs for specific groups of patients (Figure 2).
The acceptable mismatch program was introduced in 1996 for
highly sensitized patients (PRA >85%). In the program, it is
determined which HLA antigens the patient does not have
antibodies against, and priority is given for any donor with
acceptable antigens.56,57 In the Eurotransplant Senior Program
started in 1999, non-sensitized recipients aged >65 years are
prioritized for donors aged >65 years irrespective of HLA
matching. Allocation is based on medical urgency and waiting
time only and preferentially on a local basis to minimize cold
ischemia time.58,59 These programs have been successful in
increasing the number of transplants and shortening the
waiting time for these groups of patients.60–63
Scandiatransplant
Scandiatransplant was formed in 1969 as a collaboration
among the Nordic countries (Denmark, Finland, Iceland,
Norway, and Sweden). Kidneys were originally exclusively
exchanged on the basis of HLA matching, but the current
criteria include priority for highly sensitized and pediatric
patients.64 Unlike most schemes, it does not employ the use of
a points system. There is a mandatory exchange of at least one
donor kidney when a patient on the waiting list has zero HLA
mismatches, defined acceptable mismatches as part of the
Scandiatransplant acceptable mismatch program (see below),
or is a pediatric patient (<16 years at registration) with a
maximum of 2 HLA-A or -B mismatches for a donor
aged <40 years. Priority is given to highly sensitized patients
(PRA $80%), followed by those with acceptable mismatches
and sensitized patients (PRA 10%–80%). Only blood group-
identical exchanges are allowed, and donor-recipient age
differences of over 30 years are not permitted. There is a strict
control of balance of exchange, and kidneys are required to be
paid back within 6 months. For all other kidneys that do not
meet the mandatory exchange criteria, allocation is via local
transplant center policies.65
The Scandiatransplant acceptable mismatch program was
introduced in 2009. Patients with PRA$80% and a minimum
waiting time of 1 year (not necessary for pediatric patients)may
be accepted in the program. Within the first 3 years of the
program, the number of transplanted highly sensitized patients
significantly increased, and the mean waiting time for these
patients decreased from 42 to 37 months.66
Israel
The Israeli parliament passed the Organ Transplantation Law
in 2008 to tackle 3 major barriers to organ donation in
Israel.67 First, it banned the previously legal insurance funding
for overseas transplants and declared organ trafficking a
criminal offense. Second, it clearly defined brain death in a
Kidney
donor
Allocation of the kidney(s)
in combination with other organs





Figure 2 | Eurotransplant kidney allocation flow chart. AM,
acceptable mismatch; ESP, Eurotransplant Senior Program; ETKAS,
Eurotransplant Kidney Allocation System. Reprinted with permission
from Eurotransplant. Eurotransplant Manual Version 5.0. Chapter 4
Kidney (ETKAS and ESP). February 2016. Available at: https://www.
eurotransplant.org/cms/index.php?page¼et_manual.50 Accessed
April 18, 2016.











Hepatitis C virus status
Donation after circulatory death status
Source: Organ Procurement and Transplantation Network Policy 8.28
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way that was acceptable to both the medical and religious
communities. Third, it launched a major campaign to pro-
mote organ donation on the basis of reciprocal altruism by
granting allocation priority to registered organ donors
($3 years prior to listing), previous living donors, and first-
degree relatives of deceased donors. These measures have
significantly reduced transplant tourism and increased both
living and deceased donation and transplantation rates.68–70
The allocation system in Israel is a simple points-scoring
system. Points are awarded for waiting time (from the date
of first dialysis), age, HLA mismatch, and sensitization level.
Age points include priority for pediatric patients and also for
younger adults over older ones. There is age matching of
donors and recipients aged <18 and >60 years. Points for
sensitization are incrementally awarded for each 25% increase
in PRA, thereby providing some priority for patients who are
moderately sensitized.71
Spain
Spain is renowned as a world leader in organ donation.72,73
Although Spain’s “opt-out” system legally allows presumed
consent for organ donation, consent from relatives is always
sought. The success of the Spanish model is instead attributed
for the most part to a network of highly trained donor co-
ordinators.74 Since the program was introduced in 1989,
donation rates have dramatically increased from 14 to 36
donors per million population, which is almost double that of
an average European country.72 Remarkably, donation rates
are equal among native and immigrant populations.2
The high donation rate in Spain allows for most allocation
to occur on a local basis. The criteria vary by region but include
waiting time, HLA matching, ABO blood group, age, height,
weight, and primary renal diagnosis.74,75 If a recipient cannot
be found on local waiting lists, kidneys are offered regionally
and then nationally. There is also a national exchange system
for highly sensitized recipients (PRA >80%) and an “old for
old” program solely based on age matching.76
France
The French national kidney allocation system was first
introduced in 1996. Kidneys are allocated on 3 priority levels:
local, regional, and national. National priority was given to all
zero HLA-mismatched recipients until 2004, and thereafter
was restricted to recipients with PRA >5%.77 Highly sensi-
tized patients (PRA >80%) are prioritized nationally for
kidneys with a maximum of 1 HLA mismatch, and since
2004, also for kidneys with “acceptable mismatches”.77 All
pediatric recipients are prioritized on a national level for
pediatric donors (pediatric definition increased
from <16 to <18 years in 2004) and on a regional level for
donors aged <30 years.77 An expert kidney advisory panel
can designate national priority for emergency situations such
as loss of dialysis access. If a retrieved organ does not trigger
any national or regional priorities, it is allocated locally via a
points-scoring system introduced in 2006. This includes
recipient age, waiting time, HLA mismatch, and donor-
recipient age difference.78
Discussion
Given the tremendous impact of the kidney allocation policy
at both an individual and a societal level, allocation schemes
should be continually reviewed and adapted in line with the
evolving medical, ethical, and social landscape of kidney
transplantation. This review examined the allocation schemes
of several countries in which deceased donor kidney trans-
plantation is an accepted and well-established practice. In
these jurisdictions, the creation of national transplant orga-
nizations has been fundamental to the standardization and
regulation of the organ offering process. Local center-based
allocation decisions that were largely led by HLA matching
and clinician choice have been mostly superseded by national
(and sometimes international) protocols that are publicly
available, enabling their evaluation. Despite differences in
their specific criteria, all of these allocation policies strive for
the same core principles of transparency, accountability, and
equity of access to kidney transplantation. The importance of
this ethical framework for organ allocation is set out in
guiding principles by the World Health Organization and in
The Declaration of Istanbul.79,80 Allocation schemes that are
designed around the preferences of all relevant stakeholders
and are supported by legislation are fundamental to the
effective governance of organ donation and transplantation
programs. It is evident that in the absence of such oversights,
vulnerable populations are at a risk for injustice and exploi-
tation through unethical practices such as organ trafficking,
transplant commercialism, and transplant tourism.
A further step forward for improving the objectivity of
allocation has been the introduction of points-scoring systems,
which can be adjusted according to the changing scientific
evidence, clinical practice, or public expectations. Simulation
plays an important role in estimating the impact of proposed
changes to allocation systems. Specific outcome measures such
as life years gained from transplant or the proportion of kid-
neys allocated to specific patient groups can be simulated with
historical data to produce optimal score weights. Although
limited by the unpredictable human behavior (i.e., organ
acceptance decisions), simulation is becoming a valuable
evidence-based tool in allocation system development.
In more ethnically diverse populations, organ sharing based
largely on HLA matching has led to a marked inequity of access
for ethnic minorities, necessitating more complex algorithms to
address this issue. These inequity issues, combined with evidence
for a diminishing effect of HLAmatching on graft survival in the
era of improved immunosuppressive therapy,81 have prompted
revisions to reduce its weighting in most but not all policies.
While some countries have eliminated allocation priority for
HLA-A and/or -B matching, this has not been widely imple-
mented, and indeed, equalweighting formatching at eachof the 3
HLA loci is preserved in some allocation systems (Table 4). Poorly
HLA-matched grafts are more likely to result in HLA sensitiza-
tion, and in the event of graft failure, this jeopardizes the chances
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Table 4 | Criteria for deceased donor kidney allocation 2003 versus 2013
UK US Australia New Zealand
2003 2013 2003 2013 2014 2003 2013 2003 2013
HLA mismatch
DR þ þ þ þ þ þ þ þ þ
B þ þ þ - - þ þ þ þ
A þ - - - - þ þ þ þ
HLA loci importance DR > B/A DR > B DR > B DR only DR only DR > B/A DR > B/A DR > B > A DR > B > A
Waiting time þ þ þ þ þ þ þ þ þ
Waiting time
definition
Listing date Listing date Listing date Listing date Start of dialysis Start of dialysis Start of dialysis Latest of start of
dialysis or
listing date
Latest of start of dialysis or listing date
Priority for pediatric
recipients
þ þ þ þ þ þ þ þ þ
Definition of
pediatric recipient
<18 yr <18 yr <18 yr <18 yr <18 yr <18 yr <18 yr, first
dialysis <17 yr and
on dialysis for >1 yr
<15 yr <15 yr
Recipient age þ þb - - þ - - - -
Donor-recipient age
matching




þ þ þ þ þ þ þ - -
Applicable level of
PRA/cPRA (%)




DR DR, B - - - - - - -
Local allocation
priority
þ þ þ þ þ þ þ - -
Balance of exchange þ - þ þ - þ þ - -
Point-scoring
systems in use





























EPTS >80% defines eligibility for waiting
list, All ECD biopsied and scored by
Remuzzi classification
Eurotransplant Scandiatransplant Israel Spaina France
2003 2013 2003 2013 2003 2013 2003 2013 2003 2013
HLA mismatch
DR þ þ þ þ þ þ þ þ
B þ þ þ þ þ þ þ þ
A þ þ þ þ þ þ þ þ
HLA loci
importance
DR ¼ B ¼ A DR ¼ B ¼ A DR > B/A DR > B/A DR > B/A DR > B/A ? ? DR ¼ A ¼ B DR > A/B


















































Table 4 | (Continued) Criteria for deceased donor kidney allocation 2003 versus 2013
Eurotransplant Scandiatransplant Israel Spaina France
2003 2013 2003 2013 2003 2013 2003 2013 2003 2013
Waiting time þ þ - - þ þ þ þ þ þ
Waiting time
definition








<16 years <16 yr or >16 yr and
growth potential






<18 yr <18 yr ? ? <16 yr <18 yr
Recipient age - - - - þ þ þ þ - þ
Donor-recipient
age matching




þ þ þ þ þ þ þ þ þ þ
Applicable level of
PRA/cPRA (%)




þ þ - - - - - - - -
Local allocation
priority
þ þ - - - - þ þ - þ
Balance of
exchange
þ þ þ þ - - - - - -
Point-scoring
systems in use













AMP, ESP, prior kidney
donors
STAMP Priority for registered
organ donors of at










AMP, acceptable mismatch program; cPRA, calculated panel reactive antibody; EPTS, estimated posttransplant survival score; ESP, Eurotransplant Senior Program; HLA, human leukocyte antigen; KDPI, Kidney Donor Profile Index;
MM, mismatch; PRA, panel reactive antibody; PRD, primary renal diagnosis; STAMP, Scandiatransplant Acceptable Mismatch Program.
aNo national allocation system. Criteria applicable only at local level.
bAge & HLA-MM combined.
cSliding scale of points.


















































of HLA-compatible retransplantation. The level of HLA match-
ing, especially HLA-DR matching, is of particular importance in
younger patients who are likely to require more than 1 graft over
the course of their lifespan. Increased mismatches at first trans-
plant are associated with a higher degree of sensitization, longer
waiting time, reduced likelihood of retransplantation, and
decreased regraft survival.82Many schemeshave addressed thisby
prioritizing younger patients for well-matched grafts. For pa-
tients who are highly sensitized, the targeted approach of
acceptable mismatch programs, adopted by many countries, has
proved successful for improving access to transplantation for
these patients. Waiting time has become the dominant factor of
allocation in many schemes as concerns over inequity have
increased. In the US, this was illustrated by a complete reversal of
weighting in allocation; where previously waiting time mostly
served as a tie-breaker between 2 similarly HLA-matched re-
cipients,HLAmatchbecame the deciding factor betweenpatients
with similar waiting times.83
The severe shortage of donors, as well as an aging and
more infirm population, has led to the increasing use of more
“marginal” organs. Despite reduced graft survival, they can
offer certain patients improved life expectancy compared with
that obtained by staying on dialysis.32,84,85 However, to opti-
mize any benefit gained, careful donor and recipient selection
and matching are required. Remarkably, in some countries,
there are no distinct schemes for allocating marginal grafts.
While Eurotransplant and Spain have instituted specific “old
for old” programs, the UK and France have incorporated
donor-recipient age matching into their allocation systems.
Nevertheless, these approaches have been criticized for using
chronological age as a surrogate of graft function and recip-
ient survival when many other important factors have been
described. The previous US ECD scheme was a step forward
in classifying the quality of donor organs based on several
validated donor risk factors in addition to age. However, the
scheme was criticized for the dichotomous stratification of
donor kidneys as ECD or non-ECD when in reality, the risk
for graft failure is better characterized by a continuous scale.41
The new US system reflects this with KDPI.86 This contin-
uous measure of predicted graft survival is used to allocate
kidneys on the basis of a recipient’s estimated posttransplant
survival. Although this applies only to the 20% of recipients
with the longest estimated survival, this degree of survival
matching is a first in kidney allocation. In New Zealand, a
similar prognostic index of posttransplant survival based on
multiple patient risk factors is utilized in a novel way to
provide an objective criterion (5-year survival >80%) for
access to the waiting list. This evidence-based risk stratifica-
tion ensures those listed have a reasonable expectation of
receiving and surviving a transplant. A nationally applicable
survival probability threshold for listing is perhaps the most
equitable way of determining access to the waiting list, while
also ensuring the optimal use of a scarce resource.
The transplant community should be proud of the sig-
nificant progress that has been achieved in improving the
transparency, accountability, and equity of kidney allocation.
However, in the context of the continuing shortage of donor
organs, further work is required to reduce the discard of
donated kidneys and to optimize the efficiency of allocation.
Conclusion
Despite striking shifts in the demographics of donor and
recipient populations, there has been relatively little change
in deceased donor kidney allocation over the past decade.
Given that the donor shortage shows no signs of abate-
ment, it may be timely to consider a radical change in the
ideology governing kidney allocation toward “the right
kidney to the right recipient.” Sophisticated donor-
recipient survival matching may well be the optimal
compromise between utility and equity that the transplant
community strives for.
Search strategy and selection criteria
References for this review were identified by searches of
PubMed and Google Scholar using the terms “kidney,”
“deceased donor kidney,” “cadaver kidney,” or “kidney
transplant” combined with “allocation,” “offering scheme,”
“distribution,” or “selection criteria” for publications in any
language before April 30, 2016. Data were also obtained by
direct contact with national transplant registries, their web-
sites, and reports, including UK Transplant (http://www.odt.
nhs.uk/uk-transplant-registry/), US United Network for Or-
gan Sharing (https://www.unos.org/), Australia and New
Zealand Dialysis & Transplant Registry (http://www.anzdata.
org.au/v1/), Eurotransplant (https://www.eurotransplant.org/
cms/), Scandiatransplant (http://www.scandiatransplant.org/),
Israel (https://www.adi.gov.il/), Spain Organizacion Nacional
de Trasplantes (http://www.ont.es/), and France Agence de la
Biomedecine (http://www.agence-biomedecine.fr/).
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Introduction: There is significant intercentre variability
in access to renal transplantation in the UK due to
poorly understood factors. The overarching aims of
this study are to improve equity of access to kidney
and kidney–pancreas transplantation across the UK and
to optimise organ allocation to maximise the benefit
and cost-effectiveness of transplantation.
Methods and analysis: 6844 patients aged 18–
75 years starting dialysis and/or receiving a transplant
together with matched patients active on the transplant
list from all 72 UK renal units were recruited between
November 2011 and March 2013 and will be followed
for at least 3 years. The outcomes of interest include
patient survival, access to the transplant list, receipt of
a transplant, patient-reported outcome measures
(PROMs) including quality of life, treatment
satisfaction, well-being and health status on different
forms of renal replacement therapy. Sociodemographic
and clinical data were prospectively collected from case
notes and from interviews with patients and local
clinical teams. Qualitative process exploration with
clinical staff will help identify unit-specific factors that
influence access to renal transplantation. A health
economic analysis will explore costs and outcomes
associated with alternative approaches to organ
allocation. The study will deliver: (1) an understanding
of patient and unit-specific factors influencing access
to renal transplantation in the UK, informing potential
changes to practices and policies to optimise
outcomes and reduce intercentre variability; (2) a
patient-survival probability model to standardise access
to the renal transplant list and (3) an understanding of
PROMs and health economic impact of kidney and
kidney–pancreas transplantation to inform the
development of a more sophisticated and fairer organ
allocation algorithm.
Ethics and dissemination: The protocol has been
independently peer reviewed by National Institute for
Health Research (NIHR) and approved by the East of
England Research Ethics Committee. The results will
be published in peer-reviewed journals and presented
at conferences.
INTRODUCTION
Kidney transplantation is widely regarded to
be the best treatment for selected patients
with end-stage renal disease (ESRD). When
compared with dialysis, transplantation leads
to a twofold to threefold increase in life
expectancy and, it is often believed, a better
quality of life (QoL).1–4 Over the last decade,
transplant survival results have improved pro-
gressively and 1-year, 5-year and 10-year graft
survival rates are now >90%, >70% and
>60%, respectively. For selected patients with
ESRD due to type 1 diabetes, combined (or
simultaneous) pancreas and kidney (SPK)
transplantation offers a better life expectancy
compared with renal transplantation alone
(70% vs 30% at 10 years5 and ameliorates
diabetes complications).5 6
These successes have led to a greater
demand for transplantation with an ever
Strengths and limitations of this study
▪ First research programme involving all renal and
transplant units in the UK.
▪ An in-depth analysis (quantitative and qualitative) of
access to transplantation and transplant outcome.
▪ Correlation with patient-reported outcome mea-
sures, health status and quality of life.
▪ Health economic analysis exploring costs and
outcomes associated with alternative approaches
to organ allocation.
▪ Limitation due to recruitment process and
comorbidity data recorded at enrolment rather
than same time point for all study cohorts.
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increasing gap between supply and demand. The dem-
ography of patients with ESRD is also changing with an
ageing population having more comorbid conditions
that may preclude transplantation.7 8 Currently, fewer
than 40% of all patients with ESRD in the UK are listed
as suitable candidates for transplantation and only care-
fully selected patients, without severe cardiovascular
disease, undergo an SPK transplant. The need for
research on the impact of pretransplant comorbidity on
transplant outcome has been identified as a major prior-
ity in the UK by the Renal Association.9
It is important, in the interest of fairness and equity,
that access to the transplant waiting-list is, so far as is pos-
sible, standardised, transparent and based on validated
criteria. Recent evidence shows that access to transplant-
ation varies between and within the UK centres and dif-
ferences in assessment for comorbidity are likely to be a
major reason.10 However, even when the effects of
comorbidity are accounted for, there remains variation in
access to transplantation suggesting that other centre-
specific factors are implicated.11–13 It is unclear which
patient-specific and centre-specific factors are responsible
for such variations,11 14 or indeed which centre practices
represent the optimal approach. It is also unclear which
patient-specific and centre-specific factors impact on out-
comes following transplantation but the development of
a standardised approach would enable an evidence-based
decision-making at individual patient level.
Successful kidney transplantation appears to improve
QoL and health status compared with dialysis, but the
benefit may not be apparent in all patient groups15–17
and is not supported by all studies.18 Furthermore, the
impact of kidney–pancreas transplantation on QoL has
not been conclusively established.19 There is a growing
body of evidence supporting the cost-effectiveness of
transplantation,20 21 but there are unresolved questions
about which patients may benefit the most from trans-
plantation and how organ allocation can be further opti-
mised given scarce supply.
There is considerable interest in the development of
organ allocation schemes based on net transplant
benefit and significant work has already been under-
taken in the context of liver transplantation22 and car-
diothoracic transplantation23 in the UK and the USA.
However, existing kidney allocation policies don’t take
into account the potential impact of comorbid disease
on transplant outcome nor do they address the best use
of the increasing number of extended criteria deceased
donor organs.24–28 Recent research has quantified the
benefit of kidney and SPK transplantation in order to
develop a survival probability model as a basis for listing
for transplantation (in the UK)29 or as a potential alloca-
tion model (in the USA).30 No work has yet been
carried out incorporating cost-effectiveness, health
status, QoL and other patient-reported outcome mea-
sures (PROMs) in any allocation algorithms.
In order to address some of these challenges in trans-
plantation, the UK National Institute for Health
Research (NIHR) Access to Transplantation and
Transplant Outcome Measures (ATTOM) research pro-
gramme has been developed by a consortium involving
all renal and transplant units in the UK. The overarch-
ing aims of the programme are to investigate how we
might maximise the net benefit to society from kidney
and SPK transplantation, by selecting recipients in a
robust and transparent way so as to achieve the best
balance between cost, prolongation of life, QoL and
acceptability to patients and wider society. The five
related research aims of the study are listed below.
1. To identify patient-specific and centre-specific factors
that influence (a) access to the transplant waiting-list
and to develop a survival probability model as a basis
for standardising access to the transplant waiting-list
and (b) access to transplantation (deceased donor
kidney and pancreas and living donor kidney) for
wait-listed patients.
2. To identify patient-specific and centre-specific factors
that influence patient survival for transplant wait-
listed dialysis patients, after deceased donor kidney
transplantation, after SPK transplantation, after living
donor kidney transplantation and after pre-emptive
transplantation (transplantation as a first mode of
renal replacement therapy (RRT) prior to the initi-
ation of dialysis treatment).
3. To evaluate QoL and other PROMs for patients on
dialysis, after deceased donor kidney transplantation,
after SPK transplantation, after living donor kidney
transplantation, after pre-emptive transplantation, in
waiting-list controls for kidney and SPK transplant-
ation and in those whose transplants have failed fol-
lowing recruitment to ATTOM.
4. To perform a health economic analysis to explore
costs and outcomes associated with alternative
approaches to organ allocation.
5. To utilise survival, health status, QoL, treatment satis-
faction and costs to determine an optimal organ allo-
cation policy as defined by the maximisation of
clinical and cost–benefits derived from
transplantation.
We describe the study population and the method-
ology underpinning the study analyses.
METHODS AND ANALYSIS
Study population
All 72 renal units (of which 23 are renal transplant
units) in the UK contributed to the ATTOM pro-
gramme. Between 1 November 2011 and 31 March
2013, 6360 patients aged 18–75 years were recruited in
three cohorts: incident dialysis patients, incident kidney
and SPK transplant patients and prevalent listed patients
selected as controls for transplanted patients (figure 1).
A total of 484 patients moved cohorts (13 patients
moved twice) resulting in 6844 registrations within
ATTOM (figure 2). In each centre, recruitment took
place over a 1-year period aiming to include every
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patient <75 years of age starting RRT. Controls were
selected automatically from the UK Transplant Registry
database on a fortnightly basis and were matched for:
age (within 5 years), time on the list, pre-emptive/on
dialysis and the type of transplant (deceased donor or
living donor).
Patient-level data (see online supplementary
appendix 1) were collected prospectively at the time of
starting dialysis, at the time of transplantation or when
identified as a control from the transplant list.
Dedicated research nurses collected clinical and
demographic information from the case notes and local
electronic databases, and collected health status and
well-being data from patients via completion of the
EuroQoL five dimensions (EQ-5D)31 and 12-item
Well-being Questionnaire (W-BQ12).32–35 The data were
uploaded onto a secure website designed, developed
and maintained by the UK Renal Registry (UKRR). Data
completeness for the items recorded is illustrated in
figure 3A, B. Data collection accuracy was ensured using
uniform definitions and a training process for the
research nurses. An independent data validation of
coding of 5% of case notes in all research sites con-
firmed >98% concordance for all coded fields.
The demographic characteristics of the three study
cohorts are illustrated in table 1.
Analysis
Access to transplantation
Patient-level and centre-level factors influencing access to
transplantation for patients starting dialysis are identified
through quantitative and qualitative analysis. Patients are
followed up for 4 years with data provided by the UKRR/
Scottish Renal Registry and the UK Transplant Registry at
National Health Service Blood and Transplant (NHSBT)
in order to identify whether they are wait-listed for trans-
plant or not, and if wait-listed, whether they received a
transplant or not (figure 4). This will inform the analysis
of the factors influencing access to listing after starting
dialysis and subsequent transplantation.
The qualitative analysis aims to identify systems and
processes consistently associated with better (or worse)
outcomes in units across the UK, to help define best
practice in transplant work-up and listing. This work-
stream consists of 40 initial qualitative interviews with
key stakeholders and patients in a sample of 9 units
stratified by proportion of listed dialysis patients,
whether transplant or dialysis centre and geography to
include spread of deprivation and ethnicity of the catch-
ment area. This is followed by a purpose-designed struc-
tured questionnaire for use in a survey of all the UK
renal and transplant units. A Delphi consensus study will
provide better understanding of professional views on
what characterises patients who should (and should not)
be assessed for transplant listing and how they should be
assessed. The Delphi study, undertaken by emailed elec-
tronic questionnaire with two rounds includes transplant
surgeons and nephrologists from each centre.
Participants are asked to agree or disagree with a series
of statements about the eligibility criteria for listing. The
initial overall responses are fed back and participants
invited to reconsider their views in this second round
prior to summarising final levels of agreement. Finally,
both patient-level and centre-level factors (from the
survey) are explored to determine their influence on
transplant listing and subsequent access to
transplantation.
Survival with transplantation versus dialysis
Using data derived from the access to transplantation
analysis, a multivariate Cox proportional hazards model
will estimate the potential risk factors for mortality while
on dialysis and their associated HRs, taking into account
patient-level and centre-level factors in a multilevel mod-
elling approach. Changes over time in the impact of
factors measured at baseline on outcome are modelled
using time-varying coefficients. Interactions between
variables (eg, age and comorbidity) are included in the
final model if significant. This will allow the develop-
ment of a survival probability prediction tool, which can
inform nationally agreed thresholds (such as ‘predicted
survival >80% at 2 years after start of dialysis’) at which a
patient should be activated and deactivated on the trans-
plant list. The survival probability tool could be incorpo-
rated on a desktop or web-based platform enabling
Figure 2 Number of patients changing between the study
cohorts and the direction of change.
Figure 1 ATTOM, Access to Transplantation and Transplant
Outcome Measures (ATTOM) study patient recruitment and
cohort distribution.
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clinicians to discuss risk versus benefits with patients
when considering transplant listing. A nationally agreed
survival probability threshold will also enable robust
intercentre comparison to audit listing practices.
Follow-up of the dialysis cohort in conjunction with the
cohorts illustrated in figure 5, beyond the 5-year dur-
ation of this project will enable further refinement of
the survival probability assessment tool including the
option to predict quality-adjusted life years gained with
transplantation.
The study cohorts enable the analysis of patient-
specific factors that influence survival for listed patients,
after kidney transplantation (live and deceased donors)
or after SPK transplantation. A multilevel modelling
approach is used to analyse transplantation outcome
data and the modelling explores how the outcome vari-
ables depend on one or more of the explanatory factors
(patient and centre level). The models are developed
on the basis of manual variable selection based on clin-
ical and statistical input and are built up by repeatedly
incorporating the most statistically significant variable
and retesting all others in the presence of included vari-
ables, using clinical input to ensure development of a
clinically appropriate model. Clinically relevant interac-
tions between variables are predetermined and consid-
ered in the model building.
Figure 3 (A and B) Data completeness for each item collected in the study.
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Evaluation of PROMs
All patients in the ATTOM programme were asked by
the research nurses to complete measures of health
status (using the EQ-5D and W-BQ12) at or soon after
recruitment and at 6 months in those transplanted
patients and matched controls on the waiting-list for
transplant who were recruited during the first 6 months
of nurse data collection. The EQ-5D provides an overall
measure of perceived health ‘today’ and five individual
items measuring mobility, pain, self-care, usual activities
and anxiety/depression.31 The W-BQ12 has subscales to
measure negative well-being (including depressed and
anxious mood), energy and positive well-being over the
past few weeks and an overall measure of general well-
being.32–35 In addition, a detailed PROMs study on a
subset of 652 ATTOM patients (table 2) recruited in a
quasi-random manner (the first eligible patient for each
group seen each month by each nurse) is evaluating
QoL and the impact of the renal condition on QoL.
This uses the individualised Renal-Dependent QoL
(RDQoL) measure36 together with the Audit of
Diabetes-Dependent QoL (ADDQoL) for people who
also have diabetes37 38 or a version of the ADDQoL with
minor adaptations for people receiving an SPK trans-
plant. These questionnaires are administered at 3 and
12 months post-transplant and at comparable times for
those on dialysis. The Renal Treatment Satisfaction
Questionnaire status (RTSQs) version39 is given along-
side the RDQoL at each time point, and the Diabetes
Treatment Satisfaction Questionnaire status
(DTSQs40 41) version is given to all those with diabetes
(with minor adaptations for those who have received an
SPK transplant). In addition, change versions of the
RTSQ and DTSQ (the RTSQc and DTSQc)42–44 are
given at 12 months to provide a direct comparison
between satisfaction with current treatment and satisfac-
tion with the treatment used before the study began.
The EQ-5D and W-BQ12 are also included with the
12-month questionnaires in the detailed PROMs
cohorts. The target patient groups and the timing of
each questionnaire are summarised in table 3.
Transplant recipients completed baseline questionnaires
before transplantation where possible (patients receiving
pre-emptive transplants) and within a few weeks of
Table 1 Demographic characteristics of the study cohorts
Incident dialysis Incident transplant Matched controls
N 2623 2262 1959
Age at registration to ATTOM
Mean±SD 56.18±13.55 49.34±13.44 50.38±12.83
Median (IQR) 58.39 (47.48–67.14) 50.28 (40.07–59.89) 51.14 (41.67–60.34)
Gender (%)
Male 64.93 62.81 57.91
Female 35.07 37.19 42.09
Ethnicity (%)
White 79.95 82.45 74.54
Asian 11.23 9.40 12.42
Black 7.09 6.21 10.93
Chinese 0.69 0.75 0.92
Mixed 0.65 0.80 0.87
Not specified 0.38 0.40 0.31
Age first seen by nephrologist
Mean±SD 50.14±15.66 39.85±15.36 39.38±15.41
Median (IQR) 52.76 (39.85–62.68) 40.59 (28.65–51.61) 39.91 (28.24–51.48)
ATTOM, Access to Transplantation and Transplant Outcome Measures.
Figure 4 Quantitative and qualitative analysis approach for access to transplantation workstream.
Oniscu GC, et al. BMJ Open 2016;6:e010377. doi:10.1136/bmjopen-2015-010377 5
Open Access
group.bmj.com on February 29, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
transplantation (deceased donor transplants). Patients
were given the option to complete the questionnaires via
telephone interviews or using mailed paper
questionnaires.
Demographic and clinical data are used by the health
psychologists alongside QoL and PROMs using multi-
level modelling techniques in investigating the factors
determining QoL measured by the RDQoL and health
status measured by the EQ-5D and exploring the rela-
tionship between these two outcomes.
Sixty of the detailed PROMs patients (including
patients from each treatment group purposively sampled
to include those reporting above and below the mean
for their treatment group on RDQoL scores) are
included in a qualitative interview study to elicit further
information about their experiences, with particular
interest in variations in QoL, reasons for satisfaction or
dissatisfaction with treatment and their understanding
and views about the current and future possible organ
allocation schemes.
Health economic analysis
The proposed health economic analysis focuses on the
development of a model to simulate different
approaches for allocating deceased donor kidneys to
patients on the transplant waiting-list. Rather than
attempting to identify one optimal allocation scheme,
the analysis explores a range of conceptual schemes that
reflect varying levels of emphasis on the principles of
equity and efficiency. Each allocation scheme is evalu-
ated in terms of cost and health outcomes captured by
estimating quality-adjusted life years (QALYs).
The model is developed as a discrete event simulation
(DES). This approach offers the flexibility to incorpor-
ate the influence of patient-level characteristics, such as
age and comorbidities, in the estimation of both costs
and health gains, to model competing risks and to
capture the dynamic consequences of the allocation
process for all patients subject to a constrained supply of
donor organs.45 The model is populated using various
sources of data with costs of RRT from NHS reference
costs and variable hospital costs drawn on patient-level
resource use from Hospital Episodes Statistics (HES).
Survival for patients on the waiting-list and following
transplant is estimated by fitting predictive models to his-
torical data from NHSBT, while health state utility esti-
mates are based on EQ-5D data prospectively collected
in the ATTOM study.
Novel allocation schemes
An important outcome of ATTOM is to propose alterna-
tive organ allocation policies that consider efficiency
and equity factors as well as QoL gains from transplant-
ation utilising data on survival, health status, QoL and
financial costs.
Under the current UK allocation scheme, kidneys are
allocated according to an algorithm that among other
variables favours those who have waited longest and have
a better tissue-type match to the donated organ. Apart
from avoiding extreme age mismatches, no account is
taken of other more complex indicators such as the
‘quality’ of the kidney, patient QoL and cost-
effectiveness of different types of transplant (such as
donation after brain death (DBD) or donation after cir-
culatory death (DCD) transplants). Furthermore, no
attempt is made to pair estimated graft life with esti-
mated recipient survival. In several countries, there is
now great interest in developing organ allocation
schemes based on transplant benefit, while the USA has
introduced an allocation procedure taking into account
the estimated post-transplant survival and the donor
kidney quality (as measured by the kidney donor profile
index).30
The principles of organ allocation procedures based
on net benefit involve the calculation of scores that
reflect the potential benefit of transplantation based on
comprehensive outcome analyses, an individual’s life
expectancy with and without a given transplant and to
prioritise patients who have most to gain. At a point
Figure 5 Study cohorts for survival analysis comparison.




Incident dialysis patients 147
Kidney transplant waiting-list patients 135
SPK transplant waiting-list 29
Deceased donor kidney transplant recipients 120
Living donor kidney transplant recipients 104
SPK transplant recipients 103
Failed transplant 14
PROMs, patient-reported outcome measures; SPK, simultaneous
pancreas and kidney.
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when a donor organ becomes available, the expected
number of days of life without a transplant can be com-
pared with the expected number of days of life following
receipt of a transplant. This procedure requires the
development of statistical models for survival following
wait listing and for survival post-transplantation.
On the basis of the information obtained in the
study, we will also explore deceased donor kidney allo-
cation (including kidneys from DCD donors) on the
basis of a continuous index of donor organ longevity,
along with a continuous index of potential transplant
recipients that predicts their likely survival when trans-
planted over that on dialysis (ie, life years gained due
to transplantation). We will incorporate information
on QoL into the allocation model by assigning scores
for transplantation with different types of organs (ie,
DCD or DBD) versus dialysis, informed by the PROMs
workstream. Similarly, the cost-effectiveness of trans-
plantation with different types of donor organs could
be explored in the model. These data will then be
assessed alongside other factors that predict length of
wait and survival enabling the development of model
(s) which predict an accurate difference in the overall
net benefit of a particular type of transplant, thus
maximising organ utilisation and the overall benefit
for the patients. The impact of potential models of
organ allocation will be tested using simulations where
the properties of different schemes can be explored
and compared, and the impact of policy changes can
be forecast. Allocation schemes that focus on different
aspects, such as maximum benefit from an organ or
equal access to transplantation, can be simulated and
the results used to help identify an allocation scheme
that provides a balance between efficiency and equity
that is acceptable to patients and society.
ETHICS AND DISSEMINATION
Renal transplantation is one of the most successful ther-
apies in modern medicine. However, the landscape of
renal transplantation has changed significantly over the
last decade with an increasing need, in an older popula-
tion with more comorbidities and a different donor
population, with a higher number of extended criteria
donors and DCD. As a consequence, there are a
number of major challenges currently facing the provi-
sion of renal transplant services. Some of these chal-
lenges raise ethical concerns regarding the transparency
of the selection process, the consistency of the decision-
making process and the equity of access to the trans-
plantation. These issues are at the core of ATTOM and
the involvement of patients and ethicists throughout the
design and conduct of the study are key to the success
of this programme.
Comorbidity, particularly cardiovascular comorbidity,
is common in patients with chronic kidney disease
(CKD) and may be an important factor leading to
inequity in access to transplantation.10 Previous studies
have demonstrated that demographic variables such as
gender, age, geographical location and level of social
deprivation influence access to transplantation10 14 46–49
and their interpretation varies significantly between








Those in first 6 months of data collection for
transplant and matched control patients
Patients in detailed PROMs cohort




Those in first 6 months of data collection for
transplant and matched control patients
Patients in detailed PROMs cohort
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Patients in detailed PROMs cohort
Renal Treatment Satisfaction Questionnaire—
change version (RTSQc)
1 year* Patients in detailed PROMs cohort




Patients in detailed PROMs cohort who have
diabetes




Patients in detailed PROMs cohort who have
diabetes
Diabetes Treatment Satisfaction Questionnaire—
change version (DTSQc)†
1 year* Patients in detailed PROMs cohort who have
diabetes
*Detailed PROMs cohort only.
†Modified versions of these questionnaires were completed by recipients of deceased donor SPK transplants.
PROMs, patient-reported outcome measures; QoL, quality of life; SPK, simultaneous pancreas and kidney.
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centres, raising further concerns about an equal chance
of consideration for transplantation. Unlike previous
reports, which are retrospective or based on registry ana-
lyses, ATTOM is collecting prospective comorbidity data
at the time of patients starting dialysis and assesses its
impact according to the outcome as shown in figure 4.
Furthermore, the planned analyses will enable us to
assess further potential inequities in access to transplant-
ation after listing and establish the impact of comorbid-
ity and sociodemographic variables on the outcome of
renal transplantation, SPK transplantation and dialysis.
The study design and the data collected in ATTOM
allow individual patient predictions to be generated,
facilitating more informed decision-making. Importantly,
it will provide uniformly applicable and explicit
evidence-based assessment criteria for entry onto the
national transplant waiting-list for kidney and SPK trans-
plantation addressing some of the major ethical con-
cerns highlighted above.
Combining a quantitative and qualitative analysis is
one of the novel aspects of ATTOM, allowing an
in-depth analysis of individual centre practices, policies
and beliefs as well as the views held by patients. By iden-
tifying the recipient and organisational factors that most
influence access to transplantation and subsequent
transplant outcome, the findings will address key ethical
concerns and indicate where clinical practice can be
changed or refined to achieve fairer and more transpar-
ent access to transplantation.
The impact of comorbidity on SPK transplantation
outcomes is also unclear, particularly given the more
stringent selection criteria for this procedure.50 There is
an ongoing debate regarding the survival benefit of SPK
transplantation over and above renal transplantation
alone, particularly living donor renal transplantation.
ATTOM addresses this issue by directly comparing out-
comes in patients taking account of differences in socio-
demographics and comorbidity.
There is a strong perception that successful kidney
transplantation improves health-related QoL compared
with dialysis. One of the ATTOM workstreams addresses
these issues providing information on quality of health,
QoL, well-being and treatment satisfaction using a com-
bination of established generic instruments as well as
recently developed condition-specific measurement tools
designed for people with CKD. Furthermore, the study
may identify which particular subgroups of patients are
likely to gain most or least from transplant because of
comorbid disease.
ATTOM includes a health economic analysis that pro-
vides insight into long-term cost and survival differences
associated with dialysis and transplantation. While the
effectiveness of transplantation has already been estab-
lished, ATTOM considers current clinical pathways and
enables further exploration of the impact of donor and
recipient factors on both costs and outcomes in the
modelling of alternative approaches to allocating organs
in the UK.
Organ allocation schemes (addressed in workstream
5) and issues such as which patients should receive pri-
ority, which organs should be used and which criteria
should inform the allocation decision are at the heart of
ethical debates in transplantation.
Data from this study will be curated by the NHSBT
and UK Registry providing an ethical reassurance
regarding the use of the information collected in the
study.
The results of ATTOM will be of direct relevance to
patients and their clinicians, and are expected to
reshape the provision of renal transplantation in the UK
by evaluating the entire CKD pathway from dialysis to
transplantation. From a public perspective, ATTOM will
provide unprecedented transparency in the decision-
making with regard to the use of a scarce national
resource. Therefore, we plan to disseminate these find-
ings widely in peer-reviewed journals, at national and
international conferences and thorough public engage-
ment days. Furthermore, we intend to engage all rele-
vant stakeholders in the discussions concerning any
proposed alternative organ allocation schemes.
In conclusion, ATTOM is the first research pro-
gramme involving all renal dialysis and renal transplant
units in the UK that explores in depth the relationship
between access to transplantation and transplant out-
comes. The outputs of the study are likely to have a sig-
nificant impact on the delivery of renal transplantation
in the UK.
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A B S T R A C T
Background. Living donor kidney transplantation (LDKT) pro-
vides more timely access to transplantation and better clinical
outcomes than deceased donor kidney transplantation
(DDKT). This study investigated disparities in the utilization of
LDKT in the UK.
Methods. A total of 2055 adults undergoing kidney transplanta-
tion between November 2011 and March 2013 were prospec-
tively recruited from all 23 UK transplant centres as part of the
Access to Transplantation and Transplant Outcome Measures
(ATTOM) study. Recipient variables independently associated
with receipt of LDKT versus DDKT were identified.
Results. Of the 2055 patients, 807 (39.3%) received LDKT and
1248 (60.7%) received DDKT. Multivariable modelling demon-
strated a significant reduction in the likelihood of LDKT for
older age {odds ratio [OR] 0.11 [95% confidence interval (CI)
0.08–0.17], P< 0.0001 for 65–75 years versus 18–34 years};
Asian ethnicity [OR 0.55 (95% CI 0.39–0.77), P¼ 0.0006 versus
White]; Black ethnicity [OR 0.64 (95% CI 0.42–0.99), P¼ 0.047
versus White]; divorced, separated or widowed [OR 0.63 (95%
CI 0.46–0.88), P¼ 0.030 versus married]; no qualifications [OR
0.55 (95% CI 0.42–0.74), P< 0.0001 versus higher education
qualifications]; no car ownership [OR 0.51 (95% CI 0.37–0.72),
P¼ 0.0001] and no home ownership [OR 0.65 (95% CI 0.85–
0.79), P¼ 0.002]. The odds of LDKT varied significantly
between countries in the UK.
Conclusions. Among patients undergoing kidney transplanta-
tion in the UK, there are significant age, ethnic, socio-economic
and geographic disparities in the utilization of LDKT. Further
work is needed to explore the potential for targeted interven-
tions to improve equity in living donor transplantation.
Keywords: inequity, kidney transplantation, living donor, pre-
emptive transplantation, sociodemographic disparities
I N T R O D U C T I O N
For patients with end-stage renal disease (ESRD), living
donor kidney transplantation (LDKT) provides better clinical
outcomes and more timely access to transplantation than
deceased donor kidney transplantation (DDKT) [1–3].
Current UK Renal Association guidelines recommend that
LDKT be considered the treatment of choice for all patients
suitable for kidney transplantation, whenever an appropriate
living donor is available [4]. In contrast to the lengthy waiting
time for DDKT, the LDKT procedure can be scheduled with-
out delay, thereby minimizing the time that patients are
exposed to pre-transplant dialysis and its associated morbid-
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transplantation). Pre-emptive LDKT is considered by many
to be an optimal treatment, providing superior graft and
patient survival compared with kidney transplantation fol-
lowing a period of dialysis [2, 4–6].
Despite these advantages, only one-third of kidney trans-
plants undertaken in the UK are from living donors [7].
Internationally, the UK falls behind many other countries in
terms of LDKT activity [8]. A recent strategy set out by
National Health Service Blood and Transplant (NHSBT)
aims to increase LDKT activity in the UK from the current
rate of 17 transplants per million population (pmp) to 26
transplants pmp by 2020 [9].
There are limited data on the factors that may prevent or
enable patients to receive LDKT in the UK. A better under-
standing of these factors will facilitate the identification of
target patient groups and aid the development of appropriate
interventions to improve LDKT rates. The principal aim of
this study was to identify the recipient characteristics associ-
ated with achieving LDKT compared with DDKT in a
national sample of UK kidney transplant recipients. The
study was conducted as part of the Access to Transplantation
and Transplant Outcome Measures (ATTOM) research
programme.
M A T E R I A L S A N D M E T H O D S
Study population
ATTOM is a national prospective cohort study investigat-
ing the factors that influence access, clinical and patient-
reported outcomes and cost-effectiveness of renal transplan-
tation in the UK. A full description of the ATTOM study
methods and protocol has been reported previously [10]. As
part of the ATTOM study, incident kidney transplant recipi-
ents were recruited at the time of transplantation from all 23
UK renal transplant centres. In each centre, recruitment took
place over a 12-month period, between 1 November 2011 and
31 March 2013. Patients 18–75 years of age were eligible for
inclusion. A total of 3002 patients received kidney-only trans-
plants in the UK within the recruitment period; 134 were out-
side the study age criteria and 775 declined to participate or
were not able to be approached for recruitment. In all, 38 of
2093 recruited patients were excluded from the analysis due
to missing data for the main outcome variable (living or
deceased donor). Thus the final analysis cohort of 2055
patients represented 72% of eligible study participants
(Figure 1). There were no significant differences in the age,
gender or ethnicity distributions between study participants
and the national registry adult kidney transplant recipient
population (data not shown) [11].
Data collection
Extensive demographic, socio-economic, clinical and comor-
bidity data were collected for each patient at the time of trans-
plantation. Trained research nurses collected uniformly defined
data items from patient interviews, case notes and local elec-
tronic patient information systems.
Ethnicity was coded as White, Black, Asian or other (includ-
ing patients of Chinese and mixed origin). The level of highest
educational attainment was coded as no qualifications, qualifi-
cations at the secondary education level or equivalent [e.g.
General Certificate of Secondary Education (GCSE), General
Certificate of Education Advanced level (A-level), “National
Vocational Qualification (NVQ) level 1-3]” or qualifications at
FIGURE 1: Study population (asterisk refers to recruitment that took place over a 12-month period in each centre between 1 November 2011
and 31 March 2013).























































































|the higher education level or equivalent (e.g. bachelor’s degree,
higher degree, “NVQ level 4–5)”. Employment status was coded
as employed (including full time, part time or self-employed),
unemployed, long-term sick/disabled, retired or other (includ-
ing those looking after the family home, those not in work for
some other reason and students). The primary renal diagnosis
was classified by ERA-EDTA codes [12]. Donor details and
recipient calculated reaction frequency (cRF) were obtained
from linkage to UK Transplant Registry data. The cRF is a
measure of recipient human leucocyte antigen (HLA) sensitiza-
tion, calculated as the percentage of 10 000 recent donors to
which the recipient has pre-formed HLA antibodies. A comor-
bidity score was calculated for each patient using a modified
Charlson comorbidity index for patients with ESRD [13]. The
index consists of weighted scores assigned to 14 comorbid con-
ditions (myocardial infarction, congestive heart failure, periph-
eral vascular disease, cerebrovascular disease, dementia, chronic
pulmonary disease, rheumatological disease, peptic ulcer dis-
ease, diabetes without complications, diabetes with complica-
tions, leukaemia, lymphoma, moderate–severe liver disease and
metastatic disease). Our data set did not include two of the con-
ditions (rheumatological disease and peptic ulcer disease).
Scores were therefore calculated from the remaining 12
variables.
Statistical methods
Baseline characteristics of LDKT and DDKT recipients and
donors were compared by chi-squared tests for categorical data
and Wilcoxon tests for non-parametric continuous data.
Recipient variables associated with receiving LDKT versus
DDKT were analysed using logistic regression. Variables leading
to a change in log likelihood at P< 0.15 on univariable analysis
were entered into the multivariable model. The importance of
each variable in the multivariable model was tested by examin-
ing the difference in log likelihood between the model with and
without the variable. If the difference was not significant
(P> 0.05) the variable was removed. Each time a variable was
removed, the effect of removing each of the remaining variables
was retested until the most parsimonious model was achieved.
Potential interactions between variables were tested, none were
significant. Less than 7% of values were missing for any variable.
For modelling purposes, missing values were imputed using the
fully conditional specification logistic regression method. In all,
10 imputed data sets were modelled separately then combined
to produce final parameter estimates. Sensitivity analysis using
casewise deletion of missing values did not change conclusions.
Complex links between socio-economic deprivation and eth-
nicity with respect to access to and outcomes from renal
replacement therapy (RRT) have previously been reported [14,
15]. To avoid any confounding and/or interaction from ethnic-
ity, a subgroup analysis was undertaken in White patients only,
using the same multivariable modelling methods as described
above.
A second subgroup analysis examined the recipient variables
associated with receiving a transplant pre-emptively versus
post-initiation of dialysis in the LDKT cohort. Multivariable
modelling methods were the same as described above.
All data were analysed using SAS 9.4 (SAS Institute, Cary,
NC, USA).
R E S U L T S
Type of transplant received
Of 2055 kidney transplant recipients, 1248 (60.7%) received
DDKT (583 donors after brain death and 665 donors after cir-
culatory death) and 807 (39.3%) received LDKT. A significantly
higher proportion of LDKT recipients received pre-emptive
transplants compared with DDKT recipients (35.5% versus
12.0%; P< 0.0001).
Recipient characteristics
There were considerable differences in the characteristics of
LDKT versus DDKT recipients (Table 1). LDKT recipients
were significantly younger than DDKT recipients (median age
46 versus 53 years) and a higher proportion were of White eth-
nicity (87.1 versus 79.5%) and married or living with a partner
(65.1 versus 60.5%). LDKT recipients were more likely to have
obtained qualifications at the secondary education level (53.0
versus 47.9%) and at the higher education level (27.3 versus
18.3%). Compared with DDKT recipients, LDKT recipients had
higher rates of employment (43.7 versus 31.3%), car ownership
(91.0 versus 80.2%) and home ownership (66.1 versus 62.0%),
suggesting they were a less socio-economically deprived popula-
tion. The cause of renal failure was less likely to be diabetes,
hypertension or renal vascular disease in the LDKT group.
LDKT recipients had a significantly lower prevalence of comor-
bidity compared with DDKT recipients. The proportion of kid-
ney transplants that were LDKTs was significantly higher in
Northern Ireland (NI) at 68.5%, compared with 39.0% in
England, 36.6% in Wales and 31.2% in Scotland.
Donor characteristics
Characteristics of the donors are shown in Tables 2 and 3.
Living donors were significantly younger and more likely to be
female than deceased donors. A higher proportion of deceased
donors were of White ethnicity compared with living donors. A
total of 354 (43.9%) living donors were not genetically related to
the recipient. Parent, child, other blood relative and spouse liv-
ing donors were more likely to be female. Pooled/altruistic liv-
ing donors had the highest proportion of White donors.
Factors associated with the probability of LDKT among
transplant recipients
Associations between recipient variables and the likelihood
of LDKT versus DDKT were characterized using univariable
and multivariable logistic regression (Table 4, Figure 2). The
multivariable model demonstrated that with each sequential
increase in age group, there was a marked reduction in the
probability of LDKT versus DDKT, such that patients 65–75
years of age were ~90% less likely to undergo LDKT compared
with patients 18–34 years of age {odds ratio [OR] 0.11 [95%
confidence interval (CI) 0.08–0.17], P< 0.0001}. Compared
with White patients, Asian patients [OR 0.55 (95% CI 0.39–
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Table 1. Kidney transplant recipient characteristics by type of donor
Living donor transplant recipients (n¼ 807) Deceased donor transplant recipients (n¼ 1248) P-value*
Demographic variables
Median age, years 46 (34–56) 53 (44–63) <0.0001
Age group (years) <0.0001
18–34 229 (28.4) 128 (10.3)
35–49 261 (32.3) 359 (28.8)
50–64 249 (30.9) 526 (42.2)
65–75 68 (8.4) 235 (18.8)
Gender 0.191
Male 493 (61.1) 798 (63.9)
Female 314 (38.9) 450 (36.1)
Ethnicitya 0.0002
White 703 (87.1) 989 (79.5)
Asian 61 (7.6) 138 (11.1)
Black 35 (4.3) 94 (7.6)
Other 8 (1.0) 23 (1.9)
Socio-economic variables
Civil statusa <0.0001
Married/living with partner 494 (65.1) 697 (60.5)
Divorced/separated/widowed 66 (8.7) 201 (17.5)
Single 199 (26.2) 254 (22.1)
Qualificationsa <0.0001
Higher education 207 (27.3) 210 (18.3)
Secondary education 402 (53.0) 551 (47.9)
No qualifications 150 (19.8) 390 (33.9)
Employment statusa <0.0001
Employed 332 (43.7) 361 (31.3)
Unemployed 59 (7.8) 92 (8.0)
Long-term sick/disability 182 (24.0) 343 (29.7)
Retired 112 (14.7) 287 (24.9)
Other 75 (9.9) 71 (6.2)
Car ownershipa 691 (91.0) 928 (80.2) <0.0001
Home ownershipa 501 (66.1) 716 (62.0) 0.068
Clinical variables
Primary renal diagnosisa <0.0001
Diabetic nephropathy 48 (6.0) 132 (10.6)
Glomerulonephritis 229 (28.5) 311 (24.9)
Polycystic kidney disease 113 (14.1) 209 (16.8)
Pyelonephritis 127 (15.8) 133 (10.7)
Hypertensive nephropathy 37 (4.6) 86 (6.9)
Renal vascular disease 10 (1.2) 27 (2.2)
Other 156 (19.4) 193 (15.5)
Uncertain 84 (10.5) 156 (12.5)
Charlson comorbidity scorea <0.0001
0 625 (77.7) 851 (68.4)
1 91 (11.3) 168 (13.5)
2 59 (7.3) 136 (10.9)
3 29 (3.6) 90 (7.2)
Previous transplant 117 (14.5) 157 (12.6) 0.212
Highly sensitized (cRF > 85%)a 96 (11.9) 119 (9.5) 0.086
Pre-transplant treatment modalitya <0.0001
Haemodialysis 351 (43.7) 718 (57.6)
Haemodiafiltration 14 (1.7) 39 (3.1)
Continuous ambulatory peritoneal dialysis 73 (9.1) 204 (16.4)
Automated peritoneal dialysis 67 (8.3) 130 (10.4)
Failing transplant 14 (1.7) 6 (0.5)
Pre-emptive 285 (35.5) 150 (12.0)
Geographic variables
Country <0.0001
England 670 (83.0) 1049 (84.1)
Wales 34 (4.2) 59 (4.7)
Northern Ireland 50 (6.2) 23 (1.8)
Scotland 53 (6.6) 117 (9.4)
Data are median (IQR) or number (%).
aData are missing for some participants and excluded from percentage calculations. Numbers of missing data are shown in Supplementary data, Table S1.
*Wilcoxon test for age. All others chi-squared test.
























































|0.77), P¼ 0.0006] and Black patients [OR 0.64 (95% CI 0.42–
0.99), P¼ 0.047] were less likely to undergo LDKT than DDKT.
Patients who were divorced, separated or widowed had a lower
probability of LDKT compared with patients who were married
or living with a partner [OR 0.63 (95% CI 0.46–0.88), P¼ 0.03].
Having no formal qualifications [OR 0.55 (95% CI 0.42–0.74),
P< 0.0001] and having only secondary education qualifications
[OR 0.76 (95% CI 0.59–0.97), P¼ 0.01] reduced the odds of
LDKT compared with patients with higher education qualifica-
tions. Not owning a car [OR 0.51 (95% CI 0.37–0.72),
P< 0.0001] and not owning a home [OR 0.65 (95% CI 0.49–
0.85), P¼ 0.002] decreased the odds of LDKT versus DDKT.
With adjustment for recipient variables, the odds of LDKT ver-
sus DDKT were >3-fold higher for patients in NI [OR 3.25
(95% CI 1.89–5.57), P< 0.0001] compared with patients in
England. Further analysis showed the odds of LDKT in NI were
also higher compared with Wales [OR 3.77 (95% CI 1.88–7.56),
P¼ 0.0002] and Scotland [OR 4.53 (95% CI 2.42–8.48),
P< 0.0001], but there were no significant differences between
patients in England, Wales and Scotland.
Factors associated with the probability of LDKT among
White ethnicity transplant recipients
The same analysis was undertaken in a subgroup of White
patients only (n ¼ 1692) and confirmed that the effects of
socio-economic factors on the likelihood of LDKT versus
DDKT were independent of ethnicity (Table 5).
Factors associated with the probability of pre-emptive
transplantation among living donor kidney transplant
recipients
A further subgroup analysis in the LDKT group examined
factors associated with achieving pre-emptive transplantation
versus transplantation after the initiation of dialysis (Table 6).
Patients with missing data for pre-transplant treatment modal-
ity (n ¼ 3) and patients with a previous transplant (n ¼ 117)
were excluded, leaving a final cohort of 687 LDKT recipients.
Multivariable analysis demonstrated a significantly decreased
likelihood of pre-emptive LDKT for Asian patients [OR 0.45
(95% CI 0.23–0.86), P¼ 0.016], unemployed patients [OR 0.44
(95% CI 0.21–0.92), P¼ 0.029], patients unable to work due to
long-term sickness/disability [OR 0.44 (95% CI 0.28–0.68),
P¼ 0.0002], retired patients [OR 0.47 (95% CI 0.29–0.75),
P¼ 0.002], not owning a car [OR 0.41 (95% CI 0.19–0.86),
P¼ 0.018] and not owning a home [OR 0.65 (95% CI 0.44–
0.96), P¼ 0.029].
D I S C U S S I O N
Among patients undergoing kidney transplantation in the UK,
there are significant age, ethnic, socio-economic and geographic
Table 3. Living donor characteristics by donor–recipient relationship
















18–34 0 (0.0) 51 (68.0) 49 (25.0) 5 (14.7) 10 (5.3) 12 (12.9) 14 (19.2)
35–49 33 (22.5) 24 (32.0) 94 (48.0) 14 (41.2) 69 (36.7) 29 (31.2) 32 (43.8)
50–64 94 (64.0) 0 (0.0) 44 (22.5) 15 (44.1) 94 (50.0) 38 (40.9) 22 (30.1)
65–75 20 (13.6) 0 (0.0) 9 (4.6) 0 (0.0) 15 (8.0) 12 (12.9) 5 (6.9)
>75 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.2) 0 (0.0)
Gendera
Male 62 (42.2) 34 (45.3) 99 (50.5) 16 (47.1) 72 (38.3) 50 (53.8) 43 (59.7)
Female 85 (57.8) 41 (54.7) 97 (49.5) 18 (53.0) 116 (61.7) 43 (46.2) 29 (40.3)
Ethnicitya
White 132 (89.8) 64 (85.3) 169 (86.2) 30 (88.2) 170 (90.4) 86 (92.5) 65 (89.0)
Asian 9 (6.1) 5 (6.7) 15 (7.7) 2 (5.9) 11 (5.9) 2 (2.2) 6 (8.2)
Black 2 (1.4) 5 (6.7) 10 (5.1) 2 (5.9) 4 (2.1) 4 (4.3) 1 (1.4)
Other 4 (2.7) 1 (1.3) 2 (1.0) 0 (0.0) 3 (1.6) 1 (1.1) 1 (1.4)
Data are number (%).
aData are missing for some participants and excluded from percentage calculations. Numbers of missing data are shown in Supplementary data, Table S1.






Median age, years 48 (39–57) 54 (42–64) <0.0001
Age groupa (years) <0.0001
<18 0 (0.0) 28 (2.2)
18–34 141 (17.5) 156 (12.5)
35–49 295 (36.6) 296 (23.7)
50–64 307 (38.1) 497 (39.8)
65–75 61 (7.6) 236 (18.9)
>75 2 (0.3) 35 (2.8)
Gendera 0.002
Male 376 (46.7) 671 (53.8)
Female 429 (53.3) 577 (46.2)
Ethnicitya <0.0001
White 716 (88.8) 1169 (95.0)
Asian 50 (6.2) 22 (1.8)
Black 28 (3.5) 22 (1.8)
Other 12 (1.5) 17 (1.4)
Data are median (IQR) or number (%).
aData are missing for some participants and excluded from percentage calculations.
Numbers of missing data are shown in Supplementary data, Table S1.
*Wilcoxon test for age. All others chi-squared test.
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Table 4. Univariable and multivariable logistic regression analysis of factors associated with LDKT versus DDKT
Univariable Multivariable
OR (95% CI) P-value OR (95% CI) P-value
Demographic variables
Age group (years)
18–34 1 (reference) 1 (reference)
35–49 0.41 (0.31–0.53) <0.0001 0.34 (0.25–0.46) <0.0001
50–64 0.27 (0.20–0.34) <0.0001 0.19 (0.14–0.27) <0.0001
65–75 0.16 (0.11–0.23) <0.0001 0.11 (0.08–0.17) <0.0001
Gender
Male 1 (reference)
Female 1.13 (0.94–1.36) 0.192
Ethnicity
White 1 (reference) 1 (reference)
Asian 0.62 (0.45–0.85) 0.003 0.55 (0.39–0.77) 0.0006
Black 0.52 (0.35–0.78) 0.001 0.64 (0.42–0.99) 0.047
Other 0.49 (0.22–1.10) 0.081 0.46 (0.19–1.11) 0.084
Socio-economic variables
Civil status
Married/living with partner 1 (reference) 1 (reference)
Divorced/separated/widowed 0.46 (0.34–0.63) <0.0001 0.63 (0.46–0.88) 0.030
Single 1.10 (0.88–1.36) 0.406 0.77 (0.58–1.02) 0.067
Qualifications
Higher education 1 (reference) 1 (reference)
Secondary education 0.73 (0.58–0.92) 0.009 0.76 (0.59–0.97) 0.010
No qualifications 0.39 (0.30–0.51) <0.0001 0.55 (0.42–0.74) <0.0001
Employment status
Employed 1 (reference)
Unemployed 0.71 (0.50–1.02) 0.064
Long-term sick/disability 0.58 (0.46–0.73) <0.0001
Retired 0.42 (0.33–0.55) <0.0001
Other 1.12 (0.79–1.58) 0.542
Car ownership
Yes 1 (reference) 1 (reference)
No 0.41 (0.31–0.55) <0.0001 0.51 (0.37–0.72) 0.0001
Home ownership
Yes 1 (reference) 1 (reference)
No 0.82 (0.68–1.00) 0.053 0.65 (0.49–0.85) 0.002
Clinical variables
Primary renal diagnosis
Diabetic nephropathy 1 (reference)
Glomerulonephritis 2.03 (1.40–2.94) 0.0002
Polycystic kidney disease 1.48 (0.99–2.22) 0.054
Pyelonephritis 2.62 (1.74–3.95) <0.0001
Hypertensive nephropathy 1.19 (0.72–1.98) 0.498
Renal vascular disease 1.02 (0.46–2.26) 0.968
Other 2.22 (1.50–3.29) <0.0001
Uncertain 1.48 (0.97–2.27) 0.068
Charlson comorbidity score
0 1 (reference)
1 0.74 (0.56–0.97) 0.031
2 0.59 (0.43–0.82) 0.002
3 0.45 (0.30–0.70) 0.0003
Previous transplant
No 1 (reference)
Yes 1.18 (0.91–1.53) 0.212
Highly sensitized (cRF > 85%)
No 1 (reference)
Yes 1.28 (0.97–1.71) 0.087
Geographic variables
England 1 (reference) 1 (reference)
Wales 0.90 (0.59–1.39) 0.642 0.86 (0.54–1.38) 0.539
Northern Ireland 3.40 (2.06–5.63) <0.0001 3.25 (1.89–5.57) <0.0001
Scotland 0.71 (0.51–1.00) 0.047 0.72 (0.50–1.03) 0.073














































disparities in the utilization of LDKT versus DDKT. Older age;
Black and Asian ethnicity; being divorced, separated or wid-
owed; lower educational attainment and measures of greater
socio-economic deprivation (non-car and non-home owner-
ship) were significantly and independently associated with a
reduced likelihood of LDKT versus DDKT. For the period of
the study, geographic differences were also noted, with patients
in NI having a greater probability of LDKT versus DDKT com-
pared with patients in the rest of the UK. Furthermore, the
study demonstrated that among those who do undergo LDKT,
ethnic and socio-economic disparities persist in determining
whether LDKT is received pre-emptively. Asian ethnicity,
unemployment and greater socio-economic deprivation were
associated with a lower likelihood of pre-emptive LDKT versus
LDKT after the initiation of dialysis.
A major strength of the present study is that we recruited all
patients prospectively and collected accurate, reliable and com-
prehensive data. A large proportion (72%) of the national adult
kidney transplant population was included in the study.
Nevertheless, as it was not possible to recruit the entire kidney
transplant population, it must be recognized that the study is
limited by a risk of selection bias. Reassuringly, the age, gender
and ethnicity of study participants were not significantly differ-
ent from the national adult kidney transplant population [11].
Furthermore, the study cohort included patients from all 23 UK
renal transplant centres as well as nationally comparable pro-
portions of LDKT, DDKT and pre-emptive recipients, thereby
reducing the potential for bias. However, differences in other
unmeasured characteristics between study participants and
non-participants cannot be ruled out. Another limitation of the
study is that we were unable to account for the fact that some
patients may not have had a medically suitable living donor.
This could be a potential explanation for the observed lower uti-
lization of LDKT for certain patient groups. It is known that
ethnic minorities have a higher prevalence of hypertension and
diabetes with associated ESRD, thus precluding kidney dona-
tion [16, 17]. Similarly, greater socio-economic deprivation is
linked to poorer health [18], potentially limiting the pool of liv-
ing donors available to more deprived patients. Furthermore,
due to the observational nature of the study, the results can only
describe associations and thus the causality of the observed rela-
tionships cannot be inferred.
In recent years, a great deal of attention has been directed
towards disparities in access to DDKT in the UK. Individuals
who are older, more socially deprived, from ethnic minority
backgrounds or treated in certain transplant centres are less
likely to be listed for and subsequently receive DDKT [19–23].
Despite LDKT providing optimal clinical outcomes for patients
with ESRD, there have been limited data on whether patients
experience disparities in utilizing this treatment. Udayaraj et al.
[24], reported a lower probability of LDKT for patients with
greater socio-economic deprivation and patients from Black
and South Asian backgrounds in the UK. However, this study
analysed the rates of LDKT among patients starting RRT, there-
fore a major confounding factor is the poorer health among
more socio-economically deprived and ethnic minority popula-
tions, leading to a higher proportion of patients being medically
unsuitable for transplantation. The present study adds new
knowledge about the factors associated with receiving LDKT as
opposed to DDKT among a cohort of patients deemed suitable
to undergo transplantation. This is a select population of
patients who have already successfully navigated the process of
FIGURE 2: Multivariable logistic regression analysis of factors associated with LDKT versus DDKT. N. Ireland, Northern Ireland.
























































































transplant referral, evaluation and listing. Therefore, it is con-
cerning that the striking disparities observed appear to occur
over and above the well-recognized inequities that patients face
before even reaching this stage. These findings are not confined
to the UK. Our results are consistent with those of a USA study
by Gore et al. [25], which reported lower odds of LDKT relative
to DDKT for patients who were older, from ethnic minority
groups, with lower socio-economic status and with lower levels
of education. Roodnat et al. [26], showed the same factors
reduced the likelihood of LDKT versus DDKT in The
Netherlands. It is interesting that similar results have been dem-
onstrated both within publicly funded as well as private health
care systems, suggesting factors other than financial disadvant-
age play an important role.
The well-recognized markers of socio-economic deprivation
(car ownership and home ownership) were strongly associated
with a reduced likelihood of LDKT versus DDKT in this study.
A subgroup analysis of only White patients confirmed that the
effects of socio-economic deprivation were independent of eth-
nicity. Lower rates of LDKT in socio-economically deprived
patients have also been reported in Australia [27] and the USA
[28, 29]. The reasons behind this finding are unclear. It is
known that living donor–recipient pairs usually come from the
same socio-economic group [30]. In the UK, kidney trans-
plantation including medication and aftercare are provided
free of charge. However, it is possible that other costs such as
transportation, childcare and lost income from time off work
could play a role in deterring potential living donors or
deterring those in need of a kidney from approaching poten-
tial donors [31]. A financial reimbursement policy for
expenses incurred by living donors does exist in the UK, but
it is not implemented consistently by transplant centres. A
recent qualitative study of DDKT recipients found that many
were unaware of the living donor reimbursement policy [32].
Despite this, socio-economically deprived patients did not
perceive financial concerns to be a major barrier to LDKT and
described passivity and disempowerment in treatment decisions,
short-term focus and lack of social support as more significant
obstacles to LDKT [32].
It is well recognized that ethnic minority patients wait
longer for DDKT in the UK, due to the mismatch between
the HLA types of minority patients and those of the predom-
inantly White donor pool [33]. One might, therefore, expect
a higher uptake of LDKT in ethnic minority patients. Our
study found the opposite, with patients from Black and
Asian backgrounds having lower odds of LDKT than DDKT
compared with White patients. Similar disparities have been
reported in the USA [15, 34] and Canada [35]. These dispar-
ities have worsened over time and are likely contributing to
differences in outcomes between White and non-White
patients [36]. The reasons for these disparities are not well
understood. Possible explanations cited include cultural and
religious beliefs [37, 38], reluctance to engage with the medi-
cal system [39, 40], institutional prejudice [41, 42], language
barriers [43] and concern over a higher risk for living donors
from minority ethnic backgrounds [44–46].
We have demonstrated that a patient’s level of educational
attainment is independently associated with their likelihood
of LDKT versus DDKT. Educational attainment is related to
health literacy, which has been shown to be an important
factor for both potential kidney transplant recipients as well
as potential living donors in successfully navigating the living
donation and transplantation process [47, 48]. Higher aca-
demic achievement may be linked to a better ability to under-
stand the benefits of LDKT or to take part in informed and
shared decision making.
The finding that patients who were married or living with a
partner had better access to LDKT is likely to be related to the
opportunity for spousal donation. Spouses represented a consid-
erable proportion (23.3%) of living donors in this study, and the
Table 5. Multivariable logistic regression analysis of factors associated
with LDKT versus DDKT among White patients only
Recipient variables OR (95% CI) P-value
Age group (years)
18–34 1 (reference)
35–49 0.31 (0.22–0.44) <0.0001
50–64 0.17 (0.12–0.25) <0.0001
65–75 0.11 (0.07–0.17) <0.0001
Civil status
Married/living with partner 1 (reference)
Divorced/separated/widowed 0.60 (0.42–0.86) 0.006
Single 0.70 (0.51–0.96) 0.028
Qualifications
Higher education 1 (reference)
Secondary education 0.73 (0.55–0.96) 0.027
No qualifications 0.53 (0.38–0.74) 0.0001
Car ownership
Yes 1 (reference)
No 0.50 (0.35–0.73) 0.0003
Home ownership
Yes 1 (reference)
No 0.68 (0.50–0.91) 0.01
Country
England 1 (reference)
Wales 0.91 (0.56–1.47) 0.693
Northern Ireland 3.43 (1.98–5.95) <0.0001
Scotland 0.71 (0.49–1.04) 0.076
Table 6. Multivariable logistic regression analysis of factors associated
with pre-emptive LDKT
Recipient variables OR (95% CI) P-value
Ethnicity
White 1 (reference)
Asian 0.45 (0.23–0.86) 0.016
Black 1.19 (0.53–2.65) 0.672
Other 1.17 (0.17–7.79) 0.874
Employment status
Employed 1 (reference)
Unemployed 0.44 (0.21–0.92) 0.029
Long-term sick/disability 0.44 (0.28–0.68) 0.0002
Retired 0.47 (0.29–0.75) 0.002
Other 1.41 (0.80–2.50) 0.240
Car ownership
Yes 1 (reference)
No 0.41 (0.19–0.86) 0.018
Home ownership
Yes 1 (reference)
No 0.65 (0.44–0.96) 0.029























































































|majority were female (61.7%). Being married or living with a part-
ner may also confer other benefits, such as having a better social
support network or access to more unrelated or child donors.
Older age was associated with dramatically reduced odds of
LDKT versus DDKT. Previous research has demonstrated that
older age is associated with a lower probability of attempted
donor recruitment [49]. Older patients have reported an unwill-
ingness to put younger donors at risk, particularly their children
[50]. In our study, 18.2% of the living donors were parents while
only 9.3% were children.
Despite adjustment for demographic and socio-economic
factors, we found striking geographic differences in LDKT activ-
ity, with patients in NI experiencing higher odds of LDKT versus
DDKT compared with patients in England, Wales and Scotland.
Our results reflect the actual number of LDKTs pmp, which
were around twice as high in NI (31.1) compared with the rest of
the UK (England 15.9, Wales 16.6, Scotland 10.9) at the time of
the study [51]. Around this time, an initiative was begun in NI
to promote LDKT and pre-emptive transplant as the treatment
of choice. The key measures included education to promote a
change of mindset among nephrologists (particularly non-
transplant nephrologists) as well as the entire transplant
team, together with improved infrastructure and more
streamlined services to enable timely workup and transplan-
tation (e.g. one-stop living donor assessment clinic).
Effective leadership, persistence and gaining the support of
commissioners and management were critical in achieving
these changes [A. Courtney (personal communication, 17
January 2017)]. Our results and the national figures indicate
that such a strategy can be very successful in increasing
LDKT utilization. The higher LDKT rate in NI led to a lower
DDKT rate (NI 15.0, England 24.9, Wales 33.0, Scotland
26.7) [51] and there are now very few long-waiting patients
on the waiting list in NI [52]. Moreover, the number of
LDKTs in NI has continued to increase (40 pmp in 2016,
one of the highest rates in the world), demonstrating that the
changes have led to a sustained improvement rather than
a temporary peak in activity. This is encouraging when
exploring potential avenues to improve LDKT across the UK
as a whole.
Our study showed for the first time in the UK that socio-
economic deprivation, unemployment and Asian ethnicity were
independently associated with a lower likelihood of pre-emptive
LDKT. These findings are consistent with studies from the USA
and Australia [5, 25, 27]. The disparity experienced by socio-
economically deprived individuals is likely to be related to an
increased likelihood of late referral to specialist renal services in
the UK [53]; however, this does not explain the disparity for
patients of Asian ethnicity.
LDKT, and in particular pre-emptive LDKT, provides opti-
mal clinical outcomes for patients with ESRD, yet its uptake is
variable within the UK. This study has identified specific patient
groups with a lower likelihood of undergoing LDKT relative to
DDKT. We have demonstrated that demographic, socio-
economic and geographic factors are more strongly associated
with the type of transplant received rather than clinical factors,
including comorbidity, primary renal diagnosis, HLA sensitiza-
tion or previous transplantation. Moreover, a remarkable
finding is that even among LDKT recipients, disparities persist
in receiving pre-emptive transplantation. This demonstrates the
strength of social factors in influencing access to health care and
may reflect similar inequities across a wide range of health care
services. The demonstrated disparities may reflect both barriers
in certain patient groups as well as important positive factors in
others. Furthermore, these influencing factors are likely to apply
to both potential recipients and donors. If particular groups
experience avoidable barriers to LDKT receiving or donating,
there is a responsibility to provide tailored resources to remove
these barriers. Improving access to LDKT will not only benefit
individual patients, but will also have favourable effects for the
wider ESRD population by effectively increasing the overall
pool of available organs. However, both donor and recipient
welfare and autonomy undoubtedly remain the primary focus.
Some patients may prefer not to pursue LDKT due to concerns
about risks to their potential donors, just as some potential
donors may be unwilling to donate [50, 54].
Identifying disadvantaged patient groups is essential to
directing further research into potentially modifiable factors
and appropriate interventions. Several studies in the USA have
explored targeted interventions, including culturally sensitive
education programmes [55, 56], home-based education [57, 58]
and patient advocates [59], with promising results for reducing
disparities in LDKT. Similar programmes in the UK may pro-
vide a more equitable opportunity for disadvantaged patients to
explore the option of LDKT.
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Objective: To explore how patients who are wait-listed
for or who have received a kidney transplant
understand the current UK kidney allocation system,
and their views on ways to allocate kidneys in the
future.
Design: Qualitative study using semistructured
interviews and thematic analysis based on a pragmatic
approach.
Participants: 10 deceased-donor kidney transplant
recipients, 10 live-donor kidney transplant recipients,
12 participants currently wait-listed for a kidney
transplant and 4 participants whose kidney transplant
failed.
Setting: Semistructured telephone interviews
conducted with participants in their own homes across
the UK.
Results: Three main themes were identified:
uncertainty of knowledge of the allocation scheme;
evaluation of the system and participant suggestions
for future allocation schemes. Most participants
identified human leucocyte anitgen matching as a
factor in determining kidney allocation, but were often
uncertain of the accuracy of their knowledge. In the
absence of information that would allow a full
assessment, the majority of participants consider that
the current system is effective. A minority of
participants were concerned about the perceived lack
of transparency of the general decision-making
processes within the scheme. Most participants felt
that people who are younger and those better matched
to the donor kidney should be prioritised for kidney
allocation, but in contrast to the current scheme, less
priority was considered appropriate for longer waiting
patients. Some non-medical themes were also
discussed, such as whether parents of dependent
children should be prioritised for allocation, and
whether patients with substance abuse problems be
deprioritised.
Conclusions: Our participants held differing views
about the most important factors for kidney allocation,
some of which were in contrast to the current scheme.
Patient participation in reviewing future allocation
policies will provide insight as to what is considered
acceptable to patients and inform healthcare staff of
the kinds of information patients would find most
useful.
INTRODUCTION
Transplantation is widely viewed as the best
treatment for most people with advanced
chronic kidney disease (CKD).1 Although
transplant rates are increasing, there con-
tinues to be a mismatch between supply and
demand.2 3 National kidney allocation pol-
icies aim to balance the competing goals of
optimising outcomes and providing equity of
access to donated organs, in a way that is
acceptable to patients and healthcare profes-
sionals. In the current UK allocation scheme
Strengths and limitations of this study
▪ Qualitative methods such as thematic analysis
are well suited to understanding the beliefs
underlying individual attitudes and opinions of
the current kidney allocation system.
▪ The study interviewed a wide selection of partici-
pants, including those currently waiting for a
transplant, participants who received a deceased
donor or living-donor transplant and those
whose transplant failed.
▪ The interviews were conducted with participants
recruited to Access to Transplantation and
Transplant Outcomes (ATTOM) so the results
cannot be generalised necessarily to all renal
patients or other organ allocation schemes.
▪ Only English-speaking participants were recruited
so the results may not reflect fully the views of
people of ethnic minority origin. Those patients
deemed unsuitable for transplant listing were
also not recruited.
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for kidneys from deceased heart-beating donors,4 5 per-
fectly matched kidneys are prioritised for children
(<18 years), patients with antibodies to numerous
human leucocyte antigens (HLA) and patients homozy-
gous for HLA-DR. Within these groups, longer waiting
patients get priority. Imperfectly matched kidneys are
offered to blood-group and HLA-compatible recipients
using a points-based system taking into account waiting
time and recipient age and HLA-mismatch, aiming to
give younger patients better-matched kidneys. Other
factors for which points are given include HLA-DR and
HLA-B homozygosity, age difference between donor and
recipient, blood-group match and geographical location
of recipient and donor to minimise extracorporeal
kidney storage time. When a donor is identified, kidneys
are offered sequentially to wait-listed patients starting
with the highest-ranked patient, then the next highest,
until accepted. This scheme was introduced in 2006;4 5
details are available online (http://www.odt.nhs.uk/pdf/
kidney_allocation_policy.pdf). Since then, there have
been significant changes in donor and recipient demo-
graphics, and other factors have emerged as predictors
of post-transplant outcomes. In line with the objectives
of the scheme,4 recent discussions suggest a shift in
focus towards ‘transplant benefit’ and matching more
carefully the donor and recipient. For this reason, the
Kidney Advisory Group of National Health Service
Blood and Transplant are reviewing the UK kidney allo-
cation system.
Involving stakeholders in developing kidney allocation
schemes helps ensure acceptability.6 Patients’ perspec-
tives and their preferences for factors determining alloca-
tion are important for assessing the acceptability of a
system and managing patients’ expectations of outcomes.
Accounting for the outcomes most important to patients
may improve patient satisfaction and their ability to make
informed decisions regarding listing, but few studies have
been conducted on the views of renal patients about
kidney allocation schemes. Such studies have indicated
broad agreement between factors considered important
to patients and those used, such as HLA matching.7 8
Most UK studies have used discrete choice experiments
or questionnaire surveys,8–10 thus not allowing for further
explanation of the reasoning and beliefs behind peoples’
preferences or the opportunity to assess how patients
interpret questions. Qualitative research, in contrast, pro-
vides a deeper understanding of the beliefs underlying
individual attitudes and opinions and is capable of identi-
fying unanticipated beliefs or preferences. The objectives
of this study were to identify what patients know and
think of the current UK kidney allocation system, and
what factors they believe should influence allocation.
METHOD
Study context
This qualitative study was conducted as part of the
Access to Transplantation and Transplant Outcomes
(ATTOM) programme.11 ATTOM aimed to examine the
reasons for disparities in transplant availability12 13 and
learn how to optimise UK transplant outcomes.
Research nurses from all 72 UK renal units recruited
participants from November 2011 to March 2013. The
current study was conducted within a work-stream exam-
ining detailed patient-reported outcome measures in
651 patients fluent in English receiving differing treat-
ments for stage 5 CKD, who completed questionnaires
on quality of life and treatment satisfaction. Methods
have been reported in detail elsewhere.11 The main aim
of the interviews was to explore participant’s question-
naire responses related to their quality of life and treat-
ment satisfaction, and additionally explore participants’
thoughts about how kidneys are allocated, which is the
focus of this paper. Thematic analysis based on a prag-
matic approach was used. This is a flexible approach not
limited to any one epistemology that acknowledges there
are differing ways of making sense of the world. Analyses
were conducted in line with established guidelines.14
Participants
To ensure inclusion of participants who reported differ-
ing levels of negative impact of their renal condition on
their quality of life (QoL), participants were selected
based on their Renal Dependent Quality of Life
(RDQoL) questionnaire15 scores, completed 12 months
following recruitment to ATTOM. The RDQoL is a
21-item disease-specific measure of the impact of CKD
on QoL. The impact of CKD on various life domains,
and the importance of these domains for QoL, are rated
by participants. Impact is multiplied by importance to
give a weighted-impact score for each domain. Average
weighted-impact (AWI) scores are calculated by dividing
the summed weighted-impact scores of each applicable
domain by the number of applicable domains, to give a
score between −9 (most negative impact) and +3 (most
positive impact). Means and SDs were calculated from a
subsample of 256 participants. Selecting participants
with scores either above or below one SD of the mean
allowed for consistent criteria to be used across treat-
ment groups, and selected participants from a wide
range of RDQoL AWI scores. Participants were not strati-
fied by demographic variables, but the groups were rep-
resentative of their cohorts for age, sex and ethnicity,
although the living-donor kidney (LD) recipients inter-
viewed were older than the average LD recipient.
Sixty participants were selected to take part (see online
supplementary appendix 1); 40 agreed, and 38 were
interviewed. Of the 20 who did not participate, 6
declined, 2 were too ill and 12 could not be contacted.
Two agreed to participate but could not subsequently be
contacted. Two interviews were excluded from analyses (1
wait-listed patient was removed from the list and 1 trans-
plant recipient reported transplant failure at interview).
Interview schedule
An interview schedule was developed (box 1), guided by
the published literature.16 Participants were asked about
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their knowledge of the kidney allocation system, and
how they would like to see kidneys allocated in future.
The interview also included a list of 13 factors that are
or could potentially be used to determine allocation
(table 1). The list included factors that are used in the
UK scheme and those considered important by patients
in previous research.7–10 16 Current determinants of allo-
cation were comprehensibly phrased; for example, cold
ischaemia time was referred to as the ‘travelling distance
between donor kidney and recipient’. Other factors
were related to one another, such as likelihood of dying
without a transplant and gain in life expectancy, but
were assessed separately, in line with previous research.7
Participants were asked to rate the importance of these
factors in deciding priority for who should be allocated
a kidney from 0 (not at all important) to 10 (most
important). All factors were rated by participants at the
end of the interviews, to avoid influencing participants’
opinions about the system. Participants were encouraged
to elaborate on their answers and to think out loud
when making their ratings.
Data collection
Semistructured telephone interviews were conducted
between December 2013 and August 2014. All partici-
pants had been contacted previously by authors (AG or
JB) when arranging completion of questionnaires.
Postdoctoral research fellow (AG) conducted the inter-
views. She has qualitative research experience and
formal training including the use of NVivo software
(QSR International, US) for qualitative analysis.
Participants were informed that the interview would
explore their questionnaire responses related to their
QoL and treatment satisfaction, to broaden the research
team’s understanding of participant experiences. The
interview would also explore participants’ thoughts
about how kidneys are allocated (box 1). Participants
agreeing to take part were phoned at an agreed time for
interview.
Data analysis
Interviews were audio-recorded and transcribed. Field
notes were made by AG after every interview. Interviews
averaged 52 min in length (range =28–91 min). Field
notes were reviewed and transcripts read three times for
familiarisation prior to analysis. Independent initial
coding by AG of 5 interviews established major themes
derived from the data which enabled development of a
coding framework (AG, CB, MC). This showed signifi-
cant levels of agreement on independent coding of the
Box 1 Questions regarding kidney allocation from the
wider interview schedule
The broad questions were asked of all participants. The second
set of questions include examples of questions used selectively to
obtain further information or explanation from participants.
Broad questions
▸ Can you please tell me what you know of the current system
that is used for allocating kidneys to people on the waiting
list?
▸ Where did you learn about the allocation system?
▸ If you could decide how the allocation system works, how
would you like to see the kidneys being allocated?
▸ Who do you think should decide who receives a kidney?
Examples of prompts and probing questions
▸ What factors determine who gets a kidney?
▸ Can you tell me what you know of how tissue type and blood
group influence kidney allocation? Can you tell me how the
system tries to reduce the risk of rejection in other ways?
▸ Can you tell me what you know of how waiting time affects
kidney allocation?
▸ What sort of person do you think is most likely to get a
kidney? Why do you think that they have this advantage? Is
this fair?
▸ Do you think that there are other people who should have an
advantage? Who? Why?
▸ What sort of person do you think is least likely to get a
kidney? Why do you think so? Is this fair?
▸ Do you think it is important that everyone has an equal
chance of getting a kidney? Why?
▸ Do you think that sometimes people shouldn’t have an equal
chance? Who? Why?
▸ Where did you learn about the allocation system; healthcare
staff? Other patients? The internet?
▸ Was the information you were given consistent with other
information you received?
▸ What factors should be taken into account when deciding who
receives a kidney?
▸ What factors do you think should be given priority? Can you
explain why?
Table 1 Participants’ ratings of how important they
believe each factor to be in reaching a decision about who
receives a kidney transplant as evidenced by mean
importance scores
Ranking Factor Mean SD Range
1 HLA/tissue matching 8.66 1.76 1–10
2 Likelihood of dying
without a transplant
8.30 1.72 5–10
3 Age <18 years of
potential recipient
8.28 2.09 3–10
4 Blood-group match 8.09 2.33 1–10





7 Age 18–60 years 7.14 2.30 3–10
8 Gain in quality of life 6.73 3.12 0–10
9 Waiting time 6.59 2.31 0–10
10 Gain in life expectancy 6.48 2.97 0–10






13 Age 60 years+ 5.54 1.90 3–10
Factors rated from 0 (not at all important) to 10 (most important).
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next five interviews (AG and JB). There was substantial
coder agreement, and AG coded the remaining 26 inter-
views. The coding was completed in MSWord, then
entered into NVivo10 software. Reiteration of earlier




Table 2 shows participant characteristics. Participants
were recruited through 11 UK transplant centres. The
sample consisted of 10 deceased-donor (DD) kidney
transplant recipients, 10 LD kidney transplant recipients,
4 participants whose transplant failed postrecruitment to
ATTOM (Tx failed) and 12 participants wait-listed for a
kidney transplant (WL). Four LD recipients received a
transplant from a relative (1 parent donor, 3
adult-offspring donors), while 5 received an unrelated
transplant through the national paired LD exchange
scheme. The donors included in the scheme were rela-
tives (n=1), spouses (n=3) or friends (n=1). One LD
recipient received a transplant from a non-directed
(altruistic) living donor. Two LD recipients were never
wait-listed for a DD transplant. Wait-listed participants
were waiting for an average of 41 months. More DD
Table 2 Summary of demographic characteristics, time spent on dialysis and on waiting list for the four participant groups
DD (N=10) LD (N=10) WL (N=12) Tx failed (N=4)
Variable M (SD) M (SD) M (SD) M (SD)
Age (years) 52 (14.44) 53 (9.32) 53 (10.65) 53 (12.82)
Time on waiting list (months) 37 (34.48) – (–) 41 (26.99) 13 (11.59)
Time on dialysis (months) 28 (24.59) 28 (31.67) 39 (31.53) 15 (0.82)
Variable N (%) N (%) N (%) N (%)
Sex (female) 5 (50%) 5 (50%) 5 (41.6%) 1 (25%)
Diabetes (yes) 3 (30%) 1 (10%) 1 (8.3%) 1 (25%)
Previous transplant failure (yes) 2 (20%) 4 (40%) 6 (50%) 1 (25%)
Treatment modality (pretransplant)
Predialysis 3 (30%) 3 (30%) 2 (16.7%) –
Peritoneal dialysis (PD) 1 (10%) 1 (10%) 2 (16.7%) –
Haemodialysis (HD) 6 (60%) 6 (60%) 8 (66.6%) 4 (100%)
Marital status
Single 2 (20%) 2 (20%) 3 (25%) 1 (25%)
Living with partner 1 (10%) – – –
Married 5 (50%) 7 (70%) 7 (58.4%) 1 (25%)
Divorced/separated 1 (10%) 1 (10%) 1 (8.3%) 2 (50%)
Widowed 1 (10%) – 1 (8.3%) –
Education
No qualifications 2 (20%) 1 (10%) – 1 (25%)
Basic (O level/A level/NVQ 1–3) 4 (40%) 6 (60%) 9 (75.0%) 1 (25%)
Higher (degree/higher degree/NVQ 4–5) 4 (40%) 3 (30%) 3 (25.0%) 2 (50%)
Ethnicity
White 7 (70%) 10 (100%) 8 (66.7%) 4 (100%)
Black – – 3 (25%) –
Chinese 1 (10%) – –
Asian 1 (10%) – 1 (8.3%) –
Mixed 1 (10%) – – –
Transplant centre
Belfast 1 (10%) 2 (20%) – –
Birmingham 1 (10%) – 2 (16.7%) 1 (25%)
Bristol 2 (20%) – 1 (8.3%) –
Cambridge 1 (10%) 1 (10%) – –
Cardiff 1 (10%) – 1 (8.3%) 1 (25%)
Edinburgh 1 (10%) 4 (40%) 2 (16.7%) –
Guys – – – 2 (50%)
London West 1 (10%) 1 (10%) 3 (25%) –
Newcastle – – 1 (8.3%) –
Plymouth 2 (20%) – – –
St. Georges – 2 (20%) 2 (16.7%) –
DD, deceased-donor-kidney-transplant group; LD, living-donor-kidney-transplant group; Tx failed, patients whose transplant failed; WL,
patients wait-listed for a deceased-donor-kidney-transplant.
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Table 3 Themes and illustrative quotations






▸ “Well I know that erm, the individual recipient has to match the donor with a blood
type and antibody type and erm, I think there are 6 different numbers you’ve got to
match with, or as near as a match with, before you can actually match up” (Man, WL
pre-dialysis).
▸ “It goes by tissue matching. Basically like the lottery. I think you get, there’s six
things they got to match and the closest match, that’s how they allocate the kidneys
they give it to the closest match” (Man, DD transplant).
▸ “A lot of it goes on age and um compatibility so I believe the blood group is one of
the first things” (Woman, (non-related) LD transplant).
▸ “I understand it’s prioritises people who have been on the list for longer, waiting
longer” (Man, WL CAPD).
▸ “I know they like to have as good an age match between donors and recipients as
possible” (Woman, (non-related) LD transplant).
▸ “As far as I know obviously it’s all computerised and it’s the best match who gets
them” (Woman, (non-related) LD transplant).
▸ “Well as I understand it um at (NHS) Blood and Transplant have a national allocation
system. They, that essentially works on a combination of blood type and things like
that and tissue typing, the kidneys are allocated on best match but that is flexed by
need and time on the waiting list. So you have a combination of best match,
overridden by someone who may have an urgent need or someone who spent an
extremely long time on the waiting list” (Man, DD transplant).
Knowledge
uncertainty
▸ “I don’t know, I don’t know what the system is” (Man, HD following failed DD
transplant).
▸ “I don’t, I haven’t got a clue how they’re allocated” (Man, (related) LD transplant).
▸ “I pretty much confess to a certain amount of ignorance because when I had my first
one there was a points system and I was a young father, 40, and as I said to you
before they wanted to try and transplant a few people early on, so I did, they claim,
they say there’s not a points system any more but I think probably some people’s
need is greater than others. And so I’m a little bit in the dark” (Man, WL HD).
▸ “I don’t know masses about it I’ve gotta be honest but my, my guess is they, erm
they would look at how match(ed) the kidney is, they would look at how long people
have been on the waiting list, they would look at probably age, I would say those are
probably the key things, how long you’ve been on there, what kind of a match it’s
gonna be for you and what age, say how much kind of benefit you’re gonna get from
it” (Man, (related) LD transplant).
▸ “Well you get slightly different stories from slightly different people it has to be said.
Um you know allegedly there’s not a top of the list; right I mean allegedly it kind of
works by a points system and all this kind of thing. But, um if you, I mean I only
know in my personal circumstance I’ve been told that you know, I am now near the






▸ “I think the guidelines are very fair! I mean it’s unfortunate if you’ve got a, a different
metabolism as much as you’re a different blood group or your whatever it is, the
kidney doesn’t match” (Man, DD transplant).
▸ “I think it’s fair, you know I don’t think anybody should be playing God and deciding
ok this person is more needy therefore you get it. Sometimes it’s unfair when you
see like, somebody who is young, with family and stuff not getting one, but then I
wouldn’t want to be the person on that board deciding between that person and
somebody else. The way they do allocate kidneys is much more neutral” (Woman,
DD transplant).
▸ “Not knowing enough about how it’s allocated, I would have to assume it’s been set
up in a good way that it is fairly fair… I would just have to assume that it’s been set
up in a good way so” (Man, (non-related) LD transplant).
▸ “(It’s) probably not a fair system but I mean there’s also things like I mean I know it
shouldn’t matter but I’m not sure geographically um, I mean allegedly it’s all one
system and you would get a kidney you know from the south of England or whatever
but… um technically everybody should have an equal chance, I’m not entirely sure
Continued
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Theme Subtheme Illustrative quotations
that’s how it works. But I don’t think that’s necessarily wrong” (Woman, WL
predialysis).
Trust ▸ “Well not knowing enough about how it’s allocated, I would have to assume it’s been
set up in a good way that it is fairly fair but um, so yes I do not know all the ins and
outs of the allocation system so I um, I would just have to assume that it’s been set
up in a good way” (Man, (non-related) LD transplant).
▸ “I suppose the consultant sees the patient and we should all trust the consultants
that they’re gonna be… if there’s fraudulent or back-handed things going on then if
we can see everything’s kosher and they’re making the right decisions for the right
reasons” (Woman, predialysis DD transplant).
▸ “I hope that it is (a fair system). I don’t have any knowledge of it but I hope that there
is and they’re not cheating me out of a kidney!” (Man, WL CAPD).
Patient
suggestions
Medical priority ▸ “I suppose priority would be um people who really needed it if they were ill. But then
I think you have to look at, there’s so many points to look at isn’t there. You’ve gotta
be healthy enough to receive it. It’s no good going through a major operation if you
… you’ve got to be fit enough to have it)” (Woman, HD following failed DD
transplant).
▸ “But I think that because of the time and the money it costs I think the money should
be best spent and the person most suitable to that kidney… the one that’s most
likely to be successful” (Man, (related) LD transplant).
▸ “And if it’s so much to do with the individual then I guess it has to be um a match, a
match basis like they’re on cos they, ultimately whether it’s going to work or not,
medically, whether it’s going to work or not, they don’t just have to take the gamble
medically on that and the best match has to be the thing that takes priority over
everything. Always cos then the long-term prognosis is what they care about”
(Woman, (non-related) LD transplant).
▸ “If you give a kidney to someone who doesn’t best match it, it might only last them
an hour or a day and then it’s wasted. Someone who’s a 100% match it could go
forever and forever, you know it could last them forever” (Woman WL HD).
▸ “Well it shouldn’t really matter because as I say it’s only if it’s a proper match. I mean
obviously if you’ve got a guy with a couple of kids and a guy at 60, then it’s the
same match, a proper match then obviously the younger person should get it. But
there’s no point. They match the kidneys at present to the age group if they possibly
can. I mean there’s little point in putting a 60 year old kidney into a 20 year old is
there? It’s got to be a match” (Man, DD transplant).
▸ “I suppose like people with the worst kidney function obviously need a kidney first”
(Man, DD transplant).




▸ “I mean if you had an 85-year-old who’s been on the waiting list for goodness knows
how long, and you’ve got a 30-year old and a kidney comes up and it’s suitable for
both of them, I would have thought that common sense would say the 30-year-old
would get it” (Man, pre-dialysis, LD transplant).
▸ “You have to figure out how old are people who receive a kidney, they’re more likely
to have other health, health side effects than someone who’s younger… and also if
you’re older you know, and you’re like a widow or something then your social life is
gonna be less than someone who’s younger you know, who’s just got married and
has got kids and stuff like that” (Man, DD transplant).
▸ “I’ve lived my life. I’m 66 now and if there was a young person lying in bed beside
me and two of us could, I would say give it to that, give it to that young life. Yes I
would. But that’s my personal thought. So I’ve lived my life, this guy’s just starting
out, you know” (Woman, DD transplant).
▸ “If you were something like 80 you wouldn’t expect to live more than another ten
years or something like that, where if you get it when you’re 20, you could live
another 60 years or something like that. So um, so yes I think it’s quite important
obviously if it can give a longer, if you’re saying if it can give a longer lifespan then
it’s, um, that should be weighted into it” (Man, (non-related) LD transplant).
Continued
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recipients reported having fewer educational qualifica-
tions, were from a wider range of transplant centres and
had greater ethnic diversity than the other groups.
Main qualitative analyses
Three main themes emerged: certainty of knowledge;
evaluation of the system and patient suggestions (see
online supplementary appendix 2). See table 3 for
themes and subthemes.
Certainty of knowledge
Few participants reported detailed knowledge of the
system, while many were unsure of how kidneys are allo-
cated. Despite this, the majority correctly identified
medical factors such as blood group and HLA typing as
important, although all participants referred to HLA
matching as ‘tissue matching’. Several participants
correctly believed that recipient age was a factor, with
younger people more likely to be prioritised. One DD
recipient felt that there was an upper age limit for
receiving a transplant, but was unsure of accuracy: “I
think if you’re over, I don’t know, 60 or 70 you may be
less likely to get one… I don’t know whether I’m right
in that or not, but that’s my perception” (Woman, non-
related LD transplant).
Some transplant recipients were correctly aware that
waiting time is a factor, but very few were aware of how
multiple factors combine to determine organ allocation.
Some felt more knowledgeable about how factors inter-
relate than others, but were still uncertain that their
information was accurate. Participants whose transplants
failed were knowledgeable about HLA typing and its
importance in determining allocation. One participant
in particular was very knowledgeable of the system,
Table 3 Continued
Theme Subtheme Illustrative quotations
▸ “Well if that person was the main parent and they got two kids whatever, and if that
person doesn’t survive because they didn’t receive a kidney, and then the kids have
to go into care then you know there should be some priority over that [when] you’ve
got two dependants, you know, little ones to look after (rather) than someone who
hasn’t got anyone (to look after)” (Man, DD transplant).
Priority based on
recipient factors
▸ “I had a two year old child when I first had a transplant so I mean, you could argue
that there was a child dependent on me but that, I‘m no more special than anyone
else” (Woman, WL predialysis).
▸ “That’s their fault (they had children)! If you choose to have children, you don’t think
well if I have more children I’m more likely to get a kidney transplant. No that’s not
fair” (Woman, pre-dialysis DD transplant).
▸ “I think everyone should be treated equally whatever age” (Woman, DD transplant).
▸ “I may have been more predisposed to say you know that younger ones should have
priority, but since my father died I would have argued very strongly that he was
entitled to just as many, you know as equal an opportunity as anyone else” (Woman,
DD transplant).
▸ “I mean people might say oh yes you know she’s a mum and she’s got two young
children, she should have priority whereas that’s chap’s 70 and shouldn’t… I don’t
think that’s a fair way to do it because who’s to say, who’s to judge that that person
is more deserving of it, or would benefit from it more? I think that has to be a medical
decision” (Woman, WL pre-dialysis).
▸ “Why should someone of a younger age be more entitled than someone of an older
age?” (Man, (related) LD transplant).
▸ “If a young person has a chance of a decent life but then a middle aged man wants
a chance of a decent life, he’s got a family. He may be older, he’s got a family and
you know you can get to my stage of life and still have a family, still have a wife and
you still want your shot! I think everybody should have an equal shot” (Man, WL HD).
Deservingness ▸ “You think about it people go on the transplant list, on the donor list then they should
be worth more, get more marks than people who are not on it. So if you’ve been on
the transplant list 20 years, and on the donor list for 20 years and you’re an equal
match as somebody that’s not on the, on the donor list, you should give them
priority” (Man, pre-dialysis DD transplant).
▸ “If people are grossly overweight, diabetic you know I mean a lot of, I mean you
could argue the case all these people are sort of self-inflicted like you know?” (Man,
LD transplant).
▸ “I think people uh, who are extremely ill and who deserve it, which for me would be
young people, people with families, that kind of thing” (Man, WL pre-dialysis).
CAPD, continuous ambulatory peritoneal dialysis; DD, deceased-donor-kidney-transplant group; HD, haemodialysis; LD, living-donor-kidney-
transplant group; Tx failed, patients whose transplant failed; WL, patients wait-listed for a deceased-donor-kidney-transplant.
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although he was uncertain about his accuracy: “I believe
there’s a points system and how that works specifically I
don’t really know. But I believe that the kidneys would
be allocated on what would be the best match, medical
match. I believe that children will probably take priority
over older people. Whether that’s true or not I don’t
know but that’s what I understand. I believe if there is
more than; if there’s a really good match but more than
uh, you know one person that it would be a match to,
then that’s when I believe the time you’ve been waiting
on the waiting list would then come in. So if there’s a
donor kidney that would match four people it would go
to the person who’s been on the list the longest” (Man,
on HD following failed DD transplant).
Some participants correctly believed that it is a
national allocation system, with a small minority incor-
rectly believing that wait-listed participants move up the
list in a sequential order. Three LD recipients were
unsure of the system, but overall, LD recipients and WL
participants were more familiar with the points system
than the DD recipients who were beneficiaries of this
system. WL participants were more likely to report
seeking information, and participants whose transplants
failed recalled being given information from surgeons
and transplant coordinators, while those wait-listed for a
transplant and LD recipients mentioned medical staff,
seminars and information evenings more often. DD reci-
pients reported receiving written information and
researching the scheme on the internet. Most reported
being satisfied with the information they received,
although a fifth of participants expressed a wish for
further information.
Evaluation of the system
When asked to describe the current system, 22 partici-
pants made evaluative judgements about its fairness.
Patients regarded equity and fairness as synonymous. On
the basis of their current knowledge of the system, 17
participants felt that the current system was fair,
although 5 felt that it was not. They believed that some
people were prioritised over others based on age and/or
ethnicity, but did not necessarily believe that the system
required change.
Several participants felt that they could trust their
doctors, but also felt that if more information was avail-
able they could trust them more. One DD recipient
believed very strongly that non-related living donation
contradicts the information given about matching.
Although details of the scheme are available online, this
participant felt there was a lack of transparency: “…
there’s also this sneaking suspicion that someone some-
where gets to make a moral judgement on when the
kidneys are handed out and to whom … I’d be much
happier if I knew that it was absolutely numerical and
somebody wasn’t making a judgement call on it at some
point … you’ve got no way of checking that because
none of this is in the open” (Man, DD transplant).
Patient suggestions
When participants were asked how kidneys should be
allocated, various factors were discussed, including
matching, age, perceived medical need, dependants,
waiting time and lifestyle factors. These factors were
categorised under the themes medical priority, increas-
ing life expectancy, priority based on recipient factors
and deservingness.
Medical priority
When asked what factors should be important in decid-
ing who receives a kidney transplant, the main factor
recognised spontaneously to be of primary importance
by 20 participants was matching (HLA and/or blood),
within the context of medical priority. Participants felt
so strongly about the importance of matching that many
felt non-medical factors such as waiting time were irrele-
vant: “Your time on the transplant list is governed by if
you’re a perfect tissue match. That’s it. You know you’ve
got,… if it’s not a perfect tissue match it’s not going to
take and if it’s not going to take it’s not worth having…
you’ve just got to wait. You can’t decide well I’ve waited
5 years I should have the next one” (Man, WL, on HD).
Non-medical factors were considered secondary to
having a successful, well-matched kidney: “I think what
you’re looking for is two things, you want the kidney to
last and be as close a match as possible” (Woman, DD
transplant). Nine participants also felt that people with
the most perceived medical need or who are the most ill
should be given priority: “Some people may be very, very
ill and need the transplant… that should be taken into
account” (Man, (related) LD transplant).
Increasing life expectancy
Participants held opposing beliefs about the importance
of recipient factors in prioritising kidney allocation.
These were often based on beliefs surrounding increas-
ing life expectancy. Many participants felt that young
people have yet to live their lives fully, and prioritising
them allows them this chance: “I probably think that if
you had to choose between a 20-year-old or a
90-year-old, I would probably give it to the younger one
because they got their life to live whereas the 90-year-old
has lived their life” (Man, DD transplant). At the same
time, being older was considered to bring more risk of
having other conditions that may complicate the success
of a transplant and limit any gains in life expectancy.
Priority based on recipient factors
Although many participants felt that medical priority
through matching was important, eight others felt it was
unfair for anyone to receive priority based on recipient
factors, including time on the waiting list, ethnicity, reli-
gion, younger age or having children: “I don’t see why
one person should have advantage over another”
(Woman, (non-related) LD transplant). These partici-
pants felt that those who are younger should not receive
priority, there should be an equal chance for all to
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receive a transplant: “everybody should get an equal
chance, just because you’re older, you still want to live,
you still want to see your grandkids or your great-
grandchild” (Woman, WL, on HD). Participants also
noted that it would be unfair if those unable or unwill-
ing to have children because of their renal condition
were less likely to receive a transplant.
Deservingness
The issue of deservingness was also considered when dis-
cussing what factors should be used; two WL participants
felt that patients who abuse their body via drugs or
alcohol should be given less priority, while one DD trans-
plant recipient believed that those willing to donate
organs or who are already on the Organ Donor Register
should be given priority if they require a transplant:
“People who are willing to donate should be given a bit
more priority than people who haven’t, as an incentive
(to donate)” (Man, DD transplant).
At the end of each interview, participants were asked
to rate the importance of 13 factors in deciding priority
for who should be allocated a kidney (table 1). Factors
relating to medical priority were rated the highest; tissue
matching was regarded as the most important, with the
likelihood of dying soon without a transplant being con-
sidered the second most important factor. Being
younger than 18 years of age was considered the third
most important. No variable was considered unimport-
ant, although having other medical conditions, being
older than 60 years, and having children or dependants
were rated as least important for kidney transplant
allocation.
DISCUSSION
Although participants in our study were knowledgeable
about some aspects of the current UK allocation system,
they were not certain their knowledge was accurate.
Participants may have been reluctant to place confi-
dence in their knowledge, assuming that the interviewer
had greater knowledge than them, though the woman
interviewer made no claim to such knowledge.
Interestingly, some groups such as those currently wait-
listed were more knowledgeable than others. These par-
ticipants had been wait-listed for 41 months on average
and were more likely to report seeking information. In
contrast, DD recipients may not have retained informa-
tion about a system in which they are no longer involved.
Although LD recipients received donations outside of
the allocation scheme, they were more likely to be aware
of the points system than DD recipients. Most were listed
for a DD transplant before receiving a LD transplant
and fewer LD recipients and WL patients reported
having no qualifications. The DD recipients were from a
wider range of transplant centres and had greater ethnic
diversity. It may be that the differences in knowledge
reflect these differences in sociodemographic factors,
rather than treatment group, but further work is
warranted to assess if this is the case. However, the find-
ings suggest that few participants are confident in their
knowledge of the system.
Few participants were aware of the structure of the
kidney allocation system, believing that patients receive a
kidney in a sequential order. In the absence of full
knowledge of the allocation system, participants may
attempt to make sense of the system by oversimplifying it
through incorrectly anchoring it to their social represen-
tation of what constitutes a waiting list.17 Reference to
being on a ‘waiting list’ may contribute to confusion
about the way the system is structured. Perhaps replacing
the term ‘waiting list’ with ‘waiting pool’ may therefore
facilitate more appropriate understanding of how the
allocation system works. Although the technical details
of the allocation scheme are available online, few partici-
pants had accessed this information. Information is
more effective if tailored to patients,18 and there is a risk
that highly technical information may not be helpful to
most patients. Health literacy is low in patients with
kidney disease19 and patients’ knowledge of their
disease may be limited,20 so how best to make informa-
tion available to patients may need to be reconsidered.
In line with previous research from the USA,21 the
majority of participants trusted that the allocation system
was fair, while a minority of participants perceived a lack
of transparency in how kidneys are allocated. Feeling
ill-informed may lead to dissatisfaction with subsequent
treatment. Despite this, the majority of participants said
they were content with the information they received, so
the provision of further medical detail may not be
required. Instead, an explanation of how the factors
inter-relate in the allocation process may be more
useful. Managing expectations of transplantation affects
how patients cope post-transplant,22 23 so it is important
that more information be provided about the weight
given to matching, and the quality of the kidneys, to
help manage patient expectations of transplant survival.
Longer waiting times have been shown previously to be
an important factor to UK patients,8 10 but this was not
found here. Participants believed that medical priority
was the most important; where there is a good match it
should be used regardless of waiting time, with a prefer-
ence for waiting longer for a better-matched kidney. In a
US study, Louis et al16 suggested that when patients have
seen how detrimental a poor match can be, they may
place more value on matching. In the current study,
almost half of participants had at least one previous
transplant, and all participants whose transplant failed
considered matching to be of utmost importance. This
may help explain the lack of weight given to waiting
time by these participants.
Better matching and younger age were considered the
most important factors in determining kidney allocation,
which have been identified previously as important to
Australian and UK patients.7 8 Participants were more
likely to prioritise children based on the expectation of
increasing life expectancy, and being older was
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considered to bring more risk of having other conditions
that may limit life expectancy, or even preclude trans-
plantation. In contrast, a substantial minority of partici-
pants felt that no personal characteristics, including age,
should be used to prioritise patients. The reason the
current scheme prioritises younger patients for better-
matched kidneys is in part to ensure that future trans-
plantation is more easily achieved through avoiding
development of antibodies to HLA. The provision of
patient-friendly information would explain the reasoning
behind prioritising particular groups, which may lead to
greater acceptance and understanding of the factors
used and of the system overall.
Participants felt that those who have the most medical
need for a transplant should be prioritised. There was
also acknowledgment that kidneys should be allocated to
those who have the best chance of surviving and main-
taining a functioning transplant.7 Allocating kidneys
according to medical criteria was considered the best
way to allocate organs, which has been found previously
in liver transplantation where medical need is assumed
to be an objective way to allocate organs, despite the fact
that it may require moral judgement.24 Patients are
aware of some of the issues surrounding allocation, but
without complete information, patients cannot make
well-informed judgements about policies. Previous
scheme development has included patient representa-
tion, but providing further information to patients about
the system may help them feel more confident of their
knowledge and opinions as to how the system might be
improved.
Although medical need and the use of medical cri-
teria were seen to be important, non-medical and recipi-
ent factors were also discussed. For example, having
children or dependants was one of the lowest-rated
factors, but was raised repeatedly in the interviews. In
line with our findings, there is inconsistency in the lit-
erature in preferences for this factor, with some UK
studies indicating that patients wish to give greater prior-
ity to those with dependants,9 while an Australian study
reported more mixed views.7 Those who do not believe
that priority should be based on recipient factors were
less likely to consider having dependants as worthy of
prioritising patients for kidney allocation, so there is no
consensus as to its perceived importance.
A small number of participants felt that patients
whose kidneys were damaged by behaviours such as
substance misuse were less deserving of a kidney trans-
plant. Other research has shown that participants con-
sider moral deservingness when discussing kidney
transplantation.7 Previous research from the UK and the
Netherlands has shown that kidney recipients reported
feeling gratitude and a sense of duty to their donors to
take care of their kidney,22 23 so allocating transplants to
those considered at risk of not taking care of their
kidneys may explain why these factors were considered
important in the current study.
The factors rated by participants at the end of the
interview showed general agreement with the factors
discussed in the interviews. Ratings varied widely,
however. Participants found it difficult to distinguish
the perceived importance of the factors listed with
many showing ceiling effects. In contrast, participants
were able to show distinct preferences when asked
more general questions about how kidneys should be
allocated in the interviews. Although participants were
encouraged to elaborate on their ratings, few partici-
pants did so, although some of the factors had already
been discussed in the interviews. Despite this, the dif-
ferences in ratings and those factors discussed in inter-
views suggest that qualitative designs may be more
effective in eliciting greater insight into participants’
beliefs and preferences.
Strengths and weaknesses of the study
The interviews were conducted with participants
recruited to ATTOM, and as with all qualitative studies,
the results cannot be generalised to all renal patients or
other organ allocation schemes. No attempt was made
to achieve a representative sample, so any frequencies
given are not necessarily representative of the patient
group as a whole. Moreover, comparisons between
groups should be noted with caution, as the groups dif-
fered in demographic factors such as education level
and ethnicity. The interviews were conducted with
English-speaking participants from a subsample of trans-
plant centres in the UK. The results therefore may not
reflect fully the views of people of ethnic minority
origin. Patients deemed unsuitable for transplant listing
were not included in the present interview sample.
Despite this, collecting qualitative data allowed us to
delve further into patients’ understanding of the alloca-
tion system. This is one of only a handful of studies
examining patient beliefs about kidney allocation. Very
little research has examined patients’ views of kidney
allocation and this study is timely to inform forthcoming
guideline development and allocation scheme revision.
Assessing a large group of patients who have yet to be
listed would inform us of what patients know of the
system before, during and after listing for a kidney trans-
plant. This study does not provide a comprehensive
understanding of patient knowledge, but instead pro-
vides a snapshot of such knowledge (or lack of knowl-
edge) may relate to patient suggestions for the
allocation scheme.
A representative survey to quantify knowledge, as well
as issues regarding age priority, waiting time and the
importance of dependants, would help further to
describe and understand patient’s beliefs and priorities.
This study focused exclusively on renal patients; there
is a case for considering the views of potential kidney
donors and perhaps the wider population for their
level of engagement and knowledge of transplantation
issues.
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CONCLUSIONS
This study highlights that patients vary in their views and
their priorities for kidney allocation. Most participants
were uncertain of the accuracy of their knowledge. The
majority of participants were aware that a number of
factors are important, and most were content with their
level of knowledge, so tailoring information to allow
greater explanation of how factors in the allocation
system relate to one another may be important in
increasing patients’ perceived ability to make informed
decisions about the system. Although further work is
warranted to assess it, replacing the term ‘waiting list’
with ‘waiting pool’ may perhaps facilitate more appropri-
ate understanding of how a points-based allocation
system works. Policymakers should continue to consult
with patients, as it reveals patient knowledge and under-
standing, identifies information needs and provides
guidelines for what factors may be considered accept-
able to patients, which may help increase patients’ confi-
dence in being involved in treatment decision-making,
and ultimately increase patient satisfaction.
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Abstract
Background: Comorbidity is increasingly common in kidney transplant recipients, yet the
implications for transplant outcomes are not fully understood. We analysed the relationship
between recipient comorbidity and survival outcomes in a UK-wide prospective cohort study –
ATTOM.
Methods: 2100 adult kidney transplant recipients were recruited from all 23 UK transplant
centres between 2011-2013. Data on 15 comorbidities were collected at the time of
transplantation. Multivariable Cox regression models were used to analyse the relationship
between comorbidity and 2-year graft survival, patient survival and transplant survival (earliest of
graft failure or patient death) for deceased-donor kidney transplant (DDKT) recipients (n=1288)
and living-donor kidney transplant (LDKT) recipients (n=812).
Results: For DDKT recipients, peripheral vascular disease (HR 3.04, 95%CI 1.37, 6.74, p=0.006)
and obesity (HR 2.27, 95%CI 1.27, 4.06, p=0.006) were independent risk factors for graft loss,
while heart failure (HR 3.77, 95%CI 1.79, 7.95, p=0.0005), cerebrovascular disease (HR 3.45,
95%CI 1.72, 6.92, p=0.0005) and chronic liver disease (HR 4.36, 95%CI 1.29, 14.71, p=0.018)
were associated with an increased risk of mortality. For LDKT recipients, heart failure (HR 3.83,
95%CI 1.15, 12.81, p=0.029) and diabetes (HR 2.23, 95%CI 1.03, 4.81, p=0.042) were associated
with poorer transplant survival.
Conclusion: The key comorbidities that predict poorer 2-year survival outcomes after kidney
transplantation have been identified in this large prospective cohort study. The findings will
facilitate assessment of individual patient risks and evidence-based decision making.
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Introduction
Kidney transplantation is widely regarded as the treatment of choice for end-stage renal disease
(ESRD). However, outcomes after transplantation vary considerably between patients and
prediction of individual risk is challenging due to the increasing prevalence of complex
comorbidity among the ESRD population. Conditions such as diabetes, hypertension and obesity
which contribute to the development of ESRD are on the rise,1 while ESRD itself is an important
risk factor for other comorbidities such as cardiovascular disease.2, 3 Over the past decade, the
proportion of deceased-donor kidney transplant (DDKT) recipients older than 60 years of age has
increased from 17% to 29% in the UK,4 and the burden of comorbidity among patients
undergoing kidney transplantation has also risen significantly.5-7
Despite this, there are limited data on the impact of comorbidity on transplant outcomes. A small
number of studies have demonstrated the overall detrimental effect of comorbidity on transplant
outcomes using various comorbidity indices.5, 8-10 However, this does not allow characterisation
of the risks associated with specific comorbid conditions.. Retrospective registry analyses have
identified several comorbidities as risk factors for transplant outcomes, but the results show
considerable heterogeneity and are limited by the reliability of the data.11-13 Up-to-date and
reliable evidence is essential to enable clinicians to fully inform patients of their individual risks
and likely outcomes, thereby facilitating shared decision-making and informed consent.
We conducted a national prospective cohort study to investigate the impact of a wide range of
baseline comorbid conditions on survival outcomes following kidney transplantation. We report
the two-year survival outcomes of the study which was conducted as part of the Access to
Transplantation and Transplant Outcome Measures (ATTOM) research programme.
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Materials and Methods
Study design and participants
ATTOM is a national prospective cohort study investigating the factors that influence access
to and outcomes from renal transplantation in the UK. A full description of the ATTOM
protocol has been reported previously.14 A cohort of 2262 incident kidney transplant
recipients were recruited to ATTOM at the time of transplantation, from all 23 UK renal
transplant centres. In each centre recruitment took place over a 12-month period between 1st
November 2011 and 31st March 2013. Patients aged 18-75 years were eligible for
recruitment. For the purposes of this analysis, multi-organ transplant recipients (n=162) were
excluded. The final study sample (n=2100) represented 73% of eligible study participants
from the national kidney-only transplant population (Figure 1). Patients were followed up for
two years from the date of transplant. DDKT recipients (n=1288) and living-donor kidney
transplant (LDKT) recipients (n=812) were analysed separately.
Data variables
The variables of interest were recipient comorbidities at the time of transplantation
comprising diabetes, ischaemic heart disease (IHD), heart failure (HF), atrial fibrillation,
cardiac valve replacement, pacemaker, cerebrovascular disease (CVD), peripheral vascular
disease (PVD), abdominal aortic aneurysm, chronic respiratory disease, chronic liver disease
(CLD), blood borne viruses, malignancy, mental illness (definitions given in Supplementary
Table S1) and body mass index (BMI).
The primary outcome measures were graft survival, patient survival and transplant survival.
Graft survival was defined as the time from transplantation to graft failure (earliest of return
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to dialysis or re-transplantation), with censoring for death with a functioning graft, at last
follow-up or at two years. Patient survival was defined as the time from transplantation to
patient death, with censoring at last follow-up or at two years. Transplant survival is a
composite outcome defined as the time from transplantation to the earliest of graft failure or
patient death, with censoring at last follow-up or at two years.
Potential confounders considered in multivariable analyses included (a) recipient variables:
age, gender, ethnicity, primary renal disease (as classified by ERA-EDTA codes15), time on
dialysis, previous transplantation, sensitisation level, smoking status; (b) donor variables: age,
gender, ethnicity, BMI; (c) transplant variables: human leukocyte antigen (HLA) mismatches
(MM), cold ischaemia time (CIT), delayed graft function (DGF). Ethnicity was coded as
White, Black, Asian and Other (including Chinese and mixed origin). Recipient calculated
reaction frequency (cRF) ≥85% was used to define highly sensitised recipients. The cRF is
the percentage of a pool of 10,000 UK donors to whom the recipient has unacceptable HLA
antibodies. HLA mismatches were classified into 4 levels as defined by the current UK
deceased-donor kidney allocation scheme: level 1 (000 HLA-A, B, DR MM), level 2 (0DR +
0/1B MM), level 3 (0DR + 2B MM) or (1DR + 0/1B MM) and level 4 (1DR + 2B MM) or
(2DR MM).16
Data collection
Baseline recipient variables (including comorbidity) were collected by trained research nurses
at the time of transplantation from patient interviews, case notes, local electronic patient
information systems and/or confirmed with the patient’s named consultant nephrologist.
Independent validation of 5% of data entries in all research sites confirmed >98%
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concordance for all data fields.14 Donor and transplant variables and 2-year graft and patient
survival data were obtained through linkage with the UK Transplant Registry.
Statistical methods
Baseline characteristics were compared with chi-squared tests for categorical data and Mann–
Whitney U tests for non-parametric continuous data. The impact of comorbidity on two-year
survival outcomes was examined using Kaplan-Meier estimates and Cox proportional hazards
regression models. DDKT and LDKT recipients were analysed separately. As there were no
significant differences in outcomes between recipients of donors after circulatory death and
donors after brain death, all DDKT recipients were analysed together. For DDKT recipients,
separate multivariable models were built for the three different outcomes of transplant, graft
and patient survival. For LDKT recipients, modelling was only possible for transplant
survival, as the lower number of graft failures and patient deaths prevented modelling of graft
and patient survival separately. All comorbidities were considered for inclusion in the
multivariable models, and those leading to a significant (p<0.05) change in log likelihood
were retained using a manual backward elimination method. Models were adjusted for
statistically significant variables as well as variables selected a priori on the basis of clinical
relevance. Continuous variables were explored as linear, fractional polynomials and
categorical variables. In all models, the effect of the time on dialysis variable was only found
to be significant after 3 years, and thus it was converted to a binary variable (<3 years versus
≥ 3 years) as this provided the best fit in each model. The relationship between recipient BMI
and graft survival was also found to be better represented by converting BMI to a categorical
variable, in accordance with the World Health Organisation (WHO) BMI classifications.17
Potential interactions between all variables were tested, none were significant. The
proportional hazards assumption was found to be satisfied for all variables after checking log
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cumulative hazards plots and Schoenfeld residuals. Frailty models were used to check for
inter-centre variation by using the likelihood ratio test to assess the change in -2LogL after
inclusion of transplant centre as a random effect. The adjusted risk difference (ARD) was
calculated using methods described by Laubender et al.18 The ARD describes the absolute
effect of the comorbidity risk factor on survival probabilities after adjustment for covariates
in the multivariable model. Standard errors of the ARD were derived from bootstrap methods
using 1000 resamples of the data. Patients with missing data were excluded, the extent of
missing data is shown in Supplementary Table S2. Sensitivity analyses were conducted to test
robustness of the results; each model was adjusted for a risk score developed from UK
Transplant Registry data for kidney transplants performed in the 5 years prior to the study
recruitment period (2006 - 2011), rather than adjusting for individual confounding factors.
This minimised the number of degrees of freedom in the models, and enabled checking for
any missed comorbidity effects. All analyses were conducted using SAS® 9.4 (SAS Institute
Inc, Cary, USA).
Ethics approval




Characteristics of the DDKT (n=1288) and LDKT (n=812) recipients, donors and transplants
are shown in Table 1. These were consistent with UK Transplant Registry data for the study
recruitment period.19, 20 The demographics of recruited versus excluded patients were
compared (Supplementary Table S3). There was a higher proportion of White patients in the
recruited group compared with the excluded group, however there were no significant
differences in age group, gender or type of transplant. Table 2 shows the prevalence of
comorbidity in the study cohort at the time of transplantation. DDKT recipients had
significantly higher rates of diabetes (16.0% vs 10.3%, p=0.0002), IHD (9.8% vs 7.0%,
p=0.029), HF (3.1% vs 1.6%, p=0.033), CVD (5.8% vs 3.1%, p=0.004) and PVD (3.3% vs
1.7%, p=0.027) compared with LDKT recipients.
DDKT recipients
a) Transplant survival
Overall, there were 134 “transplant failures” (85 graft failures and 49 patient deaths). The
Kaplan-Meier estimate for two-year transplant survival was 89.4% (95% confidence interval
[CI] 87.6, 91.0). After adjustment for relevant factors in the multivariable Cox regression
model, HF (HR 2.39, 95% CI 1.30, 4.37, p=0.005) and CVD (HR 2.33, 95% CI 1.40, 3.88,
p=0.001) were associated with a significant increase in the risk of transplant failure (Table 3).
There was no significant inter-centre variation in transplant survival when including
transplant centre as a random effect in the model (difference in -2LogL=0.02, degrees of
freedom [df]=1, p=0.885). For HF, the ARD was 0.117 (standard error [SE] 0.052) (i.e.
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patients with heart failure had an 11.7% increased risk of transplant failure within 2 years
compared to those without heart failure, after adjustment for all other factors in the
multivariable model). For CVD, the ARD was 0.101 (SE 0.043). The effect of adding DGF to
the final model is shown in Supplementary Table S4.
b) Graft survival
At two years, there were 85 graft failures, and the Kaplan-Meier estimate of graft survival
was 93.2% (95% CI 91.7, 94.5). Multivariable Cox regression modelling showed PVD (HR
3.04, 95% CI 1.37, 6.74, p=0.006) and obesity (BMI ≥30.0) (HR 2.27, 95% CI 1.27, 4.06,
p=0.006, compared with normal BMI 18.5 – 24.9) to be independent risk factors for graft loss
(Table 3). The obesity variable was explored further in the model by dividing it into class I
and class II and above (BMI 30.0 – 34.9 and ≥35.0 respectively) (Supplementary Table S5).
There were too few patients with obesity class III (BMI ≥40.0) (n=7) to include this as a
separate category. There was no significant variation in the risk of graft failure for the
different classes of obesity, therefore the broader category of obesity (BMI ≥30.0) was
retained in the main model (Table 3). No centre effect on graft survival was found when
modelling centre as a random effect (difference in -2LogL=0.23, df=1, p=0.632). Among
patients with PVD, the risk of graft failure was highest in the first ten days following
transplantation, as demonstrated by the initial steep drop in the survival curve before the
more gradual decline (Figure 2A); 85.7% graft failures in the PVD group occurred during this
early post-operative period, compared with 26.9% among patients without PVD. In contrast,
the impact of obesity on graft survival followed a more gradual decline over the two-year
period (Figure 2B). Unadjusted two-year graft survival estimates for patients with and
without PVD and obesity are shown in Table 4. The ARD for PVD was 0.104 (SE 0.058) and
for obesity was 0.060 (SE 0.029). The incidence of delayed graft function was 31.1% for all
14
patients, 48.7% for patients with PVD and 39.1% for patients with obesity. Adding DGF to
the final model resulted in a reduction in the effect of PVD (Supplementary Table S4). The
cause of graft failure for all patients as well as patients with PVD and obesity in the DDKT
cohort is shown in Table 5.
c) Patient survival
There were 56 patient deaths, of which 49 were deaths with a functioning graft. The two-year
Kaplan-Meier survival estimate was 95.4% (95% CI 94.1, 96.5). The comorbidities
significantly associated with inferior patient survival in the multivariable model included HF
(HR 3.77, 95% CI 1.79, 7.95, p=0.0005), CVD (HR 3.45, 95% CI 1.72, 6.92, p=0.0005) and
CLD (HR 4.36, 95% CI 1.29, 14.71, p=0.018) (Table 3). There were no significant centre
differences in patient survival (difference in -2LogL=0.01, df=1, p=0.925). Among patients
with HF and CVD, just over half of patient deaths occurred in the second year after
transplantation (55.6% and 58.3% respectively), while 100% of deaths among patients with
CLD occurred within the first year post-transplantation. This is demonstrated by the survival
curves in Figures 3A, 3B and 3C. Unadjusted 2-year patient survival estimates for patients
with and without HF, CVD and CLD are shown in Table 6. For HF, CVD and CLD the ARD
was 0.159 (SE 0.057), 0.041 (SE 0.027) and 0.056 (SE 0.091) respectively. The effect of
adding DGF to the final model is shown in Supplementary Table S4.
LDKT recipients
In the LDKT cohort it was only possible to model transplant survival, as the smaller number
of recipients and outcome events prevented meaningful analysis of separate graft and patient
survival models. There were 42 “transplant failures” (26 graft failures and 16 patient deaths).
The Kaplan-Meier estimate for transplant survival at 2 years was 94.7% (95% CI 92.9, 96.0).
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The multivariable model demonstrated significantly higher risk of transplant failure for HF
(HR 3.83, 95% CI 1.15, 12.81, p=0.029) and diabetes (HR 2.23, 95% CI 1.03, 4.81, p=0.042)
(Table 7). There was no significant centre effect on LDKT transplant survival (difference in -
2LogL=0.11, df=1, p=0.741). The ARD for HF was 0.121 (SE 0.099) and for diabetes was
0.056 (SE 0.036).
Sensitivity analyses
Each multivariable model was checked by adjusting for a risk score (Supplementary Boxes
S1, S2, S3 and S4) rather than entering the confounding factors individually into the model
(Supplementary Tables S6, S7, S8 and S9). No additional comorbidities were identified as
significant, and hazard ratios were very similar to the original models, confirming the
reliability of the results.
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Discussion
In this national observational study, we have collected data prospectively on a wide range of
comorbid conditions and identified those that predict poorer survival outcomes after kidney
transplantation. Among DDKT recipients, PVD and obesity were associated with a two- to
three-fold increased risk of graft failure within two years of transplantation, while the risk of
death was three- to four-fold higher with HF, CVD and CLD. For LDKT recipients, HF and
diabetes were associated with significant detrimental effects on overall transplant survival,
but longer follow up is required to determine the separate effects on graft and patient
survival.
Among DDKT recipients, a history of PVD increased the risk of graft failure by 10.4% after
adjusting for confounding factors, with the majority of graft failures occurring in the early
post-operative period. PVD is typically diagnosed clinically by measuring the ankle-brachial
pressure index (ABPI), and our results are in agreement with a US study of 819 patients
which reported a 2.77 times increased risk of graft failure for patients with a low ABPI
(<0.9).21 Pre-existing PVD affecting the aorta or iliac arteries may complicate implantation of
the kidney graft, resulting in difficult anastomoses, cholesterol emboli or hypoperfusion of
the graft, and subsequent failure in the early post-operative period.22, 23 Our data showed a
high incidence of technical operative issues as the cause of graft failure among PVD patients
(42.9%). We also found that the addition of DGF to the regression model for DDKT graft
survival reduced the effect of PVD and is thus a potential mediator of this effect. Despite
being a high risk group, patients with PVD still derive a significant survival benefit from
transplantation compared with dialysis.24, 25 As such, a history of PVD should not preclude
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transplantation, but given the high risk of early complications, appropriate pre-operative
planning and informed consent of patients is crucial.
Obesity is an ongoing topic of controversy with regard to patient suitability for kidney
transplantation. Some centres do not exclude patients with obesity, while others restrict
access to the waiting list at specific BMI thresholds, which may differ considerably between
centres, and even between clinicians within the same centre.26 Despite conflicting outcomes
from early single centre studies, more recent meta-analyses have confirmed the detrimental
effect of obesity on graft survival.27-30 Our results are in keeping with this evidence; with
obesity conferring a 6% increased risk of graft failure among DDKT recipients. The
mechanisms for this are unclear. There was a high incidence of acute rejection as a cause of
graft failure among obese patients (44%) and this could be a potential cause for the higher
risk of graft failure associated with obesity. Difficulties in achieving and maintaining the
narrow therapeutic target concentrations of immunosuppressive drugs in obese patients have
previously been reported.31
We found that HF was associated with a 15.9% higher risk of mortality after DDKT and
12.1% higher risk of transplant failure after LDKT. We acknowledge that in patients on
dialysis, it can be difficult to make a clear distinction between HF and fluid overload;
however, our findings demonstrate that a diagnosis of heart failure in the patient’s record
predicts poorer survival, irrespective of how the diagnosis was made or the exact
pathophysiology. It is also noteworthy that although HF was identified as a significant risk
factor, no effect was observed for IHD. Our findings concur with the results of a US study
which found that pre-transplant impaired left ventricular systolic function (on single photon
emission computed tomography (SPECT)) was associated with a significantly higher risk of
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both cardiac mortality and all-cause mortality after kidney transplantation, while cardiac
ischaemia (on SPECT) was not.32 Our findings suggest that either IHD does not increase the
risk of death within two years post-transplantation, or that current risk stratification of
patients with IHD in the UK is effective.
CVD was associated with a 4.1% elevated risk of death among DDKT recipients. It is known
that patients with ESRD have more severe carotid atherosclerosis than the general population
and are at substantially greater risk of stroke.33-35 A large US registry analysis demonstrated
that transplantation reduced the risk of cerebrovascular events from 11.8% to 6.8% compared
to patients remaining on the waiting list.36 However, previous CVD remains a strong risk
factor for further post-transplantation events and mortality.35, 37, 38 Post-transplantation
cerebrovascular events are associated with high mortality,39 which is worse for haemorrhagic
strokes (48%) compared with ischaemic strokes (6%).38 In a prospective randomised
controlled trial including 1652 kidney transplant recipients (ALERT trial), the use of
Fluvastatin did not reduce the incidence of cerebrovascular events or mortality.38 Further
trials are needed to assess the ability of therapies to reduce the risk of further cerebrovascular
events and mortality in this high risk population.
CLD was independently associated with 5.6% increased risk of mortality within two years of
DDKT. There is a paucity of published research regarding CLD in kidney transplant
outcomes. Previous studies have focussed on the role of hepatitis B and C related liver
disease as predictors of increased mortality after kidney transplantation.40-42 The present
study is the first to demonstrate that CLD of any aetiology leads to reduced survival after
DDKT. Further research is required to understand the underlying mechanisms.
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Interestingly, a diagnosis of diabetes was identified as a risk factor for transplant failure
among LDKT recipients, but not for DDKT recipients. The reason for this finding is unclear.
Diabetes is a well-recognised risk factor for mortality after transplantation, primarily due to
elevated cardiovascular risk.43 It may be that this cardiovascular risk was actually accounted
for by other comorbidity variables in the models for DDKT recipients, while in the LDKT
cohort with a significantly lower prevalence of other comorbidities, diabetes may have served
as more general marker of poorer outcomes. A recent large population cohort study in
Australia and New Zealand demonstrated that patients with Type 2 diabetes had significantly
poorer survival after kidney transplantation, with the highest risk being among younger
patients under the age of 40 years.44 In our study the LDKT population was significantly
younger than the DDKT population and this may explain why diabetes was a significant risk
factor in this population. The 5.6% higher risk of transplant failure among patients with
diabetes (and 12% higher risk for patients with heart failure discussed previously) must be
given due consideration in the context of LDKT, given the potential implications for both the
recipient as well as the live donor.
A major strength of the present study is that it is a prospective and comprehensive analysis of
a large cohort of transplant recipients from all UK transplant centres. The cohort included a
large proportion of the national adult transplant population with a minimal amount of missing
data, which adds to the reliability of the study. There are a number of limitations to this study.
First, for practical reasons we used relatively broad definitions for each comorbidity and were
unable to distinguish between differing levels of severity or duration for each condition. All
comorbidity data were collected at the time of transplantation when patients were recruited to
the study. Therefore, we were unable to assess the progression or improvement of each
condition after transplantation, and whether this impacted on outcomes. Secondly, it should
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be noted that the study population is largely of white ethnicity and thus conclusions with
respect to other ethnic groups may be less certain. Thirdly, due to the favourable survival
outcomes of LDKT recipients, we were only able to analyse the composite outcome of
transplant survival in this cohort, as there were too few events for separate analysis of graft
and patient survival. Transplant survival (also known as graft survival not censored for death)
is a commonly analysed end-point in the transplant literature, as it demonstrates the overall
success of a transplant.45, 46 However, in the DDKT analysis we found that this method
masked the importance of several comorbidity risk factors that were found to be significant
when analysing graft and patient survival separately. Therefore, it is important that we carry
out separate graft and patient survival analyses in the LDKT cohort after longer follow-up
time. Finally, the results from this study describe associations and no causation can be
inferred.
This study quantifies the risks associated with specific comorbid conditions in the context of
kidney transplantation. The findings can be utilised in everyday clinical practice to fully
inform patients of their individual risks and outcomes, to inform future wait-listing and
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Recipient age, years (median, IQR) 54 (44 - 63) 46 (34 - 56) <0.0001
Recipient age group, years (n, %) <0.0001
18 – 34 132 (10.3) 229 (28.2)
35 – 49 369 (28.7) 263 (32.4)
50 – 64 543 (42.2) 252 (31.0)
65 – 75 244 (18.9) 68 (8.4)
Recipient gender (n, %) 0.267
Male 824 (64.0) 500 (61.6)
Female 464 (36.0) 312 (38.4)
Recipient ethnicity (n, %) 0.0002
White 1023 (79.7) 707 (87.1)
Asian 140 (10.9) 62 (7.6)
Black 96 (7.5) 35 (4.3)
Other 25 (2.0) 8 (1.0)
Primary renal disease (n, %) <0.0001
Polycystic kidney disease 219 (17.0) 112 (13.9)
Diabetic nephropathy 134 (10.4) 48 (5.9)
Glomerulonephritis 320 (24.9) 232 (28.7)
Pyelonephritis 138 (10.7) 128 (15.8)
Hypertensive nephropathy 89 (6.9) 37 (4.6)
Renal vascular disease 29 (2.3) 9 (1.1)
Other 163 (12.7) 85 (10.5)
Uncertain 194 (15.1) 157 (19.4)
Time on dialysis (n, %) <0.0001
Pre-emptive 137 (10.6) 279 (34.4)
0 - 1 year 160 (12.4) 198 (24.4)
1 - 3 years 366 (28.4) 185 (22.8)
3 - 5 years 295 (22.9) 78 (9.6)
> 5 years 330 (25.6) 72 (8.9)
Previous transplant (n, %) 165 (12.9) 117 (14.5) 0.297
Highly sensitised, cRF≥85% (n, %) 126 (9.8) 95 (11.7) 0.163
Smoking status (n, %) 0.702
Non-smoker 137 (11.7) 78 (10.7)
Ex-smoker 325 (27.7) 212 (29.2)
Smoker 710 (60.6) 437 (60.1)
Donor variables
Donor age, years (median, IQR) 54 (43 - 64) 48 (39 - 57) <0.0001
Donor age group, years (n, %) <0.0001
<18 31 (2.4) 0
18 – 34 160 (12.4) 143 (17.6)
35 – 49 303 (23.5) 298 (36.7)
50 – 64 512 (39.8) 308 (37.9)
65 – 75 234 (18.2) 61 (7.5)
>75 48 (3.7) 2 (0.3)
Donor gender (n, %) 0.001
Male 696 (54.0) 379 (46.7)
Female 592 (46.0) 432 (53.3)
Donor ethnicity (n, %) <0.0001
White 1208 (95.2) 720 (88.7)
Asian 21 (1.7) 52 (6.4)
Black 23 (1.8) 28 (3.5)
Other 17 (1.3) 12 (1.5)
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Donor BMI, kg/m2 (n, %) <0.0001
Underweight (<18.5) 0 0
Normal (18.5 - 24.9) 463 (37.3) 254 (32.9)
Overweight (25.0 - 29.9) 494 (39.7) 390 (50.5)
Obese (≥30.0) 286 (23.0) 128 (16.6)
Transplant variables
HLA MM level (n, %) <0.0001
1 155 (12.0) 91 (11.2)
2 355 (27.6) 105 (12.9)
3 679 (52.7) 360 (44.3)
4 99 (7.7) 256 (31.5)
CIT, hours (median, IQR) 14.5 (11.4 - 17.3) 3.3 (2.4 - 4.1) <0.0001
Delayed graft function (n, %) 378 (31.1) 30 (3.9) <0.0001
DDKT; deceased-donor kidney transplant, LDKT; living-donor kidney
transplant, IQR; interquartile range, cRF; calculated reaction frequency, BMI;
body mass index, HLA MM; human leukocyte antigen mismatch, CIT; cold
ischaemia time. Data are missing for some participants and excluded from
percentage calculations. Number of missing data are shown in Supplementary
Table S2.
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Diabetes (n, %) 205 (16.0) 83 (10.3) 0.0002
Ischaemic heart disease (n, %) 126 (9.8) 57 (7.0) 0.029
Heart failure (n, %) 40 (3.1) 13 (1.6) 0.033
Atrial fibrillation (n, %) 25 (1.9) 12 (1.5) 0.434
Cardiac valve replacement (n, %) 10 (0.8) 8 (1.0) 0.609
Pacemaker (n, %) 10 (0.8) 5 (0.6) 0.673
Cerebrovascular disease (n, %) 75 (5.8) 25 (3.1) 0.004
Peripheral vascular disease (n, %) 43 (3.3) 14 (1.7) 0.027
Abdominal aortic aneurysm (n, %) 4 (0.3) 2 (0.3) 0.790
Chronic respiratory disease (n, %) 108 (8.4) 59 (7.3) 0.359
Chronic liver disease (n, %) 25 (1.9) 14 (1.7) 0.722
Blood borne viruses (n, %) 38 (3.0) 13 (1.6) 0.051
Malignancy (n, %) 93 (7.2) 49 (6.1) 0.294
Mental illness (n, %) 75 (5.8) 41 (5.1) 0.453
BMI, kg/m2 (n, %) 0.121
Underweight (<18.5) 26 (2.1) 23 (3.0)
Normal (18.5 - 24.9) 461 (37.5) 312 (40.8)
Overweight (25.0 - 29.9) 462 (37.6) 282 (36.9)
Obese (≥30.0) 281 (22.9) 147 (19.2)
Number of comorbidities (n, %) 0.002
0 573 (46.7) 414 (54.4)
1 - 2 579 (47.2) 316 (41.5)
≥3 74 (6.0) 31 (4.1)
DDKT; deceased-donor kidney transplant, LDKT; living-donor kidney
transplant, BMI; body mass index. Data are missing for some participants and
excluded from percentage calculations. Number of missing data are shown in
Supplementary Table S2.
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Table 3. Cox regression analysis for impact of comorbidity on 2-year survival outcomes of deceased donor kidney transplants
Transplant survival model Graft survival model Patient survival model
Variables HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Recipient comorbidity
Heart failure 2.39 (1.30, 4.37) 0.005 - - 3.77 (1.79, 7.95) 0.0005
Cerebrovascular disease 2.33 (1.40, 3.88) 0.001 - - 3.45 (1.72, 6.92) 0.0005
Chronic liver disease - - - - 4.36 (1.29, 14.71) 0.018
Peripheral vascular disease - - 3.04 (1.37, 6.74) 0.006 - -
BMI, kg/m2
Underweight (<18.5) - - 0.86 (0.11, 6.49) 0.885 - -
Normal (18.5 - 24.9) - - 1 (reference) - -
Overweight (25.0 - 29.9) - - 1.48 (0.84, 2.61) 0.180 - -
Obese (≥30.0) - - 2.27 (1.27, 4.06) 0.006 - -
Other variables
Time on dialysis (years)
< 3 1 (reference) 1 (reference) 1 (reference)
≥ 3 2.08 (1.41, 3.08) 0.0002 1.84 (1.11, 3.04) 0.018 2.47 (1.36, 4.50) 0.003
Recipient age (per 10 years) 1.10 (0.92, 1.30) 0.290 0.84 (0.68, 1.05) 0.128 1.67 (1.23, 2.25) 0.0009
Recipient ethnicity
White 1 (reference) 1 (reference) - -
Asian 0.67 (0.35, 1.29) 0.228 0.76 (0.35, 1.69) 0.504 - -
Black 1.23 (0.68, 2.21) 0.495 1.52 (0.77, 3.02) 0.228 - -
Other 0.37 (0.05, 2.63) 0.317 0.62 (0.08, 4.53) 0.636 - -
Highly sensitised (cRF≥85%) 1.47 (0.87, 2.47) 0.153 2.22 (1.18, 4.19) 0.014 - -
Donor age (per 10 years) 1.14 (0.99, 1.31) 0.066 1.23 (1.02, 1.48) 0.028 1.11 (0.89, 1.39) 0.349
HLA MM level
1 1 (reference) 1 (reference) 1 (reference)
2 1.18 (0.62, 2.27) 0.612 2.94 (1.08, 7.98) 0.035 0.40 (0.16, 1.01) 0.052
3 1.05 (0.57, 1.94) 0.866 2.25 (0.85, 5.93) 0.103 0.46 (0.21, 1.01) 0.051
4 1.25 (0.53, 2.93) 0.612 2.78 (0.81, 9.59) 0.106 0.66 (0.22, 2.01) 0.467
Cold ischaemia time (per hour) 1.04 (1.01, 1.08) 0.028 1.01 (0.97, 1.06) 0.568 1.04 (0.99, 1.10) 0.118
HR; hazard ratio, CI; confidence interval, BMI; body mass index, cRF; calculated reaction frequency, HLA MM; human leukocyte antigen mismatch.
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Table 4. Kaplan-Meier estimates for 2-year graft survival of
deceased-donor kidney transplants
Comorbidity Survival (95% CI) p-value
Peripheral vascular disease 0.006
No 93.6 (92.0, 94.8)
Yes 83.5 (68.5, 91.8)
BMI, kg/m2 0.012
Normal (18.5 - 24.9) 95.2 (92.7, 96.8)
Obese (≥30.0) 90.1 (85.9, 93.1)
p-value is for log-rank test.
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Table 5. Cause of graft failure among DDKT cohort
Cause of graft failure All patients Obese patients PVD patients
Acute rejection 26 (34.2%) 11 (44.0%) 1 (14.3%)
Vascular thrombosis 6 (7.9%) 0 (0%) 1 (14.3%)
Technical operative issues 9 (11.8%) 3 (12.0%) 3 (42.9%)
Non-viable kidney 9 (11.8%) 3 (12.0%) 1 (14.3%)
Infection 1 (1.3%) 0 (0%) 0 (0%)
Recurrent primary renal disease 4 (5.3%) 0 (0%) 0 (0%)
Other 21 (27.6%) 8 (32.0%) 1 (14.3%)
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Table 6. Kaplan-Meier estimates for 2-year patient survival after
deceased-donor kidney transplantation
Comorbidity Survival (95% CI) p-value
Heart failure <0.0001
No 96.0 (94.8, 97.0)
Yes 75.8 (58.5, 86.7)
Cerebrovascular disease <0.0001
No 96.2 (94.9, 97.1)
Yes 82.7 (71.5, 89.8)
Chronic liver disease 0.003
No 95.7 (94.3, 96.7)
Yes 83.6 (62.0, 93.5)
p-value is for log-rank test.
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Table 7. Cox regression analysis for impact of comorbidity on 2-
year transplant survival of living-donor kidney transplants
Variables HR (95% CI) p-value
Recipient comorbidity
Heart failure 3.83 (1.15, 12.81) 0.029
Diabetes 2.23 (1.03, 4.81) 0.042
Other variables
Time on dialysis (years)
< 3 1 (reference)
≥ 3 2.16 (1.13, 4.11) 0.019
Recipient age (per 10 years) 1.01 (0.80, 1.28) 0.926
Donor age (per 10 years) 1.03 (0.81, 1.31) 0.828
HLA MM level
1 1 (reference)
2 0.76 (0.23, 2.51) 0.657
3 0.74 (0.29, 1.86) 0.520
4 0.67 (0.25, 1.82) 0.428




Figure 1. Study population and analyses
Patients were recruited from all 23 UK renal transplant centres. Recruitment took place over a 12-month period
in each centre, between 1st November 2011 and 31st March 2013
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Figure 2. Kaplan-Meier curves for 2-year graft survival of deceased-donor kidney transplants
A. Peripheral vascular disease (PVD)
B. Body mass index (BMI)
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Figure 3. Kaplan-Meier curves for 2-year patient survival after deceased-donor kidney transplantation
A. Heart failure (HF)
B. Cerebrovascular disease (CVD)
C. Chronic liver disease (CLD)
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Supplementary Material
Table S1. Comorbidity variable definitions
Comorbidity Definition (presence of any of the following)
Diabetes  Any cause of diabetes
 Type I diabetes – Insulin required from time of diagnosis




 Angina – chest pain on exertion, relieved by rest or Glyceryl Trinitrate. As
reported by patient or as documented in the case notes, with or without ECG
changes, exercise tolerance testing or other imaging
 Non-ST segment elevation myocardial infarction (NSTEMI) – troponin rise and
non-ST segment elevation ischaemic ECG changes such as ST depression, T-wave
inversion or no ECG changes.
 ST segment elevation myocardial infarction (STEMI) – troponin rise and ST
segment elevation on ECG.
 Percutaneous coronary intervention (coronary angioplasty with or without stent
insertion)
 Coronary artery bypass graft operation
Heart failure  Congestive cardiac failure
 Left ventricular failure
 Right ventricular failure
 Left or right ventricular dysfunction on cardiac echo
 Ejection fraction <30% on cardiac echo




 Any kind of cardiac valve replacement or repair
Pacemaker  Permanent pacemaker in-situ
Cerebrovascular
disease
 Transient ischaemic attack (TIA) – also known as “mini-stroke”. Transient
episode of neurologic dysfunction caused by ischaemia without infarction.
Symptoms typically lasting less than 24 hours.










 Claudication – lower limb pain on walking as reported by the patient, with or
without doppler or angiographic evidence.
 Radiological diagnosis




o Amputation of any part of limb
Abdominal aortic
aneurysm
 Radiological diagnosis under surveillance
 Previous endovascular aneurysm repair
 Previous open surgical repair
Chronic respiratory
disease
 Any kind of chronic respiratory disease including:
 Asthma – inflammatory condition of the lungs causing recurrent attacks of
breathlessness and wheezing, differs in severity and occurs in all age groups.
 Chronic obstructive pulmonary disease (COPD) – chronic and progressive airflow
obstruction that is not fully reversible. FEV1/FVC ratio <0.7 and FEV1 < 80%
predicted.
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 Bronchiectasis – abnormal and irreversible dilatation of the bronchi due to
destruction of elastic and muscular tissue by acute or chronic inflammation and
infection. Results in chronic infections and airway obstruction.
Chronic liver
disease
 Persistent enzyme evidence of hepatic dysfunction with imaging or biopsy
evidence of cirrhotic or non-cirrhotic liver disease






Malignancy  Diagnosis of any malignancy in the past or in the present. Does not include benign
tumours such as breast adenoma, colon polyp, actinic keratosis etc.
Mental illness  Any diagnosis of mental illness e.g. depression, psychosis, bipolar disorder,
substance abuse, deliberate self-harm, schizophrenia
Data for comorbidities were extracted from patient case notes, local electronic patient information systems
and/or confirmed with the patients named consultant nephrologist at the time of recruitment to ATTOM.
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Recipient age 0 0
Recipient gender 0 0
Recipient ethnicity 4 (0.31%) 0
Primary renal disease 2 (0.16%) 4 (0.49%)
Time on dialysis 0 0
Previous transplant 7 (0.54%) 4 (0.49%)
Sensitisation level 0 0
Smoking status 116 (9.0%) 85 (10.5%)
Donor variables
Donor age 0 0
Donor gender 0 1 (0.12%)
Donor ethnicity 19 (1.48%) 0
Donor BMI 45 (3.49%) 40 (4.93%)
Transplant variables
HLA MM level 0 0
CIT (per hour) 17 (1.32%) 66 (8.13%)
Recipient comorbidity
variables
Diabetes 3 (0.23%) 2 (0.25%)
Ischaemic heart disease 3 (0.23%) 2 (0.25%)
Heart failure 2 (0.16%) 2 (0.25%)
Atrial fibrillation 2 (0.16%) 2 (0.25%)
Cardiac valve replacement 3 (0.23%) 4 (0.49%)
Pacemaker 2 (0.16%) 3 (0.37%)
Cerebrovascular disease 2 (0.16%) 3 (0.37%)
Peripheral vascular disease 2 (0.16%) 3 (0.37%)
Abdominal aortic aneurysm 2 (0.16%) 3 (0.37%)
Chronic respiratory disease 2 (0.16%) 2 (0.25%)
Chronic liver disease 2 (0.16%) 2 (0.25%)
Blood borne viruses 3 (0.23%) 2 (0.25%)
Malignancy 2 (0.16%) 2 (0.25%)
Mental illness 2 (0.16%) 2 (0.25%)
BMI 58 (4.50%) 48 (5.91%)
Outcome variables
Delayed graft function 74 (5.7%) 49 (6.0%)
Graft survival 2 (0.16%) 3 (0.37%)
Patient survival 1 (0.08%) 3 (0.37%)
Cause of graft failure 9 (10.58%) 2 (7.69%)
DDKT; Deceased-donor kidney transplant, LDKT; Living-
donor kidney transplant, BMI; body mass index, CIT; cold
ischaemia time.
Data are number (%).
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Table S3. Demographics of excluded vs recruited kidney transplant
recipients
Variable Excluded (%) Recruited (%) p-value
Age group 0.307
18 – 34 15.5 17.2
35 – 49 29.0 30.1
50 – 64 38.0 37.9














Table S4. Cox regression analysis for impact of comorbidity and delayed graft function on 2-year survival outcomes of deceased donor kidney
transplants
Transplant survival model Graft survival model Patient survival model
Variables HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Recipient comorbidity
Heart failure 2.77 (1.50, 5.12) 0.001 - - 3.86 (1.82, 8.20) 0.0004
Cerebrovascular disease 2.05 (1.17, 3.59) 0.012 - - 3.50 (1.73, 7.08) 0.0005
Chronic liver disease - - - - 4.68 (1.39, 15.79) 0.013
Peripheral vascular disease - - 2.58 (1.01, 6.59) 0.047 - -
BMI, kg/m2
Underweight (<18.5) - - 1.52 (0.19, 11.67) 0.688 - -
Normal (18.5 - 24.9) - - 1 (reference) - -
Overweight (25.0 - 29.9) - - 1.96 (1.01, 3.78) 0.046 - -
Obese (≥30.0) - - 2.83 (1.43, 5.62) 0.003 - -
Other variables
Delayed graft function 1.75 (1.19, 2.56) 0.004 1.86 (1.12, 3.09) 0.017 1.24 (0.70, 2.20) 0.463
Time on dialysis (years)
< 3 1 (reference) 1 (reference) 1 (reference)
≥ 3 2.06 (1.35, 3.13) 0.0008 2.02 (1.15, 3.55) 0.014 2.26 (1.24, 4.15) 0.008
Recipient age (per 10 years) 1.06 (0.88, 1.28) 0.528 0.81 (0.64, 1.03) 0.086 1.56 (1.17, 2.15) 0.0003
Recipient ethnicity
White 1 (reference) 1 (reference) - -
Asian 0.76 (0.39, 1.47) 0.418 0.88 (0.40, 1.96) 0.756 - -
Black 0.83 (0.41, 1.67) 0.598 1.10 (0.49, 2.46) 0.826 - -
Other 0.00 (0.00, 0.00) . 0.00 (0.00, 0.00) . - -
Highly sensitised (cRF≥85%) 1.52 (0.86, 2.67) 0.151 2.35 (1.16, 4.77) 0.018 - -
Donor age (per 10 years) 1.09 (0.93, 1.27) 0.280 1.14 (0.93, 1.40) 0.208 1.07 (0.86, 1.35) 0.538
HLA MM level
1 1 (reference) 1 (reference) 1 (reference)
2 1.25 (0.61, 2.58) 0.544 3.95 (1.14, 13.72) 0.018 0.39 (0.15, 1.04) 0.059
3 1.15 (0.58, 2.27) 0.696 2.94 (0.86, 9.97) 0.084 0.51 (0.23, 1.16) 0.107
4 1.03 (0.38, 2.79) 0.951 2.19 (0.42, 11.42) 0.323 0.74 (0.24, 2.33) 0.608
Cold ischaemia time (per hour) 1.03 (0.99, 1.07) 0.105 1.02 (0.95, 1.06) 0.940 1.05 (0.99, 1.11) 0.102
HR; hazard ratio, CI; confidence interval, BMI; body mass index, cRF; calculated reaction frequency, HLA MM; human leukocyte antigen mismatch.
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Table S5. Cox regression analysis for impact of BMI on 2-year graft
survival of deceased donor kidney transplants
BMI (kg/m2) n HR (95% CI) p-value
Underweight (<18.5) 26 0.88 (0.11, 6.49) 0.885
Normal (18.5 - 24.9) 461 1 (reference)
Overweight (25.0 - 29.9) 462 1.48 (0.84, 2.61) 0.180
Obese class I (30.0 - 34.9) 222 2.29 (1.23, 4.26) 0.009
Obese class II/III (≥35.0) 59 2.19 (0.87, 5.46) 0.094
Model adjusted for peripheral vascular disease, time on dialysis, recipient
age, recipient ethnicity, highly sensitised (cRF≥85%), donor age, HLA MM
level and cold ischaemia time.
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Table S6. Cox regression model for 2-year transplant survival
of deceased-donor kidney transplants (including risk score)
Variables HR (95% CI) p-value
Heart failure 2.38 (1.30, 4.34) 0.005
Cerebrovascular disease 2.21 (1.34, 3.67) 0.002
Time on dialysis (years)
< 3 1 (reference)
≥ 3 2.17 (1.49, 3.16) <0.0001
Risk score (per unit) 1.11 (1.03, 1.19) 0.005
HR; hazard ratio, CI; confidence interval.
Model is adjusted for a risk score (Box S1) that incorporates
relevant confounding variables.
Box S1. Risk score for 2-year transplant survival based on UK transplant registry data for deceased-
donor kidney transplants in 2006 - 2011 (n=6469)
Transplant survival risk score = exp [ - 0.3687 if recipient age 30-39
- 0.3885 if recipient age 40-49
- 0.2020 if recipient age 50-59
- 0.1863 if recipient age 60-64
+ 0.1589 if recipient age is 65-75
+ 0.1808 if recipient ethnicity Asian
+ 0.2745 if recipient ethnicity Black
- 0.5727 if recipient ethnicity Other
+ 0.2494 if recipient highly sensitised (cRF≥85%)
+ 0.02475 x donor age
- 0.2978 if HLA MM level 1
+ 0.1518 if HLA MM level 3
- 0.07197 if HLA MM level 4
+ 0.00613 x cold ischaemic time in hours ]
exp; exponential function, HLA MM; human leukocyte antigen mismatch, cRF; calculated reaction frequency.
HLA MM is classified into 4 levels as defined by the current UK deceased-donor kidney allocation scheme (see
Methods section). “Other” is any ethnicity other than White, Asian or Black.
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Table S7. Cox regression model for 2-year graft survival of
deceased-donor kidney transplants (including risk score)
Variables HR (95% CI) p-value
Peripheral vascular disease 2.74 (1.25, 5.99) 0.012
BMI, kg/m2
Underweight (<18.5) 0.97 (0.13, 7.23) 0.977
Normal (18.5 - 24.9) 1 (reference)
Overweight (25.0 - 29.9) 1.33 (0.76, 2.34) 0.319
Obese (≥30.0) 2.14 (1.20, 3.80) 0.010
Time on dialysis (years)
< 3 1 (reference)
≥ 3 2.08 (1.29, 3.35) 0.003
Risk score (per unit) 1.21 (1.07, 1.37) 0.003
HR; hazard ratio, CI; confidence interval, BMI; body mass index.
Model is adjusted for a risk score (Box S2) that incorporates
relevant confounding variables.
Box S2. Risk score for 2-year graft survival based on UK transplant registry data for deceased-donor
kidney transplants in 2006 - 2011 (n=5569)
Graft survival risk score = exp [ - 0.5205 if recipient age 30-39
- 0.6398 if recipient age 40-49
- 0.5586 if recipient age 50-59
- 0.6910 if recipient age 60-64
- 0.4789 if recipient age is 65-75
+ 0.1503 if recipient ethnicity Asian
+ 0.2982 if recipient ethnicity Black
- 0.6247 if recipient ethnicity Other
+ 0.02813 x donor age
- 0.1626 if HLA MM level 1
+ 0.2599 if HLA MM level 3
- 0.06468 if HLA MM level 4
+ 0.00347 x cold ischaemic time in hours ]
exp; exponential function, HLA MM; human leukocyte antigen mismatch. HLA MM is classified into 4 levels
as defined by the current UK deceased-donor kidney allocation scheme (see Methods section). “Other” is any
ethnicity other than White, Asian or Black.
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Table S8. Cox regression model for 2-year patient survival of
deceased-donor kidney transplants (including risk score)
Variables HR (95% CI) p-value
Comorbidity
Heart failure 3.72 (1.76, 7.87) 0.0006
Cerebrovascular disease 3.37 (1.69, 6.71) 0.0005
Chronic liver disease 3.94 (1.21, 12.83) 0.023
Time on dialysis (years)
< 3 1 (reference)
≥ 3 2.34 (1.30, 4.22) 0.005
Risk score (per unit) 1.02 (1.01, 1.03) 0.0009
HR; hazard ratio, CI; confidence interval.
Model is adjusted for a risk score (Box S3) that incorporates
relevant confounding variables.
Box S3. Risk score for 2-year patient survival based on UK transplant registry data for deceased-donor
kidney transplants in 2006 - 2011 (n=5569)
Patient survival risk score = exp [ - 0.8798 if recipient age 30-39
+ 1.4404 if recipient age 40-49
+ 1.8680 if recipient age 50-59
+ 2.1586 if recipient age 60-64
+ 2.8002 if recipient age is 65-75
+ 0.01730 x donor age
- 0.4345 if HLA MM level 1
- 0.01808 if HLA MM level 3
- 0.1475 if HLA MM level 4
+ 0.01632 x cold ischaemic time in hours ]
exp; exponential function, HLA MM; human leukocyte antigen mismatch. HLA MM is classified into 4 levels
as defined by the current UK deceased-donor kidney allocation scheme (see Methods section).
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Table S9. Cox regression model for 2-year transplant survival
of living-donor kidney transplants (including risk score)
Variables HR (95% CI) p-value
Comorbidity
Heart failure 3.63 (1.10, 11.97) 0.035
Diabetes 2.21 (1.05, 4.66) 0.037
Other variables
Time on dialysis (years)
< 3 1 (reference)
≥ 3 2.20 (1.16, 4.16) 0.016
Risk score (per unit) 1.02 (0.46, 2.23) 0.968
HR; hazard ratio, CI; confidence interval.
Diabetes includes any diagnosis of diabetes (both as a primary
renal disease and a comorbidity).
Model is adjusted for a risk score (Box S4) that incorporates
relevant confounding variables.
Box S4. Risk score for 2-year transplant survival based on UK transplant registry data for living-donor
kidney transplants in 2006 - 2011 (n=3837)
Transplant survival risk score = exp [ - 0.1519 if recipient age 30-39
- 0.2066 if recipient age 40-49
- 0.4011 if recipient age 50-59
- 0.05848 if recipient age 60-64
+ 0.3659 if recipient age is 65-75
+ 0.00879 x donor age
- 0.07066 if HLA MM level 1
- 0.01556 if HLA MM level 3
- 0.2242 if HLA MM level 4 ]
exp; exponential function, HLA MM; human leukocyte antigen mismatch. HLA MM is classified into 4 levels
as defined by the current UK deceased-donor kidney allocation scheme (see Methods section).
